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ABSTRACT 
 
Background: Human immunodeficiency virus (HIV) remains a global health problem. 
In sub-Saharan Africa, where the majority of HIV infected individuals live, 1.5 million 
HIV positive individuals die and 1.2 million become infected every year. Ensuring 
timely access to anti-retroviral therapy (ART) and efficacious HIV prevention 
strategies could potentially end the epidemic. To realise these benefits, individuals 
need access to frequent HIV testing and retesting. Facility-based HIV testing and 
counseling (HTC) is not popular in the region. HIV self-testing (HIVST), where 
individuals test in the privacy of their own homes, has been found to potentially 
achieve the required levels of HIV testing needed to achieve these goals. However 
no economic analysis of HIVST has been undertaken to inform policy makers 
whether it is a cost-effective option to scale-up in the region.    
 
Objective: To undertake a cost-utility analysis (CUA), from the health provider and 
societal perspectives, that estimates the incremental cost per quality-adjusted life 
year (QALY) gained by providing Malawian communities HIVST, in addition to routine 
provision of facility-based HTC.  
 
Methods: A decision-analytical model parameterised using primary cost and health-
related quality of life (HRQoL) data collected from three observational studies: (1) a 
cross-sectional study recruiting individuals (n=1,241) who accessed HIVST and 
facility-based HTC; (2) a cohort study following up HIV positive individuals (n=330) 
accessing HIV treatment after HIVST or facility-based HTC; and (3) a cohort study of 
adults (n=822) admitted to the medical wards at Queen Elizabeth Central Hospital. In 
addition, evidence from the literature was synthesised to estimate epidemiological 
parameter inputs. Primary costing was undertaken to estimate health provider costs. 
Participants were asked about the direct non-medical and indirect costs they 
incurred, and their HRQoL measured using the EuroQol EQ-5D. Costs were adjusted 
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to 2014 US and INT Dollars, and the primary cost-effectiveness outcome was 
expressed in terms of incremental cost per QALY gained.     
 
Results: The health provider cost per participant tested through HIVST (US$8.78) 
was comparable to that for facility-based HTC (US$7.53-US$10.57), although the 
mean societal costs of HTC were US$ 2.38 (95%CI: US$0.87-US$3.89) lower with 
HIVST. The mean total health provider (US$22.74 v US$28.33) and societal cost 
(US$25.56 v US$32.22) during the pre-ART period was lower for those who had 
accessed HIVST to learn their status than for those who accessed facility-based HTC. 
Mean total health provider and societal costs during the first year of accessing ART 
were comparable between those who had accessed HIVST and facility-HTC (mean 
total societal cost: US$251.14 v US$261.57). HIV positive individuals who had more 
advanced HIV disease, measured by the CD4 count, had lower EQ-5D utility scores. 
Health-related quality of life improved once individuals started ART, with the 
majority of participants reporting perfect health one year after starting ART.  The 
mean cost of hospital admission was high, for example the mean health provider 
cost of managing Cryptococcal Meningitis and Pulmonary Tuberculosis was 
US$837.92 and US$473.11, respectively, and was associated with low EQ-5D utility 
scores. The CUA found the incremental cost-effectiveness ratio (ICER) of providing 
HIVST in addition routine facility-based HTC to be US$316.18 per QALY gained from 
the health provider perspective (societal perspective: US$332.05 per QALY gained). 
The sensitivity analysis found the ICER was comparable if the cost of HIVST was 
higher, if there were lower rates of linkage into HIV treatment after HIVST and if the 
HIV prevalence in the population was lower.  
 
Conclusion: HIVST was found to be an affordable and cost-effective option for 
Malawi based on International guidelines (ICER below three times the gross 
domestic product: US$250 in Malawi). Undertaking primary economic data 
collection in resource-constrained settings was feasible and provided robust 
estimates for use in decision-analytic models. 
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CHAPTER 1: Introduction 
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1 Overview of Chapter 1 
In this chapter, I will introduce my PhD thesis and research question. I will provide a 
brief introduction to HIV and HIV self-testing. I will introduce my primary research 
question, the importance of investigating it and how my interest in it arose.  I will 
then provide an overview of the structure of the thesis, and provide a brief 
description of the individual chapters within it.  
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1.1 Introduction  
Human immunodeficiency virus (HIV) is a viral infection that without treatment leads 
to acquired immunodeficiency syndrome (AIDS) and death. The syndrome was first 
described in 1981 (Gottlieb et al., 1981), the virus isolated in 1984 (Gallo et al., 1984) 
and the first anti-HIV drug treatment became available in 1987 (Yarchoan and Broder, 
1989). Over subsequent decades the virus spread across Africa with millions of 
individuals becoming infected and millions dying. In 2014, 35 million people 
worldwide were living with HV, with over two thirds living in Africa (UNAIDS, 2014b). 
During this time, HIV treatment was becoming more widely available, improving the 
health outcomes of HIV positive individuals, however there was a need to improve 
uptake of HIV testing in Africa.  
 
“Good quality HIV counseling and testing services are few and far between, 
clinical care and the resources to treat opportunistic infections are minimal, 
and for most people with HIV and AIDS, there is no access to antiretroviral 
drugs” (Harries et al., 2001)  
 
The situation changed after 2000. International health organisations and National 
Ministries of Health realised there was an urgent need to provide HIV care to the 
millions dying in Africa. HIV services, supported by national governments and 
international donors were massively scaled-up with millions being successfully 
started onto life-saving anti-retroviral treatment. People with HIV were living longer, 
and fewer children were born with HIV.  
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However, whilst many of those with HIV had better access to treatment, millions 
continued to fall between the cracks (UNAIDS, 2014b). Of more concern was that we 
still did not understand how to effectively prevent the millions of new individuals 
becoming infected with the virus (Galarraga et al., 2009). The high incidence, 
combined with high costs of delivering life-long anti-retroviral therapy (ART), now 
threaten the long-term viability of HIV services which have increased delivery of ART 
by twenty-fold since 2003 (UNAIDS, 2012, 2010).   
 
The last few years of HIV prevention research has yielded promising findings. There 
are promising strategies that will effectively prevent new HIV infections. The 
majority of these new approaches revolve around the benefits of anti-HIV drugs in 
terms of significantly reducing the risk of transmission and infection (Abdool Karim 
et al., 2010, Grant et al., 2010, Cohen et al., 2011, Gray et al., 2007a, Granich et al., 
2009). A key requirement of all proposed strategies is high uptake of HIV testing and 
counselling (HTC), with the most promising (early ART for HIV prevention) (Granich 
et al., 2009) having significant requirements for regular repeat testing in order to 
identify HIV infection early.  
 
In Africa human and financial resources are scare. HIV testing services, as currently 
provided, have poor uptake amongst the population (Staveteig et al., 2013). People 
do not like attending health facilities that require them to travel distances and spend 
their own money to visit, and where testing and counseling are offered in very busy 
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places with little privacy (Morin et al., 2006, Kalichman and Simbayi, 2003, WHO, 
2015). Testing for HIV is a life-changing event and has major implications for an 
individual. A large volume of research suggests that offering HIV testing and 
counseling closer to an individual’s home, or in the privacy of their home, would 
significantly increase uptake (Suthar et al., 2013, Sabapathy et al., 2012). However, 
the costs of these services are high, and new approaches are being investigated.  
 
HIV self-testing is seen to offer promise (WHO, 2013b, UNAIDS, 2014a). The first HIV 
oral self-test kit was approved for over the counter sale in the USA in 2012. HIV self-
testing allows individuals to learn their HIV status in privacy, and can be provided 
through a number of flexible delivery strategies. Research in Malawi has identified 
HIV self-testing has high population uptake, and used by those individuals who have 
been traditionally hard to reach by current HIV testing strategies (Choko et al., 2011, 
MacPherson et al., 2014, Choko et al., 2015b). However, there have been no 
empirical investigations into the costs and cost-effectiveness of HIV self-testing to 
inform policy makers on its affordability and value for money.  
 
1.2 Origin of my interest 
In 2007, I worked as a medical doctor in a rural hospital in South Africa. During my 
two years working there, I witnessed the large-scale scale-up of HIV treatment that 
was taking place all over sub-Saharan Africa. As a doctor, I saw many HIV infected 
individuals, and would assess and start anti-retroviral therapy. Some days we would 
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start treatment on as many as 30 individuals who had visited the hospital or one of 
the many primary health care clinics that served the local population.  One of the 
things that struck me, and which is commonly seen in research contexts, was the late 
presentation of HIV infected individuals at the clinics and hospitals. The majority of 
people I saw presented with late stage HIV infection, often presenting with 
Tuberculosis or more severe opportunistic diseases. Many of these individuals had 
only recently had an HIV test or only tested after they presented to the health facility 
with an AIDS defining illness.  
 
HIV testing and counselling was only being offered in the health facilities in the 
region. I then became involved in setting up and evaluating a home and mobile HIV 
testing and counseling service in the region (Maheswaran et al., 2012). In working on 
this programme, I became interested in approaches to evaluating public health 
services. After returning to the UK and beginning my public health training, I 
undertook a Masters degree in health economics. During this degree and the 
Master’s dissertation, I became interested in economic evaluations and decision-
analytic models (Maheswaran and Barton, 2012). I decided to combine these two 
interests, and consequently decided to investigate the cost-effectiveness of HIV self-
testing for my PhD topic.  
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1.3 Research question 
In this PhD, I investigated the cost-effectiveness and broader economic impact of a 
population-level strategy based on providing home-based HIV self-testing in Malawi. 
Specifically, my research question is: 
 
“How cost-effective is home-based HIV self-testing in Blantyre, Malawi?” 
 
1.4 Overview of the PhD thesis 
The thesis consists of nine chapters. Chapter Two provides the context: the location 
of my study, the characteristics of the study population, and it includes an overview 
of HIV infection and the medical consequences of the infection more generally. I also 
provide an overview of the HIV epidemic in sub-Saharan Africa, and in Malawi and 
then describe HIV testing and counseling, how it is provided, and issues regarding 
current uptake of HIV testing in sub-Saharan Africa and, more specifically, in Malawi. 
I further describe HIV self-testing and why it may provide a solution to the problem 
of how to increase uptake of HIV testing in the region. I also provide a description of 
the study population for the studies undertaken in the PhD and the HIV self-testing 
intervention that was being investigated in Blantyre, Malawi (HitTB Study) 
 
Chapter Three provides a review of the literature relating to economic evaluations 
undertaken in sub-Saharan Africa. I provide a description of the growth of this 
research area over the last decade, and of previous economic evaluations of HIV 
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testing and counseling, and other HIV management strategies in sub-Saharan Africa. 
I describe how these influenced my methodological approach to answering my 
research question.  
 
Chapter Four provides an overview of the research question and the methods used 
in answering the research question. I discuss the rationale for my choice of methods 
and their strengths and limitations.  
 
Chapter Five provides a description of the study undertaken amongst those 
accessing facility-based HIV testing and counselling and HIV self-testing (HIVST). The 
aim of the study was to investigate the health provider costs of providing both 
modalities of HTC, the costs incurred by users in accessing the services, and the 
health-related quality of life amongst those who underwent HIV testing.  
 
Chapter Six provides a description of the study undertaken amongst HIV positive 
individuals who accessed HIV treatment after being diagnosed HIV positive. In this 
study, I recruited a cohort of those who tested HIV positive after accessing either 
facility-based HIV testing or HIV self-testing. I provide a description of the costs and 
health-related quality of life impact of accessing HIV care. I investigate whether the 
modality of HIV testing has an impact on health provider costs, on the costs incurred 
by HIV positive individuals as they accessed care, or on the quality of life of HIV 
positive individuals as they accessed HIV care.  
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Chapter Seven provides a description of the study undertaken amongst hospitalised 
patients in the main hospital in Blantyre, Malawi. In this study, individuals admitted 
to the hospital were followed-up during their admission to investigate the health 
provider costs of providing medical care, the costs incurred by patients and their 
families and carers during the hospital admissions, and the health-related quality of 
life of the patients during their hospital admission. The primary aim of this part of 
the thesis was to investigate the economic outcomes associated with providing 
hospital care to those with more advanced HIV infection.  
 
Chapter Eight is the main decision-analytic modeling component of the thesis. In this 
chapter I provide a description of the economic modeling work undertaken to 
investigate the primary research question, and of the economic data collected in the 
preceding chapters to populate the models. The chapter generates estimates of the 
incremental cost-effectiveness of providing HIVST in addition to facility-based HIV 
testing services, in Blantyre, Malawi.  
 
In Chapter Nine I provide a summary of my research, and discuss its strengths and 
limitations. I relate the findings to previous research and discuss implications for 
future research and policy. The Chapter concludes by providing the key conclusions 
of my thesis, and the implications for health policy in Malawi and the region.  
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1.5 Summary of Chapter 1 
In this chapter I have provided a brief introduction to HIV, and HIV testing in Africa. I 
have discussed the changes in HIV and HIV care in Africa, and how my interest in this 
subject arose. I have also provided an overview of the chapters within my PhD.  
 
In the following Chapter I will provide a detailed background to the country of 
Malawi, and the setting the research was undertaken. I will provide an overview of 
HIV and HIV testing, and public health issues relating to them  
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CHAPTER 2: Background 
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2. Overview of Chapter 2 
In this chapter I will briefly describe the country of Malawi. I will provide a detailed 
overview of HIV and of how the infection impacts on an individual’s health. I will 
discuss the progression of HIV disease and the additional illnesses to which 
individuals are susceptible because of the effect of HIV on the immune system.  
 
I will describe the public health impact the HIV epidemic has had on Malawi, and 
how the country’s health care providers have responded. I will discuss the treatment 
of HIV positive individuals and link this to the importance of HIV testing and 
counselling. I will then provide a detailed overview of HIV testing and HIV self-testing.  
 
I will introduce the HITTB study that was investigating the provision of HIV self-
testing in Blantyre, and the population from which I recruited participants to 
investigate my research question. 
 
 
 
 
 35 
2.1 Malawi country profile 
2.1.1 Introduction 
Malawi is a land-locked, low-income country in southern Africa (Figure 1) with a 
population of approximately 16 million and a gross domestic product (GDP) per 
capita of approximately US$250 in 2014 (World Bank, no date, WHO, no date-a). It is 
one of the poorest countries in the world. The country is facing a generalised HIV 
epidemic, which predominantly affects the general heterosexual population. The HIV 
prevalence amongst adults aged 15 to 49 years is approximately 10% (UNAIDS, 
2014b).   
 
Figure 1: Map of Africa 
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2.1.2 The population of Malawi 
The population of Malawi grew from 6 million in 1980 to over 16 million in 2014 
(Figure 2). Approximately half the population are female, and over 80% of the 
population live in rural settings. In Malawi, 40% of the population is aged less than 
15 years, and only 5% is aged over 60 years (Figure 3).  
 
Figure 2: Population characteristics of Malawi 
(Source: World Bank) 
 
Life expectancy at birth in Malawi rose during the 1980’s, but fell during the 1990’s. 
The last decade has seen a significant increase in the life expectancy at birth from 48 
years in 2004 to over 55 years in 2013. Strong evidence suggests that the changes in 
life expectancy over the last 20 years are directly related to the emergence of the 
HIV epidemic in the 1990’s, with subsequent increases in life expectancy directly 
attributable to the scale-up of anti-retroviral therapy in the region (Jahn et al., 2008, 
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Glynn et al., 2014). Mortality and morbidity amongst the population is high, with 
Malawians losing on average 8 years of full health during their lifetime (WHO, no 
date-a). 
 
Figure 3: Population demographics and life expectancy in Malawi  
 
Source: World Bank (no date) 
 
2.1.3 The economy and living standards in Malawi 
Malawi is a low-income country that has experienced slow and fluctuating levels of 
growth in its economy over the last two decades (Figure 4). The gross domestic 
product (GDP) of Malawi grew at a rate approximately 5% in 2014 (World Bank, no 
date). Although the global financial crisis in 2008 affected the Malawian economy, its 
recovery has been in keeping with other countries in the region (Figure 5). The 
country continues to experience high rates of inflation in the prices for consumer 
goods (23.4% in 2014) (Figure 6), and an unstable local currency, the Malawian 
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Kwacha (MWK). The currency was devalued in 2011 and its exchange value against 
the US dollar is approximately 450 MWK (in 2014) (World Bank, no date).  
 
Figure 4: Gross Domestic Product in Malawi from 1980-2014  
Source: World Bank (no date) 
 
Figure 5: Global changes in Gross Domestic Product in comparison to 2010  
 
Source: World Bank (no date) 
 39 
Figure 6: Inflation in consumer prices in Malawi from 1981-2014  
Source: World Bank (no date) 
 
Figure 7 highlights how the economy has historically been built around an 
agricultural base, especially in rural areas where the majority of the population is 
composed of subsistence farmers. Agriculture contributes for approximately a third 
of the GDP in Malawi (in 2014), and accounts for the majority of exports; products 
include tobacco, tea and coffee.  
 
The last two decades have seen a rise in the service industry (Figure 7), coinciding 
with the gradual migration of rural inhabitants to the urban cities (Figure 2). Over 
80% of adults aged 15-64 are economically active. The average income in Malawi 
was approximately US$250 per annum in 2014, with three-quarters of the 
population living on less than US$2 a day (World Bank, no date).  
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Figure 7: Labour force participation and Economic productivity in Malawi 
Source: World Bank (no date) 
 
The Malawian government spends approximately 8% of the GDP on healthcare 
(Figure 8); in 2014 this equated to approximately US$80 per capita per annum 
(World Bank, no date, WHO, no date-a). However, a significant amount of funding 
(approx. 90%) for HIV services in Malawi comes from international donors (World 
Bank, 2010). The last few years have seen a significant loss of budgetary support 
from international donors (Figure 9). This has been partly as a consequence of the 
global financial crisis in 2008 (The aids2031 Consortium 2010).  
 
Living standards in Malawi have improved over the last decade (Figure 10). Only 10% 
of the population has access to electricity, primarily because of lack of infrastructure 
to supply the predominantly rural population. The majority of the population has 
access to clean drinking water. There has also been a significant increase in 
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educational attainment in Malawi, however this has predominantly been seen in 
completion of primary school education and not for secondary educational 
attainment (Figure 11). 
 
Figure 8: Malawian government spending on health and education  
Source: World Bank (no date) 
 
Figure 9: Non-government funding of health services in Malawi  
Source: World Bank (no date) 
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Figure 10: Access to Electricity and Water in Malawi  
Source: World Bank (no date) 
 
 
Figure 11: Educational attainment in Malawi  
Source: World Bank (no date)  
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2.1.4 Health of Malawians  
Table 1 highlights that there have been outstanding improvements in the health of 
the population (WHO, no date-a). This is mainly as a result of reduced maternal and 
childhood mortality (Figure 12), alongside improvements in childhood nutrition and 
immunisations, and reduced incidence and mortality from infectious diseases 
including Tuberculosis and Malaria (Table 1 & Figure 13). Nevertheless this reduced 
mortality from infectious diseases has been partially replaced by an increase in 
mortality from ‘Western’ causes such as hypertension, cardiovascular disease and 
road traffic accidents (Soliman and Juma, 2008, Bowie, 2007, Chokotho et al., 2014). 
However, much of the improved outcomes amongst the adult population in Malawi 
have been attributed to improved provision of HIV care and treatment (Jahn et al., 
2008, Glynn et al., 2014). 
 
Table 1: Malawi‘s Progress on Millennium Development Goals 
Indicator Baseline (2000)* Current (2013)** 
Under-five mortality rate (per 1000 live births)  245 68 
Maternal mortality ratio (per 100,000 live births)  1100 510 
Deaths due to HIV/AIDS (per 100,000 population)  723.1 256.6 
Deaths due to malaria (per 100,000 population)  159.4 59.6 
Deaths due to tuberculosis among HIV-negative people 
(per 100,000 population)  
32 9.3 
Data from World Health Organization (WHO, no date-a)  
*1990: under-five mortality & maternal mortality 
**2012: for deaths due to HIV/AIDS and malaria 
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Figure 12: Changes in mortality rates in Malawi 1980-2014  
Source: World Bank (no date) 
 
Figure 13: Child health and Tuberculosis incidence, Malawi 1980-2014  
Source: World Bank (no date) 
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2.2 Human Immunodeficiency Virus (HIV) 
2.2.1 Introduction 
HIV is a viral infection that is transmitted between humans through sexual contact, 
blood products or from infected mothers to their children during pregnancy or 
breast-feeding. The impact of HIV at the population level differs across regions 
depending on predominant modes of transmission, populations affected and 
treatments available. In sub-Saharan Africa, HIV transmission has mainly been 
amongst the general heterosexual population. As a consequence HIV prevalence in 
some of the most severely affected countries in sub-Saharan Africa is as high as 18%, 
with the prevalence highest amongst economically and sexually active 25-35 year 
olds (Hallett et al., 2010).   
 
2.2.2 Clinical consequences of HIV infection  
HIV infection results in a slowly progressive immunodeficiency syndrome 
characterised by declining levels of CD4 T-helper cells. As a consequence, individuals 
are at increased risk of other communicable and non-communicable diseases, and 
without treatment will die within 8-11 years, on average. The illnesses that HIV 
infected individuals are susceptible to are viewed by many as: (1) AIDS-defining 
diseases; or (2) non-AIDS diseases. AIDS defining diseases are seen as posing a 
particular risk to individuals with HIV because their immune system is already 
significantly weakened. These infections or malignancies are known as 
“opportunistic” as they take advantage of a weakened immune system. Importantly, 
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AIDS-defining illnesses rarely occur in healthy HIV negative individuals. Non-AIDS 
diseases occur in HIV negative individuals, but tend to occur at a higher rate with 
poorer outcomes in HIV infected individuals. These illnesses generally occur during 
the early stages of HIV infection when the immune system is only slightly weakened. 
 
The link between HIV-infection and non-AIDS defining illnesses is more complex. In 
HIV-infected individuals, these illnesses may be more common because of 
complications of treatment, including ART (Group et al., 2007), or because of co-
infection with other infectious agents (Rockstroh, 2006), or simply because of 
chronic immunosuppression. Recent evidence highlights that the risk of non-AIDS 
diseases decreases with increasing CD4+ counts, though to a lesser degree than for 
AIDS-defining diseases (Baker et al., 2008). Importantly, whilst AIDS-defining illness 
occur more commonly when an individual’s CD4 count falls below 200 cell/μl, non-
AIDS diseases are commonly seen in individuals with CD4 counts above 200 cells/μl 
(Baker et al., 2008).   
 
At the beginning of the HIV epidemic, when knowledge of HIV was limited and there 
was an urgent need for monitoring the epidemic as well as understanding clinical 
impact and disease progression, two classification systems were developed: the U.S. 
Centers for Disease Control and Prevention (CDC) classification system (Schneider et 
al., 2008) and the World Health Organization (WHO) Clinical Staging and Disease 
Classification System (WHO, 2007). These two systems continue to be used, 
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especially in resource-poor settings, to provide clinicians and patients with 
important information about HIV disease stage and clinical management. Appendix 
II summarises the WHO and CDC classifications of HIV associated clinical conditions.  
 
The CDC disease staging system assesses the severity of HIV disease in three broad 
categories by CD4 cell count and by the presence of specific HIV-related conditions. 
The definition of AIDS includes all HIV-infections with CD4 counts of <200 cells/µL (or 
CD4 percentage <14%) as well as certain HIV-related conditions and symptoms.  
 
The WHO system classifies HIV disease into four clinical stages on the basis of clinical 
manifestations that can be recognised and treated by clinicians in diverse settings, 
including resource-constrained settings, and by clinicians with varying levels of HIV 
expertise and training. In the following section, I describe the common HIV-
associated medical illnesses. 
 
2.2.2.1 Tuberculosis (TB) 
TB infection can occur in a variety of human organs, commonly in the lungs, brain, 
heart and abdomen. If TB infection results in TB disease of the lungs it is referred to 
as Pulmonary Tuberculosis (PTB). If TB infection results in TB disease that affects any 
organ outside of the lung it is referred to as Extra-Pulmonary Tuberculosis (EPTB).  
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TB is the commonest cause of mortality and morbidity in HIV infected individuals (De 
Cock et al., 1992, Connolly et al., 1999, Mukadi et al., 2001) and remains so even 
after patients are initiated onto ART (Lawn et al., 2005, Lawn et al., 2006, Etard et al., 
2006, Saraceni et al., 2008). The interaction between HIV and TB is very strong. One 
in four individuals dying with TB in sub-Saharan Africa is HIV co-infected, and about 
15% of new TB cases are HIV positive (WHO, 2009a). In resource-poor settings, many 
individuals infected with TB may need hospital care at some point during their illness. 
Individuals infected with TB often present late with severe illness that necessitates 
admission to hospital. Individuals may also be admitted to hospital for further 
diagnostic investigation, whilst in many resource-poor settings those needing re-
treatment for TB are given their treatment in hospital.  
 
2.2.2.2 Common infections  
Bacterial Pneumonia is one of the commonest causes of mortality and morbidity in 
resource-poor settings (Murray et al., 2012, Lozano et al., 2012), with excess rates 
seen in people with HIV infection (Polsky et al., 1986, Hirschtick et al., 1995). Risk 
increases with decreasing CD4 cell count (Boschini et al., 1996).  
 
Bacterial meningitis is a common cause of death in resource-poor settings (Murray 
et al., 2012, Lozano et al., 2012). Streptococcus pneumonia is the most common 
causative organism. HIV infected individuals are at increased risk of developing 
bacterial meningitis (Gilks et al., 1996).  
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Urinary Tract infections have higher incidence in those infected with HIV, with early 
evidence suggesting that the risk increases with falling CD4 count (Evans et al., 1995).   
 
Salmonellosis is a bacterial infection from contaminated food or water, and is also 
found more commonly in people who are HIV-positive (Gordon et al., 2002). 
 
2.2.2.3 Opportunistic infections – AIDS defining  
Cryptococcal meningitis is a common opportunistic infection in the central nervous 
system associated with HIV. It is caused by a fungus that is present in soil. Individuals 
nearly always need hospital admission for treatment, and despite this mortality 
remains high (Jarvis et al., 2014). Infection mainly appears in HIV-infected individuals 
when their CD4 count falls below 100 cells/μl (Jarvis and Harrison, 2007). 
 
Pneumocystis Carinii Pneumonia (PCP) is an opportunistic infection of the lungs that 
occurs in the late stages of HIV infection and is associated with very high mortality 
(Phair et al., 1990).  
 
Candidiasis is a common HIV-related infection. In HIV infected individuals it is often 
localised to the mouth or throat, or oesophagus. Whilst the associated risk of 
mortality is low, infection affects an individual’s ability to eat (Sangeorzan et al., 
1994).  
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2.2.2.4 Common cancers and other complications – AIDS defining 
Kaposi's sarcoma is a tumor of the blood vessel walls, and the commonest HIV-
associated malignancy. Kaposi's sarcoma can also affect the internal organs, 
including the digestive tract and lungs. The incidence has reduced significantly with 
the introduction of ART (Brodt et al., 1998).  
 
Wasting syndrome is defined as an involuntary weight loss of >10%, and is 
commonly, but not necessarily, associated with chronic diarrhoea (Mangili et al., 
2006).   
 
Neurological complications: one of the most common neurological complications is 
AIDS dementia complex, which leads to behavioural changes and diminished mental 
functioning (Nath et al., 2008). 
 
2.2.3 HIV care and treatment 
The advent of anti-retroviral therapy (ART) has had a major impact. ART consists of a 
combination of anti-retroviral drugs that reduce HIV viral loads, allowing an 
individual’s immune system to recover. ART has become increasingly available in 
sub-Saharan Africa. In 2003 there were only about 100,000 people with access to 
treatment (WHO, 2004). How we provide HIV treatment in Africa has evolved over 
the last few years with HIV infected individuals being initiated earlier and earlier 
onto anti-retroviral treatment (Figure 14) (WHO, 2009b, WHO, 2010b, WHO, 2014, 
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UNAIDS, 2014b). There are now over 9 million individuals alive on treatment, 
however this still only accounts for about one third of those in need of ART (UNAIDS, 
2014b). 
 
Figure 14: WHO guideline changes for ART initiation and numbers of Africans on ART 
 
 
The successful scale-up of ART in sub-Saharan Africa has had a major impact on the 
health outcomes of those affected (May et al., 2010a). HIV infected individuals in the 
region have life expectancies comparable to HIV uninfected individuals with timely 
initiation of ART (Johnson et al., 2013, Mills et al., 2011). They also have a 96% 
reduction in the risk of transmission to uninfected sexual partners (Cohen et al., 
2011). ART also reduces the risk of HIV associated illnesses (Ledergerber et al., 1999, 
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Palella et al., 1998). Figure 15 shows data from high-income settings highlighting the 
fall in incidence of many AIDS-defining illness after initiation of ART (Ledergerber et 
al., 1999). In sub-Saharan Arica, initiation of ART has been found to reduce the risk of 
HIV associated illnesses and progression to AIDS (Lawn et al., 2006, Jarvis and 
Harrison, 2007, Badri et al., 2006a, Ford et al., 2010).  
 
Figure 15: Impact of starting anti-retroviral drugs on the risk of developing HIV-associated 
comorbidities* 
*Figure taken from: Ledergerber et al., 1999 
   
HIV treatment in Malawi and many countries in sub-Saharan Africa is provided 
utilising the WHO’s public health approach to scaling-up access to anti-retroviral 
therapy (Gilks et al., 2006). The majority of care is provided by health professionals 
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other than doctors, using a simplified approach to assessing patient’s eligibility for 
treatment and subsequent management on anti-retroviral therapy (Malawi MoH, 
2011a).  
 
The cost of providing ART in sub-Saharan Africa, whilst low in comparison to costs in 
high-income countries, represents a considerable burden and is likely to increase 
over the coming years (The aids2031 Consortium 2010). The continued high HIV 
incidence and improved outcomes in those already initiated will result in an ever-
expanding treatment population and in larger numbers needing more costly second 
and third-line drug regimens.  
 
In addition the WHO guidelines for when to initiate individuals onto ART have been 
continually updated. At the time of starting this PhD the World Health Organisation 
(WHO) recommended initiating ART when an individual’s CD4 count falls below 350 
cells/μl, unless there are clear benefits of earlier initiation on HIV transmission, 
namely amongst pregnant women or where an individual’s sexual partner is HIV 
negative (WHO, 2013a). The WHO updated their guidelines in 2014 advising 
initiation of ART in individuals whose CD4 count was below 500 cells/μl (WHO, 2014). 
Taking into account recent evidence that suggests immediate initiation of ART in all 
those infected with HIV (Cohen et al., 2011, Group et al., 2015b, Group et al., 2015a), 
it is likely all of the 25 million HIV infected individuals in the region will need access 
to ART.  
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2.3 The HIV epidemic in sub-Saharan Africa and Malawi 
2.3.1 HIV in sub-Saharan Africa 
In 2014, over 35 million people are currently living with HIV worldwide, whilst HIV 
accounts for 10.7% and 14.7% of deaths in 15-49 year old men and women, 
respectively (UNAIDS, 2014b, Murray et al., 2014). Figure 16 shows the number of 
people currently living with HIV worldwide, and highlights the disproportionate 
burden in sub-Saharan Africa, especially in Southern Africa, where Malawi is located.    
 
 
Figure 16: Number of people living with HIV 
Source: (UNAIDS, 2013a) 
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In most parts of sub-Saharan Africa, HIV remains the most common cause of years of 
life lost due to premature mortality and years lived with disability (Murray et al., 
2012). In 2012, an estimated 7 million Africans were on anti-retroviral treatment 
(ART); however, 1.2 million lives were lost to HIV/AIDS and 1.6 million people were 
newly infected in the region (UNAIDS, 2013a). Figure 17 highlights that despite the 
large numbers on ART, the majority of people living with HIV in sub-Saharan Africa 
do not have access to treatment. Despite the scale-up of HIV prevention and 
treatment services, HIV associated co-morbidities continues to place a significant 
financial burden on health systems in the region (Padian et al., 2011).  
 
Figure 17: Percentage of people living with HIV who are receiving anti-retroviral therapy 
Source: (UNAIDS, 2013a) 
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2.3.2 Malawi and HIV 
Malawi has been severely affected by the HIV epidemic with an HIV prevalence of 
approximately 11%, and as high as 18% in urban areas (WHO, no date-a, Choko et al., 
2011). Its transmission is predominantly heterosexual (UNAIDS, 2012).  
 
In 2004, Malawi scaled up its HIV services by providing free HIV care, decentralised 
from hospitals to primary health clinics, and by shifting much of the clinical 
responsibilities of care to non-physician clinicians, nurses and lay workers 
(Bemelmans et al., 2010, Lowrance et al., 2008). This has enabled Malawi to achieve 
higher anti-retroviral treatment coverage than many of its better-resourced 
neighbouring countries (Bemelmans et al., 2010, UNAIDS, 2012), with comparable 
individual-level health outcomes (Weigel et al., 2012), and a significant beneficial 
impact on population-level mortality (Floyd et al., 2010). Malawi supports its HIV 
treatment and prevention services primarily from funds provided by international 
donors, which currently account for over 90% of the HIV budget (MoH, 2012).   
 
By 2010, the Malawian health sector had successfully initiated ART in approximately 
300,000 HIV positive individuals and was offering HIV testing to approximately 1.2 
million individuals per year (MoH, 2011b, MoH, 2012). While all this has been 
achieved at relatively low cost, the WHO revised its guidelines in 2010, and again in 
2013. On both revisions, the WHO has progressively recommended earlier and 
earlier initiation of ART (WHO, 2010c, WHO, 2013a). This has led not only to a 
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significant increase in the number of HIV positive individuals in need of ART, but now 
means that nearly 95% of people living with HIV should be starting ART for their own 
individual benefit.  
 
Figure 18 shows the estimated number of HIV positive individuals living in Malawi 
(UNAIDS, 2012, UNAIDS, 2013a, UNAIDS, 2014b), the number of HIV positive 
individuals initiated onto ART every three months and the total number alive and 
receiving ART (MoH, 2014). Figure 18 shows that despite the numbers being initiated 
onto ART in Malawi, ART coverage at the population level remains below 50%. The 
most recent UNAIDS estimates suggests that about one half of those in need of ART 
do not currently receive treatment (UNAIDS, 2012). In 2014, approximately 540,000 
Malawians were alive and receiving anti-retroviral therapy for their HIV infection. 
However, HIV testing services were not testing more individuals, reaching more first 
time HIV testers or detecting more HIV positive individuals than in 2010 (Figure 19) 
(MoH, 2014).  
 
Malawi needs to not only sustain current efforts in providing anti-retroviral therapy, 
but to increase provision and uptake of HIV testing services, which remain sub-
optimal (Macpherson et al., 2012c).  
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Figure 18: Number of Malawians living with HIV, on ART and newly initiated onto ART 
 
Source: Malawi MoH; UNAIDS 
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Figure 19: Provision and uptake of HIV testing and counseling (HTC) services in Malawi 
 
Source: Malawi MoH; UNAIDS 
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2.4 Financing HIV services  
HIV programmes in sub-Saharan Africa have seen significant increases in funding 
through both international donors and domestic public sources. Figure 20 shows 
that over the last decade, funding for HIV programmes in low and middle-income 
has increased by approximately five-fold, with an estimated US$ 19 billion spent 
annually, with approximately US$10 billion coming from International funding 
organisations (UNAIDS, 2013a). Countries in Eastern and Southern Africa account for 
approximately one half of all HIV-related spending. Care and treatment services 
consume 55% of HIV expenditure (UNAIDS, 2013a).  
 
Figure 20: Funding of HIV programmes in low and middle-income countries in the last 
decade 
Source: (UNAIDS, 2013a) 
 
Whilst the last decade has seen year on year increases in available funds for HIV 
programmes in the region, there are concerns over the long-term sustainability of 
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these programmes, which are heavily reliant on international funding sources (The 
aids2031 Consortium, 2010). This is likely to rise over the coming years with strong 
evidence suggesting that initiating ART in HIV infected individuals earlier than 
current recommendations, effectively immediate initiation of treatment once HIV 
diagnosis is known, improves health outcomes (Group, 2015b, Group, 2015a). Even 
without considering the financial impact of immediate initiation of ART, the costs of 
providing HIV treatment is expected to increase substantially over the coming few 
years (Figure 21). This has increased the need to monitor and evaluate HIV financial 
resources critically over time as part of the overall response to the HIV pandemic, 
especially in countries that already have limited resources and a higher burden of 
HIV infection. 
 
Figure 21: Forecasts for spending on HIV services in Africa (2015-2030)   
Source: UNAIDS, 2015 
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2.5 HIV testing and counselling 
2.5.1 Introduction 
HIV testing is the critical first step in accessing HIV treatment and care, and presents 
an ideal opportunity to facilitate timely access to HIV prevention and treatment 
services. HIV testing and counselling (HTC) is where an individual who wants to learn 
their HIV status is offered counselling before and after undergoing HIV testing. The 
counselling informs individuals of the risks and benefits of undergoing HIV testing, 
and about HIV treatment and prevention services available to them. There is some 
evidence to suggest amongst those who subsequently test HIV positive, HTC has a 
beneficial effect on reducing high-risk sexual behaviours; this benefit is not evident 
amongst those who subsequently test HIV negative (Fonner et al., 2012).  
 
However, HTC has grown in importance with the recent publication of several 
studies supporting the efficacy of biomedical HIV prevention strategies (Gray et al., 
2007a, Abdool Karim et al., 2010, Granich et al., 2009, Grant et al., 2010, Cohen et al., 
2011). The evidence suggests that HIV infected individuals who are well managed on 
ART are unlikely to transmit HIV to their uninfected sexual partners (Cohen et al., 
2011). Additionally, HIV negative individuals who undergo male circumcision or the 
use of ARV drugs as pre-exposure prophylaxis (either orally or as a topical vaginal 
microbicidal agent) are at reduced risk of acquiring HIV infection (Grant et al., 2010, 
Gray et al., 2007a).  
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At the population level, using a combination of these strategies, or though providing 
all HIV infected individuals with ART as soon as they are known to be HIV positive, 
may reverse the HIV epidemic (Padian et al., 2011, Granich et al., 2009, Powers et al., 
2011a). However, for the majority of these strategies to work, individuals need to 
know their HIV status, posing significant requirements for not just offering HIV 
testing, but also for frequent re-testing. 
 
2.5.2 Approaches to HIV testing and counselling 
The way in which HIV testing and counselling (HTC) is delivered has evolved over the 
last 20 years. In sub-Saharan Africa, HTC services were implemented in health 
facilities in the 1990s primarily through the voluntary counselling and testing (VCT) 
modality that required individuals to visit facilities and request an HIV test (Cooper 
et al., 2007).  
 
The increasing availability of affordable anti-retroviral drug regimens in the region, 
the low uptake of HIV testing and the need to prevent transmission of HIV from 
mothers to their uninfected children, coupled with the finding that much of the 
morbidity and mortality associated with HIV was attributable to TB (Connolly et al., 
1999, Mukadi et al., 2001), shifted the focus of HIV testing away from VCT to 
provider-initiated HIV testing and counselling (PITC) (Nash et al., 2011).  
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PITC puts the emphasis on healthcare providers to offer the option of HTC actively to 
all their clients. However, uptake of HTC remained low in the region, with only 40% 
of people living with HIV aware of their HIV status (Staveteig et al., 2013), and only 
37% of those eligible for ART receiving treatment (UNAIDS, 2014b).  
 
2.5.3 Community-based HIV testing and counselling 
Increasingly, it has been recognised that whilst the majority of people want to test 
for HIV, the lack of confidentiality, social barriers, and cost and inaccessibility 
associated with facility-based testing act as deterrents (Kalichman and Simbayi, 2003, 
Wolff et al., 2005, Morin et al., 2006, Wringe et al., 2009, Angotti et al., 2009). This 
tension between confidentiality and convenience has led many to investigate the 
potential role of home-based and mobile HTC services.  
 
Home-based HTC offers promise by bringing HIV testing to individuals in the privacy 
of their homes (Fylkesnes and Siziya, 2004, Bateganya et al., 2007, Were et al., 2003, 
Maheswaran et al., 2012, Molesworth et al., 2010). Mobile HTC services take HIV 
testing from overcrowded health facilities to places near individuals’ homes 
(Maheswaran et al., 2012, Morin et al., 2006, Bassett et al., 2014, Ostermann et al., 
2011, Labhardt et al., 2014, Sweat et al., 2011).  
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Home-based and mobile HTC services have been found to be acceptable, feasible 
and effective in identifying HIV infected individuals, with increased testing 
completion rates, different populations reached and increased population coverage 
compared to facility-based HTC services. (Were et al., 2003, Wolff et al., 2005, 
Tanser et al., 2008, Menzies et al., 2009, Negin et al., 2009, Amolloh et al., 2011, 
Tumwesigye et al., 2010, Sabapathy et al., 2012, Maheswaran et al., 2012, Suthar et 
al., 2013, Bassett et al., 2014). When home-based and mobile HTC services have 
been provided to communities, overall awareness and disclosure of HIV status is 
increased and good linkage to ART services achieved (Nuwaha et al., 2009, 
Sabapathy et al., 2012, Tumwesigye et al., 2010, Amolloh et al., 2011, Labhardt et al., 
2014, Sweat et al., 2011, Suthar et al., 2013). Recently they have been found to be 
potentially cost-effective strategies in Africa (Smith et al., 2015, Bassett et al., 2014).   
 
This has led the WHO to actively encourage the scale-up of home-based and mobile 
HTC services in sub-Saharan Africa (WHO, 2012). However, provision has been 
limited, possibly related to concerns about its sustainability and cost-effectiveness 
(Sabapathy et al., 2012, Suthar et al., 2013). 
 
2.5.4 HIV self-testing  
There has been a recent interest in investigating the role of oral HIV self-testing 
because of the WHO recommendations that most adults living in high HIV prevalent 
settings should re-test for HIV at regular intervals (UNAIDS, 2012), and the recent US 
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Food and Drug Administration (FDA) approval of over the counter oral HIV self-test 
kits (Walensky and Bassett, 2011, Myers et al., 2013).  
 
Oral HIV self-testing involves individuals testing themselves using an oral swab, 
wiping the inside of their mouth and then waiting fifteen minutes before 
interpreting their test result. HIV counsellors using rapid finger-prick tests currently 
do the HIV testing in sub-Saharan Africa. Oral self-testing adds to the confidentiality 
of the HIV testing process by reducing the involvement of counsellors.  
 
Oral self-testing for HIV has been found to be feasible, acceptable and accurate in 
sub-Saharan Africa. In Blantyre, Malawi, the provision of HIV self-testing through 
resident community counsellors achieved annual uptake of HIV testing amongst 
community residents of approximately 75% for the two years the service was 
provided (Choko et al., 2015b). Importantly, it achieves high uptake amongst 
“difficult-to-reach” groups of men, couples and repeat testers (Zachary et al., 2012, 
Napierala Mavedzenge et al., 2013, Pant Pai et al., 2013, Choko et al., 2011).  
 
The first major study investigating the population uptake and coverage of HIV self-
testing services was recently published in PLOS Medicine. The peer-reviewed 
publication, which I co-wrote, is shown in Appendix III. In addition, a separate peer-
reviewed publication in the Journal of the American Medical Association examining 
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the potential of offering home-assessment and initiation of anti-retroviral therapy 
after HIV self-testing, for which I undertook the costing component of the study, is 
shown in Appendix IV.  
 
HIVST has the potential of increasing the feasibility of implementing home-based HIV 
testing programmes at relatively low cost (WHO, 2013b). However, there is a need to 
better understand the costs and cost-effectiveness associated with its provision 
(Mavedzenge et al., 2013, Choko et al., 2015b). 
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2.6 Study sites and study populations 
2.6.1 Study site: Blantyre, Malawi 
Blantyre is the second city of Malawi, after the capital Lilongwe, and is located in the 
southern region of Malawi (Figure 22). In 2008, when the last national census in 
Malawi was conducted, the population of Blantyre City was approximately 660,00, 
with a total population of just over one million when the suburbs of the city were 
taken into account (National Statistics Office, 2010).  
 
HIV prevalence amongst adults in Blantyre has recently been estimated to be 
approximately 18% (Choko et al., 2011). In the city an estimated 10% of adults are in 
formal full-time employment (Choko et al., 2011), although a large proportion of the 
population are in informal employment (World Bank, no date). 
 
Residents of Blantyre can access free healthcare at their local primary health clinics, 
or at the Queen Elizabeth Central Hospital (QECH). Residents also have access to 
private healthcare through two private hospitals: the Mwaiwanthu Private Hospital 
and the Seventh-day Adventist Hospital. The primary health clinics provide 
outpatient care for the local population, including HIV testing and counselling (HTC), 
and HIV treatment. HTC and HIV treatment are also provided to outpatients at QECH.  
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Figure 22: Map of Malawi and Location of Blantyre City 
 
 
2.6.2 HitTB study  
2.6.2.1 Introduction to HitTB study 
The HitTB study is a community cluster randomised trial of approximately 34,000 
adults (ISRCTN02004005). The main objective of the trial is to investigate the impact 
on adult mortality of provision of intensified HIV and TB prevention services. The 
trial provides residents of communities randomised to the intervention with access 
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to home-based HIVST, and with facilitated linkage into HIV and TB treatment and 
prevention services.   
 
2.6.2.2 HIV self-testing in the HitTB study 
In the HitTB study, resident community counsellors provide HIVST to adults aged ≥16 
years. They advertise the service and distribute the HIV self-test kits. Residents who 
want to undergo HIVST visit the locally resident counsellors to receive pre-test 
counselling for HIV, and directions on how to use the HIV self-test kits. Residents 
who demonstrate they are able to perform the self-test are given a HIV self-test kit 
to take home and test on their own. Residents are also given generic post-test 
counselling and referral cards to enable linkage into their local HIV treatment center. 
The post-test counseling and referral process is not specific to HIV status, and 
therefore ensures individuals do not have to disclose their test result to the 
counsellor.  
 
The HIVST is provided using the OraQuick ADVANCE HIV I/II (OraSure Technologies, 
Bethlehem, USA) test kits. This is the first, and currently the only, HIV self-test kit 
that has obtained approval from the Federal Drug and Administration in the USA for 
over the counter sale. The self-testing process involves the individual rubbing the 
inside of their mouth with the oral test kit, and then waiting for 15 minutes before 
reading the test result.  
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2.6.2.3 HitTB cluster-randomised trial 
In the trial, neighbourhoods were defined on the basis of existing community 
catchment areas. The catchment areas are used by local community health services 
to divide the local population into smaller catchments for their health workers to 
provide community-based services. In the trial, the communities were enumerated 
before providing the intervention to determine the age and sex distribution of the 
population, and total population size.  Global position systems (GPS) were used to 
map the boundaries of the communities.  
 
The resulting trial compromised a total adult population of 34,000 people (≥16 year 
of age), with the population divided into 28 study clusters. On average, clusters were 
compromised of 1,200 adults. Clusters were randomised on a 1:1 basis, with 14 
clusters randomised to receive standard facility HTC, and 14 clusters to HIVST (Figure 
23). Individuals residing in the intervention clusters could also access standard 
facility-based HTC. HIVST was provided for a 2-year period in each of the 
intervention clusters and the service was gradually introduced from February to May 
2012.  In the trial, the primary evaluation involves investigating the impact on adult 
mortality and undiagnosed HIV, all of which are being evaluated at the time of 
writing, with the findings still blinded. This is being undertaken through a post-
intervention surveillance study.  
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Figure 23: Map of Blantyre City and HitTB Study Clusters 
 
 
2.6.2.3 Provision of HIV care and treatment in HitTB study 
The trial residents could access HIV testing and treatment services at their local 
primary health clinics (Ndirande or Chilomoni) or through the outpatient clinic at 
Queen Elizabeth Central Hospital. HIV counsellors provide HIV testing and 
counselling (HTC) at these outpatient clinics.   
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Individuals may attend the clinics for the primary purpose of undergoing an HIV test, 
or they may be at the clinic for a medical reason (e.g Tuberculosis; antenatal care) 
and be referred to the HIV counsellors for HTC. The HIV counsellors provide 
counselling, and if the individual consents, HIV testing. Individuals who test HIV 
negative on the first rapid finger-prick test are informed they are HIV negative. 
Individuals who test HIV positive on the first finger-prick test have a repeat finger-
prick test using an alternative rapid test kit. Individuals who subsequently test HIV 
positive are informed of their HIV positive test result and asked to return to the HIV 
treatment clinic at a given appointment date. On this return visit, individuals 
undergo confirmatory HIV testing and subsequent assessment for eligibility for 
initiation of ART.  
 
The decision to start ART and which anti-retroviral drug regimen to provide are 
based on Malawi National ART guidelines (MoH, 2014). The assessment for ART 
eligibility involves an assessment of their HIV clinical disease stage, this follows the 
WHO HIV disease staging approach. Those who are found to have advanced HIV 
disease stage (WHO stage 3 or 4) are immediately started onto ART. All individuals 
have venous blood taken for assessment of their CD4 count. Individuals who do not 
have advanced HIV disease (WHO stage 3 or 4) are initiated onto ART if their CD4 
count is below 350 cell/ul or if they are pregnant (MoH, 2014).  
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Individuals who are started onto ART are provided with sufficient anti-retroviral 
drugs to last until their next appointment date. Individuals who are not found 
eligible to start ART are entered into pre-ART care. Pre-ART care involves provision of 
cotrimoxazole preventative (CPT) and Isoniazid preventative therapy (IPT). They 
undergo repeat CD4 measurements every 6 months for re-assessment of eligibility to 
start ART.  The nurse sees individuals who are started onto ART on each and every 
repeat visit for HIV clinical assessment and ART drug adherence. If any clinical 
problems manifest they are referred to the clinical officer or medical doctor at the 
clinic for further assessment. If no problems are found they are provided with their 
next supply of anti-retroviral drugs. The interval between each subsequent visit to 
the clinic may be gradually extended if the patient has good adherence to therapy 
and no HIV clinical disease progression.  
 
2.6.3 Queen Elizabeth Central Hospital 
Queen Elizabeth Central Hospital (QECH) is the largest hospital in Malawi. The 
hospital is based in the centre of Blantyre and provides a combination of primary, 
secondary and tertiary level medical care. QECH has approximately 1,500 beds, and 
admits approximately 25,000 adult patients per year. The hospital serves a 
population of approximately 1 million in the Blantyre District, with many of its 
tertiary referrals coming from further afield. The HIV prevalence among inpatients in 
QECH has previously been reported as high as 70% in patients admitted to medical 
wards and 36% in patients admitted to surgical wards (Lewis et al., 2003, SanJoaquin 
et al., 2013). 
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2.6.4 Primary health clinics: Ndirande and Chilomoni 
Ndirande and Chilomoni health centers are both located in the city of Blantyre, and 
are the two clinics that serve residents of the HitTB trial. Both are primary health 
centers where local residents visit for initial medical assessment and to access a 
range of outpatient based medical care. The clinics provide HIV testing and HIV 
treatment, as well as other primary health services including: immunizations; 
maternal and child services; family planning; and care for patients with Tuberculosis. 
The HIV testing services acts as stand-alone HIV testing facilities, with individuals 
able to visit the testing center without medical referral, or visit the center after being 
referred by medical personnel. Individuals who test HIV positive are then referred to 
the HIV treatment center at the respective health facility.  
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2.7 Summary of Chapter 2 
In this chapter I provided an overview of the country of Malawi, and highlighted the 
economic constraints the country faces, including the low levels of funding available 
to fund its health services and dependency on the international community to 
sustain the health of its population. I provided an overview of HIV and its impact on 
an individual’s health. I highlighted the range of HIV associated illnesses that HIV 
positive individuals suffer from and how providing ART can improve their health. I 
also described the HIV epidemic in Africa and Malawi, and the current response to 
the epidemic in the region. I highlighted that despite the major efforts made in 
tackling the HIV epidemic in the region, millions continue to die. I highlighted that 
despite the major advances in the provision of HIV care a major limitation has been 
the poor uptake of HIV testing.  
 
I provided a description of HIV testing and its evolution over the last few decades, 
including the emergence of HIV self-testing as a potential solution to meeting the 
current and future demands on increasing awareness of HIV status and subsequent 
uptake of increasingly efficacious interventions that could potentially end the 
epidemic in the region. I ended by providing a description of the HIV self-testing 
study and study sites that I am utilising to collect primary economic data to answer 
my primary research question. In the next chapter I will provide a detailed overview 
around economic evaluations targeted at HIV and HIV testing in sub-Saharan Africa. 
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CHAPTER 3: Methodological Issues 
around Economic Evaluations of 
HIV interventions in sub-Saharan 
Africa 
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3. Overview of Chapter 3 
There have been several recent systematic reviews of economic evaluations of HIV 
interventions related to sub-Saharan Africa. In this Chapter I review the findings 
from these systematic reviews, and specific economic evaluations of HIV prevention 
and treatment interventions in order to highlight potential issues relating to 
undertaken them. I also provide a targeted review of previous approaches to 
undertaking decision-analytical modelling of HIV interventions. The findings from 
this appraisal were then used to develop the methods that address my primary 
research question.  
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3.1 Economic evaluations in resource-poor sub-Saharan settings 
3.1.1 Introduction 
There has been a significant increase in the number of economic evaluations of HIV-
related interventions in sub-Saharan Africa (Creese et al., 2002, Walker, 2003, 
Scotland et al., 2003b, Uthman et al., 2010, Galarraga et al., 2009, Gomez et al., 2013, 
Sweeney et al., 2012, Johri and Ako-Arrey, 2011, Remme et al., 2014, Santa-Ana-
Tellez et al., 2011).  
 
One of the earliest reviews in this field examined economic evaluations of HIV 
treatment and prevention interventions undertaken in Africa from 1984-2000 
(Creese et al., 2002). Further systematic reviews were undertaken to examine the 
cost-effectiveness of HIV prevention strategies in resource-poor strategies (Walker, 
2003, Galarraga et al., 2009), including the cost-effectiveness of interventions to 
prevent mother to child transmission of HIV (PMTCT) (Scotland et al., 2003a, Johri 
and Ako-Arrey, 2011).  
 
More recently, reviews have focussed on components of HIV treatment and 
prevention including examining the cost-effectiveness of providing voluntary male 
circumcision (Uthman et al., 2010), pre-exposure prophylaxis for HIV prevention 
(Gomez et al., 2013), interventions to improve outcomes amongst AIDS orphans and 
vulnerable children (Santa-Ana-Tellez et al., 2011) and gender-responsive 
interventions for HIV (Remme et al., 2014).  
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3.1.2 Findings from previous reviews 
A common finding of many reviews around economic evaluations in HIV has been 
the lack of relevant health outcomes and cost data available for such evaluations 
(Galarraga et al., 2009, Kahn et al., 2011, Creese et al., 2002, Beck et al., 2010, 
Meyer-Rath and Over, 2012). Additionally, there has been concern around the lack 
of transparent, comparable and standardised methods for evaluations in the region 
(Galarraga et al., 2009, Walensky et al., 2010a, Loubiere et al., 2010, Uthman et al., 
2010, Beck et al., 2010). Several evaluations have not captured the long-term 
consequences of interventions (Simpson, 2010) (Weatherly et al., 2009, Kelly et al., 
2005), the real world costs of implementing interventions (Creese et al., 2002, Beck 
et al., 2010) or the uptake/performance of the intervention at the population level 
(Kahn et al., 2011, Schwartlander et al., 2011, Uthman et al., 2010).  
 
This has led to concerns about potential bias in findings and in the ability to make 
comparisons across interventions and settings, and these (largely valid) criticisms 
have reduced the desired impact on rational decision-making (Beck et al., 2010).  In 
addition, the lack of routinely collected cost data by healthcare providers 
necessitates the collection of ad hoc data which may be inaccurate or applicable only 
to specific settings, thus reducing generalisability and potentially introducing 
inaccuracies (Beck et al., 2010). Another factor is that notwithstanding the problems 
of generalising between settings, this is often necessary because of the scarcity of 
local cost-effectiveness data. 
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Finally, the human and financial resources needed to undertake evaluations in a 
resource-constrained setting may deter such analyses. A common theme from 
previous reviews has been the predominant use of decision-analytic modelling to 
undertake economic evaluations (Creese et al., 2002, Johri and Ako-Arrey, 2011, 
Uthman et al., 2010). Many of these issues are common to economic evaluations in 
general; however, appropriate solutions may differ depending on context, resources 
and setting (Kelly et al., 2005).  
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3.2 Economic evaluations of HIV testing strategies  
3.2.1 Introduction 
The benefits of timely initiation of ART and continued low uptake of HIV testing 
through traditional facility-based approaches in Africa highlights the need to 
investigate modalities and strategies to increase uptake of HIV testing (Labhardt et 
al., 2014, Suthar et al., 2013, Sabapathy et al., 2012, Lugada et al., 2010). However, 
policy makers need to be aware of the potential value for money from investing in 
these different approaches so that the limited resources they have available to 
provide these services can be optimised (WHO, 2015).  
 
3.2.2 Comparing costs of different HIV testing strategies 
Table 2 shows the findings from two costing studies that compared the cost of 
providing home-based or mobile HIV testing to facility-based provision of HTC 
(Menzies et al., 2009, Grabbe et al., 2010). In both studies, facility-based provision of 
HTC was associated with higher costs than provision of HIV testing through home-
based or mobile services as a consequence of the higher capital costs associated 
with managing a health facility (Menzies et al., 2009, Grabbe et al., 2010). However, 
the higher HIV prevalence amongst health facility testers results in HIV infected 
individuals, unaware of their status, being identified at a lower cost than through 
home-based or mobile HTC services (Menzies et al., 2009, Grabbe et al., 2010). 
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Table 2: Comparison of costs of HIV testing through different modalities 
 Grabbe et al., 2010 
Kenya 
Menzies et al., 2010  
Uganda 
 
2007 US Dollars 
 
2007 US Dollars 
  
 Stand-alone 
testing facility 
Mobile testing 
service  
Stand-alone 
testing facility 
Hospital-based  Household-member  
(contact tracing) 
Home-
based  
       
Cost per HTC client  $26.75 $14.91 $19.26 $11.68 $13.85 $8.29 
Cost per new HTC client $43.69 $16.58 $29.70 $14.73 $14.54 $9.21 
Cost per HIV positive individual 
identified 
$189.14 $157.21 $100.59 $43.10 $231.65 $163.93 
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3.2.3 Community-based HIV testing strategies 
Community-based HTC services have been found to be popular. (Were et al., 2003, 
Wolff et al., 2005, Tanser et al., 2008, Menzies et al., 2009, Negin et al., 2009, 
Amolloh et al., 2011, Tumwesigye et al., 2010). Table 3 highlights the different 
estimates for the costs of providing HIV testing in the communities, with costs 
ranging from US$2.45 to US$33.54 (in 2012 prices) (Suthar et al., 2013). The 
approaches to quantifying the costs of community-based HIV testing strategies have 
also differed, with many analyses not taking into account the costs of all resources 
used in the provision of the service (Table 3).   
 
These analyses only provide estimates of the costs of getting individuals tested 
(Table 3) (Suthar et al., 2013).  As will be highlighted in Chapter 4 of the PhD (Figure 
24), this type of economic analysis would be considered a partial evaluation.  
 
The cost of providing community-based HIV testing services may be lower than 
facility-based HTC, whilst the cost to detect HIV positive individuals through 
community-based HTC may be higher (Table 2). This information alone can be 
misleading as it fails to take into account the consequences of HIV testing, namely of 
the costs and health outcomes after learning ones HIV status.  
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Table 3: Comparison of costs of community-based HIV testing strategies 
Study Modality of 
HTC 
Country Resources included in cost 
estimates 
Cost per HTC Client 
(2012 US dollars) 
Molesworth et 
al., 2010  
 
Home-based Malawi 
 
Testing supplies  $2.45 
 
Tumwesigye et 
al., 2010  
 
Home-based Uganda Testing supplies, personnel, 
and transportation  
$7.77 
Menzies et al., 
2009  
Home-based Uganda Testing supplies, personnel, 
transportation, vehicles, 
buildings, utilities, training, and 
equipment  
 
$9.16 
Negin et al., 
2009  
Home-based Kenya Testing supplies, personnel, 
and transportation  
 
$9.43 
Helleringer et 
al., 2009 
Home-based Malawi Testing supplies, personnel, 
transportation, buildings, 
utilities, and training  
 
$14.37 
Menzies et al., 
2009 
Contact 
tracing 
Uganda Testing supplies, personnel, 
transportation, vehicles, 
buildings, utilities, training, and 
equipment  
 
$15.30 
Edgil et al., 
2011 
Mobile Swaziland Testing supplies  $3.26 
Chamie et al., 
2014  
Mobile Uganda Testing supplies, personnel, 
and buildings  
 
$8.27 
Kahn et al., 
2011  
Mobile Kenya Testing supplies, personnel, 
training, and contingency 
expenses  
 
$10.55 
Grabbe et al., 
2010  
Mobile Kenya Testing supplies, personnel, 
vehicles, buildings, utilities, and 
equipment  
 
$16.47 
Terris-Prestholt 
et al., 2006  
Mobile Uganda Testing supplies, personnel, 
vehicles, buildings, and 
equipment  
$33.54 
Adapted from Suthar et al., 2013  
 
HIV infected individuals only tend to access facility-based HTC services in the later 
stages of their HIV infection, when they have low CD4 counts (Nash et al., 2011, 
Kigozi et al., 2009) and when they may be suffering from HIV-related co-morbidities 
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(Lawn et al., 2010b). Consequently, the beneficial effect of ART on improving survival 
is limited (May et al., 2010a). This is compounded by the poor uptake of HIV care 
subsequent to a positive test through facility-based services (Rosen and Fox, 2011). 
Community-based HIV testers have been found to have higher CD4 counts than 
facility-based testers at the time of accessing the HIV testing service (Dalal et al., 
2013, Wachira et al., 2012b). They will have experienced a shorter time period 
during which they may have suffered HIV associated illnesses or infected others 
(Dalal et al., 2013, Wachira et al., 2012b).  
 
These factors suggest that HIV positive individuals identified through community-
based HIV testing strategies will have better health outcomes and be associated with 
lower future costs. In addition, economic evaluations of HTC strategies in high-
income settings increasingly take into account future HIV related costs and 
consequences (Brennan and Akehurst, 2000, Beck et al., 2012, Shroufi et al., 2013), 
and the impact of increased anti-retroviral treatment coverage on HIV transmission 
(Brennan and Akehurst, 2000, Shroufi et al., 2013, Safren et al., 2012, Lipscomb et al., 
2009). Taking these factors into account in an economic evaluation is therefore 
important.  
 
3.2.4 Cost of providing HIV treatment 
Economic evidence from high-income settings suggests that as clinical care for HIV 
infected individuals has improved, so has the costs of providing HIV treatment 
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(Schackman et al., 2006, Mandalia et al., 2010). Until recently there was limited data 
around the costs of providing HIV treatment to inform policy makers (Levy et al., 
2006, Beck et al., 2010). Even now the majority of the economic data comes from 
South Africa (Harling and Wood, 2007, Rosen et al., 2008, Martinson et al., 2009, 
Long et al., 2010), or from estimates based on international donor supported 
services (Menzies et al., 2011, Larson et al., 2013, Menzies et al., 2012, Marseille et 
al., 2012). The cost of providing HIV treatment may to be higher in these settings 
where care is frequently provided by doctors or in well-resourced health facilities. 
The costs of providing HIV treatment by health professional other than doctors have 
been found to be significantly lower (Johns et al., 2014, Babigumira et al., 2009).  
 
The cost of providing HIV treatment has been found to be higher for those with 
more advanced HIV disease (Leisegang et al., 2009). Additionally, estimates for the 
costs of providing HIV treatment vary depending on the setting where care is 
provided, with costs generally being higher in decentralised primary care clinics than 
in central referral hospitals (Rosen et al., 2008), and falling with time as HIV 
treatment sites either mature or increase in populations served by the treatment 
site (Menzies et al., 2011, Menzies et al., 2012, Marseille et al., 2012).  
 
3.2.5 Impact of HIV treatment on health-related quality of life 
HIV infection affects the health-related quality of life (HRQoL), with those with more 
advanced HIV infection generally having poorer HRQoL (Bajunirwe et al., 2009, 
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Peltzer and Phaswana-Mafuya, 2008). Anti-retroviral therapy has been found to have 
a beneficial impact on the HRQoL of individuals with HIV infection (Mutabazi-
Mwesigire et al., 2014, Stangl et al., 2007, Rosen et al., 2014, Beard et al., 2009). 
Studies that have used the EuroQol EQ-5D (EuroQol, 1990) measure to examine 
HRQoL in HIV infected individuals have shown comparable findings. Their findings 
suggest people with late stage HIV infection have poorer EQ-5D utility scores 
(Hughes et al., 2004), whilst those on anti-retroviral therapy have higher EQ-5D 
utility scores (Louwagie et al., 2007), and HRQoL improves over the course of time 
on anti-retroviral therapy (Jelsma et al., 2005). 
 
3.2.6 Economic evaluation of HIV testing strategies 
Early economic evaluations of HIV testing strategies found that providing free HIV 
testing and counselling services at fixed health facilities was a cost-effective 
intervention in sub-Saharan Africa (Sweat et al., 2000, Thielman et al., 2006). In 
these evaluations the provision of free HTC at health facilities was compared to no 
provision of HTC, and was undertaken at a time when anti-retroviral therapy was not 
available to those who tested HIV positive (Sweat et al., 2000, Thielman et al., 2006). 
The analysis suggested that providing free HTC services would cost below US$50 per 
disability-adjusted life year (DALY) saved (Sweat et al., 2000, Thielman et al., 2006). 
 
Prior to starting the PhD no full economic evaluation had been undertaken of 
community-based HIV testing or HIV self-testing strategies in sub-Saharan Africa. 
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Recently, two full economic evaluations have been undertaken of home-based HIV 
testing (Smith et al., 2015) and mobile HIV testing (Bassett et al., 2014). 
Implementing home-based and mobile HIV testing services were found to be a cost-
effective strategy in South Africa (ICER < 3 X GDP per capita) (Bassett et al., 2014, 
Smith et al., 2015).  
 
In South Africa the estimated incremental cost-effectiveness ratio (ICER) for 
providing home-based HIV testing in addition to facility-based HTC was 2012 
US$1,090 per DALY averted (Smith et al., 2015). In their analysis the ICER estimate 
was sensitive to the cost of providing anti-retroviral therapy to HIV positive 
individuals (Smith et al., 2015). In South Africa the estimated ICER for providing 
mobile HIV testing in addition to facility-based HTC was 2012 US$2,400 per life year 
saved (Bassett et al., 2014). In the analysis the ICER estimates were sensitive to the 
prevalence of undiagnosed HIV in the population and likelihood of linking into HIV 
treatment amongst those who test HIV positive (Bassett et al., 2014). The model of 
mobile HIV testing investigated also included provision of on site CD4 measurement 
and ART assessment, which have been found to be associated with increasing 
linkage into HIV treatment services (Jani et al., 2011).  
 
A recent cost-effectiveness analysis investigated the potential impact of 
implementing HIVST in addition to facility-based HTC in Zimbabwe (Cambiano et al., 
2015). This modelling study investigated a range of hypothetical scenarios relating to 
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the effects of the cost of implementing HIVST, uptake of HIVST, linkage into HIV 
treatment services, and ART eligibility criteria on the incremental cost-effectiveness 
of implementing HIVST. Table 4 shows the scenarios modelled and the cost-
effectiveness findings from the analysis. In their primary analysis the authors 
assumed the cost of an HIV self-test episode to be 2015 US$3 (a third of the cost of 
an HTC episode through health facilities), with ART initiated once an individuals CD4 
count fell below 500 cells/ul (Cambiano et al., 2015). The ICER was found to be 
sensitive to the cost of an HIVST episode, with implementation not cost-effective if 
the cost was comparable to that of a facility-based HTC episode. Additionally, the 
authors found that the ICER was sensitive to the likelihood of linking into HIV 
treatment amongst HIV self-testers who tested HIV positive.  
 
Table 4: Cost-effectiveness of HIV self-testing from Cambiano et al., 2015 
 
Scenario and input parameters 
 
Cost-effectiveness findings 
Base case 
Cost of HIVST: US$3 
Cost of facility HTC: US$9 
ART Initiation CD4 <=500 cells/ul 
Annual proportion tested in facility scenario: 50% 
Annual proportion tested in HIVST + Facility HTC Scenario: 57% 
Linkage into HIV treatment after HIVST: 60%   
CD4 measurement: US$10 
Annual cost of ART: US$97 
Cost of managing WHO stage IV illness: US$200 
 
 
 
 
 
Cost saving and more effective 
Alternative Scenario 1 
Cost of HIVST: US$9 
Otherwise same as base case 
 
 
Not cost-effective up to ICER of 
2015 US10,000/DALY averted  
Alternative scenario 2 
ART initiation at CD4 <350 cells/ul 
Otherwise same as base case 
 
 
Cost saving and less effective 
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Economic evaluations of HTC strategies in resource-rich and resource-poor settings 
have found that the main drivers of cost-effectiveness are the underlying HIV 
prevalence in the population, the CD4 count of HIV infected individuals at diagnosis, 
the proportion of testers linking into HIV treatment, the cost of providing HIV 
treatment, and the cost per person reached (Safren et al., 2012, Shroufi et al., 2013, 
Brennan and Akehurst, 2000, Kigozi et al., 2009, Beck et al., 2012, Fox-Rushby and 
Hanson, 2001, Beard et al., 2009, Venkatesh et al., 2013, Smith et al., 2015, 
Cambiano et al., 2015, Bassett et al., 2014).  
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3.3 Decision-analytic modelling of HIV interventions 
3.3.1 Overview 
Decision-analytic modelling in HIV has gradually evolved over the last few years as 
more information has become available on the progression of HIV infection with and 
without treatment, the drivers of costs and health outcomes of interventions, the 
population impact of interventions and on modelling techniques (Simpson, 2010, 
Anderson and Garnett, 2000, Weinstein, 2006, Marseille et al., 2012, Menzies et al., 
2012).  
 
However, there are concerns over the methodological quality of many HIV 
modelling-based evaluations (Simpson, 2010), including poor reflection of actual 
treatment pathways, use of input parameters which  do not reflect current 
epidemiological knowledge, and a lack of consideration of adverse consequences of 
interventions (Johnson and White, 2011, Simpson, 2010). 
 
Table 5, Table 6 and Table 7 provide an informal review of model-based economic 
evaluations undertaken in sub-Saharan Africa. Appendix V shows the literature 
search strategy utilised to find these studies.  Some studies are not included because 
they have used the same model to investigate the cost-effectiveness of a range of 
different HIV interventions (Losina et al., 2009, Walensky et al., 2012, Walensky et al., 
2009, Walensky et al., 2010b, Walensky et al., 2011, Goldie et al., 2006).  
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3.3.2 Modelling HIV prevention strategies 
Models used to investigate the cost-effectiveness of prevention of mother to child 
transmission (PMTCT) interventions have traditionally used simple decision trees and 
modelled impact on HIV transmission to uninfected infants using constant rates of 
transmission, obtained from published literature or primary studies (Table 5) (Sweat 
et al., 2004, Binagwaho et al., 2013).  
 
These have recently increased in complexity with investigators modelling HIV disease 
progression in mothers and infants using mutually exclusive health states 
represented by CD4 count categories (Fasawe et al., 2013, Ciaranello et al., 2013). 
This change has come about as a consequence of changes in the management of HIV 
positive pregnant women.  
 
In the early stages of PMTCT, the role of ART was to prevent HIV transmission to 
uninfected infants, and mothers and infants were given short course anti-retroviral 
drugs to achieve this (WHO, 2003b). Currently the WHO recommends that all HIV 
infected pregnant women should initiate HAART and remain on it life-long (WHO, 
2010a). This reduces the risk of transmission during breast-feeding and improves 
health outcomes in mothers (Tudor Car et al., 2011). In order to evaluate the cost-
effectiveness of these different strategies, investigators have rightly added 
complexity to their models to incorporate long-term costs and consequences of 
providing or not providing mothers with life-long ART (Ciaranello et al., 2013).  
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Transmission of HIV from mothers to their uninfected children can occur during 
pregnancy, during delivery or through breastfeeding. These are relatively definable 
and constant risks that can be obtained through primary clinical trials (Parazzini et al., 
1999, Guay et al., 1999), and therefore modellers have not needed to explicitly 
model the indirect impact of HIV care on HIV incidence. However, for most other HIV 
prevention strategies, incorporating this indirect effect has driven modelling 
approaches. Dynamic transmission models provide a powerful mathematical 
approach to incorporating these effects (Pitman et al., 2012).  
 
As Table 6 highlights, the investigation of cost-effectiveness of HIV prevention 
interventions have often used these compartmental dynamic transmission models 
(Pretorius et al., 2010, Nichols et al., 2013, Cremin et al., 2013). Dynamic 
transmission models represent the impact of the intervention on risk of HIV 
transmission by altering the flow of individuals from higher infectious compartments 
to lower infectious compartments, thereby modelling the reduced risk of a 
susceptible uninfected individual acquiring HIV infection when they come into 
contact with an HIV infected individual. These interactions between categories of 
individuals enable the quantification of the indirect effects of an intervention. 
 
As Table 6 shows, for HIV prevention interventions modellers have predominantly 
used stage of HIV infection to define compartments. This has been based on the 
scientific literature (Hollingsworth et al., 2008) which has shown that HIV infected 
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individuals are most infectious and that the risk of sexual transmission is highest 
during the first few months after acquiring HIV infection. Individuals quickly suppress 
the HIV viral load and become significantly less infectious, until the late stages of HIV 
infection when their HIV viral load increases considerably again as does their 
infectiousness.  
 
Interestingly, several economic evaluations of HIV prevention strategies have also 
used models that do not explicitly model changing risk of HIV transmission (Kahn et 
al., 2006, Gray et al., 2007b, Hallett et al., 2011, Walensky et al., 2012, van Hulst et 
al., 2008). In these analyses, investigators have followed common approaches used 
in modelling HIV treatment strategies, with HIV incidence assumed to remain 
constant over time.  
 
3.3.3 Modelling HIV treatment strategies 
In decision-analytical modelling, static Markov models are commonly used, with 
compartments used to define mutually independent health states which cohorts 
transition through (Cleary et al., 2006, Bachmann, 2006, Marseille et al., 2009, Athan 
et al., 2010, Rutstein et al., 2013, Pitter et al., 2007, Jarvis et al., 2013).  
 
Markov models differ in the defining characteristics of these compartments or 
health states, and in the fact that there is no interaction between compartments. In 
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dynamic transmission models, the compartments represent the infectiousness or 
non-infectiousness of the average population in that compartment, whilst in Markov 
models they are used to define the health-related quality of life (HRQoL) and costs 
associated with a cohort in a particular health state.  
 
Modellers using Markov models to investigate the cost-effectiveness of HIV 
treatment interventions in sub-Saharan Africa have predominantly used CD4 counts 
to define health states (Table 7). This has also been driven by the scientific literature, 
which highlights that the CD4 count of an individual influences their HRQoL (Hughes 
et al., 2004, Jelsma et al., 2005), the costs for caring for them (Leisegang et al., 2009), 
their risks of HIV-associated mortality (Brinkhof et al., 2009) and likelihood of 
comorbidities (Brinkhof et al., 2007).  
 
Over the last few years there has been a change in the number of health states and 
in the CD4 count ranges which each compartment represents. This has mainly been 
in response to changes in the clinical management of HIV infected individuals and to 
increasing knowledge about the epidemiology of HIV disease progression. 
Recommendations increasingly indicate initiation of HAART earlier in HIV disease 
(WHO, 2014), with recent findings from randomised trials suggesting that this trend 
will continue (Group, 2015a, Group, 2015b).   
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Whilst there are similarities between Cohort Markov models and dynamic 
transmission models, many differences between them exist; of most importance has 
been differences in the capture of the indirect effects of an intervention. Recent 
findings from South Africa demonstrated that even initiating ART at current CD4 
count thresholds and achieving relatively low population ART coverage can achieve 
significant reductions in HIV incidence (Tanser et al., 2013). This has highlighted the 
need to incorporate the indirect population effects of HIV treatment strategies. 
Whilst dynamic transmission models allow us to do this, they fail to represent the 
uncertainty in the decision-making process (Brennan et al., 2006).  Decision-analytic 
models estimate outcomes based on the data used to parameterise the model. Data 
used to parameterise models could be obtained through primary data collection 
from a sample of individuals representative of the population of interest, through 
synthesising secondary data, or as is the case for certain parameters used in dynamic 
transmission models, by fitting models to observed data. There will always be some 
degree of uncertainty in these estimates. This uncertainty is taken into account in 
Markov models by undertaking probabilistic sensitivity analysis, running the model 
several thousands of times and varying parameters across the range of possible 
values (Petrou and Gray, 2011b, Briggs et al., 2008).  
 
Representing uncertainty is essential for policy makers, who need to understand the 
robustness of findings of cost-effectiveness (Briggs et al., 2012a). Probabilistic 
sensitivity analysis provides the optimal approach to representing this uncertainty in 
decision-analytic modelling (Briggs et al., 2012a). However, of the studies described 
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in Table 7 only five studies (Bachmann, 2006, Cleary et al., 2006, Marseille et al., 
2009, Bendavid et al., 2011, van Hulst et al., 2008) undertook such analysis.  
 
A shortcoming of both cohort Markov models and dynamic transmission models is 
that they fail to take into account the random nature of events at the individual level. 
The increasing computational power available over the last decade has enabled 
modellers to incorporate this issue into HIV cost-effectiveness models using 
individual sampling models, where costs and outcomes are simulated at an 
individual level (Losina et al., 2009, Walensky et al., 2012, Walensky et al., 2009, 
Walensky et al., 2010b, Walensky et al., 2011, Goldie et al., 2006, Bendavid et al., 
2008, Bendavid et al., 2011, Hallett et al., 2011, Gray et al., 2007b). An important 
advantage of this approach has been the ability to make parameters conditional on 
attributes of an individual, thereby adding both memory and legitimate 
heterogeneity to the modelling process (Barton et al., 2004, O'Hagan et al., 2007).  
 
In HIV cost-effectiveness modelling this has allowed modellers to make transitions 
between health states, costs and health outcomes conditional on individual 
attributes, including whether an individual has had previous TB, the duration of time 
on ART, CD4 count at initiation and HIV RNA viral load response to treatment (Losina 
et al., 2009, Walensky et al., 2012, Walensky et al., 2009, Walensky et al., 2010b, 
Walensky et al., 2011, Goldie et al., 2006, Bendavid et al., 2008, Bendavid et al., 2011, 
Hallett et al., 2011, Gray et al., 2007b). The need for incorporation of these factors is 
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evident as from the current literature that highlights that these events influence 
subsequent response to treatment, disease progression and costs of care (Lawn et 
al., 2010a, Martinson et al., 2009, Leisegang et al., 2009, Harling and Wood, 2007).  
 
The three published cost-effectiveness analysis of community-based HIV testing 
strategies have used either dynamic transmission modelling (Cambiano et al., 2015, 
Smith et al., 2015) or individual sampling models (Bassett et al., 2014). The 
differences in modelling approaches suggest there is no agreed consensus of the 
optimal approach.  
 
 
 
 
 
 
 
 
 100 
Table 5: Overview of Models evaluating cost-effectiveness of Prevention of Mother-To-Child Transmission (PMTCT) of HIV 
Study Objective Modelling approach How was HIV disease progression modelled? Approach to HIV transmission? 
Sweat et al., 2004  Investigate cost-effectiveness of nevirapine in the PMTCT in eight Africa countries. 
No Interaction 
Decision Tree 
Decision tree with single HIV 
state 
Constant risk determined by 
maternal/infant HIV treatment 
given 
Binagwaho et al., 2012 
 
Investigate cost-effectiveness of a range of 
PMTCT strategies in Rwanda. 
No interaction 
Markov Model 
Decision tree with single HIV 
state 
Constant risk determined by 
maternal/infant HIV treatment 
given 
Fasawe et al., 2013 Investigate cost-effectiveness of a range of PMTCT strategies in Malawi 
No interaction 
Markov Model 
Health states defined by CD4 
stratum (>350; 350-200; 199-0). 
Constant risk determined by 
maternal/infant HIV treatment 
given 
Ciaranello et al., 2013 Investigate cost-effectiveness of a range of PMTCT strategies in Zimbabwe 
No interaction 
Markov Model 
Health states defined by CD4 
stratum (>350; 350-200; 199-0) 
 
HIV associated co-morbidities 
Constant risk of HIV transmission 
determined by maternal/infant 
HIV treatment given 
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Table 6: Overview of Models evaluating cost-effectiveness of interventions to tackle transmission and acquisition of HIV infection 
Study Objective Modelling approach How was HIV disease progression modelled? Approach to HIV transmission? 
Kahn et al., 2006 Investigate cost-effectiveness of adult male circumcision in South Africa. 
No interaction 
Decision Tree Decision tree with single HIV state 
Constant risk of HIV transmission 
determined by circumcision status 
Gray et al., 2007 
Investigate cost-effectiveness and impact 
on HIV incidence of male circumcision in 
Uganda 
No interaction 
Individual simulation 
Health states defined by stage of HIV 
infection (Acute; Latent; AIDS) 
Constant risk of HIV transmission 
determined by stage of HIV 
infection 
Pretorius et al., 2010 Investigate cost-effectiveness and impact on HIV transmission of PreP in South Africa. 
Interaction 
System dynamics 
Did not model HIV progression 
 
Compartmental model with 
additional risk heterogeneity 
determined by Age; Sex; HAART; 
PreP; Condom use 
Hallet et al., 2011 
Investigate cost-effectiveness and impact 
on HIV transmission of PreP and HAART 
amongst serodiscordant heterosexual 
couples in South Africa. 
No Interaction 
Individual simulation 
Health states defined by CD4 stratum 
(>500; 350-500; 350-200; <200) 
Constant risk of HIV transmission 
determined by HIV health state 
Walensky et al., 2012 Investigate cost-effectiveness of PreP in South Africa 
No interaction 
Individual simulation 
Health states defined by stage of HIV 
infection (Acute; Chronic) 
 
HIV-associated comorbidities. 
Impact on HIV transmission not 
incorporated 
Nichols et al., 2013 Investigate cost-effectiveness of PreP in Zambia 
Interaction 
System dynamics 
Health states defined by stage of HIV 
infection (Acute; Chronic; Early AIDS; 
Late AIDS) 
Compartmental model with 
additional risk heterogeneity 
determined by sexual activity 
Cremin et al., 2013 
Investigate cost-effectiveness and impact 
on HIV transmission of PreP, HAART and 
Male Circumcision in high HIV prevalent 
settings. 
Interaction 
System dynamics 
Health states defined by a 
combination of stage of HIV infection 
+ CD4 stratum (Acute infection >350; 
350-200; Early AIDS; Advanced AIDS; 
Severe AIDS) 
Compartmental model with 
additional risk heterogeneity 
determined by Age; Sex; HAART; 
PreP; Condom use; Sexual activity 
van Hulst  et al., 2008 
Investigate cost-effectiveness of different 
screening strategies for blood donations in 
Ghana. 
No interaction 
Markov Model 
Health states defined by WHO HIV 
Stages (Stage 1, 2, 3 & 4) 
Constant risk of HIV transmission 
determined by blood transfusion 
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Table 7: Modelling approaches to evaluating cost-effectiveness of HIV treatment interventions 
Study Objective Modelling approach 
How was HIV disease progression 
modelled? 
Approach to HIV 
transmission? 
Goldie et al., 2006 Investigate cost-effectiveness of providing HAART in the Ivory Coast. 
No interaction 
Individual simulation 
Health states defined by stage of HIV infection 
(Acute; Chronic) + HIV-associated comorbidities. 
Impact on HIV transmission 
not incorporated 
Bachmann, 2006 Investigate cost-effectiveness of providing HAART, TB treatment and HIV prophylaxis in Southern Africa. 
No interaction 
Markov Model 
Health states defined by CD4 stratum (350-200; 
<200) + HIV associated comorbidities 
Impact on HIV transmission 
not incorporated 
Cleary et al., 2006 Investigate cost-effectiveness of providing HAART in South Africa. 
No interaction 
Markov Model 
Health states defined by CD4 stratum (199-50; 
<50) 
Impact on HIV transmission 
not incorporated 
Bendavid et al., 2008 
Investigate cost-effectiveness of clinical and laboratory 
monitoring strategies for those on HAART in South 
Africa 
No interaction 
Individual simulation 
Health states defined by CD4 stratum (>350; 
350-201; 200-51; <50) + HIV associated co-
morbidities 
Impact on HIV transmission 
not incorporated 
Marseille et al., 2009 Investigate cost-effectiveness of providing home-based HAART to HIV infected individuals in Uganda. 
No interaction 
Markov Model 
Health states defined by WHO HIV Stages (Stage 
1, 2, 3 & 4) 
Impact on HIV transmission 
not incorporated 
Athan et al., 2010 
Investigate cost-effectiveness of using routine CD4 
count monitoring to guide initiation of HAART in 
resource-limited settings. 
No interaction 
Markov Model 
Health states defined by CD4 stratum (>350; 
350-200; AIDS) + HIV associated comorbidities 
Impact on HIV transmission 
not incorporated 
Kahn et al., 2011 Investigate cost-effectiveness of clinical and laboratory monitoring strategies for those on HAART in Uganda. 
No interaction 
Decision Tree 
Used a decision tree but with separate health 
states for HIV-associated co-morbidities. HIV 
infected health state was not subdivided. 
Impact on HIV transmission 
not incorporated 
Bendavid et al., 2011  Investigate cost-effectiveness of different first line HAART regimens in Southern Africa. 
No interaction 
Individual simulation 
Health states defined by CD4 stratum (>500; 
500-351; 350-201; <200) + HIV associated co-
morbidities 
Impact on HIV transmission 
not incorporated 
Rutstein et al., 2012  
Investigate cost-effectiveness of different contact 
tracing approaches to identifying HIV infected sexual 
partners of those already in care in Malawi 
No interaction 
Markov Model 
Health states defined by stage of HIV infection 
and treatment eligibility (Acute; Chronic; HAART 
Eligible) 
Impact on HIV transmission 
not incorporated 
Pitter et al., 2007 
Investigate cost-effectiveness of providing 
cotrimoxazole prophylaxis among persons infected 
with HIV in Uganda. 
No interaction 
Markov Model 
Health states defined by CD4 stratum (>500; 
<500) + HIV associated co-morbidities 
Impact on HIV transmission 
not incorporated 
Jarvis et al., 2013 
Investigate cost-effectiveness of cryptococcal antigen 
screening in HIV infected individuals in South Africa 
with CD4 counts less than 100 cell/ul. 
No interaction 
Markov Model 
Health states defined by CD4 stratum (100-50; 
<50) + HIV associated co-morbidities 
Impact on HIV transmission 
not incorporated 
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3.4 Summary of Chapter 3 
In this chapter I provided an overview of previous economic evaluations undertaken 
in HIV testing and approaches to performing economic evaluations of HIV 
interventions. I also provided a discussion of modelling approaches to performing 
economic evaluations of HIV interventions. The modelling approaches utilised have 
to an extent been driven by whether the objective of the analysis was to investigate 
strategies to prevent HIV transmission or to treat those infected with HIV. I 
highlighted the complexity of trying to incorporate the impact of HIV treatment on 
both HIV disease progression and HIV transmission.  
 
This chapter highlights the importance of considering the long terms costs of 
providing care and health outcomes of HIV positive individuals identified through 
HIV testing services. This supports the rationale for undertaking the primary 
observational studies described in Chapters 5, 6 and 7 of the PhD. 
 
As will become apparent in Chapter 8 of the PhD, I utilise a decision-analytical 
approach that primarily considers the impact of HIV treatment on HIV disease 
progression, without explicitly taking into account the changing impact on HIV 
transmission through higher population coverage of ART.  
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CHAPTER 4: Overview of PhD 
Research Methods  
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4. Overview of Chapter 4 
In this chapter I will discuss the broad research, epidemiological and health 
economic methods used in the studies presented in my PhD. I will begin by 
introducing the primary research question, and the aims and objectives of the PhD. I 
will provide an overview of how the research studies undertaken in chapter 5 to 8 
aim to meet the objectives of the PhD and thereby answer my primary research 
question.   
 
I will provide an overview of the methods of health economic evaluation and the 
approach I use to investigate the cost-effectiveness of HIVST. I will describe the 
rationale for using decision-analytic modelling to undertake my primary economic 
evaluation, and provide a review of how modelling can be performed.  I will also 
provide a description of the methods used in the three primary observational studies 
undertaken in chapters 5, 6 and 7. In addition, I will describe the approaches to 
collecting and estimating the costs and health related quality of life data that will be 
used to parameterise the models.  
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4.1 Overview of PhD research  
4.1.1 Primary research question 
The primary research question of my PhD is: “How cost-effective is home-based HIV 
self-testing in Blantyre, Malawi?” In order to answer my research question, I needed 
to decide on the appropriate methods. As the research was being undertaken in the 
context of a larger cluster-randomised trial, it provided an opportunity to collect 
primary data from participants of the trial who have been randomised to receive or 
not receive the exposure of interest (HIV self-testing). This was also necessary 
because of the lack of relevant data to answer this question.  
 
A recent publication by Cambiano and colleagues highlights 18 issues with regards to 
lack of data they encountered when trying to evaluate the cost-effectiveness of 
HIVST (Cambiano et al., 2014, Cambiano et al., 2015). As highlighted in the previous 
and preceding chapters of this thesis, there are probably even more data needs than 
that.  Of note, the authors only mention two issues with regards to costs and health-
related quality of life (highlighted below) (Cambiano et al., 2014). 
 
“What is the cost of implementing HIVST in resource-limited settings?”  
“What is the quality of life following a positive or a negative HIVST as 
compared to the same result communicated by a provider?”  
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These two issues are likely to play an important role in the investigation of the cost-
effectiveness of HIVST. However, other issues regarding costs and quality of life need 
to be considered also. An economic evaluation is a comparative analysis of the costs 
and consequences of an intervention, and consequently will also require the 
investigation of the costs and quality of life consequences of HIVST and current 
approaches to providing HIV testing and counselling. For example, does it cost the 
same to manage someone on ART who self-tested as someone who accessed HIV 
testing at the health facility? Do those who self-tested have the same health-related 
quality of life as facility testers after they access HIV treatment? In addition, HIV 
testing is the entry point into accessing HIV treatment, and when someone starts 
ART has an impact on their subsequent risk of developing HIV associated diseases. If 
offering HIVST results in more timely initiation of ART amongst those who test 
positive, many of these HIV associated diseases could be averted.  
 
4.1.2 Rationale of overall study design 
In answering my main research question I used decision-analytic modeling to 
undertake a cost-utility analysis (CUA). The on-going study (HitTB study) is a cluster-
randomised trial. Undertaking an economic evaluation alongside a randomised 
clinical trial potentially provides the least biased estimates for economic and health 
outcomes data.  
 
 108 
HIV testing strategies reach different populations and at differing stages in their 
disease progression. As this impacts on subsequent health outcomes and cost of 
providing care, there is a need to incorporate the long-term costs and health 
outcomes subsequent to entering HIV care. Whilst it may have been possible to 
follow-up Hit-TB trial participants, the large sample sizes and long follow-up 
suggested a decision-analytical modelling approach would be more efficient, and 
enabled the incorporation of other relevant evidence from secondary sources 
(Petrou and Gray, 2011b, Buxton et al., 1997).   
 
In addition, whilst there is a lack of primary economic data with regards to HIV, there 
is a large amount of research undertaken to investigate outcomes amongst HIV 
positive individuals who have and have not started anti-retroviral therapy. Decision-
analytic models allows us to synthesize this data, analogous to performing a meta-
analysis, so that estimates of cost-effectiveness are potentially based on all the 
available evidence rather than from evidence from a single randomised trial 
(Drummond et al., 2005b, Briggs et al., 2008, Briggs et al., 2012b).   
 
4.1.3 Aims and objectives 
The broad aim is to investigate the costs and health benefits of providing residents in 
Blantyre, Malawi access to HIV self-testing (HIVST) in addition to facility-based HIV 
testing and counselling (HTC) services, thereby allowing estimation of its value for 
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money within an economic evaluation framework. The specific primary and 
secondary objectives of the PhD are listed below. 
 
Primary objective:  
To undertake a decision-analytic modelling based cost-utility analysis to 
estimate the incremental cost per quality-adjusted life year (QALY) gained 
from the provision of HIV self-testing in conjunction with traditional facility-
based HIV testing and counselling services in Blantyre, Malawi.  
-> Investigated in Chapter 8 of PhD 
 
Secondary objectives:  
To compare and contrast the costs to individuals and to healthcare providers, 
and health-related quality of life outcomes, amongst individuals who access 
facility-based or HIV self-testing services in Blantyre, Malawi.  
-> Investigated in Chapter 5 of PhD 
 
To compare and contrast the costs to individuals and to healthcare providers, 
and health-related quality of life outcomes, amongst HIV positive individuals 
who access HIV care and treatment services subsequent to testing at facility-
based or through HIV self-testing services in Blantyre, Malawi. 
-> Investigated in Chapter 6 of PhD 
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To estimate the costs, to individuals and to healthcare providers, and health-
related quality of life of adults who are admitted to the medical wards in 
Queen Elizabeth Central Hospital, Blantyre, Malawi, for the management of 
medical illnesses.  
->Investigated in Chapter 7 of PhD 
 
To investigate the relative impact of HIV infection on costs and health-related 
quality of life of adults who are admitted to the medical wards in Queen 
Elizabeth Central Hospital, Blantyre, Malawi, for the management of medical 
illnesses.  
->Investigated in Chapter 7 of PhD 
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4.2 Economic evaluation 
4.2.1 Overview  
Economic evaluations are a relatively new research tool in healthcare research, and 
over the last few decades the findings of evaluations are playing an increasing role in 
decision-making in healthcare. Their basic premise is that resources are scare, and 
there is potentially an infinite number of alternative ways to use these resources. In 
addition, health is an important good that all members of society should have access 
to. Therefore decisions have to be made on how to allocate finite resources. 
Economic evaluations provide an approach to aide this process. They build on clinical 
effectiveness research by relating relevant costs associated with providing an 
intervention to the consequences of its provision, and by comparing the costs and 
consequences of alternative approaches to providing healthcare interventions to 
their alternatives, thereby aiding decisions about whether implementing a new 
intervention represents an efficient use of resources (Drummond et al., 2005b).  
 
4.2.2 Why undertake an economic evaluation  
Health and healthcare research rapidly evolve. The burden of an illness can change 
over time, and new illnesses emerge. In addition, the approaches to treating illness 
change over time as new health technologies are found. In this rapidly evolving 
environment, decisions have to be made on how to use the finite resources available. 
Economic evaluation is an analytical tool that allows the systematic appraisal of the 
costs and consequences of diseases and health technologies to provide policy 
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makers with additional information on which to make decisions (Drummond et al., 
2005b). The primary reason to undertake them is to provide information, additional 
to clinical effectiveness, for decision makers, thereby helping them reduce the 
uncertainty around their decision.  
 
Economic evaluations can vary in the scope of the analysis undertaken. Figure 24 
provides a description of the evaluations undertaken by the scope of the costs and 
consequences considered in the analysis. The different types of analysis provide 
different types of information that may be useful for a policy maker who needs to 
make the decision.  
 
Figure 24: Approaches to performing an economic evaluation 
Courtesy of Drummond et al., 2005  
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Economic evaluations help reduce the uncertainty that policy makers face when they 
are making a decision (Brennan and Akehurst, 2000). They can make comparisons 
between two or more interventions to inform the relative costs and consequences 
incurred through each intervention. They can link the costs of providing an 
intervention to the health outcomes of receiving the intervention. Whilst a new 
intervention may be more effective than current practice, it may also be significantly 
more costly than current practice. Therefore funding the new intervention may not 
be affordable for the policy maker, or funding it may result in other interventions not 
being funded.  
 
However there have been concerns that decision makers often find that economic 
evaluations have a very narrow focus, whilst diseases are complex and unpredictable, 
making their findings potentially less useful (Lessard, 2007). There are concerns that 
economic evaluations place far too much emphasis on efficiency and fail to consider 
issues of equity, an issue that is of importance for policy makers (Coast, 2004, Nord 
et al., 1999, Stolk et al., 2004).  There is uncertainty amongst decision makers on the 
value of findings from analyses undertaken in other settings, where costs of 
healthcare and approaches to delivering health services differ from their settings 
(Hoffmann et al., 2002, Drummond et al., 2005a). There are also concerns that the 
methods utilised are complex and lack transparency, making it difficult for policy 
makers to evaluate the quality of findings generated (Hoffmann et al., 2002, 
Brousselle and Lessard, 2011, Eddama and Coast, 2008).  
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4.2.3 Why undertake economic evaluations in resource-poor sub-Saharan settings 
Resource-poor countries in sub-Saharan Africa face even more challenges when it 
comes to ensuring the health of their population. Health providers have less financial 
and human resources available to provide healthcare to their population. In addition, 
the burden of illness is usually higher in these countries, with lower life expectancy 
and higher levels of morbidity (Murray et al., 2012, Lozano et al., 2012). In resource-
poor settings the challenges are not always what health interventions to provide, but 
whether there are sufficient resources to provide them. The optimal medical 
management of HIV is sub-Saharan Africa is not limited by knowledge of what 
interventions improve the health of those affected, but by what resources are 
available.  
 
The problem often facing resource-rich countries is the too rapid uptake of new 
health technologies, driving up the costs for healthcare providers. In resource-poor 
settings the concern is different, where new health technologies take time before 
they are utilised, and are utilised without an evidence base or driven by international 
donor preferences (Kriza et al., 2014, Chalkidou et al., 2010). There is an opportunity 
cost to this. If the new technology proves to be effective, affordable and offers good 
value for money for health providers, delays in introduction reduces potential health 
benefits to the population. Conversely, if new health technologies are introduced 
without an evidence base that includes an assessment of cost-effectiveness, 
healthcare providers in the country risk wasting what limited financial and human 
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resources they have, and what could be better spent providing alternative health 
technologies.  
 
The financial climate and limited resources in the region has led to increasing 
demand for economic evaluations from local and international policy makers, and 
international donors (Walensky and Kuritzkes, 2010, Denny and Emanuel, 2008, 
WHO, 2001, WHO, 2003a, Kahn and Marseille, 2000, Schwartlander et al., 2011). The 
scientific literature reflects the long-standing interest of economic evaluations in 
resource-poor settings. Economic evaluations and reviews of cost-effectiveness 
studies have been undertaken for HIV (Creese et al., 2002), Malaria (Morel et al., 
2005), Tuberculosis (Baltussen et al., 2005), mental health (Chisholm and Saxena, 
2012), maternal and child health (Ginsberg et al., 2012), cancer care (Ginsberg et al., 
2012, Goldie et al., 2005), cardiovascular and other non-communicable diseases 
(Ortegon et al., 2012, Anderson et al., 2009, Gaziano, 2008). Their use will become 
ever more vital if concerted efforts are to be made to optimise the provision of basic 
and novel health technologies in the region.  
 
4.2.4 Types of economic evaluation  
The three main types of full economic evaluations are cost-effectiveness analysis 
(CEA), cost-utility analysis (CUA) and cost-benefit analysis (CBA) (Palmer et al., 1999, 
Drummond et al., 2005b). Table 8 provides a brief overview of the main types of full 
economic evaluations. 
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Table 8: Approaches to performing an economic evaluation 
 
Cost-Effectiveness Analysis 
 
Cost-Benefit Analysis 
 
 
Cost-Utility Analysis 
 
Costs measured in monetary 
units 
 
 
Costs measured in monetary 
units 
 
Costs measured in monetary 
units 
 
Consequences measures in 
the most appropriate natural 
or physical units 
x Life years 
x HIV tests performed 
 
 
Consequences measured 
using same units as costs 
x Monetary units 
 
Consequences measured 
using a utility based measure 
x Quality adjusted life 
years (QALYs) 
x Disability adjust life 
years (DALYs)  
 
 
Can only be used to compare 
within a comparable 
treatment/illness 
 
 
Can be used to compare 
across a range of treatment 
areas 
 
Can be used to compare 
across a range of treatment 
areas 
  
Concern and methodological 
challenges over valuing 
health in monetary terms 
 
 
Concerns over the optimal 
approaches to value 
QALYs/DALYs 
  
Provides a simple decision 
rule based on net benefit, 
where positive net benefit 
implies adoption of 
intervention 
 
 
Requires an explicit decision 
rule to determine threshold 
for willingness to pay 
Source: Drummond et al., 2005b 
 
A cost-effective analysis (CEA) relates the costs of providing an intervention to the 
health effects from receiving the intervention, with the health effect quantified in 
natural units. The natural units can range from procedures or tests performed, to life 
years saved. Their use is primarily limited by the lack of a standardised measure of 
health effect that can then allow fair and legitimate comparisons to be made across 
interventions targeting different aspects of health. This contrasts with cost-utility 
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analysis (CUA) where the use of a universal preference-based measure of health, 
allows comparisons to be made across a diverse range of interventions. For example 
the findings of a CUA of cancer treatments can be directly compared to that of an 
HIV intervention. This allows decisions to be made on allocative efficiency and 
therefore more useful for policy makers (Drummond et al., 2005b). Cost-benefit 
analysis (CBA) offers, but differs in that the health effects are quantified in monetary 
values. CBA are not commonly used in health economic evaluations, a major barrier 
has been the issue of valuing health benefits in monetary terms (Drummond et al., 
2005b).  CUAs and CEAs remain the most common types of full economic evaluations 
undertaken by the academic research community, and in previous evaluations of HIV 
interventions (Galarraga et al., 2009, Kahn et al., 2011, Creese et al., 2002, Beck et al., 
2010, Meyer-Rath and Over, 2012). 
 
4.2.5 Rationale for undertaking a cost-utility analysis in this PHD   
There is an increasing volume of economic evaluations in resource-poor settings, 
with analysis being undertaken in other disease areas as well as in HIV (Creese et al., 
2002, Ortegon et al., 2012, Ginsberg et al., 2012, Goldie et al., 2005). The findings 
from a CUA will be of more value for policy makers who may wish to compare 
findings across a range of disease areas to inform decisions on allocative efficiency. 
Consequently in this PhD I undertook a CUA to answer the primary research question. 
The description and findings of the analysis are presented in Chapter 8 of the PhD. 
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4.3 Decision-analytic models 
4.3.1 Introduction 
Economic evaluations can be undertaken using patient-level data obtained alongside 
clinical trials, using decision-analytic models, or using a combination with decision-
analytic models extrapolating findings beyond the period of the clinical trial 
(Drummond et al., 2005b).  
 
Clinical trials are designed to answer clinical effectiveness questions. Undertaking 
economic evaluations alongside clinical trials has the benefit of obtaining timely 
evidence on cost-effectiveness, with the evidence obtained at low cost, and with 
findings potentially robust to concerns over validity (Petrou and Gray, 2011a). Whilst 
clinical trials provide high quality evidence of clinical effectiveness, their use for 
‘piggy backing’ an economic evaluation can be challenging (Glick et al., 2014, Gray et 
al., 1997). Clinical trials are costly and may only evaluate a limited number of 
comparators (Sculpher et al., 2006b). The time period of the evaluation may be too 
short to incorporate all consequences relevant to investigate cost-effectiveness. The 
sample size may be too small to detect differences in cost-effectiveness between 
comparators, and the findings may not be transferable to a setting other than where 
the trial was undertaken (Sculpher et al., 2006a, Sculpher et al., 2006b).  
 
Decision-analytic modeling offers an explicit, quantitative, and systematic approach 
to combining all relevant information to provide estimates of cost-effectiveness and 
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the uncertainty surrounding the estimates. Whilst its use has come under scrutiny 
(Campbell et al., 2007, Sheldon, 1996, Cooper et al., 2005), it may be unavoidable in 
several circumstances (Buxton et al., 1997). Decision-analytic models have the 
advantage of being flexible to the time period of analysis, comparators considered 
and populations investigated (Petrou and Gray, 2011b, Sun and Faunce, 2008, 
Barton et al., 2004, Briggs et al., 2008, Brennan and Akehurst, 2000). They are able 
to combine evidence from a range of primary and/or secondary sources, thereby 
allowing evaluations of comparators that may not have been compared directly 
(Buxton et al., 1997). They can extrapolate beyond the observed end-point in a 
clinical study to an end-point relevant to the economic evaluation (Brennan and 
Akehurst, 2000). Unlike clinical trials which may require large numbers of 
participants, long periods of follow-up and considerable investment of human and 
financial resources, they can be a low cost option to the estimation of cost-
effectiveness (Royston, 1999). Consequently, their role may be of greater 
significance in resource-poor settings, where the opportunity costs of research are 
considerable.  
 
4.3.2 Approaches to decision-analytic modeling  
A decision-analytic model is a tool to evaluate the impact of a decision, thereby 
allowing comparisons between two or more alternative decision options. A range of 
terminology is used to describe decision-analytic models, and often these can be 
conflicting or inconsistent (Brennan et al., 2006, Barton et al., 2004, Briggs et al., 
2008). A common approach to describing model structures has been to consider 
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three factors: (1) who is being modelled; (2) is there interaction between those being 
modelled; (3) what is the time between events being modeled (Brennan et al., 2006, 
Barton et al., 2004, Briggs et al., 2008). However, the increasing use of decision-
analytic modeling in healthcare decision-making has resulted in the development of 
a range of guidelines for the undertaking, presentation and validation of decision-
analytic models (Briggs et al., 2012b, Eddy et al., 2012, Siebert et al., 2012, Briggs et 
al., 2008). The International Society for Pharmacoeconomics and Outcomes Research 
(ISPOR) provides a range of good practice guidelines for the undertaking of decision-
analytic modelling in cost-effectiveness research (Briggs et al., 2012b, Eddy et al., 
2012, Siebert et al., 2012). In the PhD, I adhered to these good practices and used 
their guidelines for the development and undertaking of the cost-effectiveness 
analysis.  
 
4.3.3 Decision trees 
A decision tree is the simplest model structure used in decision-analytic modeling. A 
decision tree comprises the possible pathways resulting from the two or more 
potential decisions being evaluated. The pathways represent all the possible clinical 
outcomes, with probabilities attached to the likelihood of these outcomes occurring 
and values attached to quantify each outcome (Brennan et al., 2006, Barton et al., 
2004, Briggs et al., 2008). The values attached to these outcomes in health economic 
evaluations are comprised of costs and health outcomes (e.g. quality-adjusted life 
years). Decision trees predominantly model cohorts of individuals, thereby allowing 
mean values to be estimated, and assume there is no interaction within or between 
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the groups being modeled (Brennan et al., 2006). In addition, decision trees model 
the event over a predefined time period dependent on decision is being evaluated. 
Figure 25 shows a simple decision tree modeling the impact of providing two 
alternative treatments options. In this example the incremental cost-effectiveness 
ratio is estimated by dividing the difference in the total cost of providing the 
treatment by the total difference in health outcomes (i.e. US$500/Life saved).  
 
Figure 25: Simple Decision trees 
 
 
Decision trees are a useful to model relatively simple decisions and can allow for 
multiple outcomes to be evaluated. However, as the potential outcomes increase in 
number, or if there is a need to model outcomes that may recur over time, the 
number of branches will increase and their structure can become complicated. In 
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addition, decision trees are not able to consider outcomes that may vary over time, 
or that recur over time (e.g. side effects from drug therapy).  
 
4.3.4 Markov models 
Markov models are more complex than decision trees, and provide a possible 
solution to some of the limitations of decision trees. In a Markov model, we simulate 
a cohort of individuals transitioning through the health states, with probabilities 
determining the proportion of the cohort who transition from one to another health 
state (Briggs and Sculpher, 1998, Briggs et al., 2006).  
 
Figure 26 shows an example of a Markov model that examines the impact of 
initiating anti-retroviral therapy at different CD4 counts in HIV positive individuals. 
The model provides a more simplistic approach to represent HIV disease progression 
than a decision tree would.  The Markov model uses mutually exclusive health states 
that in a decision tree would need to be represented by a multitude of branches 
(Briggs and Sculpher, 1998).  In this example, the health states represent mutually 
exclusive and distinct stages of HIV disease progression. Individuals enter a health 
state, if their HIV disease progresses they transition into another health state, whilst 
if their HIV disease remains stable they remain in the same health state. The 
likelihood of transitioning to another health state is modeled over time by applying a 
fixed time interval between each potential transition. In addition, the modeller can 
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determine the exact time interval between each potential transition to another 
health state.    
 
Figure 26: Markov models 
 
 
In the Markov model, a transition probability is assigned to model the likelihood of 
movement between health states or remaining in the same health state, with all 
probabilities emanating from one health state adding up to a total of one (Briggs and 
Sculpher, 1998). Each health state is then assigned a cost and health outcome (e.g. a 
utility score). In the final analysis the total costs and health outcomes are estimated 
by multiplying the time spent in each health state by the cost and health outcome 
assigned to the health state.  An advantage of Markov models is their ability to 
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model events that may recur over time (Brennan et al., 2006, Barton et al., 2004). In 
the example in Figure 26 there is an additional health state to represent the 
development of TB amongst HIV positive individuals. HIV positive individuals may 
acquire TB and have their disease treated. However, they may still be at risk of re-
acquiring TB, and the Markov model can provide a simplified approach to 
representing this continued risk.   
 
Markov models do have several limitations. Markov models simulate the transition 
of cohorts of individuals and consequently cannot take into account individual-level 
characteristics (Barton et al., 2004). This assumption, called the “Markovian 
assumption” does not allow the model to record past events or allow transition 
probabilities, costs or health outcomes to be dependent on individual-level 
characteristics (Briggs and Sculpher, 1998, Barton et al., 2004). For example, in the 
model shown in Figure 26, individuals who acquire TB could be eligible to start anti-
retroviral therapy (irrespective of their CD4 count). As the model lacks memory, it 
cannot differentiate between those who have had a history of TB and those who 
have not. This limitation can be resolved by adding an additional health state for 
those who are HIV positive and had a history of past TB disease. However, with 
increasing complexity and past events occurring, the number of health states will 
need to increase to allow transition probabilities (and potentially costs and health 
outcomes) to be dependent on past events.  If there is a need to model events on a 
large number of past events or individual-level characteristics, the model may have 
too many health states.  
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4.3.5 Individual sampling models (ISM) 
An individual sampling model (sometimes referred as Monte Carlo simulation or 
microsimulation) overcomes the ‘memoryless’ feature of Markov models (O'Hagan 
et al., 2007, Barton et al., 2004, Brennan et al., 2006). ISM simulates the transition of 
an individual through the model as they accumulate costs, and record their health 
outcomes. The model then repeats the analysis for a large enough number of 
individuals to estimate the mean costs and health outcomes.  As the model 
simulates an individual it can vary its parameters based on the characteristics of the 
individual (Brennan et al., 2006, Barton et al., 2004). For example, the risk of 
mortality in an HIV positive individuals could be simulated as two different values 
based on whether the individual has had TB disease in the past or not.  An advantage 
of this approach is that the number of health states can be minimised, making it 
easier to describe the model structure to the reader (Brennan et al., 2006, Barton et 
al., 2004).  
 
4.3.6 Decision models that allow interaction  
A limitation of decision trees, Markov models and ISMs is that they do not allow for 
interaction between the individuals being modeled. One situation where this may be 
important is in modeling infectious diseases, where the risk of acquiring the 
infectious disease will be dependent on the number of individuals who already have 
the infection. For example in the treatment of TB, getting individuals onto TB 
treatment reduces their risk of transmitting the infection to un-infected individuals. 
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Not taking this into account would bias against interventions that reduce the 
infectious period.  
 
Health economists have increasingly used transmission dynamic modeling 
(sometimes referred to as system dynamic models) to take into account the 
interaction between individuals (Jit and Brisson, 2011). However, transmission 
dynamic models simulate groups of individuals and therefore have comparable 
limitations to Markov models with regards to the issue being ‘memoryless’ and the 
inability to take into account individual-level characteristics (Barton et al., 2004). An 
alternative approach to enable both consideration of interaction between 
individuals and individual-level characteristics is to use discrete event simulation 
(DES) (Barton et al., 2004). DES provides the greatest flexibility in decision-analytic 
modeling, but also the greatest needs in terms of model parameters and 
computational time (Karnon, 2003, Barton et al., 2004, Brennan et al., 2006). They 
allow interaction between individuals, and allow events to be conditional on 
individual-level characteristics or to vary over time (Karnon, 2003).  
 
4.3.7 Summary of modeling approaches  
A range of different modelling approaches exists for undertaking decision analytical 
modelling. Each will have its associated advantage and disadvantage, and it is up to 
the modeller with input from clinical experts in the field to determine the most 
suitable strategy (Sun and Faunce, 2008). Barton and colleagues provide a simplified 
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approach to deciding a suitable modelling approach for undertaking decision-
analytic modelling (Figure 27) (Barton et al., 2004).   
 
In Chapter 8 of the PhD I undertake decision-analytic modelling to answer my 
primary research question. In Chapter 8 I highlight why I used an individual 
simulation model (ISM) to investigate my primary objective:  
 
“To undertake a decision-analytic modelling based cost-utility analysis to 
estimate the incremental cost per quality-adjusted life year (QALY) gained 
from the provision of HIV self testing in conjunction with traditional facility-
based HIV testing and counselling services in Blantyre, Malawi”  
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Figure 27: An approach to determining the appropriate model structure 
Source: Barton et al., 2004   
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4.4 Cross-sectional and longitudinal studies 
4.4.1 Introduction 
In the collection of primary economic and health-related quality of life data, 
decisions need to be made on how and from whom the data is to be collected. The 
main trial in the HitTB Study was a cluster-randomised trial, with communities being 
the unit of randomisation, with the study using a post-intervention prevalence 
survey to investigate the primary outcomes. This necessitated design of my own 
studies, undertaken in the trial population, to investigate the primary research 
question of the thesis.  
 
4.4.2 Cross-sectional studies 
Cross-sectional studies are observational studies that allow us to describe an 
exposure or outcome of interest, although they can be used to investigate 
associations between the two (Rothman et al., 2008). Their use is not just limited to 
investigating aetiology of diseases (Rothman et al., 2008), and they play a major role 
in both public health and health economics research. In these areas, the objective 
may be limited to only understanding or measuring the prevalence of a risk factor or 
health outcome; use of health services; or measuring the HRQoL of a population.  
 
They have the advantage that they are relatively inexpensive and quick to perform, 
can be used to investigate multiple factors, and not affected by issues of loss to 
follow-up (Rothman et al., 2008, Feldman and McKinlay, 1994). However, these 
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studies do not allow us to investigate a causal relationship between an exposure and 
outcome (Rothman et al., 2008, Feldman and McKinlay, 1994).  
 
In Chapter 5 of the PhD I investigate one of the objectives of my thesis: 
 
“To compare and contrast the costs to individuals and to healthcare providers, 
and health-related quality of life outcomes, amongst individuals who access 
facility-based or home-based HIV testing services in the HitTB study 
population.” 
 
In investigating this objective, I deemed a cross-sectional study an appropriate study 
design. The benefit was that it allowed me to investigate a range of issues, namely 
HRQoL, direct non-medical costs and indirect non-medical costs of HIV self-testers 
and facility testers at the same time. Additionally, it allowed me compare and 
contrast between the two populations by the modality of HIV testing received. The 
objective was not to investigate whether offering HIV self-testing would improve the 
quality of life of HIV testers, or reduce costs.  
 
4.4.3 Longitudinal studies 
A cohort, or longitudinal, study is an observational study where several observations 
are undertaken on participants over a period of time. In epidemiology, the objective 
is to investigate a causal relationship between an exposure and health outcome 
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(Feldman and McKinlay, 1994, Rothman et al., 2008). Through undertaking the study 
prospectively, the investigator is also able to investigate whether there are changes 
in outcomes of interest over time, and compare changes in outcomes between two 
or more groups (Goldstein and Goldstein, 1979, Feldman and McKinlay, 1994, Diehr 
et al., 1995). The advantages of longitudinal studies come at a cost. Following up 
participants in low-income settings, where participants may not have a fixed abode, 
postal address or telephone contact number, may be difficult and bias findings.  
 
In Chapter 6 of my PhD I investigate one of the objectives of my thesis: 
 
“To compare and contrast the costs to individuals and to healthcare providers, 
and health-related quality of life outcomes, amongst HIV positive individuals 
who access HIV care and treatment services subsequent to testing at facility-
based or home-based testing services in the HitTB study population.” 
 
For the purposes of the research described in Chapter 6 a longitudinal study design 
was optimal. A longitudinal study would provide me with an unbiased estimate of 
treatment effect. I wanted to examine the costs and health outcomes of receiving 
HIV treatment and compare between those who had received HIVST to those who 
had received facility-based HTC. Individuals access HIV treatment after learning their 
HIV status, and therefore the exposure I was interested in, modality of HIV testing 
received, occurred before the outcomes I was examining.  
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In Chapter 7 of my PhD I investigate two further objectives of my thesis: 
 
“To estimate the costs, to individuals and to healthcare providers, and health-
related quality of life of adults who are admitted to the medical wards in 
Queen Elizabeth Central Hospital, Blantyre, Malawi, for the management of 
medical illnesses.”  
 
“To investigate the relative impact of HIV infection on costs and health-
related quality of life of adults who are admitted to the medical wards in 
Queen Elizabeth Central Hospital, Blantyre, Malawi, for the management of 
medical illnesses.”  
 
A longitudinal study design was again deemed appropriate as it allowed unbiased 
estimation of economic variables, to investigate whether HIV status, the exposure, 
had an independent effect on the total direct health provider costs, direct non-
medical costs and indirect costs during hospitalisation.  
 
4.5 Cost analysis 
4.5.1 Introduction 
In undertaking an economic evaluation one needs to estimate the impact of the 
current treatment and the alternative treatment options on economic costs. To do 
this requires consideration of a range of methodological issues ranging from the 
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viewpoint of the cost analysis, the time period over which the costs are to be 
considered and the methods used to estimate the costs (Drummond et al., 2005b).  
 
4.5.2 Costing perspective 
An economic evaluation can be undertaken from either the health provider or 
societal perspective. The choice of perspective will determine which costs are to be 
estimated.  
 
The health provider perspective is often considered the primary perspective in 
economic analysis, especially where the Government incurs the majority of costs of 
healthcare provision in a country. The rationale for using the health provider 
perspective stems from the use of CUA in determining budget allocation decisions to 
maximise utility (in this case QALYs). The budget that is being maximised is the 
budget available to the healthcare provider (or payee), and therefore it argued that 
only these costs should be considered in the analysis (Edelson et al., 1990, 
Johannesson and O'Conor, 1997b, Williams, 1985). In Malawi, HIV services and 
hospital care are provided free of user fees, and the cost is incurred by the Ministry 
of Health (MoH). The MoH is the decision maker and primarily responsible for 
determining which services are to be provided.  
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However, diseases and their treatment not only incur a cost to the health provider, 
but also to those affected. It is therefore considered important in some 
circumstances to incorporate the economic constraints of those affected into the 
analysis, and therefore undertake costing from the societal perspective (Jonsson, 
2009). It has been argued that allocation decisions are based on implementing 
interventions that are classified as cost-effective, i.e. below a threshold of 
willingness to pay for a gain in QALY, as international organisations like the World 
Health Organisation advocate (WHO, 2003a). If a fixed threshold is used in the 
decision-making, then incorporating all costs, and therefore taking the societal 
perceptive, may ensure that the analysis reflect the optimal decision for society 
(Jonsson, 2009, Johannesson and O'Conor, 1997b). To estimate the cost from the 
societal perspective requires estimating both the costs incurred by the health 
provider and the costs incurred by those affected by the disease or through 
accessing care for the treatment of the disease.  
 
4.5.3 Health provider costing 
The health provider perspective requires estimating the costs incurred by the 
healthcare provider, the Malawi MoH, in providing the relevant health services. 
Often this cost is termed the direct health provider cost and refers to the costs of 
resources that are directly used in the provision of healthcare (Johannesson, 1994, 
Drummond et al., 2005b).  
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In many countries like the UK, the health provider publishes reference costs that 
inform health economic evaluations. These reference costs are grouped into 
healthcare resource groups and are provided to analysts undertaking economic 
evaluations. In Malawi, and the majority of countries in sub-Saharan Africa, 
comparable reference cost estimates are not available. It is therefore often 
necessary to collect primary cost data, which ideally requires both the assessment of 
resource inputs used in care provision, and the subsequent valuation of those 
resource inputs (Drummond et al., 2005b).  
 
In this PhD, observational studies were undertaken prospectively to collect data on 
the healthcare resources used by individuals in accessing the relevant health services.  
A more detailed description of the observational studies undertaken and data 
collection process is provided in the relevant Chapters (Chapter 5, Chapter 6 and 
Chapter 7). The healthcare resources quantified in these studies were then costed 
following standard guidelines (UNAIDS, 2011, Drummond et al., 2005b).  
 
Costing resource-use items can be complex and time-consuming, often necessitating 
some compromise in the methodological approach. Costing approaches can either 
take a ‘top-down’ or ‘bottom-up’ form, although in many cases a combination of 
approaches may be utilised (Drummond et al., 2005b, Lipscomb et al., 2009). The 
top-down method is less resource-intensive but may provide less accuracy in 
estimates and potentially reduces ability to detect cost differences (Drummond et al., 
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2005b, Lipscomb et al., 2009). The approach involves assigning aggregate level cost 
data to service outputs, where service output units may range from hospital 
admission days to outpatient visits. Whilst the approach is simpler, it may not be 
appropriate in many cases because of the heterogeneous nature of care provided in 
hospitals (Carey and Burgess, 2000).  
 
The bottom-up approach involves quantifying all the resources used in providing 
care and costing each resource input to determine the total cost. The bottom-up 
approach allows total costs of a service output to be more closely related to the 
actual resources used, and is often felt to be more accurate than the top-down 
approach (Berlin and Smith, 2004, Negrini et al., 2004). Whilst there is no consensus 
on the correct approach, it is widely accepted that the choice needs to take into 
account the objective of the analysis and understanding of the relative costs of 
different inputs and their likely impact on total cost (Drummond et al., 2005b). Often 
it may be optimal to use a combination of the two approaches (Baker, 1995, Carey 
and Burgess, 2000), which may be determined by regulatory or advisory boards 
(NICE, 2008, UNAIDS, 2011).  
 
In Chapters 5, 6 and 7 I provide more detailed description of the methods used in 
estimating the costs for resource-use items. The exact methods used varied 
depending on the healthcare resources that were being costed. Broadly, this 
involved first examining the healthcare service and determining the outputs of the 
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service (e.g. outpatient visit; day of hospital admission; investigations performed). 
Second, interviews were undertaken with senior staff members working at the 
healthcare organisation to quantify the inputs used in providing the healthcare 
resource-use item (e.g. staff inputs; consumables; equipment; etc.). Third the unit 
costs of the inputs used in providing the healthcare resource-use items were 
obtained. Fourth the unit costs were applied to the resource-use inputs to 
determine the total cost of the resource-use items. Where the healthcare service 
(e.g. HIV testing clinic) being costed only had one output (e.g. HIV test performed), 
all costs were summed and divided by the total number of outputs from the services. 
Where the healthcare service (e.g. hospital) being costed had more than one output 
(e.g. days of admission; investigations performed), a proportion of some costs (e.g. 
overhead; central administrative; utility bills) were allocated to the relevant 
resource-use item based on services delivered.       
 
4.5.4 Patient incurred costs  
Patients, or those who use healthcare services, may incur two types of costs. They 
may incur costs when they access the healthcare service, referred to as direct non-
medical costs, and as a consequence of their illness, referred to as indirect costs 
(Drummond et al., 2005b). In addition, the family member or friend who is providing 
informal care for the patient could also incur these costs. Collectively these costs are 
referred to as patient and family resource use (Drummond et al., 2005b). 
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The costs that constitute direct non-medical costs are relatively simple to quantify 
and measure, as these are the resources used in accessing medical care that are not 
classified as healthcare resources (Drummond et al., 2005b). For example a patient 
(or their care giver) may spend money on transport to attend a health facility that 
they would not have otherwise spent if they (or the patient they were caring for) 
were well or not seeking medical care. However, determining the extent of the non-
medical resources used in accessing medical care will depend on the type of medical 
care they access. For example, patients who are admitted to hospital will spend 
more money on non-medical resources (e.g. soap; clothes) that someone who 
attends an outpatient clinic would. In the studies undertaken in the PhD (Chapter 5, 
6, and 7), I undertook pilot studies to determine the range of non-medical resources 
that patients (and their care giver) could potentially spend their own money on.  
 
The issues around indirect costs are slightly more complicated with different views 
on what constitutes an indirect cost and how to quantify it (Koopmanschap et al., 
1995, Koopmanschap and van Ineveld, 1992, Ernst, 2006). The broadest approach to 
estimating the indirect cost involves valuing the loss to society from absenteeism, 
disability and premature mortality (Van Roijen et al., 1996).  However, previous 
studies have used different time horizons over which to measure indirect costs, 
differed in what activities (e.g. employment; informal care; leisure time) constitute 
as loss to society and used different tools used to measure these costs (Jacobs and 
Fassbender, 1998, Posnett and Jan, 1996, Merkesdal et al., 2005, Liljas, 1998).  For 
the purposes of the PhD, I equate the indirect cost to the cost of absenteeism that 
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resulted directly from accessing healthcare services and use the human capital 
approach to estimate this cost (Glied, 1996, Weisbrod, 1961).  
 
4.5.5 Adjusting and communicating costs 
In undertaking primary costing studies, the resources measured need to be valued to 
provide quantitative values for use in the analysis. The valuation of healthcare 
resources often necessitates the collection of unit cost data from a range of sources, 
the costs may have been obtained from different time periods or denominated in 
different currencies. To ensure that the different input costs used to determine the 
final estimates are comparable, and the findings can be generalised to different 
settings (e.g. to another country) from which the primary analysis was undertaken, 
adjustments are often required (Drummond et al., 2005b, Drummond et al., 2009). 
Costs need to be converted to the same currency and year of currency in the final 
analysis and presentation of findings. In addition, the input costs used to make the 
final estimates have to reflect the true opportunity cost of the resource item.  
 
In resource-constrained settings like Malawi, this poses some challenges. As 
previously highlighted in Chapter 2, Malawi has experienced high levels of inflation 
and receives a large amount of its healthcare funding from International donors. In 
addition, healthcare providers purchase a significant proportion of goods used in the 
production of heath (e.g. drugs, medical consumables and equipment) from 
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overseas sources, whilst others resources (e.g. staff salaries) are paid locally. This 
requires a rigorous and repeatable approach to adjusting and communicating costs.  
 
The World Health Organisation (WHO) provides guidance on how to adjust and 
communicate costs in economic evaluations (Johns et al., 2003, WHO, 2003a). In the 
studies undertaken in Chapters 5, 6, and 7 their guidance was followed. Broadly, this 
involves firstly adjusting from the year of cost to the year of analysis using the World 
Bank Gross Domestic Product (GDP) deflators and, secondly, converting the currency 
of the costs to International dollars (Johns et al., 2003, WHO, 2003a). As the primary 
objective of the economic analysis is to inform policy makers in Malawi, and the 
Malawian currency has been unstable and often devalued over the last few years, I 
present all costs in 2014 US and International dollars in the PhD. All costs were 
inflated to the year 2014 using the GDP deflators, and currencies were converted 
into 2014 US dollars using the market exchange rate, and then into 2014 
International dollars by applying the relevant purchasing power parity conversion 
factor (Shemilt et al., 2010, Taylor, 2003).  
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4.6 Health outcomes and health-related quality of life 
4.6.1 Introduction  
A CUA involves quantifying the health consequences of health interventions. An 
advantage of CUA is that the health consequences are quantified in comparable 
preference-based units thereby allowing comparisons to be made between 
interventions targeting different diseases. In CUA the consequences on health 
outcomes take into account both the impact on mortality and morbidity. For 
interventions targeting HIV this is becoming increasingly important. There are now 
an increasing number of approaches to improve the health of HIV infected 
individuals, with the disease now considered a chronic manageable infectious 
disease. Therefore, more attention has been given to improving the HRQoL of those 
affected as well as improving their survival.  
 
4.6.2 Measuring health-related quality of life  
Quality of life is a broad term that aims to describe the physical, mental, social, and 
environmental aspects of an individual’s life (WHO, 1995), whilst health-related 
quality of life focuses on the health domains relating to an individual’s life (Guyatt et 
al., 1993). In healthcare research the objective is to provide a quantitative measure 
of an individual’s HRQoL, as a sphygmomanometer does for blood pressure, so that 
the impact of diseases and treatments on an individual can be monitored, or in 
health economics, used to inform inputs into economic evaluations.   
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In health economics two primary metrics exist for quantifying HRQoL, the quality-
adjusted life year weight and the disability-adjusted life year weight. These metrics 
are used to multiply the time an individual spends in that health state and thereby 
allows calculation of quality-adjusted life years (QALYs), or disability-adjusted life 
years (DALYs). Whilst there are differences in their meaning, measurement and use, 
the weights used in calculating QALY broadly equate to the one minus the weights 
used in calculating DALYs (Murray and Acharya, 1997).  
 
There has been considerable debate over the relative merits of the use of DALYs and 
QALYs, and other measures, in economic evaluations (Airoldi and Morton, 2009, 
Anand and Hanson, 1997, Arnesen and Nord, 1999, McAlearney et al., 1999, Murray 
and Acharya, 1997, Gold et al., 2002, Sassi, 2006). Whilst both are preference-based 
measures of HRQoL, the DALY was designed to measure the burden of disease 
(Murray and Acharya, 1997, Murray et al., 2012, Sassi, 2006), whilst the QALY for 
primary use in economic evaluations (Gerard, 1992). Unlike QALYs, DALYs apply an 
additional weight depending on the age of individuals, thereby incorporating equity 
issues into an efficiency calculation (Sassi, 2006). Cost-utility analysis aims to provide 
objective assessments of efficiency, and not normative views of equity, consequently 
incorporating equity into a quantitative evaluation impacts on policy makers and 
societal views on equity (Arnesen and Nord, 1999, Gold et al., 2002).  
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Importantly in HIV there are only 4 possible weights in the calculation of DALYs, 
whilst the tools used to estimate QALYs can discriminate a significantly greater 
number of potential HIV-related health states (Sassi, 2006). As the evidence suggests 
that the impact of HIV and HIV treatment on HRQoL is complex (Alibhai et al., 2010, 
Beard et al., 2009, Louwagie et al., 2007, Peltzer and Phaswana-Mafuya, 2008), using 
QALYs as the health outcome measure in the PhD will allow me to better measure 
the impact of more timely entry into HIV care on HRQoL. 
 
4.6.3 Quality-adjusted life weights and QALY estimation 
The weights used to estimate QALYs represent an assessment of an individual’s 
health state on a scale ranging from zero, equating to death, to one, equating to 
perfect health. Although the scale can extend to negative values, representing health 
states worse than death (Dolan, 1997, Dolan et al., 1996a). A range of tools exists to 
determine these weights (Brazier et al., 1999). One common approach is to ask 
individuals to describe their own health status or health-related quality of life across 
a range of health domains (e.g. pain, mobility, mental health). The responses are 
then converted to a utility score (the QALY weight). A tariff is commonly used to 
convert the responses to the corresponding utility score (the QALY weight). The tariff 
is generally derived from a separate study undertaken in the general population of a 
country. In this study healthy volunteers representative of the general population 
are recruited and then asked to value a selection of health states derived from the 
relevant tool. The process of valuing these health states is based on the theory of 
preferences where individuals are asked to make a choice based on two different 
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health states, the exact method (e.g. standard gamble; time trade off) varies 
depending on the tool used (Brazier et al., 1999, Dolan et al., 1996b, Bleichrodt and 
Johannesson, 1997). In choosing healthy volunteers the study ensures that the 
preference-based values reflect decision-making under uncertainty (Bleichrodt and 
Gafni, 1996, Dolan and Kahneman, 2008), and reflect the methodological 
underpinnings on which cost-utility analysis is based (Brouwer et al., 2008).    
 
The utility weights (or QALY weights) derived are then converted to QALYs by 
multiplying the time spent in the relevant health state by the quality-adjusted weight 
for that health state (Drummond et al., 2005b). Therefore by asking patients about 
their HRQoL at regular intervals, using one of these measures, one can estimate their 
total quality-adjusted years lived during the time period of the analysis.  
 
4.6.4 The EuroQol EQ-5D measure  
The EQ-5D measure is an example of a tool that is commonly used to capture health 
outcomes in QALYs (Dolan, 1997) with the values utilised in cost-utility analysis 
(Drummond et al., 2005b). It is a preference-based generic measure of HRQoL. It has 
been used in over 50 countries, and translated into more than 40 languages, several 
in sub-Saharan Africa. It has been found to have construct validity (good agreement 
with disease specific measures) and is a reliable (high test-retest agreement) 
measure of HRQoL in sub-Saharan Africa and in HIV infected individuals (Jelsma et al., 
2005, Jelsma et al., 2003). 
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The EQ-5D-3L measure compromises two components, the EQ-descriptive 
component and the EQ visual analogue scale (Dolan, 1997). The descriptive 
component defines HRQoL in terms of five dimensions: ‘mobility’, ‘self care’, ‘usual 
activities’, ‘pain/discomfort’ and ‘anxiety/depression’ (Brooks, 1996). Responses in 
each dimension are divided into three ordinal levels, coded: (1) no problems; (2) 
some or moderate problems; and (3) severe or extreme problems. The potential 
responses to the descriptive system can theoretically generate 243 (35) different 
health states. More recently the EQ-5D-5L measure has been developed that is 
comparable to the EQ-5D-3L but each of the five dimensions are now divided into 
five ordinal levels. 
 
The responses to the descriptive component of the EQ-5D-3L are converted to an 
EQ-5D utility score (QALY weight) using a tariff. The tariff sets are derived from 
national surveys of the general population, with a subset of the 243 health states 
being valued, most commonly using the time trade-off method (Dolan et al., 1996a). 
The remainder of the EQ-5D health states are subsequently valued through the 
estimation of a multivariable model.  
 
There is currently no Malawian EQ-5D tariff, and for the studies undertaken in the 
PhD the Zimbabwean EQ-5D tariff set (Jelsma et al., 2003) was used to derive an EQ-
5D utility score for each participant at each relevant time point. The health economic 
literature highlights that it is accepted practice to use tariffs from another country 
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where none exists for the country of interest, provided the investigator believes the 
two populations would value health comparably (Drummond et al., 2005b). Whilst 
the populations of Zimbabwe and Malawi are different, the underlying health issues, 
the population demographics and economics in the country are sufficiently 
comparable to suggest that the two populations would value health comparably.  
 
In accordance with the EuroQol Group’s guidelines the EQ-5D was translated by a 
specialist agency employed for the PhD purposes into Chichewa, the local language 
in the study population in Blantyre, Malawi. The agency used a standardised 
translation protocol that conforms to internationally recognised guidelines (EuroQol, 
no date). Briefly, this involved 2 forward translations by two bilingual translators. 
Then 2 bilingual translators undertook two back translations into English. Finally a 
pilot study with approximately thirty lay persons was used to evaluate the semantics 
and the linguistic adaptations. The EuroQol Group provided feedback to the agency 
at each stage to ensure the EQ-5D concepts have been translated correctly. The 
EuroQoL group approved the final Chichewa version of the EQ-5D-3L for use in 
Malawi.  
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4.7 Summary of Chapter 4 
In this chapter I have provided an overview of my research question and the primary 
and secondary objectives of my PhD. I described why economic evaluations are an 
important tool in public health research and the different approaches to undertaking 
them. I provided a description and rationale for using a cost-utility analysis to 
investigate the cost-effectiveness of providing HIVST in Blantyre, Malawi. I also 
provided an overview of the methods and the economic data reported in the next 
three Chapters (Chapter 5, 6 and 7). In addition, I described how the economic data 
collected would allow me to answer the primary research question (contained in 
Chapter 8).  
 
The following four chapters (Chapters 5, 6, 7 and 8) will provide a more detailed 
description of the relevant methods used in the four studies undertaken, and 
present the findings from them. The Chapters (5, 6, 7 and 8) have been written in 
the format of a manuscript for submission for publication in peer-reviewed journals, 
although the contents of the Chapters are more detailed than required for the final 
manuscripts that have been or will be submitted. Therefore, these Chapters have a 
brief introduction into the specific topic being investigated, a detailed description of 
the methods used, and presentation of the results. In these Chapters I will also 
provide a discussion of the relevant findings, with a more detailed overall discussion 
in Chapter 9.  
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CHAPTER 5:  A comparison of the 
costs and consequences of Facility 
HIV testing and Home HIV self-
testing 
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5 Overview of Chapter 5 
In this chapter I will aim to investigate one of the secondary objectives of my PhD. 
 
To compare and contrast the costs to individuals and to healthcare providers, 
and health-related quality of life outcomes, amongst individuals who access 
facility-based or HIV self-testing services in Blantyre, Malawi 
 
As previously mentioned, the chapter has been written in the format of a manuscript 
for publication in a peer-reviewed journal. The manuscript from this chapter has 
been submitted and is currently under review.  
 
In this Chapter I investigate the costs of providing HIV self-testing and facility-based 
HIV testing and counselling. I estimate the costs for the health providers and those 
who used the service. I also compare the health-related quality of life amongst users 
of both services. The study was undertaken by recruiting only individuals who 
resided in the HiTTB study communities and the services that were costed were the 
ones that were available to the study participants. The economic data collected in 
this chapter will inform the decision-analytic modeling (Chapter 8) to estimate the 
cost-effectiveness of offering HIVST in addition to standard facility-based HTC 
services.  
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5.1 Introduction 
In sub-Saharan Africa, HIV testing and counseling (HTC) remains one of the main 
barriers to timely access to effective HIV treatment and prevention interventions 
(Cohen et al., 2011, Gray et al., 2007a, Grant et al., 2010). The region currently 
accounts for three quarters of all new infections and HIV-related deaths (UNAIDS, 
2014b). Despite increases in investments to scale-up HIV testing services, only half of 
Africans living with HIV know their HIV status (Staveteig et al., 2013, UNAIDS, 2014b).  
 
Facility-based HTC is not popular amongst Africans (Morin et al., 2006, Angotti et al., 
2009, MacPherson et al., 2012a), with evidence suggesting many of barriers could be 
overcome through community-based HTC services, including home-based and 
mobile HTC (Sabapathy et al., 2012). These HTC modalities reach HIV infected 
individuals earlier in their disease progression (Wachira et al., 2012a), reducing 
subsequent healthcare costs of providing HIV care (Leisegang et al., 2009). The high 
cost of delivering community HTC services (Suthar et al., 2013) may explain why few 
National HIV programs have implemented these services (Staveteig et al., 2013). In 
addition, the need for trained healthcare workers, restrictions of service operating 
times, fear of status disclosure and stigma, and concerns over linkage into HIV 
treatment have raised concerns over their long-term sustainability, and usage by 
hard-to-reach groups (Ostermann et al., 2011, Negin et al., 2009, Dolan, 1997, 
Sabapathy et al., 2012). HIV self-testing (HIVST) is highly acceptable, safe and 
effective at achieving high coverage rates in communities, with comparable levels of 
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linkage into HIV services as seen with facility-based HTC services (Choko et al., 2011, 
Choko et al., 2015b, MacPherson et al., 2014). 
 
In this study, I investigated the economic impact on users and healthcare providers 
offering a semi-supervised semi-restricted community distribution model of HIVST. I 
collected individual-level economic data from users of both services, and undertook 
primary costing studies of the two approaches, within the context of a large cluster-
randomised study investigating the health impact of offering HIVST in addition to 
facility-based HTC in Blantyre, Malawi.  
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5.2 Methods 
5.2.1 Ethical statement  
I obtained ethical approval from the College of Medicine Ethics Review Committee, 
University of Malawi; and the University of Warwick Biomedical Research Ethics 
Committee (Appendix I). All participants received an information leaflet in their local 
language (Appendix VI and VII), which explained the study, and all provided 
informed consent (Appendix VIII and IX). 
 
5.2.2 Study setting and study population 
The participants in the cluster-randomised trial (and therefore the population on 
which this study is based) live in three high-density urban suburbs of Blantyre 
(Ndirande, Chilomoni and Likabhula) (Choko et al., 2015b). These communities were 
demarcated into 28 clusters of approximately 1,200 adults using global-positioning 
satellites (GPS) mapping. Residents in 14 clusters were randomised to the 
intervention arm and received community-based access to HIVST and routine 
facility-based HTC. The remaining 14 clusters were allocated to the control arm and 
received access to routine facility-based HTC alone. 
 
Residents who were trained as community HIV counsellors provided HIVST. These 
community counsellors advertised the service at regular intervals, encouraging 
residents to attend the counsellor’s home to receive counselling, directions on how 
to use the self-test kits, and the self-test kits themselves. Residents self-tested in the 
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privacy of their own homes. People in the control arm had their usual continuing 
access to standard facility-based HTC. In all clusters, people had access to HIV testing 
and care services through Queen Elizabeth Central Hospital, or the two primary 
health clinics (Ndirande Health Centre and Chilomoni Health Centre).  
 
HIVST was provided for a 2-year period during the trial, with the service introduced 
into intervention clusters from February to May 2012. In this study I recruited 
participants from February 2013 to April 2014. Recruitment was restricted to 
residents of the main trial clusters and to those who had not already started anti-
retroviral therapy. A previously validated “Map Book” approach designed for the 
main trial (MacPherson et al., 2013) was used to determine whether participants 
were resident in one of the intervention or control clusters of the main trial.  
 
I recruited participants who accessed HIVST consecutively using the Quality 
Assurance (QA) cohort of the main trial (Choko et al., 2015b). In the QA component 
HIVST participants were sampled for checking of compliance with the trial protocol, 
with a minimum 5% randomly selected for home-visit by one of the trial’s study 
nurses. I recruited facility-based HTC participants consecutively from the three local 
health facilities (Queen Elizabeth Central Hospital; Ndirande Health Centre; and 
Chilomoni Health Centre). Appendixes X and XI show the case report form (CRF) 
used to elicit the relevant data form all participants.  
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5.2.3 Cost analysis 
5.2.3.1 Direct health provider costs 
I undertook economic costing of both the HIVST service and facility HTC services 
using a health provider perspective (UNAIDS, 2011, Drummond et al., 2005b). For 
the HIVST service, I interviewed community counsellors to determine resources used 
in providing the service, and programme managers and accounting staff to estimate 
costs of identified resources and other service delivery costs. All research-related 
costs were excluded. Appendix XII shows the data extraction tool used to record the 
resources used at each of the clinics during interviews with staff.  
 
I obtained the HIVST service output records to find out the number of HIV self-
testing episodes for each community counsellor, and total numbers for the service. I 
interviewed counsellors working at the facility HTC services, and administrative staff 
at the Blantyre District Health Office (which manages the two health facilities at 
Ndirande and Chilomoni), and at the Queen Elizabeth Central Hospital. I obtained 
programme output data to determine numbers of individuals tested and number of 
HIV positive individuals identified. I divided resources used in providing HIV testing 
into: (1) staff salaries; (2) staff training; (3) monitoring and evaluation; (4) 
consumables and equipment; and (4) capital/overheads.  
 
Staff salaries included employer contributions and fringe benefits. For staff training, I 
included all training provided to staff that related specifically to service provision. 
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For facility-based HTC, I included the cost of HTC refresher training, but did not 
include the cost of the initial HIV counseling training course. For HIVST, I included the 
cost of the initial HIV counseling training course, as the community workers were not 
previously trained as HIV counselors. I also included the cost of all other training 
provided to the community counselors providing HIVST, but excluded all training for 
research related activities. The cost of staff training was annuitized over their useful 
life with an annual discount rate of 3% (WHO, 2003a), and with the useful life based 
on how often the training would be repeated.  
 
The costs of consumables and equipment’s were obtained from the Malawi Ministry 
of Health (MoH) price catalogue, which includes the cost of shipping for imported 
goods. For items not supplied by the MoH, I used the on-land costs obtained from 
local suppliers. I used the international price for items bought internationally (e.g. 
HIV self-test kits), and included the cost of shipping and insurance. Equipment costs 
were likewise annuitized over their useful life with an annual discount rate of 3% 
(WHO, 2003a). As the majority of the equipment was office equipment, I assumed 
the useful life to be 3 years.  
 
The cost of monitoring and evaluation (M+E) was estimated based on activities 
undertaken locally and centrally. For facility-based HTC, I asked all staff working at 
the facilities about time spent doing M+E activities or providing local supervision, 
and allocated this cost to M+E. In addition, I included the costs of M+E visits from 
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the HIV teams at the Blantyre District Health Office and the Malawi Ministry of 
Health. For the HIVST service, I included all M+E activities undertaken centrally by 
staff working on the main trial, but excluded research-related M+E activities. The 
M+E costs were based on the proportion of total working hours spent by personnel 
at the sites of interest. 
 
Overhead and capital costs included the costs of utilities, security and building 
maintenance. I obtained these costs from the Blantyre District Health office which 
manages the Ndirande and Chilomoni health facilities. The HTC clinic at Queen 
Elizabeth Central hospital (QECH) is managed by the hospital administration. As 
QECH provides both inpatient and outpatient care, I allocated all capital and 
overhead costs based on the ratio of clinical personnel working in the HTC clinic to 
the total number of clinical personnel working at the hospital, and only included 
costs relevant to the outpatient HTC service. The costs of buildings were estimated 
from rental costs for equivalent space. The HIVST service did not incur any capital or 
overhead costs as it is provided in the community counselors’ homes at no 
additional cost.  
 
5.2.3.2 Direct non-medical and indirect costs 
I developed a questionnaire (Appendix XI), administered by an interviewer, which 
asked all participants about direct non-medical costs that they or accompanying 
 157 
family member or carers incurred in accessing HIV testing services, and their 
associated work losses. User fees were not charged for either modality of testing.  
 
The direct non-medical costs included cost of transportation, food and drinks whilst 
waiting, and other costs incurred as a consequence of getting an HIV test. Indirect 
costs were estimated by recording whether participants, or accompanying family 
member or carers, had taken time off work and multiplying work losses by self-
reported income (Pritchard and Sculpher, 2000). In addition, total time taken to 
access the testing service, including travel and waiting time, was recorded. The 
questionnaire eliciting direct non-medical and indirect costs was translated into 
Chichewa, the local language of the study population, and back translated by two 
independent bilingual Malawians to ensure accuracy. The final version of the 
questionnaire was developed following pilot testing and discussions with senior 
Malawian staff working at the Malawi-Liverpool Wellcome Trust Clinical Research 
Programme.  
 
5.2.3.3 Cost conversions 
All costs were converted into 2014 US Dollars and International Dollars (Drummond 
et al., 2005b) using data reported by the World Bank (Evans et al., 2005). For all unit 
costs, the currency, price year and country were recorded. A Gross Domestic Product 
(GDP) deflator index, provided by the World Bank, was used to adjust the cost from 
the price year to the year of reporting (2014). As some prices were for goods 
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purchased, all costs were then converted to 2014 US Dollars using the market 
exchange rate, and to 2014 International dollars using purchasing power parity 
conversion factor (Krijnse Locker and Faerber, 1984, Shemilt et al., 2010).   
 
5.2.4 Health-related quality of life 
All participants recruited into the study were asked about their HIV test result and 
their health-related quality of life (HRQoL) at the time of interview about economic 
costs. I used a self-assessed health (SAH) measure to ask individuals to rate their 
general health on a five-point Likert scale, with responses coded as: very good; good; 
fair; poor; or very poor. The SAH measure has been found to be a strong predictor of 
future health outcomes in high-income settings (Idler and Benyamini, 1997), and has 
also been used in resource-constrained settings (Gilbert and Soskolne, 2003, WHO, 
2002).  
 
The EuroQoL EQ-5D-3L (Dolan, 1997) measure was used to estimate the HRQoL of all 
study participants, a detailed description of the tool is provided in Chapter 4. Briefly, 
the EQ-5D-3L is a generic HRQoL measure, and was translated into Chichewa 
following international and EuroQoL guidelines (EuroQol, no date). The Chichewa 
version of the EQ-5D-3L used for this component of the study is shown in Appendix 
XI. The EQ-5D-3L measure consists of two principal measure components, a 
descriptive system and a visual analogue scale (EuroQol, 1990). The descriptive 
system defines HRQoL in terms of five dimensions: ‘mobility’, ‘self care’, ‘usual 
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activities’, ‘pain/discomfort’ and ‘anxiety/depression’ (Brooks, 1996). Responses in 
each dimension are divided into three ordinal levels, coded: (1) no problems; (2) 
some or moderate problems; and (3) severe or extreme problems. Responses to the 
descriptive component are then converted into an EQ-5D utility score using a tariff 
set that is derived from national surveys of the general population. As no Malawian 
EQ-5D tariff exists, and the Zimbabwean EQ-5D tariff (Jelsma et al., 2003) was used 
to derive EQ-5D utility scores for each study participant.  
 
The visual analogue scale (VAS), similar to a thermometer, ranges from 100 (best 
imaginable health state) to 0 (worst imaginable health state). Participants are asked 
to indicate how good or bad their health was on the day of response by drawing a 
line on the scale.   
 
5.2.5 Statistical analysis 
All analysis was undertaken in Stata version 13.0 (Stata Corporation, Texas, USA). 
Socio-demographic data was collected on all participants recruited into the study. 
This included sex, age, marital status, educational attainment, employment status, 
and self-reported income. For socio-economic position, I collected data on 
household assets, nine in total, and information on home environment, for example 
distance to toilet. I undertook principal component analysis to classify an individual’s 
socio-economic position based on wealth quintiles (Filmer and Pritchett, 2001). 
Appendix X shows the final case report forms used to collect individual-level socio-
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demographic and economic data. Comparisons of socio-demographic characteristics 
were made between participants resident in control clusters and intervention 
clusters using the chi-squared test. 
 
I estimated the direct health provider cost per individual tested, and the cost per HIV 
positive individual identified by dividing the total annual provider cost by the 
number of individuals tested, and the number of HIV positive individuals identified. 
For the HIVST service, I used the HIV prevalence reported in the main study to 
inform the cost per HIV positive individual identified (Choko et al., 2015b). I made 
comparisons between the mean direct non-medical and indirect costs for HIV self-
testers and facility testers, and for facility-testers who resided in control clusters and 
intervention clusters. As the cost data was skewed, I used non-parametric bootstrap 
methods, with 1000 bootstrap replications, to derive 95% confidence intervals (CI) 
for mean cost differences for relevant cost categories (Thompson and Barber, 2000).  
 
I undertook multivariable analysis to investigate the independent effect of the mode 
of HIV testing and HIV test result on the total societal costs associated with HIV 
testing. I estimated the mean total societal cost of HIV testing amongst the 
participants by summing direct and indirect costs. For the HIV self-testers, I 
estimated direct health provider cost per individual tested at the counsellor level. 
This was possible because the HIVST service records the total number of individuals 
tested by each of the community counsellors. For facility-based HIV testers, I used 
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the estimated direct health provider cost per individual tested for the clinic attended 
for testing. This component of the analysis excluded participants who had their HIV 
test at QECH. As all participants incurred a cost, and the cost data was skewed, I 
used generalized linear models (GLM) for multivariable analyses of cost data (Barber 
and Thompson, 2004). I ran model diagnostics to determine the optimal choices for 
the distributional family and link function (Manning and Mullahy, 2001). For this, I 
used a combination of the Park test, linktest, Akaike information criterion and visual 
inspection of plots of the deviance residuals to determine the optimal choice for the 
link function and the distributional family (Harrell, 2013). 
 
I compared the responses to the self-assessed health (SAH) and EQ-5D measures 
between facility-based HIV testers residing in the intervention clusters to those 
residing in control clusters. For the descriptive component of the EQ-5D, few 
respondents reported severe or extreme problems. Responses were therefore 
dichotomized into reporting: no problems; or moderate/severe problems. I used chi-
squared test for categorical variables, and student’s t-test for continuous variables.  
 
I undertook multivariable analysis to investigate the independent effect of the mode 
of HIV testing and HIV test result on the EQ-5D utility score. EQ-5D utility scores 
were non-normally distributed, skewed and truncated at 1.0. I evaluated four 
commonly used estimators to analyse these data: ordinary least squares (OLS) 
regression; Tobit regression, Fractional logit regression (Flogit), and censored least 
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absolute deviations (CLAD) regression (Powell, 1984, Austin et al., 2000, Papke and 
Wooldridge, 1996). I compared the mean squared error (MSE) and mean absolute 
error (MAE) statistics between the observed EQ-5D utility score and the estimated 
scores for the whole sample, and for sub-groups of the sample based on observed 
EQ-5D utility scores to determine the choice of estimator.  
 
For all multivariable analyses, I ran two alternative models, the first adjusted for 
modality of HIV testing received, HIV test result and age and sex, and the second 
additionally adjusted for marital status, educational attainment, income and socio-
economic position (Stangl et al., 2007). I accounted for clustering using the cluster of 
residence for the participants to produce robust variance estimators.   
 
5.2.6 Sensitivity analysis 
I undertook sensitivity analysis to investigate the impact of using an alternative tariff 
set to determine EQ-5D utility scores. I used the UK York A1 tariff (Dolan et al., 
1996a), which has been found to translate health states with ‘severe’ problems in 
one or more of the five dimensions to a lower EQ-5D utility scores than the 
Zimbabwean tariff (Jelsma et al., 2003). For the multivariable analysis of total 
societal costs, I performed additional sensitivity analyses that (i) used the median 
wage of the sample, and (ii) the total HIV testing time to value income loss. 
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5.3 Results 
5.3.1 Participant characteristics 
1,241 participants were recruited; 775 who self-tested and 466 who had facility-
based testing (253/466 were from the intervention clusters and 213/466 from the 
control clusters) (Figure 28). 
 
Figure 28: Recruitment of HIV testing participants 
 
 
Table 9 shows the characteristics of the participants, by residence status within the 
main trial and modality of HIV testing received. Individuals accessing facility-based 
HTC who were resident in the intervention clusters were not statistically significantly 
different in terms of sex, age, marital status, educational attainment, employment or 
wealth, to those who accessed facility-based testing who were resident in the 
control clusters.  
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Table 9: Characteristics of HIV testers 
   
  
Intervention Clusters Control 
Clusters 
 
 
 
*p-
value HIVST Facility HTC Facility HTC 
All   775 253 213  
Sex 
Male 288 (37.2%) 90 (35.6%) 76 (35.7%) 
0.981 
Female 487 (62.8%) 162 (64.3%) 137 (64.3%) 
Age (years) 
18-24 316 (40.8%) 64 (25.3%) 64 (30.0%) 
0.335 25-39 379 (48.9%) 149 (58.9%) 111 (52.1%) 
40+ 80 (10.3%) 40 (15.8%) 28 (17.8%) 
Marital status 
Single (never-married) 227 (29.3%) 40 (15.8%) 26 (12.2%) 
0.606 
Married/Cohabiting 455 (58.7%) 175 (69.2%) 148 (69.5%) 
Separated/Divorced 78 (10.1%) 24 (9.5%) 24 (11.3%) 
Widower/Widow 15 (1.9%) 14 (5.5%) 15 (7.0%) 
Educational 
attainment 
Up to standard 8 300 (38.7%) 132 (52.2%) 124 (58.2%) 0.402 
 Up to form 6 442 (57.0%) 113 (44.7%) 82 (38.5%) 
University or training college 32 (4.1%) 8 (3.2%) 7 (3.3%) 
Missing 1 (0.1%) 0 (0%) 0 (0%) 
Income 
Not working 400 (51.6%) 93 (36.8%) 86 (40.4%) 
0.752 
Up to 4,000 Kwacha/week 162 (20.9%) 79 (31.2%) 56 (36.3%) 
4,000 to 8,000 kwacha/week 108 (13.9%) 42 (16.6%) 34 (16.0%) 
8,000 to 12,000 kwacha/week 48 (6.2%) 18 (7.1%) 15 (7.0%) 
Over 12,000 kwacha/week 57 (7.4%) 21 (8.3%) 22 (10.3%) 
Employment 
status 
Formal employment 139 (17.9%) 75 (29.6%) 62 (29.1%) 
0.801 
 
Informal employment/Unemployed 234 (30.2%) 85 (33.6%) 67 (31.5%) 
School/University 159 (20.5%) 18 (7.1%) 15 (7.0%) 
Retired 2 (0.4%) 1 (0.4%) 1 (0.5%) 
Housework 238 (30.7%) 72 (28.5%) 68 (31.9%) 
Sick leave 2 (0.3%) 2 (0.8%) 0 (0%) 
Socio-economic 
position¶ 
Highest quintile 172 (22.2%) 32 (12.6%) 43 (20.2%) 
0.239 
2nd highest quintile 154 (19.9%) 55 (21.7%) 39 (18.3%) 
Middle quintile 148 (19.1%) 58 (22.9%) 42 (19.7%) 
2nd lowest quintile 145 (18.7%) 55 (21.7%) 48 (22.5%) 
Lowest quintile 154 (19.9%) 53 (20.95%) 41 (19.2%) 
Missing 2 (0.3%) 0 (0%) 0 (0%) 
Had HIV testing 
in last year 
Not tested 127 (16.4%) 96 (38.0%) 97 (45.5%) 
0.048 Tested once 260 (33.5%) 69 (27.3%) 64 (30.0%) 
Tested >1 388 (50.1%) 88 (34.8%) 52 (24.4%) 
*Comparison between facility testers in control and Intervention clusters 
¶Socio-economic position estimated through principal component analysis of responses to assets and housing environment 
questions 
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5.3.2 Direct health provider costs of HTC service 
The direct health provider costs of facility-HTC and HIVST are shown in Table 10. The 
mean costs per individual tested at the three health facilities were US$7.53 
(INT$20.25), US$10.57 (INT$25.18), and US$8.90 (INT$20.44), whilst the costs of 
providing HIVST were US$8.78 (INT$17.25) per-participant. The mean costs per HIV 
positive individual identified at the three health facilities were US$67.33 
(INT$181.05), US$76.39 (INT$182.03), US$28.30 (INT$65.00), whilst the mean cost 
per HIV positive individual identified through HIVST was US$97.50 (INT$191.70).  
 
At the three health facilities, staff salaries accounted for between 11.1% and 17.9%, 
staff training between 0.5% and 1.1%, monitoring and evaluation between 4.2% and 
11.9%, and consumables and equipment between 65.5% and 70.5% of the total 
International Dollar costs. In comparison, for the HIVST service staff salaries 
accounted for 30.3%, staff training for 13.0%, monitoring and evaluation for 20.8%, 
and consumables and equipment accounted for 35.9% of the total International 
Dollar cost.  
 
5.3.3 Direct non-medical and indirect costs for HTC participants 
Table 11 shows the time, and direct non-medical and indirect costs associated with 
accessing either modality of HTC. Most individuals who self-tested did not incur any 
costs, require a family member or carer to accompany them, or need to take time off 
work. Approximately 27% (124/466) of all facility testers reported taking time off 
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work to get tested, and 27% (126/466) needed a family member or carer to 
accompany them for testing. In comparison to HIVST, facility-based HTC participants 
incurred a mean additional direct non-medical cost of US$0.84 (bootstrap 95%CI: 
US$0.73-US$0.95), whilst indirect costs averaged $1.41 (bootstrap 95%CI: US$0.86-
US$1.96), with the testing process taking an additional 176.5 minutes (95%CI: 166.1-
186.9). The mean combined direct non-medical and indirect cost of facility-HTC was 
US$2.93 (bootstrap 95%CI: US$1.92-US$3.94) higher than for HIVST.  
 
5.3.4 Total societal costs of HTC 
The societal cost for facility-HTC was US$11.84 (95%CI: US$10.81-12.86) and for 
HIVST was US$9.23 (95%CI: US$9.14-US$9.32). In the multivariable analysis (Table 
12), after adjusting for individual characteristics and HIV test result, the societal 
costs was US$2.38 (95%CI: US$0.87-US$3.89) less for HIVST than for facility-based 
HTC. 
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Table 10: Annual Direct Health Provider costs of HIV testing and counselling 
 
 
 
 
Ndirande clinic 
 
Chilomoni Clinic 
 
QECH HTC Clinic¶ 
 
HIVST service 
 
Cost category 
US 
Dollars 
(2014) 
INT 
Dollars 
(2014) 
% of 
Total* 
US 
Dollars 
(2014) 
INT 
Dollars 
(2014) 
% of 
Total* 
US 
Dollars 
(2014) 
INT 
Dollars 
(2014) 
% of 
Total* 
US 
Dollars 
(2014) 
INT 
Dollars 
(2014) 
% of 
Total* 
Staff salaries 6,738 24,545 17.9% 6,433 15,019 11.1% 8,710 24,195 12.5% 23,066 79,431 30.3% 
Staff training 353 982 0.7% 530 1,472 1.1% 353 982 0.5% 12,268 34,077 13.0% 
Monitoring + Evaluation 2,098 5,828 4.3% 5,785 16,069 11.9% 2,920 8,111 4.2% 15,833 54,521 20.8% 
Consumables + Equipment 38,453 96,475 70.5% 40,910 94,070 69.6% 60,324 126,995 65.5% 82,133 94,051 35.9% 
Capital/Overheads 3,257 9,047 6.6% 3,102 8,618 6.4% 12,129 33,691 17.4% 0 0 0 
 
Total annual health provider 
cost 
 
50,899 136,876 
 
56,760 135,248 
 
84,436 193,973 
 
133,300 262,080 
 
Direct cost per individual 
tested 
 
7.53 
 
20.25 
 
10.57 
 
25.18 
 
8.90 20.44 8.78 
 
17.25 
 
Direct cost per HIV positive 
identified 
67.33 181.05 76.39 182.03 28.30 65.00 97.50 191.70 
¶Outpatient HIV Testing and counseling clinic at Queen Elizabeth Central Hospital 
*Percentages based on costs estimated in International Dollars 
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Table 11: Direct non-medical and indirect costs and time  
   
Intervention Clusters 
 
 
Control Clusters 
 
Mean Differences (95% CI)*** 
HIVST 
(n=775) 
Facility HTC 
(n=253) 
Facility HTC 
(n=213) 
HIVST V  
All Facility HTC 
Intervention Facility HTC v 
Control Facility HTC 
Patient direct non-medical costs 
2014 US Dollars (Mean/SE) 
2014 INT Dollars (Mean/SE) 
 
0 (0, 0)* 
0 (0, 0)* 
 
0.90 (0.09) 
2.49 (0.25) 
 
0.78 (0.06) 
2.17 (0.16) 
 
-0.84 (-0.95, -0.73) 
-2.32 (-2.63, -2.01)  
 
0.12 (-0.10, 0.33) 
0.32 (-0.28, 0.92) 
Time to get tested (Mean/SE)** 30.2 (1.8) 215.2 (7.0) 196.5 (6.9) -176.5 (-186.9, -166.1) 18.7 (-0.9, 38.3) 
Patient Time off work 
No 
Yes 
 
762 (98.3%) 
13 (1.7%) 
 
190 (75.1%) 
63 (24.9%) 
 
152 (71.4%) 
61 (28.6%) 
- - 
Indirect costs 
2014 US Dollars (Mean/SE) 
2014 INT Dollars (Mean/SE) 
 
0 (0, 0)* 
0 (0, 0)* 
  
1.07 (0.24) 
2.97 (0.67) 
  
1.93 (0.56) 
5.37 (1.55) 
 
-1.41 (-1.96, -0.86) 
-3.91 (-5.44, -2.38) 
 
-0.87 (-2.11, 0.38) 
-2.41 (-5.87, 1.05) 
Family or Carer accompanied 
No 
Yes 
 
762 (98.3%) 
13 (1.7%) 
 
188 (74.3%) 
65 (25.7%) 
 
152 (71.4%) 
61 (28.6%) 
- - 
Family/Carer direct non-medical costs  
2014 US Dollars (Mean/SE) 
2014 INT Dollars (Mean/SE) 
 
0 (0, 0)* 
0 (0, 0)* 
 
0.24 (0.04) 
0.68 (0.11) 
 
0.26 (0.04) 
0.72 (0.11) 
 
-0.25 (-0.31, -0.19) 
-0.70 (-0.86, -0.54) 
 
-0.02 (-0.13, 0.10) 
-0.04 (-0.36, 0.27) 
Family/Carer Time  (Mean/SE)** 0 (0, 0)* 54.3 (6.8) 51.8 (6.4) -52.4 (-43.3, -61.5) 2.5 (-16.5, 21.5) 
Family/Carer Loss of income  
2014 US Dollars (Mean/SE) 
2014 INT Dollars (Mean/SE) 
 
0 (0, 0)* 
0 (0, 0)* 
  
0.03 (0.02) 
0.09 (0.05) 
 
1.29 (0.95) 
3.57 (2.65)  
 
-0.59 (-1.43, 0.25) 
-1.64 (-3.97, 0.69) 
 
-1.25 (-3.16, 0.65) 
-3.48 (-8.70, 1.72) 
Total direct medical and indirect costs   
2014 US Dollars (Mean/SE) 
2014 INT Dollars (Mean/SE) 
 
0 (0, 0)* 
0 (0, 0)* 
 
2.22 (0.27) 
 6.18 (0.74) 
 
3.91 (1.09) 
 10.87 (3.02) 
 
-2.93 (-3.94, -1.92) 
-8.14 (-10.94, -5.35) 
 
-1.69 (-3.88, 0.51) 
-4.69 (-10.73, 1.36) 
*Median and IQR reported because of low numbers incurring costs/taking time 
** Time measured in Minutes and includes travel to and from testing site, waiting time and counseling and testing time 
***Bootstrapped estimates of Mean differences and 95%CI 
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Table 12: Multivariable analysis exploring relationship between modality of HIV testing and total Societal cost of testing*  
  
 
 
 
Total Societal cost 
Model 1 (n=1240) Model 2 (n=1237) 
2014 US Dollars 
Coef (95% CI) 
2014 INT Dollars 
Coef (95% CI) 
2014 US Dollars 
Coef (95% CI) 
2014 INT Dollars 
Coef (95% CI) 
Exposure 
Control Clusters: Facility HTC 
 
Ref Ref Ref Ref 
Intervention Clusters: Facility HTC 
 
-1.45 
(-3.62, 0.73) 
-4.24 
(-9.99, 1.52) 
-0.98 
(-2.59, 0.63) 
-2.97 
(-7.07, 1.13) 
Intervention Clusters: HIVST -3.01** 
(-5.14, -0.88) 
-12.52** 
(-18.23, -6.82) 
-2.38** 
(-3.89, -0.87) 
-10.82** 
(-14.79, -6.87) 
HIV Test 
Result 
HIV Negative 
 
Ref Ref Ref Ref 
HIV Positive 
 
1.19 
(-0.04, 2.41) 
2.76 
(-0.29, 5.81) 
1.11** 
(0.24, 1.99) 
2.57** 
(0.41, 4.72) 
Model 1: adjusted for exposure, HIV test result, age and sex 
Model 2: additionally adjusted for marital status, educational attainment, income and wealth quintile 
Missing data for HIV test result: 1; missing data for educational attainment: 1; missing data for socio-economic position: 2 
*Findings from Generalized Linear Model with Poisson distribution and Identity link function  
**p<0.05 
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5.3.5 Health-related quality of life of HTC participants 
Figure 29 compares the reported EQ-5D utility scores to the reported visual analogue 
scores. The Pearson’s correlation coefficient between the two different self-reported 
HRQoL measures was 0.448.  
 
Figure 30 shows the EQ-5D utility scores of participants by their response to their 
self-assessed health. There were no participants who reported very poor health in 
response to being asked about their SAH.  
 
Figure 29: Comparison of EQ-5D utility scores to Visual Analogue Scale scores 
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Figure 30: EQ-5D utility scores by response to Self-assessed health 
 
 
 
The HIV test result and HRQoL outcomes are shown in Table 13. There was no 
significant difference between facility testers who resided in the intervention and 
control clusters with regards to the mean EQ-5D utility score, the mean VAS score, 
the descriptive components of the EQ-5D measure or their responses to the SAH 
measure. A smaller proportion of HIVST participants reported problems in all five 
EQ-5D dimensions, with the mean EQ-5D utility score amongst them higher (0.905, 
95%CI: 0.897-0.913) than in facility testers residing in the intervention (0.828, 95%CI: 
0.812-0.844) or control (0.839, 95%CI: 0.821-0.857) clusters.  
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The mean VAS score amongst HIVST participants was also higher (82.1, 95%CI: 81.0-
83.3) than amongst facility-HTC participants residing in the intervention (74.5, 
95%CI: 72.2-76.8) or control clusters (75.4, 95%CI: 72.9-78.0). The majority of HIVST 
participants reported being in very good or good health (676/775, 87%), whilst 69% 
of all facility testers reported very good or good health (323/466).  
 
Table 13: Health-related quality of life of HIV testers 
   
Intervention Clusters 
 
 
Control Clusters 
 
 
 
p-
value 
HIVST 
(n=775) 
Facility HTC 
(n=253) 
Facility HTC 
(n=213) 
HIV Test Result HIV negative 670 (86.5%) 146 (57.7%) 115 (54.0%) 0.421 
HIV positive 104 (13.4%) 107 (42.3%) 98 (46.0%) 
Not reported 1 (0.1%) 0 (0%) 0 (0%) 
EQ-5D: Utility Score All 0.905 (0.897, 0.913) 0.828 (0.812, 0.844) 0.839 (0.821, 0.857) 0.359 
HIV negative 0.916 (0.908, 0.924) 0.853 (0.834, 0.873) 0.862 (0.839, 0.884) 0.591 
HIV positive 0.842 (0.814, 0.870) 0.794 (0.768, 0.819) 0.813 (0.786, 0.840) 0.306 
EQ-5D: VAS Score All 82.1 (81.0, 83.3) 74.5 (72.2, 76.8) 75.4 (72.9, 78.0) 0.597 
HIV negative 83.7 (82.5, 84.9) 79.4 (76.6, 82.2) 79.5 (76.0, 82.9) 0.966 
HIV positive 72.5 (69.0, 76.0) 67.9 (64.4, 71.3) 70.7 (67.0, 74.4) 0.270 
EQ-5D: Mobility No problems 689 (88.9%) 180 (71.15%) 162 (76.1%) 0.232 
Moderate or 
severe problems 
86 (11.1%) 73 (28.85%) 51 (23.9%) 
EQ-5D: Self-Care No problems 767 (99.0%) 245 (96.8%) 211 (99.1%) 0.099 
Moderate or 
severe problems 
8 (1.0%) 8 (3.2%) 2 (0.9%) 
EQ-5D: Usual Activities No problems 730 (94.2%) 209 (82.6%) 174 (81.7%) 0.796 
Moderate or 
severe problems 
45 (5.8%) 44 (17.4%) 39 (18.3%) 
EQ-5D: Pain No problems 565 (72.9%) 131 (51.8%) 112 (52.6%) 0.863 
Moderate or 
severe problems 
210 (27.1%) 122 (48.2%) 101 (47.4%) 
EQ-5D: Anxiety No problems 519 (67.0%) 126 (49.8%) 110 (51.6%) 0.692 
Moderate or 
severe problems 
256 (33.0%) 127 (50.2%) 103 (48.4%) 
Self-Assessed Health Excellent 318 (41.0%) 53 (20.9%) 42 (19.7%) 0.947 
Good 358 (46.2%) 121 (47.8%) 107 (50.2%) 
Fair 87 (11.2%) 60 (23.7%) 50 (23.5%) 
Poor 12 (1.5%) 19 (7.5%) 14 (6.6%) 
Very Poor 0 (0%) 0 (0%) 0 (0%) 
*Comparison between facility testers in control and Intervention clusters 
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In the multivariable analysis, the model diagnostics revealed the OLS estimator 
performed as well or better than the other estimators (Table 14 and Table 15). The 
EQ-5D utility scores predicted by the OLS estimator show close approximation to the 
observed EQ-5D utility scores in the sample. All estimators preformed less optimally 
in predicting lower EQ-5D utility scores.  
 
 
Table 14: Estimated predicted values compared to actual utility scores 
 
 Model Obs Mean Min Max MSE MAE 
Observed 1241 0.878 0.121 1.000   
 
Model 
OLS 1237 0.878 0.736 0.975 0.000 0.094 
TOBIT 1237 0.886 0.703 0.970 0.007 0.094 
CLAD 1237 0.891 0.670 1.042 0.012 0.093 
 Flogit 1237 0.879 0.701 0.956 0.000 0.096 
OLS: Ordinary Least Squares   MSE: Mean Squared Error 
Flogit: Fractional logit    MAE: Mean Absolute Error 
CLAD: Censored least Absolute deviations 
 
 
Table 15: MSE and MAE for regression models by utility score range 
 Observed EQ-5D utility score 
  <0 0 to <0.2 0.2 to <0.4 0.4 to <0.6 0.6 to <0.8 0.8 to <1 1 
Obs 0 1 2 30 350 310 544 
    MSE MAE MSE MAE MSE MAE MSE MAE MSE MAE MSE MAE 
OLS - - 0.759 0.759 0.430 0.430 0.302 0.302 0.010 0.102 0.030 0.050 0.101 0.101 
TOBIT - - 0.784 0.784 0.430 0.430 0.306 0.306 0.106 0.109 0.036 0.057 0.092 0.092 
CLAD - - 0.775 0.775 0.444 0.444 0.309 0.309 0.105 0.108 0.039 0.066 0.081 0.083 
Flogit - - 0.771 0.771 0.421 0.421 0.300 0.300 0.100 0.104 0.053 0.031 0.101 0.101 
OLS: Ordinary Least Squares   MSE: Mean Squared Error 
Flogit: Fractional logit    MAE: Mean Absolute Error 
CLAD: Censored least Absolute deviations 
 174 
In the fully adjusted OLS model (Table 16), individuals who accessed HIVST had a 
higher adjusted mean EQ-5D utility score of 0.046 (95%CI: 0.022-0.070) than those 
who accessed facility-HTC. Those who tested HIV positive had a lower adjusted mean 
EQ-5D utility score of 0.048 (95%CI: 0.024-0.073) than those who tested HIV 
negative. There were no significant differences in the adjusted mean EQ-5D utility 
scores between facility testers who resided in the control and intervention clusters.  
 
Table 16: Multivariable analysis exploring relationship between modality of HIV testing 
and EQ-5D utility scores* 
    
 
EQ-5D Utility Score 
(Zimbabwean Tariff) 
 
Sensitivity Analysis 
 
EQ-5D Utility Score  
(UK Tariff) 
Model 1 
(n=1240) 
Coef (95% CI) 
Model 2 
(n=1237) 
Coef (95% CI) 
Model 1 
(n=1240) 
Coef (95% CI) 
Model 2 
(n=1237) 
Coef (95% CI) 
Exposure 
Control Clusters: 
Facility HTC 
 
Ref Ref Ref Ref 
Intervention Clusters: 
Facility HTC 
 
-0.012 
(-0.038, 0.014) 
-0.011 
(-0.037, 0.015) 
-0.145 
(-0.055, 0.026) 
-0.012 
(-0.053, 0.029) 
Intervention Clusters: 
HIVST 
 
0.043** 
(0.018, 0.068) 
0.046** 
(0.022, 0.070) 
0.059** 
(0.026, 0.092) 
0.065** 
(0.031, 0.099) 
HIV Test 
Result 
 
HIV Negative 
 
 
Ref 
 
Ref 
 
Ref 
 
Ref 
HIV Positive 
 
 
-0.054** 
(-0.077, -0.031) 
-0.048** 
(-0.073, -0.024) 
-0.076** 
(-0.112, -0.040) 
-0.068** 
(-0.105, -0.031) 
Model 1: adjusted for exposure, HIV test result, age and sex 
Model 2: additionally adjusted for marital status, educational attainment, income and wealth quintile 
Missing data for HIV test result: 1; missing data for educational attainment: 1; missing data for socio-economic position: 2 
*Findings from OLS estimator 
**p<0.05 
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5.3.6 Findings from sensitivity analysis 
In the sensitivity analysis, when the UK tariff was used to derive EQ-5D utility scores, 
the adjusted mean EQ-5D utility score was 0.059 (95%CI: 0.026-0.092) higher 
amongst HIVST participants than amongst facility testers (Table 16). In addition, 
those reporting a positive HIV test result had an even lower mean adjusted utility 
decrement compared to those who reported a negative HIV test result (0.068; 
95%CI: 0.031-0.105). Table 17 shows that the total societal cost of HIVST remains 
lower than facility-based HTC when alternative approaches to valuing loss of income.  
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Table 17: Sensitivity Analysis for multivariable regression of total societal cost (Model 2)* 
 
 
Total Societal cost 
Sensitivity Analysis A 
(n=1237) 
 
Sensitivity Analysis B 
(n=1237) 
Sensitivity Analysis C 
(n=1237) 
2014 US Dollars 
Coef (95% CI) 
2014 INT Dollars 
Coef (95% CI) 
2014 US Dollars 
Coef (95% CI) 
2014 INT Dollars 
Coef (95% CI) 
2014 US Dollars 
Coef (95% CI) 
2014 INT Dollars 
Coef (95% CI) 
Exposure 
Control Clusters: Facility HTC 
 
Ref Ref Ref Ref Ref Ref 
Intervention Clusters: Facility HTC 
 
0.19 
(-0.76, 1.15) 
0.35 
(-1.66, 2.35) 
-0.32  
(-1.66, 1.03) 
-1.07 
(-4.41, 2.27) 
 0.36 
(-0.47, 1.18) 
0.82  
(-0.89, 2.53) 
Intervention Clusters: HIVST 
 
-1.12 
(-2.02, 0.22) 
-7.30** 
(-9.57, -5.04) 
-1.88** 
(-3.13, -0.62) 
-9.38** 
(-12.69, -6.07) 
-1.73** 
(-2.56, -0.92) 
-8.97** 
(-11.10, -6.84) 
HIV Test 
Result 
HIV Negative 
 
Ref Ref Ref Ref Ref Ref 
HIV Positive 
 
0.77** 
(0.45, 1.08) 
1.70** 
(0.97, 2.43) 
1.30** 
(0.63, 1.97) 
3.09** 
(1.44, 4.74) 
0.77** 
(0.47, 1.08) 
1.75** 
(1.02, 2.49) 
*Findings from Generalized Linear Model with Poisson distribution and Identity link function  
**p<0.05 
 
 
 
Sensitivity Analysis A: Using median wage rate and self-reported time off work to value income loss 
Sensitivity Analysis B: Using self-reported income and total HIV testing time to value income loss  
Sensitivity Analysis C: Using median wage rate and total HIV testing time to value income loss 
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5.4 Discussion 
In this component of the PhD, I found that HIVST reaches a healthier population, 
with users incurring lower direct non-medical and work absences, whilst the direct 
health provider costs of offering HIVST were comparable to facility-based HTC. At 
the societal level, the cost of offering HIVST was found to be significantly lower than 
the cost of facility-based HTC. Recent work has highlighted the high population 
uptake, safety and acceptable linkage into HIV treatment services when HIVST has 
been provided to communities in Blantyre, Malawi (Choko et al., 2015b). Taken 
together, these data suggest that HIVST is an affordable and potentially highly 
effective option for national policy makers in Africa wishing to increase uptake of HIV 
testing.  
 
The main finding of the analysis was the comparable cost of offering HIVST to that of 
facility-based HTC services. However it must be remembered that at the population 
level the cost of providing HIVST, in addition to routine facility-based HTC services, 
will place significant financial burden on healthcare providers. Importantly, the 
direct health provider costs of HIVST (US$8.78 in 2014 prices) compares favourably 
with previous estimates of mobile or home-based HIV testing services (US$7.77 to 
US$33.54 in 2012 prices) (Suthar et al., 2013), suggesting HIVST offers an affordable 
option for providers wishing to scale-up community-based HIV testing services. The 
relatively high current cost of the oral fluid RDT kits (2014 US$4, or US$4.80 
including shipping and insurance), compared to the cost of the standard finger-prick 
RDT kit used in health facilities (2014 US$0.69 in my analysis) accounts for much of 
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the difference in costs between the two modalities of HIV testing examine in this 
study. The cost of oral fluid RDT kits accounted for approximately one half of the 
total cost per individual tested through HIVST, whilst the cost of the rapid finger-
prick test kit accounted for only one tenth of the cost of facility-based HTC.  
 
Previous research highlights that high direct non-medical and indirect costs act as a 
deterrent to individuals accessing facility-based HTC services (Wolff et al., 2005, 
Morin et al., 2006, Wringe et al., 2009). In comparison to HIVST, I found facility 
testers incurred an additional US$2.93 to test for HIV in a health facility. In Malawi 
approximately three-quarters of the population live on less than $2 a day (Bank). 
Therefore, it is easily understandable why the high client costs of accessing facility-
based HTC may act as a deterrent, and this may partly explain the high levels of 
uptake of HIVST seen in the main trial (Choko et al., 2015b).  
 
HIV testing and counseling has been provided at health facilities in Africa for nearly a 
decade. HIV counselors at health facilities are experienced in providing HTC, and 
monitoring and evaluation systems have evolved. HIVST is still in its infancy, with 
concerns around potential harms it may cause users (Scott, 2014). Consequently, in 
the main trial HIVST was provided through a semi-supervised semi-restricted 
community distribution model. Community counselors providing HIVST needed 
additional training around delivering HIV self-testing, and had regular visits by 
supervisors to monitor the service and ensure safety and quality. This is reflected in 
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the costing’s which show that salaries, staff training, and monitoring and evaluation 
accounted for approximately two-thirds of the cost of delivering HIVST, whilst these 
costs represented less than a quarter of the cost of delivering facility-based HTC.  
 
I used the average yield from the HIVST service over the two years in operation to 
estimate the health provider cost per HIV positive individual identified through 
HIVST, assuming individuals were offered annual HIVST. In the main trial, the HIV 
prevalence amongst self-testers was found to be higher in the first year than in the 
second (representing prevalence rather than incidence testing) (Choko et al., 2015b). 
As the cost per individual tested through HIVST services may vary, it will be 
important to consider this issue in the main decision-analytical modeling, and 
investigate the impact on different costs on the final estimates of cost-effectiveness.  
 
I made comparisons between facility testers who were residents of the intervention 
clusters of the main trial, and therefore had the option of HIV self-testing, and those 
who lived in control clusters, and who therefore did not have access to HIVST. I 
found that there were no statistically significant differences between these two 
populations of facility testers, and that the yield of HIV positive individuals was 
comparable.  
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Community-based HTC strategies are a more costly approach to identifying HIV 
positive individuals (Menzies et al., 2009). I found the cost per HIV positive individual 
identified was lower at the health facilities than through HIVST, with the lowest cost 
at the HTC facility at Queen Elizabeth Central Hospital. However, those who self-
tested reported better HRQoL than those who accessed facility testing services, even 
after accounting for differences in HIV test result. In addition, previous work from 
the main trial found the median CD4 count amongst HIV self-testers who initiated 
ART to be higher than facility-based testers who initiated ART (Choko et al., 2015b). 
Evidence from studies examining HRQoL in HIV positive individuals suggests that 
HRQoL deteriorates with advancing HIV disease (Alibhai et al., 2010, Beard et al., 
2009). The finding of HIV self-testers and those identified HIV-positive through HIVST 
reporting better HRQoL than facility testers is likely to reflect lead time bias, with 
HIVST detecting individuals earlier in their HIV disease progression (Figure 31). HIVST 
is offered in the community and therefore will be utilised by individuals who may 
otherwise be well. Many of those who access facility-based HTC services are 
attending the health facility because they are unwell and or have more advanced HIV 
disease, and have been referred for HIV testing by medical personnel. The value of 
HIVST will partly depend on if HIV-positives individuals initiated onto ART, 
subsequently experience improvements in their HRQoL (Figure 32). The study 
undertaken in Chapter 6 further explores this issue by examining the impact of HIV 
disease stage (and CD4 count) on HRQoL before and after starting anti-retroviral 
therapy.  
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Figure 31: Quality of life adjusted survival without ART 
 
 
Figure 32: Quality of life adjusted survival with ART 
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5.5 Summary of Chapter 5 
In this chapter I undertook primary data collection from participants of a trial of 
HIVST in Blantyre, Malawi. I collected data from participants on the costs they 
incurred in accessing either HIVST or facility-based HTC. I also undertook primary 
costing studies to estimate the health provider cost of providing each service. I 
looked at the total societal cost of accessing each modality of HIV testing. In addition, 
I investigated the health-related quality of life of people who accessed each modality 
of HIV testing.  
 
The findings suggest that offering HIVST reduces the economic burden on clients and 
at the societal level is cost saving. The affordability of HIVST would substantially 
improve if the costs of HIV self-test kits were lower. The economic data collected 
from this chapter will be used to inform the decision-analytic modeling of the cost-
effectiveness of HIVST (Chapter 8).  This study provides estimates for the health 
provider cost of both facility-based HTC and HIVST. In addition, the multivariable 
analysis provides estimates for the societal costs of providing both facility-based HTC 
and HIVST whilst controlling for individual level characteristics and HIV test result.  
 
In Chapter 6, I will describe the study I undertook amongst HIV positive individuals 
who attended the HIV clinic to access HIV care after accessing either facility-based 
HTC or HIV self-testing.  
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CHAPTER 6: A comparison of the 
costs and consequences of 
Accessing HIV treatment 
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6 Overview of Chapter 6 
In this chapter I will aim to investigate one of the secondary objectives of my PhD. 
 
To compare and contrast the costs to individuals and to healthcare providers, 
and health-related quality of life outcomes, amongst HIV positive individuals 
who access HIV care and treatment services subsequent to testing at facility-
based or through HIV self-testing services in Blantyre, Malawi 
 
As previously mentioned, the chapter has been written in the format of a manuscript 
for publication in a peer-reviewed journal. The manuscript from this chapter will be 
submitted in the coming months.  
 
In this Chapter, I follow-up a cohort of HIV positive individuals as they access HIV 
care after accessing either HIVST or facility-based HTC. I investigate the costs of 
providing HIV care, including anti-retroviral therapy, to the population. In addition, I 
investigate the health outcomes amongst HIV positive individuals and investigate 
whether their HIV disease stage and starting anti-retroviral therapy impacts on their 
health-related quality of life. I also investigate whether the modality of HIV testing 
received prior to entering HIV care independently affects these economic outcomes. 
The economic data collected in this Chapter will inform the decision-analytic 
modelling undertaken in Chapter 8 of the PhD.  
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6.1 Introduction 
There are now over 13 million people worldwide living with HIV who are receiving 
anti-retroviral therapy (ART), with 6 million individuals started onto treatment since 
2010 (UNAIDS, 2014b). Sub-Saharan Africa accounts for three quarters of those on 
anti-retroviral therapy (UNAIDS, 2014b). Providing HIV care and treatment is costly, 
with limited data around to inform to inform policy makers (Levy et al., 2006, Beck et 
al., 2010). The existing economic data relates to services provided in South Africa 
(Harling and Wood, 2007, Rosen et al., 2008, Martinson et al., 2009, Long et al., 
2010), or from estimates based on international donor supported services (Menzies 
et al., 2011, Larson et al., 2013, Menzies et al., 2012, Marseille et al., 2012). These 
estimates tend to be higher (Johns et al., 2014, Babigumira et al., 2009), or do not 
reflect current and local approaches to providing HIV services (Menzies et al., 2011, 
Menzies et al., 2012, Marseille et al., 2012, Rosen et al., 2008). Additionally there is 
limited data on the impact of ART on preferences-based measures of health-related 
quality of life (HRQoL) for use in economic evaluations (Robberstad and Olsen, 2010, 
Beard et al., 2009), or on the costs incurred by those affected when they access HIV 
services (Chimbindi et al., 2015, Schwartlander et al., 2011).  
 
HIV self-testing (HIVST) offers an opportunity to increase awareness of HIV status at 
the population-level and potentially reach individuals earlier in their HIV disease 
stage (Choko et al., 2011). This will result in an increased financial burden on 
healthcare providers with increased numbers entering HIV treatment services. 
However, there are likely to be potential cost savings, through prevention of HIV 
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associated comorbidities, and a beneficial impact on health outcomes of those 
affected, through timely initiation of ART (Leisegang et al., 2009, Badri et al., 2006a, 
Jahn et al., 2008, May et al., 2010a). Consequently, to undertake a full economic 
evaluation of HIVST requires an understanding of the economic and quality of life 
impact of accessing HIV care, and whether there are differences in these outcomes 
between those who enter HIV care after HIVST or facility-based HIV testing and 
counselling (HTC) (Mavedzenge et al., 2013, Pant Pai et al., 2013).   
 
In this component of the PhD I investigate the economic impact associated with HIV 
infected individuals of accessed HIV treatment, and the cost to healthcare providers 
providing this care. I recruited a cohort of HIV positive individuals who attended the 
health facilities in Blantyre, Malawi to access HIV treatment. The main aims were to 
investigate the HQRoL of HIV infected individuals as they accessed HIV treatment, 
and to estimate the economic costs of HIV treatment for individuals accessing care 
and for health providers providing the care. I investigate whether there are 
differences in economic and HRQoL outcomes between those who entered HIV 
services after HIVST and after facility-based HTC. Additionally, I aimed to investigate 
the impact of HIV disease stage on these economic outcomes.  
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6.2 Methods 
6.2.1 Ethical statement  
This study follows on from the study described in Chapter 5. Ethical approval for this 
study was obtained in combination with the previous study comparing HIVST to 
facility-based HTC. This was to enable data collected from the previous study to be 
linked to this study, and to obtain information of past HIV testing on those who were 
recruited into this study but not in the previous study. Ethical approval was obtained 
from the College of Medicine Ethics Review Committee, University of Malawi; and 
the University of Warwick Biomedical Research Ethics Committee (Appendix I). All 
participants received the same information leaflets and the same procedures were 
followed to obtain informed consent (Appendix VI; VII; VIII; IX).  
 
6.2.2 Overview  
The study compares the economic impact of accessing HIV treatment for those who 
test HIV positive. The study also examines this in the context of the modality of HIV 
testing received, aiming to compare the effects of HIVST or standard facility-based 
HTC. HIV positive participants were recruited into the study if they attended health 
facilities in Blantyre, Malawi to be assessed for eligibility for ART. Observation of 
participants was divided into two time periods. The first time period (pre-ART) was 
from initial visit to the health facility until participants either initiated anti-retroviral 
therapy or were assessed to be ineligible for ART. The second time period (ART) was 
from initiation of anti-retroviral therapy until completion of the first on treatment. 
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Figure 33 provides an overview of these two time periods and how they relate to the 
clinical care participants received. For each time period, I investigated direct health 
provider costs, direct non-medical and indirect costs of accessing HIV care, and 
health-related quality of life (HRQoL) of participants.  
 
Figure 33: Description of observation period for HIV cohort study   
 
 
6.2.3 Study setting and study population 
I recruited a cohort of adults (aged>=18 years) who were participants in a cluster-
randomised trial, undertaken in three high-density urban suburbs (Ndirande, 
Chilomoni and Likabhula) of Blantyre, Malawi (Choko et al., 2015a). The methods 
used in the trial have been described previously (Chapter 2). Participants were 
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recruited into this cohort study if they were cluster residents and they attended the 
health facility to be assessed for eligibility for ART.  
 
For this study eligible participants included those who had been recruited into the 
previous cross-sectional study comparing HIVST to facility-based HTC and who tested 
HIV positive (Chapter 5). They were only recruited into this component of the study 
if they returned to the health facility to be assessed for ART eligibility following 
testing. In addition, cluster residents who attended the three health facilities to be 
assessed for ART eligibility and who had accessed either modality of HIV testing after 
the main cluster-randomised trial had started were also recruited into this cohort 
study. Recruitment was undertaken at the same three health facilities serving the 
cluster residents: Queen Elizabeth Central Hospital (QECH); Ndirande Health Centre; 
and Chilomoni Health Centre. This present study also recruited participants from 
February 2013 to April 2014. The  “Map Book” approach was again used to 
determine cluster of residence (MacPherson et al., 2013), and consequently whether 
participants were eligible for recruitment into this study.  
 
In Malawi more broadly and in the study clinics specifically, those who test HIV 
positive access the HIV treatment clinic at health facilities for subsequent HIV care. 
At the health facility HIV positive individuals are seen by a health professional for an 
initial assessment which includes CD4 count measurement, screening for presence of 
active Tuberculosis, WHO clinical staging and provision of cotrimoxazole. Individuals 
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may be required to visit the health facility multiple times to complete this 
assessment. Individuals who meet the Malawi national ART eligibility criteria (CD4 
count <350 cells/mm3 or WHO stage 3 or 4, or breastfeeding or pregnant) are 
subsequently initiated onto ART.  
 
Those who are eligible for ART attend a group counselling session to prepare for 
initiation onto treatment, and if ready, are given the anti-retroviral (ARV) 
medications. Individuals are then asked to return to the health facility at regular 
intervals to see a nurse and obtain further supplies of ARVs and other relevant 
medications (e.g. Cotrimoxazole). On each return visit to the health facility, the 
individual is seen by a nurse who assesses them for any problems including ARV drug 
adherence (or lack of) and side-effects from taking the ARVs, and screens them for 
other clinical problems including TB. The nurse may refer patients to be seen by a 
clinical officer or doctor if there are any problems that cannot be managed. At the 
clinic, individuals may also have investigations or be given medications for treatment 
of other illnesses. Of note, individuals attending the ART clinic at QECH may be 
referred by the nurse to either a doctor or clinical officer, whilst at the two health 
centres (Ndirande Health Centre and Chilomoni Health Centre), only referral to a 
clinical officer is possible. At each visit to the health facility after ART initiation, the 
nurse will provide the individual with a date for a return visit to the clinic and 
sufficient ARV drug supplies until that date. Frequency of visits may be as regular as 
one per week, or as irregular as six monthly, and will depend on the patients’ 
response to ART.  
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Participants recruited into this cohort study were seen at their first attendance to 
the health facility for assessment for ART eligibility. The field worker then saw the 
participants at each subsequent visit to the health facility.  At each visit to the health 
facility, the field worker asked the participant a series of pre-specified questions 
about the medical management they received, the direct non-medical and indirect 
costs that were incurred and their health-related quality of life. For their medical 
management, the participant was asked about the results of their CD4 
measurements, their ART regimen and any side effects experienced from taking the 
treatment, as well as findings from their screening for TB. In addition, participants 
were asked about which medical personnel they saw at the clinic, any investigations 
performed and any other medications given. Appendix XIII shows the questionnaires 
the field worker completed with participants at each visit. Participation follow-up 
was for a one year from anti-retroviral therapy initiation, with participants censored 
if they were not eligible for ART or if they were lost to follow-up. 
 
6.2.4 Cost analysis 
6.2.4.1 Direct health provider costs 
I undertook economic costing of care provision models at the three health facilities 
(QECH; Ndirande Health Centre; and Chilomoni Health Centre) providing the HIV 
care and treatment to the study participants. Economic costing was undertaken from 
the health provider perspective (UNAIDS, 2011, Drummond et al., 2005b), and 
followed the same macro-costing principles used in Chapter 5 and described in 
Chapter 4.  
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I interviewed the senior nurse at each health facility to determine the resources 
used in providing medical care provided to study participants. I also interviewed 
central administrative staff at the Blantyre District Health Office that manage the 
two health facilities (Ndirande and Chilomoni), and central administrative staff at the 
Queen Elizabeth Central Hospital (QECH) to estimate costs for central support and 
overheads. All the interviews followed the same procedures described in Chapter 5, 
and used the same data extraction tool to record resources used (Appendix XII). 
 
I estimated the average cost of visiting each of the three health facilities and the 
average cost per consultation for the different types of medical staff. Participants 
could be seen by: a counsellor, a nurse, a clinical officer or a doctor. I obtained the 
average annual salaries for each of these and the average time each spent with their 
patients.  
 
To estimate the average cost per health facility visit, I recorded all the staff that 
worked at the facility and the proportion of their working time they spent not in 
direct contact with patients. I recorded the consumables and their respective 
quantities used annually. I also made a list of all equipment at each clinic. I then 
obtained estimates for central support costs from the central administrative staff. 
These included the costs for utilities, security and building maintenance. I included 
the costs of monitoring and evaluation visits by the HIV teams at the Blantyre District 
Health Office and Malawi Ministry of Health (MoH). There was no cost available for 
 193 
the purchase or construction of the buildings at the health facilities. However, the 
rooms at the clinics are often rented for research studies, and therefore the proxy 
rental costs were used. I took into account the number of clinic rooms and waiting 
areas at each of the health facilities and multiplied these numbers by their 
respective rental costs. For the HIV Clinic at QECH, I followed the same principle for 
estimating the central administrative and overhead costs as in Chapter 5. I estimated 
the total capital and overhead costs (undertaken in Chapter 7) and allocated a 
proportion of this cost to the total running cost, based on the ratio of clinical 
personnel working in the clinic to the total number of clinical personnel working at 
the hospital, and only included costs relevant to providing the HIV treatment service. 
 
Staff salaries were obtained from the employer, and included employer 
contributions and fringe benefits. I followed the same process in obtaining unit costs 
for consumables and equipment’s used at the HIV clinics. The costs of consumables 
and equipment’s were obtained from the Malawi Ministry of Health price catalogue, 
which includes the cost of shipping for imported goods. For items not supplied by 
the Malawi MoH, I used the on-land costs obtained from local suppliers. For items 
bought internationally, I included the cost of shipping and insurance provided in the 
quote. I assumed the useful life of equipment to be 3 years, and annuitized costs at 
an annual discount rate of 3% (WHO, 2003a).  
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After estimating the total cost of each clinic, excluding the cost of direct patient 
contact, I obtained the outputs of the clinic. The clinics record and report to the 
Blantyre District health office, and Malawi MoH, the total numbers of individuals 
attending the clinic for HIV care. I divided the total cost by these attendance data to 
estimate the average health provider cost of a health facility visit.   
 
I used the international market price for the cost of medications, including anti-
retroviral medications (Health, 2013). Medications at the clinics are supplied from 
central pharmacy and dispensed by the nurses at the clinics. I therefore took into 
account the cost of dispensing the drug by central pharmacy by using the average 
costs per prescription estimated in Chapter 7. This cost was added to the 
international market price, and equated to US$0.0058 (INT$ 0.0162) per dosage of 
drug  (Chapter 7, Table 46). Investigations undertaken at the health facilities are 
processed (e.g. HIV viral load) or performed at QECH (e.g. Chest X-Ray). I therefore 
used the costs of investigations I estimated for QECH (Chapter 7, Table 43 and Table 
44). Of note, during the study period HIV viral load was not routinely undertaken.  
 
6.2.4.2 Direct non-medical and indirect costs 
HIV treatment is provided free to individuals in Malawi; however, individuals will 
incur costs when attending the health facility. These costs include the cost of 
transportation, food and drinks whilst waiting. In addition, they may take time off 
work or be accompanied by a carer or family member. As these cost categories are 
 195 
comparable to those estimated in Chapter 5, I followed the same approach in 
quantifying the direct non-medical and indirect costs incurred by individuals on each 
visit to the clinic. At each visit, participants were asked about the direct non-medical 
costs that they or their accompanying family members or carers incurred in 
accessing HIV treatment services, and the associated work losses (Appendix XIII). 
The questions were adapted from those developed in Chapter 5 and translated into 
Chichewa, the local language of the study population. The questionnaire was pilot 
tested and discussions were held with senior Malawian staff working at the Malawi-
Liverpool Wellcome Trust Clinical Research Programme, to determine if additional 
questions should be added to optimise the questionnaire.  
  
6.2.4.3 Cost conversions 
All costs were converted into 2014 US Dollars and International Dollars (Drummond 
et al., 2005b) using data reported by the World Bank (Evans et al., 2005). For all unit 
costs the currency, price year and country were recorded. A Gross Domestic Product 
(GDP) deflator index, provided by the World Bank, was used to adjust costs from the 
price year to the year of reporting (2014). All costs were then converted into 2014 
US Dollars using the market exchange rate, and to 2014 International dollars using 
the purchasing power parity conversion factor (Krijnse Locker and Faerber, 1984, 
Shemilt et al., 2010).   
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6.2.5 Health-related quality of life 
On each visit to the clinic, participants were asked about their health-related quality 
of life (HRQoL). The self-assessed health (SAH) measure was used to ask individuals 
to rate their general health on a five-point Likert scale, with responses coded as: very 
good; good; fair; poor; or very poor.  
 
The Chichewa EuroQoL EQ-5D-3L (Dolan, 1997) was used to estimate the HRQoL of 
all study participants (Appendix XIII). Participants completed both the descriptive 
EQ-5D-3L system and a visual analogue scale (EuroQol, 1990). A more detailed 
description of the EQ-5D tool is provided in Chapter 4 of the PhD. Briefly, the 
responses to the five dimensions in the EQ-5D-3L descriptive system are converted 
into an EQ-5D utility score using a tariff. Tariff sets have been derived from national 
surveys of the general population, with a subset of the 243 health states being 
valued, most commonly using the time trade-off method (EuroQol 1990). The 
remainder of the EQ-5D health states are subsequently valued through the 
estimation of a multivariable model.  As there is no Malawian EQ-5D tariff, I used the 
Zimbabwean EQ-5D tariff set (Jelsma et al., 2003) to derive an EQ-5D utility score for 
each study participant. The other component of the EQ-5D tool is the visual 
analogue scale (VAS), similar to a thermometer, and ranges from 100 (best 
imaginable health state) to 0 (worst imaginable health state). Participants record 
how good or bad their health is on that day by drawing a line on the scale.  
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6.2.6 Statistical analysis 
All analyses were undertaken in Stata version 13.0 (Stata Corporation, Texas, USA). 
Socio-demographic data was collected on all participants recruited into the study. 
For this I used the same questionnaire as used in Chapter 5 (Appendix X). The 
questionnaires recorded the sex, age, marital status, educational attainment, 
employment status, and self-reported income of participants. For socio-economic 
position, I undertook principal component analysis (described in Chapter 5) to 
classify an individual’s socio-economic position based on wealth quintiles (Filmer and 
Pritchett, 2001). 
 
I estimated the total direct health provider cost for each clinic visit recorded. The 
total direct health provider cost was estimating by adding the: (1) average cost per 
health facility visit; (2) average cost per consultation; (3) cost of all medications 
given; and (4) cost of all investigations performed. I then allocated each clinic visit 
cost to one of the two main observation periods: (1) pre-ART observation period; or 
(2) ART observation period (Figure 33). The pre-ART observation period included all 
the costs that were incurred before the participant started anti-retroviral therapy. 
The ART observation period included all the costs that were incurred after the 
participant started anti-retroviral therapy. To determine the observation period to 
which the costs were to be allocated I used the date of initiation of anti-retroviral 
therapy. I followed the same processes for the allocation of the direct non-medical 
and indirect costs to the relevant observation period.  
 198 
 I estimated the total societal cost per study participant by adding the total health 
provider cost to the total direct non-medical and indirect costs. I estimated the 
mean costs for each cost category (total health provider; total direct non-medical 
and indirect; total societal) and used non-parametric bootstrap methods, with 1000 
bootstrap replications, to derive 95% confidence intervals (CIs) for the mean cost 
estimates.  
 
I undertook multivariable analysis to investigate the association between the total 
direct health provider cost and total societal cost during the two observation periods 
and the; (1) modality of HIV testing received prior to entry into HIV care; and (2) 
baseline CD4 count on entry into HIV care. For the costs incurred in the pre-ART 
observation period, I also adjusted for the number of CD4 counts done to take into 
account that some participants were not eligible to initiate anti-retroviral therapy 
and were asked to return at approximately 6 monthly intervals for re-assessment of 
eligibility. For the ART observation period, I also adjusted for the month from 
starting ART (as a categorical variable). For these multivariable analysis I ran two 
alternative models, the first was additionally adjusted for age and sex (model 1); the 
second was additionally adjusted for age, sex, marital status, educational attainment, 
income and socio-economic position (model 2) (Stangl et al., 2007). For the 
multivariable analysis, I used generalized linear models (GLM) as the cost data was 
skewed (Barber and Thompson, 2004). I ran the same set of model diagnostics 
applied in Chapter 5 to determine the optimal choices for the distributional family 
and link function (Manning and Mullahy, 2001).  
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For the analysis of HRQoL, I estimated the mean EQ-5D utility score and VAS score, 
and used non-parametric bootstrap methods, with 1000 bootstrap replications, to 
derive 95% confidence intervals (CI) for the mean scores. I undertook multivariable 
analysis to investigate the independent effect of the CD4 count (pre-starting ART) 
and modality of HIV testing received on the EQ-5D utility score before starting ART. 
For this I followed the same approach as described in Chapter 5 and evaluated four 
commonly used estimators: ordinary least squares (OLS) regression; Tobit regression, 
Fractional logit regression (Flogit), and censored least absolute deviations (CLAD) 
regression (Powell, 1984, Austin et al., 2000, Papke and Wooldridge, 1996). For these 
multivariable analysis I ran two alternative models, the first was additionally 
adjusted for age and sex (model 1); the second was additionally adjusted for age, sex, 
marital status, educational attainment, income and socio-economic position (model 
2) (Stangl et al., 2007). 
 
For those who initiated antiretroviral therapy, I also undertook multivariable analysis 
to investigate the independent effect of the baseline CD4 count, modality of HIV 
testing received and time on anti-retroviral therapy on the EQ-5D utility score. I used 
generalised estimating equation (GEE) model to account for correlation of utility 
scores within individuals (Zeger et al., 1988, Zorn, 2001). For these multivariable 
analysis I ran two alternative models, the first was additionally adjusted for age and 
sex (model 1); the second was additionally adjusted for age, sex, marital status, 
educational attainment, income and socio-economic position (model 2) (Stangl et al., 
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2007). In addition, I also ran a third model that additionally adjusted for the baseline 
EQ-5D utility score (model 3) (Manca et al., 2005). 
  
6.2.7 Sensitivity analysis 
I undertook sensitivity analysis to investigate the impact of using an alternative tariff 
set to determine EQ-5D utility scores. I used the UK York A1 tariff (Dolan et al., 
1996a), which has been found to translate health states with ‘severe’ problems in 
one or more of the five dimensions to a lower EQ-5D utility scores than the 
Zimbabwean tariff (Jelsma et al., 2003).   
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6.3 Results 
6.3.1 Participant characteristics 
Figure 34 shows the recruitment and follow-up of participants in the study. In total, 
330 participants were recruited and observed during their attendance at the health 
facilities for assessment of eligibility for anti-retroviral therapy (pre-ART 
observations). 21.8% (72/330) were found not to be eligible to start ART, 7.9% 
(29/330) were found to be eligible for ART but did not start, and 2.1% were lost to 
follow-up before a decision had been made on whether they were eligible for anti-
retroviral therapy.  
 
In total, 68.2% (225/330) participants started ART and were followed-up in the study 
(ART observations). Of those who did start ART, 45.5% (100/225) had been on ART 
for one year when the study finished, whilst 14.7% (33/225) had been on treatment 
for less than one year. In addition, of those who did start ART, 1.3% (3/225) were 
known to have died by the end of the observation period, 32.9% (74/225) were lost 
to follow-up and 6.7% (15/225) had transferred their care to a non-study clinic.  
 
Table 18 shows the characteristics of participants who were observed for the two 
time periods of the study.  
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Figure 34: Recruitment and follow-up of participants 
LTFU: Lost to follow-up 
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Table 18: Characteristics of recruited participants   
 Pre-ART 
Observation 
ART 
Observation 
n (%) n (%) 
All  330 225 
Sex Male 131 (39.7%) 90 (40.0%) 
Female 199 (60.3%) 135 (60.0%) 
Age (years) 18-24 44 (13.3%) 29 (12.9%) 
25-39 208 (63.0%) 141 (62.7%) 
40+ 78 (23.6%) 55 (24.4%) 
Marital status Single (never-married) 24 (7.3%) 18 (8.0%) 
Married/Cohabiting 224 (67.9%) 157 (69.8%) 
Separated/Divorced 55 (16.7%) 30 (13.3%) 
Widower/Widow 27 (8.2%) 20 (8.9%) 
Educational 
attainment 
Up to standard 8 211 (63.9%) 138 (61.3%) 
Up to form 6 117 (35.5%) 85 (37.8%) 
University or training college 2 (0.6%) 2 (0.9%) 
Income 0 Kwacha/week 110 (33.3%) 77 (34.2%) 
Up to 4,000 Kwacha/week 943(28.2%) 59 (26.2%) 
4,000 to 8,000 kwacha/week 55 (16.7%) 34 (15.1%) 
8,000 to 12,000 kwacha/week 28 (8.5%) 23 (10.2%) 
Over 12,000 kwacha/week 44 (13.3%) 32 (14.2%) 
Employment status Formal employment 83 (25.2%) 55 (24.4%) 
Informal employment/Unemployed 139 (42.1%) 96 (42.7%) 
School/University 9 (2.7%) 7 (3.1%) 
Retired 2 (0.6%) 1 (0.4%) 
Housework 95 (28.8%) 65 (28.9%) 
Sick leave 2 (0.6%) 1 (0.4%) 
Socio-economic 
position¶ 
Highest quintile 63 (19.1%) 39 (17.3%) 
2nd highest quintile 71 (20.9%) 52 (23.1%) 
Middle quintile 67 (20.3%) 49 (21.8%) 
2nd lowest quintile 65 (19.7%) 44 (19.6%) 
Lowest quintile 64 (19.4%) 41 (18.2%) 
HIV Testing Location Facility-based HIV testing 269 (81.5%) 186 (82.7%) 
HIV self-testing 61 (18.5%) 39 (17.3%) 
 
 
CD4 Count 
CD4 count>=350 107 (32.4%) 34 (15.1%) 
CD4 count 200-350 82 (24.8%) 71 (31.6%) 
CD4 count 50-200 89 (27.0%) 80 (35.6%) 
CD4 count <50 15 (4.5%) 10 (4.4%) 
Not done or missing 37 (11.2%) 30 (13.3%) 
¶Socio-economic position estimated though undertaking principal component analysis of responses to assets and housing 
environment 
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6.3.2 Direct health provider costs of HIV treatment clinics 
Table 19 shows the direct health provider cost of a single consultation with the 
different health professionals working at the HIV clinics. The estimated direct health 
provider cost per consultation was estimated at US$0.18 (INT$0.49) for a HIV 
counsellor, US$0.59 (INT$1.64) for a nurse, US$0.89 (INT$2.46) for a clinical officer 
and US$5.51 (INT$15.31) for a doctor.  
 
Table 19: Direct Health Provider costs of consultation with health professional 
 
Health Professional  
 
 
Average time 
(Minutes) 
 
        Health provider cost 
2014 US 
Dollars 
2014 INT 
Dollars 
Consultation with HIV Counsellor 10  0.18 0.49 
Consultation with Nurse 20  0.59 1.64 
Consultation with Clinical Officer 30 0.89 2.46 
Consultation with Doctor* 30 5.51 15.31 
*Consultation with Doctors only at HIV clinic at Queens Elizabeth Central Hospital.   
 
Table 20 shows the annual cost of the three health facilities providing HIV care in this 
study. The costs excludes the direct cost for the time health professionals spent in 
direct contact with patients at the health facilities providing one to one consultation. 
The average cost per health facility visit was US$2.42 (INT$6.71), US$3.25 (INT$9.03), 
and US$3.57 (INT$9.75) for Ndirande, Chilomoni and QECH HIV clinics, respectively.  
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Table 20: Annual Direct Health Provider costs of HIV Treatment Clinics (excluding clinical contact) 
 
 
Costs 
 
Ndirande HIV clinic 
 
Chilomoni HIV Clinic 
 
QECH HIV Clinic 
US Dollars 
(2014) 
INT Dollars 
(2014) 
% of Total* US Dollars 
(2014) 
INT Dollars 
(2014) 
% of Total* US Dollars 
(2014) 
INT Dollars 
(2014) 
% of Total* 
Personnel Cost* 12,524 34,789 22.4% 11,494 31,928 24.1% 58,632 162,865 29.9% 
Consumables 29,543 82,004 52.9% 19,140 53,105 40.1% 60,621 159,689 29.3% 
Rental Space 1,504 4,179 2.7% 1,504 4,179 3.2% 5,732 15,921 2.9% 
Equipment 7,233 20,092 13.0% 7,621 21,169 16.0% 21,140 57,440 10.5% 
Central Support and Overheads 5,069 14,081 9.1% 7,947 22,075 16.7% 53,559 148,775 27.3% 
          
Total cost (excluding clinical contact) 55,874 155,146  47,706 132,456  199,683 544,690  
          
Average cost per clinic visitation 
(excluding clinical contact) 
2.42 6.71  3.25 9.03  3.57 9.75  
*Personnel cost excludes the proportion of time clinical personnel spent in direct contact with patients 
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6.3.3 Pre-ART observation 
6.3.3.1 Cost analysis for pre-ART observational period 
Figure 35 to Figure 37 show the respective distributions for the total health provider 
costs, total direct non-medical costs and total societal costs for participants during 
the pre-ART observational period by the modality of HIV testing received and their 
CD4 count. The box plot shows the mean costs with 95% confidence intervals, and 
dots represent outliers. 
 
 
Figure 35: Box plot showing the distribution of total health provider costs (2014 US 
Dollars) by HIV testing modality and CD4 count (n=297) 
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Figure 36: Box plot showing the distribution of total direct non-medical and indirect costs 
(2014 US dollars) by HIV testing modality and CD4 count (n=297) 
 
 
Figure 37: Box plot showing the distribution of total societal costs (2014 US dollars) by HIV 
testing modality and CD4 count (n=297) 
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Table 21 shows the mean total health provider cost, mean total direct non-medical 
and indirect costs and mean total societal cost for all participants, and by the 
participants CD4 count.  
 
For all the participants, the mean total health provider cost of the pre-ART period 
was US$27.28 (INT$71.83). The mean total health provider cost during the pre-ART 
period was highest for participants with a CD4 count greater than 350 cells/μl 
(US$43.05; bootstrap 95%CI, US$337.26-US$48.83).  
 
During the pre-ART period, the mean total direct non-medical and indirect costs 
incurred by participants was US$3.69 (INT$10.24). The mean total direct non-
medical and indirect costs was highest for participants with a CD4 count greater than 
350 cells/μl (US$6.70; bootstrap 95%CI, US$4.48-US$8.91).  
 
For all participants, the mean total societal cost was US$30.97 (INT$82.07). The 
mean total societal costs were highest for participants with a CD4 count greater than 
350 cells/μl (US$49.74; bootstrap 95%CI, US$42.84-US$56.64).  
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Table 21: Mean total costs for pre-ART observations 
  Mean Total Costs 
2014 US Dollars 2014 INT Dollars 
n Mean (95% CI)* Mean (95% CI)* 
 
 
 
Total health 
provider cost 
 
ALL 297 27.28 (24.69, 29.87) 71.83 (65.47, 78.20) 
CD4 count >350 107 43.05 (37.26, 48.83) 109.37 (95.29, 123.46) 
CD4 count 200-350 71 21.10 (19.21, 22.99) 58.29 (53.16, 63.42) 
CD4 count 50-200 79 21.44 (20.09, 22.78) 58.98 (55.27, 62.70) 
CD4 count <50 10 20.99 (16.35, 25.63) 57.56 (46.01, 69.11) 
Not done or missing 30 3.16 (2.76, 3.56) 8.60 (7.65, 9.54) 
 
 
Total direct 
non-medical 
and indirect 
cost 
ALL 297 3.69 (2.75, 4.62) 10.24 (7.68, 12.79) 
CD4 count >350 107 6.70 (4.48, 8.91) 18.60 (12.37, 24.83) 
CD4 count 200-350 71 2.48 (1.02, 3.93) 6.88 (2.82, 10.95) 
CD4 count 50-200 79 2.08 (1.17, 2.99) 5.77 (3.19, 8.35) 
CD4 count <50 10 1.51 (-0.42, 3.44) 4.20 (-1.07, 9.47) 
Not done or missing 30 0.76 (0.08, 1.46) 2.13 (0.26, 4.01) 
 
 
 
Total societal 
cost 
ALL 297 30.97 (27.94, 33.99) 82.07 (74.32, 89.82) 
CD4 count >350 107 49.74 (42.84, 56.64) 127.97 (110.86, 145.08) 
CD4 count 200-350 71 23.58 (20.92, 26.24) 65.17 (58.19, 72.25) 
CD4 count 50-200 79 23.51 (21.83, 25.20) 64.75 (60.23, 69.28) 
CD4 count <50 10 22.50 (17.17, 27.83) 61.76 (48.03, 75.49) 
Not done or missing 30 3.92 (3.12, 4.73) 10.73 (8.50, 12.95) 
*Bootstrapped estimates with 1000 replications for 95%CI 
 
Table 22 shows the mean total health provider cost, mean total direct non-medical 
and indirect costs and mean total societal cost by the modality of HIV testing 
participants accessed before attending the HIV clinic to be assessed for ART eligibility. 
The mean total health provider cost during the pre-ART period was lower for those 
participants who had accessed HIVST to learn their HIV status (US$22.74; bootstrap 
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95%CI: US$18.48-US$27.00), than those who had accessed facility-based HTC 
(US$28.33; bootstrap 95%CI: US$25.31-US$35.36). In addition, the mean total direct 
non-medical and indirect costs, and the mean total societal costs were lower for 
participants who had accessed HIVST to learn their HIV status than those who had 
accessed facility-based HTC.   
 
Table 22: Mean total costs of pre-ART observations by modality of HIV testing received 
  
Mean Total cost 
HIV self-testers 
(n=62) 
Facility HIV testers 
(n=268) 
Mean (95% CI)* Mean (95% CI)* 
 
Total Health Provider cost 
 
 
2014 US Dollars 
 
22.74 (18.48, 27.00) 
 
28.33 (25.31, 35.36) 
2014 INT Dollars 60.65 (50.49, 70.81) 74.43 (66.82, 82.04) 
 
Total direct non-medical 
and indirect cost 
 
2014 US Dollars 
 
2.81 (1.09, 4.53) 
 
3.89 (2.79, 4.99) 
2014 INT Dollars 7.81 (3.17, 12.46) 10.80 (7.85, 13.75) 
 
Total Societal cost 
 
 
2014 US Dollars 
 
25.56 (20.20, 30.91) 
 
32.22 (28.61, 35.83) 
2014 INT Dollars 68.47 (54.35, 82.59) 85.23 (75.99, 94.48) 
*Bootstrapped estimates with 1000 replications for 95%CI 
  
Table 23 shows the multivariable analysis investigating the independent effect of 
modality of HIV testing, baseline CD4 count and number of CD4 counts measured 
during the pre-ART period on mean total health provider costs. In the multivariable 
analysis (Table 23), after adjusting for individual characteristics and baseline CD4 
count, the mean total health provider cost during the pre-ART period was US$1.91 
(95%CI: US$0.60-US$3.22) lower for those who had accessed HIV care after HIVST 
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than for those who had accessed HIV care after facility-based HTC (model 2). In 
comparison to those whose CD4 count was greater than 350 cells/μl, those with 
lower CD4 counts had a lower mean total health provider cost during the pre-ART 
observation period (Table 23). The mean total health provider cost was higher for 
those who had two or more CD4 counts measured, than for those who only had one 
CD4 count measured.  
 
Table 24 shows the multivariable analysis investigating the independent effects of 
modality of HIV testing, baseline CD4 count and number of CD4 counts measured 
during the pre-ART period on the mean total societal costs. In this multivariable 
analysis, the mean total societal cost during the pre-ART period was US$2.39 (95%CI: 
US$0.69-US$4.09) lower for those who had accessed HIV care after HIVST than for 
those who had accessed HIV care after facility-based HTC (model 2). In comparison 
to those whose CD4 count was greater than 350 cells/μl, those with lower CD4 
counts had a lower adjusted mean total societal cost during the pre-ART observation 
period (Table 24). In the multivariable analysis, the mean total societal cost during 
the pre-ART period was US$10.24 (95%CI: US$5.32-US$15.16) less for those whose 
CD4 count was between 200 cells/μl and 350 cells/μl than for those whose CD4 
count was greater than 350 cells/μl (model 2). In the multivariable analysis, the 
mean total societal cost was also higher for those who had two or more CD4 counts 
measured, than for those who only had one CD4 count measured.  
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Table 23: Multivariable analysis exploring relationship between CD4 count and modality of HIV testing received and the total pre-ART Health Provider 
costs*    
 
 
 
 
 
Total Health Provider cost (2014 US Dollars) 
 
Total Health Provider cost (2014 INT Dollars) 
Model 1 
(n=330) 
Model 2 
(n=330) 
Model 1 
(n=330) 
Model 2 
(n=330) 
Coef (95% CI) Coef (95% CI) Coef (95% CI) Coef (95% CI) 
Modality of HIV testing  Facility-tested Ref Ref Ref Ref 
HIV self-tested -0.91** 
(-1.81, -0.01) 
-1.91** 
(-3.22, -0.60) 
-2.26** 
(-4.48, -0.05) 
-5.25** 
(-8.64, -1.85) 
 
 
 
Baseline CD4 count  
CD4 count >350 cells/μl Ref Ref Ref Ref 
CD4 count 200-350 cells/μl -7.64** 
(-11.31, -3.98) 
-7.77** 
(-11.37, -4.17) 
-15.77** 
(-24.37, -7.18) 
-16.03** 
(-24.34, -7.72) 
CD4 count 50-200 cells/μl -7.34** 
(-10.75, -3.93) 
-7.47** 
(-10.84, -4.10) 
-15.18** 
(-22.96, -7.39) 
-15.46** 
(-23.04, -7.88) 
CD4 count <50 cells/μl -7.59** 
(-12.76, -2.43) 
-7.95** 
(-12.73, -3.16) 
-15.96** 
(-28.51, -3.40) 
-16.70** 
(-28.06, -5.35) 
Not done or missing -25.58** 
(-28.75, -22.41) 
-25.69** 
(-28.86, -22.53) 
-65.39** 
(-72.40, -58.38) 
-65.62** 
(-72.57, -58.67) 
 
 
Number of CD4 counts 
during pre-ART period 
0 or 1 Ref Ref Ref Ref 
2 33.33** 
(25.45, 41.20) 
32.91** 
(24.86, 40.96) 
83.51 
(66.26, 100.77) 
82.44** 
(64.78, 100.11) 
3 88.33** 
(74.77, 101.89) 
87.57** 
(74.02, 101.11) 
216.62 
(183.13, 248.11) 
213.71** 
(181.27, 246.15) 
4 67.06** 
(63.78, 70.34) 
64.36** 
(60.41, 68.31) 
174.95 
(167.53, 182.38) 
168.28** 
(159.04, 177.52) 
Constant 28.80 
(25.53, 32.08) 
29.76 
(26.08, 33.43) 
73.80 
(66.48, 81.11) 
75.75** 
(67.48, 84.03) 
Model 1: adjusted for exposure, HIV test result, Age and Sex 
Model 2: additionally adjusted for martial status, educational attainment, income and wealth quintile 
*Findings from Generalized Linear Model with Poisson distribution and Identity link function 
**p<0.05 
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Table 24: Multivariable analysis exploring relationship between CD4 count and modality of HIV testing received and the total pre-ART Societal costs*    
 
 
 
 
 
Total Societal cost (2014 US Dollars) 
 
Total Societal cost (2014 INT Dollars) 
Model 1 
(n=330) 
Model 2 
(n=330) 
Model 1 
(n=330) 
Model 2 
(n=330) 
Coef (95% CI) Coef (95% CI) Coef (95% CI) Coef (95% CI) 
Modality of HIV 
testing  
Facility-tested Ref Ref Ref Ref 
HIV self-tested -1.27** 
(-2.35, -0.19) 
-2.39** 
(-4.09, -0.69) 
-3.11** 
(-5.74, -0.48) 
-6.66** 
(-11.19, -2.14) 
 
 
 
Baseline CD4 count  
CD4 count >350 cells/μl Ref Ref Ref Ref 
CD4 count 200-350 cells/μl -9.78** 
(-14.90, -4.66) 
-10.24** 
(-15.16, -5.32) 
-21.67** 
(-34.53, -8.81) 
-22.66** 
(-34.76, -10.55) 
CD4 count 50-200 cells/μl -9.77** 
(-14.47, -5.06) 
-9.97** 
(-14.67, -5.28) 
-21.89** 
(-33.50, -10.28) 
-22.21** 
(-33.59, -10.84) 
CD4 count <50 cells/μl -10.60** 
(-17.29, -3.90) 
-10.85** 
(-17.42, -4.27) 
-24.33** 
(-41.30, -7.40) 
-24.66** 
(-41.14, -8.19) 
Not done or missing -29.40** 
(-33.84, -24.97) 
-29.52** 
(-33.96, -25.08) 
-75.96** 
(-86.77, -65.14) 
-76.05** 
(-86.68, -65.41) 
 
 
Number of CD4 counts 
during pre-ART period 
0 or 1 Ref Ref Ref Ref 
2 40.70** 
(28.67, 52.73) 
40.74** 
(28.36, 53.17) 
104.02** 
(74.34, 133.69) 
104.24** 
(73.84, 134.84) 
3 96.97** 
(79.56, 114.37) 
95.76** 
(78.44, 113.08) 
239.70** 
(195.95, 283.44) 
236.71** 
(193.12, 280.29) 
4 69.05** 
(64.49, 73.60) 
65.27** 
(59.84, 70.69) 
180.65** 
(169.45, 191.84) 
171.22** 
(158.02, 184.42) 
Constant 33.29 
(28.67, 37.91) 
31.12 
(27.98, 38.27) 
86.29 
(74.91, 97.67) 
84.67 
(72.19, 97.15) 
Model 1: adjusted for exposure, HIV test result, Age and Sex 
Model 2: additionally adjusted for martial status, educational attainment, income and wealth quintile 
*Findings from Generalized Linear Model with Poisson distribution and Identity link function  
**p<0.05 
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6.3.3.2 Health-related quality of life analysis 
Figure 38 shows the distribution of the EQ-5D utility scores, derived from the 
Zimbabwean tariff, during the pre-ART observational period by the modality of HIV 
testing received prior to attending the HIV clinic, and the CD4 count on assessment 
for anti-retroviral therapy initiation. Figure 39 and Figure 40 show the distribution of 
the EQ-5D utility score, derived from the UK tariff, and the VAS scores, by modality 
of HIV testing received and CD4 count result. The box plots in Figure 38 to Figure 40 
shows the mean costs with 95% confidence intervals (CIs), and dots represent 
outliers. 
  
Figure 38: Box plot showing distribution of EQ-5D utility scores (Zimbabwean tariff) by HIV 
testing modality and CD4 count 
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Figure 39: Box plot showing distribution of EQ-5D utility scores (UK tariff) by HIV testing 
modality and CD4 count 
 
 
Figure 40: Box plot showing distribution of scores from the visual analogue scale by HIV 
testing modality and CD4 count 
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Table 25 shows the health-related quality of life scores for all participants, and by 
the participants’ category of CD4 count measured in the assessment for ART 
initiation. The mean EQ-5D utility score was highest amongst those with a CD4 count 
greater than 350 cells/μl (0.872; bootstrap 95%CI, 0.852-0.892), and lowest for 
participants with a CD4 count below 50 cells/μl (0.640; bootstrap 95%CI, 0.536-
0.744). The mean EQ-5D utility score was 0.860 (bootstrap 95%CI: 0.834-0.866) for 
those with a CD4 count between 200 cells/μl and 350 cells/μl, 0.817 (bootstrap 
95%CI: 0.790-0.843) for those with a CD4 count between 50 cells/μl and 200 cells/μl, 
and 0.847 (bootstrap 95%CI: 0.784-0.910) for those with no recorded CD4 count.  
 
Table 25: Health-related quality of life outcomes for pre-ART sample by CD4 counts 
 Pre-ART Observation 
(n=330) 
Mean (95% CI)* 
 
 
EQ-5D Utility Score 
 
ALL 0.841 (0.825, 0.857) 
CD4 count>=350 0.872 (0.852, 0.892) 
CD4 count 200-350 0.860 (0.834, 0.886) 
CD4 count 50-200 0.817 (0.790, 0.843) 
CD4 count <50 0.640 (0.536, 0.744) 
Not done or missing 0.847 (0.784, 0.910) 
 
 
EQ-5D Utility Score 
(UK Tariff) 
ALL 0.798 (0.775, 0.821) 
CD4 count>=350 0.844 (0.818, 0.871) 
CD4 count 200-350 0.822 (0.784, 0.860) 
CD4 count 50-200 0.772 (0.732, 0.813) 
CD4 count <50 0.463 (0.288, 0.637) 
Not done or missing 0.806 (0.717, 0.894) 
 
 
 
VAS Score 
ALL 73.2 (71.3, 75.1) 
CD4 count>=350 76.3 (73.5, 79.1) 
CD4 count 200-350 75.5 (71.9, 79.2) 
CD4 count 50-200 68.9 (65.4, 72.4) 
CD4 count <50 72.0 (60.3, 83.7) 
Not done or missing 69.9 (62.6, 77.2) 
*Bootstrapped estimates with 1000 replications for 95%CI 
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Table 26 shows the health-related quality of life scores by modality of HIV testing the 
participant underwent prior to attending the HIV clinic and the participant’s CD4 
count measured at assessment for ART initiation. The mean EQ-5D utility score was 
0.856 (bootstrap 95%CI, 0.821-0.891) for all participants who accessed the HIV clinic 
after HIVST, compared to 0.837 (bootstrap 95%CI: 0.820-0.855) for those who had 
accessed the HIV clinic after facility-based HTC. 
 
Table 26: Health-related quality of life outcomes for pre-ART sample by modality of HIV 
testing received and CD4 counts  
  
Pre-ART Observation 
 
HIVST (n=61) Facility HTC (n=269) 
Mean (95% CI)* Mean (95% CI)* 
 
 
 
EQ-5D Utility Score 
 
ALL 0.856 (0.821, 0.891) 0.837 (0.820, 0.855) 
CD4 count>=350 0.909 (0.874, 0.944) 0.862 (0.839, 0.884) 
CD4 count 200-350 0.850 (0.777, 0.923) 0.862 (0.833, 0.891) 
CD4 count 50-200 0.826 (0.747, 0.904) 0.815 (0.788, 0.842) 
CD4 count <50 0.706 (0.374, 1.037) 0.624 (0.497, 0.750) 
Not done or missing 0.816 (0.654, 0.979) 0.853 (0.783, 0.922) 
 
 
 
EQ-5D Utility Score 
(UK Tariff) 
ALL 0.814 (0.761, 0.868) 0.794 (0.769, 0.819) 
CD4 count>=350 0.901 (0.861, 0.940) 0.829 (0.797, 0.861) 
CD4 count 200-350 0.813 (0.722, 0.905) 0.824 (0.779, 0.868) 
CD4 count 50-200 0.761 (0.632, 0.890) 0.775 (0.735, 0.815) 
CD4 count <50 0.582 (0.205, 0.960) 0.433 (0.222, 0.644) 
Not done or missing 0.744 (0.469, 1.019) 0.818 (0.723, 0.912) 
 
 
 
VAS Score 
ALL 72.9 (68.0, 77.8) 73.3 (71.1, 75.4) 
CD4 count>=350 74.8 (69.0, 80.6) 76.7 (73.5, 79.9) 
CD4 count 200-350 72.5 (61.4, 83.7) 76.1 (72.3, 79.9) 
CD4 count 50-200 71.3 (61.7, 80.8) 68.4 (64.7, 72.0) 
CD4 count <50 91.7 (56.9, 126.5) 67.1 (53.8, 80.3) 
Not done or missing 61.7 (35.3, 88.1) 71.5 (64.1, 78.9) 
*Bootstrapped estimates with 1000 replications for 95%CI 
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In the multivariable analysis, the model diagnostics revealed the OLS estimator 
performed as well or better than the other estimators (Table 27 and Table 28). The 
CLAD estimator did not converge as the median observed EQ-5D utility score was 
censored. The EQ-5D utility scores predicted by the OLS estimator show close 
approximation to the observed EQ-5D utility scores in the sample.  
 
Table 27: Estimated predicted values compared to actual utility scores 
 Model Obs Mean Min Max MSE MAE 
Observed 330 0.841 -0.018 1.000   
 
Model 
OLS 330 0.841 0.606 0.984 0.000 0.097 
TOBIT 330 0.847 0.592 0.961 0.006 0.098 
CLAD* N/A N/A N/A N/A N/A N/A 
 Flogit 330 0.841 0.578 0.950 0.000 0.098 
OLS: Ordinary Least Squares    MSE: Mean Squared Error 
Flogit: Fractional logit     MAE: Mean Absolute Error 
CLAD: Censored least Absolute deviations  *No convergence as median EQ-5D score censored at 1.0 
 
 
Table 28: MSE and MAE for regression models by utility score range 
 Observed EQ-5D utility score 
  <0 0 to <0.2 0.2 to <0.4 0.4 to <0.6 0.6 to <0.8 0.8 to <1 1 
Obs 1 1 2 11 127 83 105 
  MSE MAE MSE MAE MSE MAE MSE MAE MSE MAE MSE MAE MSE MAE 
OLS 0.829 0.829 0.465 0.465 0.461 0.461 0.196 0.196 0.071 0.081 0.011 0.036 0.137 0.137 
TOBIT 0.842 0.842 0.458 0.458 0.467 0.467 0.199 0.199 0.077 0.087 0.016 0.040 0.129 0.129 
Flogit 0.823 0.823 0.442 0.442 0.461 0.461 0.188 0.188 0.071 0.083 0.012 0.037 0.137 0.137 
OLS: Ordinary Least Squares   FLOGIT: Fractional logit 
MSE: Mean Squared Error  MAE: Mean Absolute Error 
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Table 29 shows the results of the multivariable analysis investigating the 
independent effects of modality of HIV testing and baseline CD4 count on the mean 
EQ-5D utility score predicted by the OLS estimator. In the multivariable analysis 
(Table 29), the fully adjusted model (model 2) found that there was no significant 
difference in the mean adjusted EQ-5D utility score between those had had accessed 
HIVST and those who had access facility-based HTC prior to attending the HIV clinic 
for assessment for ART initiation.  
 
In the multivariable analysis (Table 29), the fully adjusted model (model 2) found 
that those with a CD4 count between 50 cells/μl and 200 cells/μl had a significantly 
lower mean adjusted EQ-5D utility score (0.053, 95%CI: 0.014-0.090) than those with 
a CD4 count greater than 350 cells/μl. Additionally, those with a CD4 count below 50 
cells/μl also had a significantly lower mean adjusted EQ-5D utility score (0.234, 
95%CI: 0.161-0.308) than those with a CD4 count greater than 350 cells/μl. In the 
fully adjusted model (model 2), there was no significant difference in mean EQ-5D 
utility scores between those with CD4 count greater than 350 cells/μl, and either 
those with a CD4 count between 200 cells/μl and 300 cells/μl, or those who had no 
CD4 count recorded. 
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Table 29: Multivariable analysis exploring relationship between CD4 count and modality of HIV testing received and the EQ-5D utility score before 
starting anti-retroviral therapy*    
 
 
 
 
 
EQ-5D Utility Score 
Sensitivity analysis 
EQ-5D Utility Score (UK Tariff) 
Model 1 
(n=330) 
Model 2 
(n=330) 
Model 1 
(n=330) 
Model 2 
(n=330) 
Coef (95% CI) Coef (95% CI) Coef (95% CI) Coef (95% CI) 
Modality of HIV 
testing  
Facility-tested Ref Ref Ref Ref 
HIV self-tested 0.018 
(-0.019, 0.055) 
0.022 
(-0.026, 0.060) 
0.021 
(-0.034, 0.075) 
0.027 
(-0.029, 0.082) 
Baseline CD4 count  
CD4 count>=350 Ref Ref Ref Ref 
CD4 count 200-350 -0.008 
(-0.047, 0.031) 
-0.013 
(-0.052, 0.027) 
-0.017 
(-0.074, 0.040) 
-0.022 
(-0.081, 0.035) 
CD4 count 50-200 -0.051** 
(-0.090, -0.013) 
-0.053** 
(-0.092, -0.014) 
-0.067** 
(-0.123, -0.010) 
-0.069** 
(-0.126, -0.012) 
CD4 count <50 -0.234** 
(-0.307, -0.161) 
-0.23**4 
(-0.308, -0.161) 
-0.385** 
(-0.492, -0.278) 
-0.383** 
(-0.491, -0.276) 
Not done or missing -0.024 
(-0.074, 0.026) 
-0.024 
(-0.075, 0.028) 
-0.037 
(-0.111, 0.037) 
-0.039 
(-0.115, 0.037) 
Constant 0.896 
(0.844, 0.948) 
0.901 
(0.819, 0.983) 
0.880 
(0.804, 0.956) 
0.863 
(0.743, 0.982) 
Model 1: adjusted for exposure, HIV test result, Age and Sex 
Model 2: additionally adjusted for martial status, educational attainment, income and wealth quintile 
*Findings from OLS estimator 
**p<0.05 
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6.3.4 ART observation period 
6.3.4.1 Cost analysis  
Table 30 (costs in 2014 US Dollars) and Table 31 (costs in 2014 INT Dollars) shows the 
mean monthly costs for participants by the baseline CD4 count for the period after 
initiating anti-retroviral therapy (ART), and the total costs for those participants who 
had been on ART for one year by the end of the study period. Figure 41 (costs in 
2014 US Dollars) and Figure 42 (costs in 2014 INT Dollars) show the mean monthly 
costs of providing HIV treatment by the baseline CD4 count.  
 
For all the participants, the mean health provider cost in the first month after 
initiating ART was US$18.22 (INT$30.64), with the costs falling in the second month 
to US$13.82 (INT$19.71). The mean monthly health provider costs in the subsequent 
months were comparable to that seen in the second month after initiating ART 
(Figure 41 and Figure 42). The mean monthly health provider costs for those with 
higher CD4 counts before initiating ART were comparable to those with lower CD4 
counts, and remained comparable in the subsequent months (Figure 41 and Figure 
42). 
 
The mean total health provider cost for the first year of ART provision was 
US$166.20 (INT$226.16) in those who had one year of follow-up (Table 30 and Table 
31). The costs were comparable across those with different baseline CD4 counts.  
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For all the participants, the mean direct non-medical and indirect costs in the first 
month after initiating ART was US$2.85 (INT$7.91), with the costs falling in the 
subsequent months (Figure 41 and Figure 42). The mean total direct non-medical 
and indirect cost for the first year of ART was US$8.98 (INT$36.90) in those who had 
one year of ART follow-up. Participants who had a CD4 count between 200 cells/μl 
and 350 cells/μl incurred the highest mean direct non-medical and indirect costs in 
the first year of ART (US$12.51: bootstrap 95%CI, US$5.74-US$19.28). Participants 
who had a CD4 count greater than 350 cells/μl incurred the lowest mean direct non-
medical and indirect costs in the first year of ART (US$1.35; bootstrap 95%CI, 
US$0.27-US$2.43).  
 
For all the participants, the mean societal cost in the first month after initiating ART 
was US$21.07 (INT$38.55), with the costs falling in the subsequent months (Figure 
41 and Figure 42). The mean monthly societal costs for those with higher CD4 counts 
before initiating ART were comparable to those with lower CD4 counts, and 
remained comparable in the subsequent months (Figure 41 and Figure 42). The 
mean total societal cost for the first year of ART provision in those who had one year 
of follow-up was US$178.35 (INT$259.90). The costs were comparable across those 
with different baseline CD4 counts (Table 30 and Table 31). 
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Table 30: Mean total monthly and first year costs (in 2014 US Dollars) after initiation of anti-retroviral therapy by baseline CD4 count 
 Mean monthly costs after ART initiation 
(2014 US Dollars) 
Total 1st year 
(2014 US Dollars) 
(n=100) 1st month 
(n=225) 
3rd month 
(n=187) 
6th month 
(n=153) 
12th month 
(n=100) 
Mean (95% CI)* Mean (95% CI)* Mean (95% CI)* Mean (95% CI)* Mean (95% CI) 
Total Health 
Provider cost 
 
ALL 18.22 (17.12, 19.32) 13.82 (13.06, 14.57) 13.24 (12.67, 13.80) 13.85 (13.10, 14.61) 166.20 (161.98, 170.43) 
CD4 count>=350 19.36 (16.63, 22.09) 13.80 (12.90, 14.71) 13.56 (12.18, 14.94) 13.56 (10.84, 16.28) 170.20 (160.66, 179.73) 
CD4 count 200-350 19.33 (17.13, 21.53) 13.26 (12.23, 14.30) 14.05 (12.98, 15.11) 13.33 (12.26, 14.39) 165.12, 159.49, 170.76) 
CD4 count 50-200 17.01 (15.55, 18.47) 13.45 (12.25, 14.65) 13.18 (12.15, 14.24) 14.46 (13.10, 15.81) 164.89 (158.87, 170.91) 
CD4 count <50 14.65 (11.73, 17.57) 13.43 (10.74, 16.11) 11.50 (9.60, 13.35) 12.23 (9.60, 14.86) 158.12 (130.18, 186.06) 
CD4 not done or missing 18.73 (16.20, 21.26) 16.52 (12.82, 20.22) 11.69 (10.48, 12.89) 14.23 (12.01, 16.45) 176.62 (158.91, 194.33) 
Total direct 
non-medical 
and indirect 
cost 
ALL 2.85 (2.16, 3.54) 1.25 (0.42, 2.09) 0.53 (0.29, 0.76) 0.49 (0.22, 0.75) 8.98 (5.86, 12.11) 
CD4 count>=350 3.55 (0.76, 6.34) 1.27 (-0.22, 2.75) 0.21 (0.01, 0.41) 0.22 (-0.09, 0.53) 1.35 (0.27, 2.43) 
CD4 count 200-350 3.09 (1.72, 4.47) 0.61 (0.27, 0.95) 0.85 (0.25, 1.44) 0.65 (-0.03, 1.32) 12.51 (5.74, 19.28) 
CD4 count 50-200 2.72 (1.80, 3.64) 1.18 (0.40, 1.96) 0.40 (0.08, 0.72) 0.41 (0.11, 0.70) 7.58 (5.00, 10.17) 
CD4 count <50 1.12 (0.03, 2.22) 0.53 (-0.19, 1.24) 0.53 (-0.22, 1.27) 0.17 (-0.16, 0.50) 5.10 (2.99, 7.22) 
CD4 not done or missing 2.39 (0.59, 4.19) 3.40 (-2.62, 9.42) 0.39 (-0.14, 0.92) 0.75 (-0.31, 1.81) 12.53 (-7.14, 32.21) 
Total Societal 
cost 
ALL 21.07 (19.72, 22.42) 15.07 (13.67, 13.80) 13.76 (13.08, 14.45) 14.34 (13.44, 15.24) 178.35 (171.88, 184.82) 
CD4 count>=350 22.91 (18.98, 26.84) 15.07 (13.09, 17.04) 13.77 (12.31, 15.23) 13.79 (10.73, 16.84) 172.18 (163.16, 181.21) 
CD4 count 200-350 22.42 (19.73, 25.12) 13.87 (12.63, 15.11) 14.90 (13.60, 16.19) 13.97 (12.32, 15.62) 182.17 (170.50, 193.84) 
CD4 count 50-200 19.73 (17.85, 21.61) 14.63 (12.92, 16.34) 13.59 (12.41, 14.77) 14.86 (13.36, 16.37) 175.25 (168.41, 182.08) 
CD4 count <50 15.77 (12.80, 18.75) 13.95 (10.73, 17.18) 12.02 (9.46, 14.58) 12.40 (9.38, 15.41) 164.47 (137.84, 191.09) 
CD4 not done or missing 21.12 (17.33, 24.91) 19.91 (11.06, 28.77) 12.07 (10.46, 13.68) 14.98 (12.41, 17.55) 193.03 (154.09, 231.97) 
*Bootstrapped estimates with 1000 replications for 95%CI 
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Figure 41: Mean monthly costs* (in 2014 US Dollars) after initiation of anti-retroviral therapy by the baseline CD4 count 
 
*Graphs show all three cost categories: health provider; direct non-medical and indirect; and societal costs  
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Table 31: Mean total monthly and first year costs (in 2014 INT Dollars) after initiation of anti-retroviral therapy by baseline CD4 count 
 Mean monthly costs after ART initiation 
(2014 INT Dollars) 
Total 1st year 
(2014 INT Dollars) 
(n=100) 1st month 
(n=225) 
3rd month 
(n=187) 
6th month 
(n=153) 
12th month 
(n=100) 
Mean (95% CI)* Mean (95% CI)* Mean (95% CI)* Mean (95% CI)* Mean (95% CI) 
Total Health 
Provider cost 
 
ALL 30.64 (28.22, 33.07) 19.71 (17.89, 21.52) 16.88 (15.72, 18.03) 17.89 (16.15, 19.63) 226.16 (217.16, 235.16) 
CD4 count>=350 33.39 (27.80, 38.99) 18.31 (16.19, 20.43) 16.95 (14.28, 19.62) 17.11 (11.42, 22.92) 227.60 (208.47, 246.73) 
CD4 count 200-350 32.37 (27.80, 38.99) 18.35 (15.95, 20.75) 18.43 (16.39, 20.47) 16.70 (14.53, 18.86) 222.46 (209.97, 234.95) 
CD4 count 50-200 28.15 (24.91, 31.39) 19.07 (16.23, 21.91) 17.04 (14.93, 19.15) 19.36 (15.89, 22.83) 225.28 (210.93, 239.63) 
CD4 count <50 22.02 (16.01, 28.02) 18.28 (13.35, 23.21) 13.55 (9.85, 17.24) 14.01 (9.20, 18.82) 206.96 (170.44, 243.47) 
CD4 not done or missing 31.70 (25.62, 37.79) 27.23 (17.95, 36.52) 13.81 (11.51, 16.11) 18.50 (14.34, 22.65) 251.17 (211.64, 290.71) 
Total direct 
non-medical 
and indirect 
cost 
ALL 7.91 (5.86, 9.96) 3.49 (1.11, 5.86) 1.46 (0.76, 2.16) 1.36 (0.63, 2.08) 36.90 (24.34, 49.47) 
CD4 count>=350 9.85 (2.25, 17.46) 3.51 (-0.75, 7.78) 0.58 (0.00, 1.16) 0.62 (-0.28, 1.52) 6.16 (1.14, 11.18) 
CD4 count 200-350 8.59 (4.80, 12.37) 1.69 (0.76, 2.61) 2.35 (0.64, 4.07) 1.79 (0.00, 3.59) 51.87 (23.16, 80.58) 
CD4 count 50-200 7.56 (4.96, 10.16) 3.28 (1.15, 5.41) 1.11 (0.19, 2.03) 1.13 (0.29, 1.98) 31.56 (21.64, 41.48) 
CD4 count <50 3.12 (-0.03, 6.28) 1.46 (-0.50, 3.43) 1.46 (-0.75, 3.67) 0.47 (-0.47, 1.41) 18.87 (11.08, 26.66) 
CD4 not done or missing 6.63 (1.74, 11.53) 9.43 (-7.53, 26.40) 1.08 (-0.32, 2.47) 2.08 (-0.80, 4.97) 49.46 (-22.29, 122.20) 
Total Societal 
cost 
ALL 38.55 (35.11, 42.00) 23.19 (19.74, 26.64) 18.34 (16.83, 19.84) 19.24 (17.10, 21.39) 259.90 (243.41, 276.38) 
CD4 count>=350 42.23 (32.01, 52.45) 21.82 (16.61, 27.04) 17.53 (14.43, 20.63) 17.79 (11.39, 24.20) 233.12 (214.57, 251.68) 
CD4 count 200-350 41.98 (34.97, 49.00) 20.04 (16.87, 23.20) 20.78 (17.66, 23.91) 18.49 (14.91, 22.06) 269.80 (239.28, 300.32) 
CD4 count 50-200 35.71 (31.24, 40.18) 22.35 (18.05, 26.66) 18.15 (15.74, 20.56) 20.49 (16.84, 24.15) 254.06 (236.73, 271.40) 
CD4 count <50 25.14 (17.90, 32.38) 19.75 (13.10, 26.39) 15.01 (9.46, 20.56) 14.48 (9.11, 19.85) 224.58 (188.88, 260.29) 
CD4 not done or missing 38.33 (29.32, 47.35) 36.67 (12.61, 60.73) 14.89 (11.60, 18.18) 20.58 (14.74, 26.42) 296.76 (201.82, 391.69) 
*Bootstrapped estimates with 1000 replications for 95%CI 
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Figure 42: Mean monthly costs* (in 2014 INT Dollars) after initiation of anti-retroviral therapy by the baseline CD4 count 
 
*Graphs show all three cost categories: health provider; direct non-medical and indirect; and societal costs  
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Table 32 (costs in 2014 US Dollars) and Table 33 (costs in 2014 INT Dollars) show the 
mean total monthly and first year costs amongst those who initiated ART by the 
modality of HIV testing that participants received prior to initiating treatment. Figure 
43 (costs in 2014 US Dollars) and Figure 44 (costs in 2014 INT Dollars) show the mean 
monthly costs by the modality of HIV testing received.  
 
The mean health provider cost in the first month after initiating ART for those who 
had previously accessed HIVST was significantly lower (US$15.43: bootstrap 95%CI, 
US$13.62-US$17.24), than for those who had previously accessed facility-based HTC 
(US$18.81: bootstrap 95%CI, US$17.61-US$20.00). For the subsequent months on 
ART, the mean monthly health provider costs were comparable (Figure 43 and Figure 
44).  
 
The mean total health provider costs for the first year of accessing ART, in those who 
completed one year of follow-up, were comparable between those who had 
previously accessed HIVST (US$160.78: bootstrap 95%CI, US$148.17-US$173.39) and 
those who previously accessed facility-based HTC (US$167.24: bootstrap 95%CI, 
US$163.01-US$171.46).  
 
The mean monthly and mean total first year direct non-medical and indirect costs 
during the ART period were comparable for those who had previously accessed 
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HIVST and those who had previously accessed facility-based HTC. The mean monthly 
and mean total first year societal costs during the ART period were also comparable 
between those who had previously accessed HIVST and those who had previously 
accessed facility-based HTC. The mean total societal costs, for those who had one 
year of follow-up, was US$173.60 (bootstrap 95%CI: US$54.31-US$192.88) amongst 
those who had previously accessed HIVST, and US$179.26 (bootstrap 95%CI: 
US$172.43-US$186.08) amongst those who had previously accessed facility-based 
HTC.  
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Table 32: Mean total monthly and first year costs (in 2014 US Dollars) after initiation of anti-retroviral therapy by modality of HIV testing 
 Mean monthly costs after ART initiation (2014 US Dollars) Total 1st year 
(2014 US Dollars) 
(n=100) 
1st month 
(n=225) 
3rd month 
(n=187) 
6th month 
(n=153) 
12th month 
(n=100) 
Mean (95% CI) Mean (95% CI) Mean (95% CI) Mean (95% CI) Mean (95% CI) 
Total Health Provider cost 
 
Facility testers 18.81 (17.61, 20.00) 13.99 (13.16, 14.82) 13.40 (12.76, 14.03) 13.82 (13.07, 14.55) 167.24 (163.01, 171.46) 
HIVST 15.43 (13.62, 17.24) 13.03 (10.98, 15.09) 12.55 (11.44, 13.65) 14.09 (11.10, 17.07) 160.78 (148.17, 173.39) 
Total direct non-medical 
and indirect cost 
Facility testers 2.89 (2.10, 3.67) 1.20 (0.24, 2.15) 0.46 (0.26, 0.67) 0.57 (0.26, 0.88) 8.86 (5.48, 12.25) 
HIVST 2.65 (1.02, 4.28) 1.52 (-0.04, 3.08) 0.78 (-0.16, 1.73) 0.07 (-0.08, 0.23) 9.62 (-0.55, 19.78) 
Total Societal cost 
Facility testers 21.69 (20.15, 23.24) 15.19 (13.75, 16.62) 13.86 (13.11, 14.61) 14.38 (13.48, 15.27) 179.26 (172.43, 186.08) 
HIVST 18.08 (15.62, 20.54) 14.55 (11.39, 17.72) 13.33 (11.67, 14.99) 14.16 (11.18, 17.14) 173.60 (154.31, 192.88) 
*Bootstrapped estimates with 1000 replications for 95%CI 
 
Table 33: Mean total monthly and first year costs (in 2014 INT Dollars) after initiation of anti-retroviral therapy by modality of HIV testing 
 Mean monthly costs after ART initiation (2014 INT Dollars) Total 1st year 
(2014 INT Dollars) 
(n=100) 
1st month 
(n=225) 
3rd month 
(n=187) 
6th month 
(n=153) 
12th month 
(n=100) 
Mean (95% CI) Mean (95% CI) Mean (95% CI) Mean (95% CI) Mean (95% CI) 
Total Health Provider cost 
 
Facility testers 32.09 (29.18, 35.00) 20.03 (18.14, 21.92) 17.14 (15.78, 18.51) 17.70 (16.15, 19.26) 228.18 (218.39, 237.97) 
HIVST 23.75 (20.03, 27.48) 18.27 (13.23, 23.31) 15.74 (13.56, 17.91) 18.86 (10.93, 26.79) 215.53 (190.16, 240.89) 
Total direct non-medical 
and indirect cost 
Facility testers 8.02 (5.68, 10.37) 3.32 (0.61, 6.03) 1.29 (0.71, 1.87) 1.57 (0.68, 2.47) 36.54 (23.16, 49.93) 
HIVST 7.37 (2.97, 11.77) 4.23 (0.06, 8.39) 2.18 (-0.45, 4.81) 0.20 (-0.19, 0.59) 38.81 (-0.07, 77.69) 
Total Societal cost 
Facility testers 40.11 (36.08, 44.15) 23.35 (19.40, 27.29) 18.43 (16.80, 20.07) 19.28 (17.27, 21.29) 261.57 (243.67, 279.47) 
HIVST 31.12 (24.79, 37.46) 22.50 (14.11, 30.89) 17.92 (14.04, 21.79) 19.06 (11.19, 26.94) 251.14 (204.33, 297.94) 
*Bootstrapped estimates with 1000 replications for 95%CI 
 230 
Figure 43: Mean monthly costs* (in 2014 US Dollars) after initiation of anti-retroviral therapy by modality of HIV testing received 
 
*Graphs show all three cost categories: health provider; direct non-medical and indirect; and societal costs  
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Figure 44: Mean monthly costs* (in 2014 INT Dollars) after initiation of anti-retroviral therapy by modality of HIV testing received 
 
*Graphs show all three cost categories: health provider; direct non-medical and indirect; and societal costs  
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Table 34 shows the results of the multivariable analysis investigating the 
independent effects of modality of HIV testing, baseline CD4 count and the month 
on anti-retroviral treatment on the mean monthly health provider and societal cost 
of providing HIV treatment during the ART observation period.  
 
In this multivariable analysis, the mean monthly health provider costs for those who 
had previously accessed HIVST were US$0.89 (95%CI: US$0.26-US$1.52) lower than 
for those who had previously accessed facility-based HTC. There was no significant 
difference between the two groups with respect to adjusted mean monthly societal 
costs.  
 
The baseline CD4 count did not have a significant impact on the adjusted mean 
monthly health provider or societal costs of providing anti-retroviral therapy. In the 
multivariable analysis, the adjusted mean monthly health provider costs was 
US$5.19 (95%CI: US$4.00-US$6.38) lower in the second month of ART provision than 
in the first month of ART provision, and remained comparable in the subsequent 
months. The adjusted mean monthly societal cost was US$6.88 (95%CI: US$5.30-
US$8.47) lower in the second month of ART provision than in the first month of ART 
provision, and remained comparable in the subsequent months. 
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Table 34: Multivariable analysis exploring relationship between CD4 count and modality of HIV testing received and the monthly cost of providing HIV 
treatment*   
 
 
 
Monthly Health Provider costs** Total Societal costs** 
2014 US Dollars 2014 INT Dollars 2014 US Dollars 2014 INT Dollars 
Coef (95% CI) Coef (95% CI) Coef (95% CI) Coef (95% CI) 
Modality of HIV 
testing  
Facility-tested Ref Ref Ref Ref 
HIV self-tested -0.89 (-1.52, -0.26) -1.83 (-3.16, -0.50) -0.84 (-1.70, 0.03) -1.68 (-3.77, 0.41) 
 
Baseline CD4 
count  
 
CD4 count >350 cells/μl Ref Ref Ref Ref 
CD4 count 200-350 cells/μl -0.50 (-1.23, 0.56) -0.64 (-2.33, 1.05) -0.25 (-1.28, 0.77) 0.06 (-2.54, 2.66) 
CD4 count 50-200 cells/μl -0.85 (-1.53, -0.17) -1.07 (-2.63, 0.49) -0.94 (-1.84, 0.07) -1.31 (-3.86, 1.25) 
CD4 count <50 cells/μl -0.59 (-2.06, 0.87) -1.42 (-4.22, 1.39) -1.38 (-3.09, 0.32) -3.61 (-7.23, 0.00) 
Not done or missing -0.45 (-1.38, 0.49) -0.07 (-2.30, 2.16) -0.47 (-1.89, 0.96) -0.13 (-3.81, 3.55) 
Month of anti-
retroviral 
treatment 
1st Month Ref Ref Ref Ref 
2nd Month -5.19 (-6,38, 4.00) -12.73 (-15.60, -9.86) -6.88 (-8.47, -5.30) -17.43 (-21.50, -13.37) 
3rd Month -4.37 (-5.65, -3.09) -10.85 (-13.95, -7.75) -5.90 (-7.79, -4.00) -15.09 (-20.01, -10.16) 
4th Month -5.04 (-6.21, -3.86) -12.72 (-15.52, -9.92) -6.82 (-8.39, -5.24) -17.67 (-21.68, -13.65) 
5th Month -4.46 (-5.68, -3.25) -12.12 (-14.95, -9.28) -5.81 (-7.51, -4.11) -15.85 (-20.11, -11.60) 
6th Month -4.91 (-6.10, -3.73) -13.57 (-16.36, -10.78) -7.08 (-8.59, -5.57) -19.58 (-23.35, -15.82) 
7th Month -4.18 (-5.57, -2.78) -12.51 (-15.56, -9.45) -6.30 (-8.00, -4.60) -18.37 (-22.39, -14.37) 
8th Month -4.22 (-5.46, -2.98) -12.42 (-15.56, -9.45) -6.18 (-7.76, -4.60) -17.88 (-21.82, -13.94) 
9th Month -5.24 (-6.14, -4.07) -14.65 (-17.44, -11.87) -7.19 (-8.76, -5.62) -20.07 (-24.03, -16.11) 
10th Month  -4.38 (-5.63, -3.12) -12.72 (-15.73, -9.72) -6.12 (-7.90, -4.33) -17.56 (-22.12, -13.00) 
11th Month  -4.19 (-5.64, -2.74) -12.15 (-15.69, -8.61) -6.40 (-8.12, -4.68) -18.28 (-22.61, -13.85) 
12th Month -4.29 (-5.58, -3.00) -12.61 (-15.68, -9.54) -6.46 (-8.08, -4.74) -18.64 (-22.67, -14.61) 
 
Constant 
 
19.16 (17.45, 20.86) 
 
31.90 (27.93, 35.88) 
 
20.93 (18.75, 23.12) 
 
36.84 (31.37, 42.31) 
*Findings from Generalized Linear Model with Gaussian distribution and Identity link function (i.e. OLS estimator) 
** Findings from Model 2: adjusted Age and Sex for martial status, educational attainment, income and wealth quintile 
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6.3.4.2 Health-related quality of life analysis  
Table 35 shows the mean EQ-5D utility scores and VAS scores for participants who 
started ART, by the baseline CD4 count. Figure 45 shows the mean EQ-5D utility 
scores and VAS scores over time by the baseline CD4 count. The participants who 
started ART had a mean EQ-5D utility score of 0.845 (bootstrap 95%CI: 0.829-0.862) 
before they started ART, with the mean EQ-5D utility score rising to 0.882 (bootstrap 
95%CI: 0.867-0.896) one month after initiating treatment. Across all participants, the 
mean EQ-5D utility score rose in the subsequent months to 0.920 (bootstrap 95%CI: 
0.829-0.862) by the end of the 3rd month on ART, to 0.940 (bootstrap 95%CI: 0.925-
0.955) by the end of the 6th month on ART, and 0.974 (bootstrap 95%CI: 0.961-0.987) 
by the end of the 12th month on ART.  Figure 45 shows that the increases in mean 
EQ-5D utility scores over time on ART occurred across all baseline CD4 categories. 
After 12 months on ART, the mean EQ-5D utility score was broadly similar in those 
with a higher baseline CD4 count and those with a lower baseline CD4 count. 
 
The participants who started ART had a mean VAS score of 72.0 (bootstrap 95%CI: 
69.8-74.2) before they started treatment, with the mean VAS score rising to 74.0 
(bootstrap 95%CI: 71.9-76.1) one month after initiating treatment. For all 
participants, the mean VAS score was higher in the subsequent months. The mean 
VAS score was 78.0 (bootstrap 95%CI: 75.6-80.3) by the end of the 3rd month on ART, 
80.1 (bootstrap 95%CI: 77.5-82.6) by the end of the 6th month on ART, and 81.5 
(bootstrap 95%CI: 78.2-84.7) by the end of the 12th month on ART.  
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Table 35: Health-related quality of life outcomes amongst those started onto ART by month from initiation of treatment    
  
Pre-ART 
(n=225) 
Month after starting ART 
1st month 
(n=225) 
3rd month 
(n=187) 
6th month 
(n=153) 
12th month 
(n=100) 
Mean (95% CI)* Mean (95% CI)* Mean (95% CI)* Mean (95% CI)* Mean (95% CI)* 
EQ-5D Utility Score 
 
ALL 0.845 (0.829, 0.862) 0.882 (0.867, 0.896) 0.920 (0.903, 0.937) 0.940 (0.925, 0.955) 0.974 (0.961, 0.987) 
CD4 count>=350 0.884 (0.849, 0.919) 0.917 (0.883, 0.950) 0.960 (0.922, 0.999) 0.964 (0.928, 1.000) 0.991 (0.972, 1.010) 
CD4 count 200-350 0.863 (0.835, 0.890) 0.891 (0.864, 0.917) 0.916 (0.892, 0.940) 0.945 (0.923, 0.968) 0.965 (0.939, 0.992) 
CD4 count 50-200 0.821 (0.792, 0.850) 0.874 (0.851, 0.898) 0.922 (0.891, 0.953) 0.930 (0.900, 0.960) 0.969 (0.948, 0.990) 
CD4 count <50 0.694 (0.602, 0.786) 0.790 (0.700, 0.881) 0.864 (0.798, 0.930) 0.886 (0.819, 0.952) 0.985 (0.897, 1.074) 
CD4 not done or missing 0.874 (0.832, 0.917) 0.871 (0.829, 0.912) 0.895 (0.842, 0.948) 0.957 (0.922, 0.990) 1.000 (1.000, 1.000) 
EQ-5D Utility Score 
(UK Tariff) 
ALL 0.805 (0.779, 0.831) 0.851 (0.830, 0.872) 0.898 (0.873, 0.923) 0.925 (0.905, 0.945) 0.971 (0.956, 0.985) 
CD4 count>=350 0.864 (0.821, 0.907) 0.900 (0.859, 0.940) 0.945 (0.888, 1.003) 0.960 (0.918, 1.002) 0.991 (0.972, 1.009) 
CD4 count 200-350 0.825 (0.783, 0.866) 0.862 (0.823, 0.900) 0.895 (0.862, 0.928) 0.932 (0.904, 0.961) 0.961 (0.931, 0.991) 
CD4 count 50-200 0.777 (0.730, 0.824) 0.845 (0.812, 0.878) 0.901 (0.854, 0.948) 0.912 (0.870, 0.953) 0.964 (0.939, 0.990) 
CD4 count <50 0.545 (0.365, 0.725) 0.696 (0.529, 0.863) 0.820 (0.715, 0.924) 0.841 (0.738, 0.945) 0.984 (0.901, 1.091) 
CD4 not done or missing 0.850 (0.799, 0.901) 0.837 (0.780, 0.895) 0.866 (0.794, 0.939) 0.945 (0.892, 0.997) 1.000 (1.000, 1.000) 
VAS Score 
ALL 72.0 (69.8, 74.2) 74.0 (71.9, 76.1) 78.0 (75.6, 80.3) 80.1 (77.5, 82.6) 81.5 (78.2, 84.7) 
CD4 count>=350 76.0 (70.5, 81.5) 80.7 (76.2, 85.4) 83.3 (77.2, 89.4) 83.3 (77.2, 89.4) 87.7 (76.4, 99.1) 
CD4 count 200-350 75.0 (71.2, 78.8) 75.9 (72.3, 79.2) 76.0 (71.7, 80.2) 78.5 (73.6, 83.4) 82.8 (76.9, 88.6) 
CD4 count 50-200 67.5 (63.7, 71.3) 71.2 (67.3, 74.8) 77.9 (74.0, 81.9) 81.6 (77.8, 85.4) 81.5 (76.9, 86.0) 
CD4 count <50 77.0 (62.4, 91.6) 74.7 (60.8, 88.0) 84.4 (77.6, 91.2) 82.2 (75.2, 89.2) 80.7 (66.4, 95.0) 
CD4 not done or missing 70.2 (63.5, 77.0) 69.2 (62.5, 75.8) 72.4 (65.3, 79.6) 73.8 (65.0, 82.5) 73.7 (60.6, 86.8) 
*Bootstrapped estimates with 1000 replications for 95%CI 
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Figure 45: Changes in health-related quality of life outcomes over time since initiating anti-retroviral therapy by baseline CD4 count  
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Table 36 shows the mean EQ-5D utility scores and VAS scores of participants who 
started ART by the modality of HIV testing they accessed prior to entering HIV care, 
whilst Figure 46 shows changes in these health-related quality of life scores over 
time on ART.  
 
The mean EQ-5D utility scores before starting ART was broadly similar in those who 
had previously accessed HIVST and those who had previously accessed facility-based 
HTC. In the months after starting ART, those who had previously accessed HIVST had 
comparable EQ-5D utility scores to those who had previously accessed facility-based 
HTC (Figure 46).  
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Table 36: Health-related quality of life outcomes before and after initiation of anti-retroviral therapy by modality of HIV testing 
  
Pre-ART 
(n=225) 
Month after starting ART 
1st month 
(n=225) 
3rd month 
(n=187) 
6th month 
(n=153) 
12th month 
(n=100) 
Mean (95% CI) Mean (95% CI) Mean (95% CI) Mean (95% CI) Mean (95% CI) 
EQ-5D Utility Score 
 
Facility testers 0.846 (0.828, 0.864) 0.881 (0.865, 0.898) 0.924 (0.907, 0.942) 0.941 (0.923, 0.958) 0.971 (0.956, 0.985) 
HIVST 0.844 (0.798, 0.889) 0.883 (0.849, 0.917) 0.901 (0.849, 0.917) 0.938 (0.905, 0.971) 0.938 (0.905, 0.971) 
EQ-5D Utility Score 
(UK Tariff) 
Facility testers 0.806 (0.780, 0.833) 0.851 (0.827, 0.874) 0.906 (0.884, 0.928) 0.927 (0.903, 0.951) 0.966 (0.950, 0.983) 
HIVST 0.797 (0.728, 0.866) 0.851 (0.800, 0.902) 0.862 (0.778, 0.945) 0.918 (0.872, 0.964) 0.993 (0.982, 1.004) 
VAS Score 
Facility testers 71.5 (69.0, 73.9) 73.7 (71.4, 76.1) 77.8 (75.3, 80.3) 80.1 (77.4, 82.7) 81.7 (78.4, 85.0) 
HIVST 74.4 (68.2, 80.7) 75.3 (69.6, 81.0) 80.1 (77.4, 82.7) 82.3 (75.9, 88.6) 84.6 (78.4, 85.0) 
*Bootstrapped estimates with 1000 replications for 95%CI84.6 (76.7, 92.6) 
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Figure 46: Changes in health-related quality of life outcomes after initiating anti-retroviral therapy by modality of HIV testing 
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Table 37 shows the results of the multivariable analysis investigating the 
independent effects of modality of HIV testing, baseline CD4 count, on the mean EQ-
5D utility score measured in the months after initiating anti-retroviral therapy. The 
multivariable analysis in model 3 additionally adjusted for the baseline EQ-5D utility 
score. In both models 2 and 3, the adjusted mean EQ-5D utility score was not 
significantly different for those who had previously accessed HIVST from those who 
had previously accessed facility-based HTC.  
 
In the multivariable analysis, the baseline CD4 count did not have a significant effect 
on the adjusted mean EQ-5D utility score after adjusting for the baseline EQ-5D 
utility score. The multivariable analysis shows that there was a significant 
improvement in the adjusted EQ-5D utility score with time on ART. In model 3, after 
adjusting for baseline EQ-5D utility score, with each additional month on ART, the 
mean adjusted EQ-5D utility score increased by 0.008 (95%CI: 0.007-0.009).  
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Table 37: Multivariable analysis exploring relationship between CD4 count and modality of HIV testing received on the EQ-5D utility score after starting 
ART*   
 
 
 
 
EQ-5D utility score 
Sensitivity Analysis 
EQ-5D utility score (UK Tariff)** 
Model 2 Model 3 Model 2 Model 3 
Coef (95% CI) Coef (95% CI) Coef (95% CI) Coef (95% CI) 
Modality of HIV 
testing  
Facility-tested Ref Ref Ref Ref 
HIV self-tested 0.008**  
(-0.015, 0.032) 
0.006  
(-0.016, 0.028) 
0.008 
 (-0.022, 0.039) 
0.005  
(-0.024, 0.033) 
Baseline CD4 
count  
CD4 count >350 cells/μl Ref 
 
Ref Ref Ref 
CD4 count 200-350 cells/μl -0.029**  
(-0.057, -0.001) 
-0.023  
(-0.049, 0.003) 
-0.035  
(-0.071, 0.002) 
-0.024  
(-0.058, 0.010) 
CD4 count 50-200 cells/μl -0.041**  
(-0.068, -0.013) 
-0.026  
(-0.052, 0.0001) 
-0.048**  
(-0.084, -0.012) 
-0.030  
(-0.064, 0.004) 
CD4 count <50 cells/μl -0.069**  
(-0.117, -0.022) 
-0.026  
(-0.072, 0.020) 
-0.095**  
(-0.157, -0.033) 
-0.035  
(-0.095, 0.025) 
Not done or missing -0.031  
(-0.064, 0.003) 
-0.032  
(-0.063, -0.0003) 
-0.039  
(-0.083, 0.005) 
-0.039  
(-0.080, 0.002) 
Month on ART 0.008**  
(0.007, 0.009) 
0.008**  
(0.007, 0.009) 
0.011**  
(0.009, 0.012) 
0.011**  
(0.009, 0.012) 
Baseline EQ-5D N/A 0.236**  
(0.169, 0.302) 
N/A 0.201**  
(0.143, 0.260) 
Constant 0.973  
(0.924, 1.022) 
0.762  
(0.686, 0.838) 
0.973  
(0.909, 1.037) 
0.800  
(0.722, 0.879) 
Model 2: Adjusted for Age, Sex martial status, educational attainment, income and wealth quintile 
Model 3: Additionally adjusted for EQ-5D score before starting anti-retroviral therapy 
ART: Anti-retroviral therapy 
*Findings from GEE model (Gaussian distribution and Identity link function) 
**p<0.05 
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6.3.5 Findings from sensitivity analysis 
In the sensitivity analysis, when the UK tariff was used to derive EQ-5D utility scores, 
the EQ-5D utility scores were generally lower; however, this did not impact on the 
overall findings from the multivariable analysis. The findings from the sensitivity 
analysis using the UK tariff for the pre-ART observational period are shown in Figure 
39; Table 25; Table 26; Table 29. The findings from the sensitivity analysis using the 
UK tariff for the ART observational period are shown in Figure 45; Figure 46; Table 
35; Table 36; Table 37.   
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6.4 Discussion 
In this component of the PhD I found that the costs of assessing HIV positive 
individuals for ART eligibility was higher for those detected through facility-based 
HTC than HIV self-testing, and was higher for those with a CD4 count above 350 
cells/μl than for those with a CD4 count below 350 cells/μl. I found the cost of 
providing ART was highest in the first month after initiating ART, but was 
comparable in the subsequent months, with the modality of HIV testing and CD4 
count not independently impacting on these costs. In addition, I found that the 
health-related quality of life was lower for those with more advanced HIV disease 
(measured by their CD4 count) and improved once they started ART, with the 
majority reporting perfect health after being on treatment for one year.  
 
In the pre-ART observation period, where individuals are assessed for eligibility to 
start ART, the costs (health provider and societal) were higher for those detected 
through facility-based HTC and those who had higher CD4 counts. Individuals who 
accessed HIV testing at the health facility are often doing so because they were 
attending the facility to access other medical care (e.g. TB screening) and referred 
for HIV testing by medical personnel as part of provider-initiated HIV testing and 
counselling (PITC). Consequently those who tested positive through facility-based 
HTC may be affected by another medical illness (e.g. TB), because of their weakened 
immune system, and need medical care in addition to their assessment for ART 
eligibility.  This is likely to explain why the health provider and societal costs were 
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higher for this group, who may have needed more clinic visits and additional 
medications or investigations.  
 
At the time of this study, individuals were initiated onto ART if their CD4 count was 
below 350 cells/μl or they had clinically advanced HIV disease (WHO stage 3 or 4). 
Individuals with clinically advanced HIV disease (WHO stage 3 or 4) can potentially 
have a CD4 count above 350 cells/μl, especially in Malawi where Tuberculosis (TB) is 
common, and developing active pulmonary TB disease would mean individuals 
would be clinically staged as WHO stage 3. This may explain why those who had CD4 
counts above 350 cells/μl incurred higher health provider and societal costs in the 
assessment for eligibility to initiate ART.  
 
In the multivariable analysis, I adjusted for the number of CD4 counts measured to 
take into account that some individuals were not eligible to start ART but retained in 
pre-ART care with further assessment undertaken months later. In the multivariable 
analysis of health provider costs during the pre-ART observation period (Table 23; 
model 2), those who had two CD4 counts measured incurred an additional cost of 
US$32.91 in comparison to those who had one CD4 count measured. This additional 
cost is not too dissimilar to the mean adjusted cost for those who had one CD4 count 
measured (2014 US$29.76). This suggests that the cost of re-assessing for ART 
eligibility remains comparable to the cost of the initial assessment. Individuals not 
found eligible for start ART are retained in pre-ART care. There are no 
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recommendations about medical care that should be provided to this population 
(WHO, 2014), and whilst this may reduce costs of retaining patients in HIV treatment 
it also significantly impact on retention with large numbers of those not found 
eligible not returning for further assessment (Plazy et al., 2015).   
  
In the study I estimated the annual health provider cost of managing a patient on 
ART to be approximately 2014 US$166.20 (2014 INT$ 226.16). Table 38 shows 
previous estimates for the annual health provider cost of providing ART for HIV 
positive individuals from other countries in sub-Saharan Africa. The annual HIV 
treatment estimates from this study are broadly similar to previous estimates for 
Malawi (2011 US$136) (Tagar et al., 2014), or estimates from studies undertaken 
more recently and in countries with comparable health systems and economies 
(Larson et al., 2013, Scott et al., 2014, Bratt et al., 2011, Tagar et al., 2014, Johns et 
al., 2014, Bikilla et al., 2009).  
 
Evidence suggests that as HIV treatments programmes grow and mature the average 
per patient costs of providing care will fall (Menzies et al., 2012), whilst the last 
decade has seen a significant fall in the cost of anti-retroviral drug prices (Tagar et al., 
2014). This will explain many of the differences seen in the Table 38. The higher cost 
of providing ART in South Africa is driven by the fact that much of HIV care is 
provided by medical doctors and the higher cost of wages in the country.  
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Table 38: Average annual HIV treatment costs for patients on ART 
Country of study Year of data 
collection 
Year of 
cost 
Estimated cost 
per patient per 
year on ART (US 
Dollars) 
Reference 
Malawi 2010-2011 2011 $136 (Tagar et al., 2014) 
Kenya 2007 2009 $230 to $288 (Larson et al., 2013) 
Zambia 2004-2008 2010 $556 (Marseille et al., 2012) 
Zambia 2007-2008 2011 $198 (Scott et al., 2014) 
Zambia 2008 2008 $278 (Bratt et al., 2011) 
Zambia 2010-2011 2011 $278 (Tagar et al., 2014) 
Ethopia1 2003-2005 2004/5 $235 (Bikilla et al., 2009) 
Ethiopia 2006-2007 2009 $781 (Menzies et al., 2011) 
Ethopia2 2008-2010 2011 $197-$216 (Johns et al., 2014) 
Ethiopia 2010-2011 2011 $186 (Tagar et al., 2014) 
Uganda 2006-2007 2009 $967 (Menzies et al., 2011) 
Rwanda 2010-2011 2011 $232 (Tagar et al., 2014) 
Lesotho3 2008-2009 2009 $261 to $345 (Jouquet et al., 2011) 
Multiple countries4 2007-2010 2010 $365 (Menzies et al., 2012) 
South Africa 2002-2003 2004 $2502 (Harling and Wood, 2007) 
South Africa5 2004-2005 2004 $483 (Harling et al., 2007) 
South Africa5 2004-2005 2004 $1,177 (Martinson et al., 2009) 
South Africa 2005 2006 $928 (Rosen et al., 2008) 
South Africa2,5 2008-2009 2009 $708 to $1176 (Long et al., 2011) 
South Africa 2010-2011 2011 $682 (Tagar et al., 2014) 
Nigeria 2006-2007 2009 $969 (Menzies et al., 2011) 
Burkino Faso6 2010 2012 $1,098 (Cianci et al., 2014) 
1: ART provided in Hospital outpatient setting  
2: Range of costs depending on degree of task shifting  
3: Range of costs for different ART drug Regimens  
4: Botswana, Ethiopia, Mozambique, Nigeria, Uganda and Vietnam 
5: Estimated from monthly cost 
6: Clinic for Female sex workers  
 
In the study I found the costs (health provider and societal) of managing HIV positive 
individuals on ART was not effected by either their HIV disease stage (by CD4 count) 
on initiating treatment, or the modality of HIV testing received prior to entering HIV 
care services. This finding is not unexpected. Malawi has followed a public health 
approach to scaling-up their HIV treatment services. This has required them to utilise 
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medical personnel other than doctors to provide the majority of care, with less 
reliance on diagnostic tests for clinical assessment prior to initiating ART or once on 
treatment.  Consequently the majority of individuals being clinically assessed prior to 
initiating treatment, and starting treatment are provided comparable levels of 
medical care.  
 
The higher cost in the first month of providing treatment is expected because 
patients are asked to return more frequently to ensure no early side effects of 
treatment and good adherence (Malawi MoH, 2011a). Previous studies have found 
the health provider cost of providing HIV care amongst those initiated onto 
treatment with more advanced HIV disease was higher (Leisegang et al., 2009, 
Harling and Wood, 2007). In these studies the cost of hospitalisations was included. 
In my study it was not possible to estimate this at the individual level because of the 
lack of recording in the medical records and because patients could not accurately 
provide information on their hospitalisation episodes. This was one of the driving 
factors for undertaking the hospital costing study described in Chapter 7 of the PhD.   
 
The study demonstrates the high costs incurred by patients when accessing HIV care. 
Individuals incurred a cost of approximately US$9 during their assessment for ART 
eligibility, and US$40 during the first year after starting ART. Anti-retroviral therapy 
is provided free but those accessing care may still incur costs including the costs of 
transportation to health facilities, or indirect costs as a result of losing income from 
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taking time off work to attend health facilities (Mshana et al., 2006, Rosen et al., 
2007). Additionally, these costs can also have an impact on long-term adherence to 
therapy resulting in many individuals stopping treatment (Hardon et al., 2007, Mills 
et al., 2006). In Chapter 5 of the PhD I showed how providing HIV testing in homes 
saved users considerable time and money. Previous studies have shown that in sub-
Saharan Africa, ART can be effectively provided in people’s homes through 
community distribution models (Jaffar et al., 2009, MacPherson et al., 2014). HIV 
infected individuals on ART require frequent and life-long attendance at health 
facilities to access care, and it may be necessary to consider home provision of 
treatment in the region.  
 
In this study, I found CD4 count to be significantly associated with the EQ-5D utility 
score, with participants who had lower CD4 counts to have lower EQ-5D utility 
scores. In addition, in those who started ART the EQ-5D utility scores gradually 
improved over the first year of receiving treatment with the majority of individuals 
reporting ‘perfect health’, equivalent to an EQ-5D utility score of 1. The findings are 
comparable to previous studies that have shown that those with advanced HIV 
disease (or lower CD4 counts) have poorer health-related quality of life (HRQoL), 
with quality of life improving after starting ART (Beard et al., 2009). In Chapter 5 of 
the PhD I discussed the issue that HIV self-testers reported better HRQoL and how 
this may be related to the service being utilised HIV infected people earlier in their 
disease progression (Figure 31 and Figure 32). In the study undertaken in this 
Chapter we found that HRQoL in HIV-positive individuals improves once they start 
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ART. The findings from this chapter and Chapter 5 highlight some of the potential 
gains in HRQoL through early uptake of HIV testing and timely initiation of ART in 
HIV-positive individuals unaware of their status.     
 
Qualitative studies amongst HIV positive individuals living in Africa have found 
individuals experience improvements in their HRQoL within six months of starting 
ART (Mutabazi-Mwesigire et al., 2014). Quantitative assessments of HRQoL in HIV 
positive individuals starting ART have also found significant improvement with 
initiation of ART, with much of the improvement occurring in the first few months 
after initiating treatment (Pitt et al., 2009, Jelsma et al., 2005, Stangl et al., 2007). In 
this study, participants who initiated ART also experienced significant improvements 
in their EQ-5D utility scores, with very few participants reporting any problems in 
any of the five dimensions of HRQoL within the EQ-5D descriptive system. In addition, 
I found that even amongst those with low CD4 counts, the majority reported perfect 
health (EQ-5D utility score of 1.0) after initiating ART. The findings support the 
beneficial impact of ART on quality as well as quantity of life lived amongst HIV 
infected individuals. This would support the importance of measuring quality of life 
improvements, and undertaking cost-utility analysis, when investigating 
interventions aimed at improving health outcomes amongst HIV infected individuals.  
 
Health-related quality of life is an important outcome for patients, and studies 
investigating the impact of earlier initiation of ART or other interventions in HIV 
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positive individuals will need to consider this in their outcomes. The EQ-5D measure 
has previously been shown to be responsive to changes in HRQoL amongst HIV 
positive patients accessing ART in high-income settings (Wu et al., 2013). However, 
very few studies use the EQ-5D to measure HRQoL amongst HIV infected individuals 
in sub-Saharan Africa (Beard et al., 2009, Robberstad and Olsen, 2010). The EQ-5D 
allows us measure HRQoL and therefore undertake a cost-utility analysis (CUA). The 
findings from a CUA can be more informative for policy makers than a cost-effective 
analysis as they will often need to consider funding decisions across a range of 
healthcare intervention (Drummond et al., 2005b). Researchers in sub-Saharan 
Africa have often used disability-adjusted life years (DALYs) to undertake CUA, but as 
discussed in Chapter 4 of the PhD, DALY’s have limitations. In this study, I found that 
the EQ-5D detected differences between those with advanced HIV disease and those 
with less advanced disease, as well as detecting improvements in HRQoL in 
participants who initiated ART. These findings support previous work that suggest 
the EQ-5D measure has value in HIV research (Tran et al., 2015, Tran et al., 2012), 
and consequently will support the development of economic evaluations by allowing 
outcomes to be quantified in quality-adjusted life years. 
 
In this study I would that the EQ-5D utility scores derived using the Zimbabwean 
tariff were higher than those derived from the UK tariff. There is no current 
Malawian tariff to derive EQ-5D utility scores from the responses to the descriptive 
component of the EQ-5D measure. In the PhD I have assumed that Malawians are 
more likely to value health like Zimbabweans than people from the UK (discussed in 
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Chapter 4 of PhD). However, this may not be true, and may suggest the potential 
value of developing a Malawian tariff to derive EQ-5D utility scores. However, the 
conclusions regarding the impact of HIV disease stage and impact of ART, on the EQ-
5D utility scores were comparable in the sensitivity analysis (using the UK tariff) as 
the primary analysis (using the Zimbabwean tariff). The findings from Chapter 7 of 
the PhD were I investigate the HRQoL amongst hospitalised patients, a sicker 
population, and Chapter 8 of the PHD, the final cost-utility analysis, will provide 
more information on the potential benefits of developing a Malawian tariff.   
 
I found that the modality of HIV testing received prior to accessing HIV treatment 
services had no independent impact on the EQ-5D utility score. In Chapter 5 of the 
thesis, I found EQ-5D utility scores were lower amongst HIVST who tested HIV 
positive. This difference is likely to be related to the stage of their HIV disease at the 
time of accessing HIV testing. HIV self-testing is provided in the community whilst 
facility-based HTC to those attending the health facility. Those attending the health 
facility will include those who are there seeking other medical care, including for 
diseases (e.g. TB) that arise as a consequence of their advanced HIV disease.  
 
The findings that relate to the impact of the modality of HIV testing received and 
costs or providing pre-ART and ART care, and EQ-5D utility scores should be taken 
with caution. In this study the cohort of individuals entering HIV care were recruited 
after they had attended the HIV clinic. The findings could therefore be potentially 
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biased by differential rates of linkage into HIV treatment services after HIV testing. 
Those who underwent HIVST are likely to be healthier than those who underwent 
facility-based HTC. Additionally facility HTC clients in the majority attended the 
health facility to learn their HIV status. It is likely facility HTC clients were keener to 
enter HIV care and therefore the comparisons made between these groups could be 
potentially biased.  
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6.5 Summary of Chapter 6 
In this Chapter I recruited a cohort of HIV positive individuals in Blantyre who had 
accessed wither HIVST or facility-based HTC to learn their HIV status. I followed them 
up until they had completed one year of anti-retroviral therapy (ART). I collected 
data on the healthcare resources used during this period and undertook primary 
costing studies to estimate the health provider costs of assessing them for eligibility 
to start ART, and for providing the first year of ART. I also asked participants on the 
costs they incurred and about the health-related quality of life (HRQoL).  
 
The findings suggest that there are initial differences in the health provider costs 
(during the pre-ART period) but once individuals are on ART the costs are not 
affected by their HIV disease stage. Additionally I show HRQoL is poorer amongst 
those with advanced HIV disease, but all those who start ART report near perfect 
health by the end of the first year of receiving treatment. I also show the modality of 
HIV testing received prior to entering HIV care did not have an impact on the 
majority of the economic outcomes.  
 
The economic data collected from this chapter will be used to inform the decision-
analytic modeling of the cost-effectiveness of HIV self-testing (Chapter 8).  This study 
provides estimates for the health provider and societal cost of assessing individuals 
for eligibility to start ART and for providing ART. In addition, this chapter provides 
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EQ-5D utility scores for health states to describe the progression of HIV disease 
before starting ART and after starting treatment.  
 
As the study did not allow us to quantify the economic impact of HIV disease on 
hospitalisation, a common occurrence, I will investigate this issue in Chapter 7 of the 
PhD. In Chapter 7, I will describe the study I undertook amongst adults admitted to 
the medical wards at Queen Elizabeth Central Hospital, Blantyre, Malawi.      
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CHAPTER 7: Economic and Health-
Related Quality of Life Outcomes 
for Hospitalised Patients Co-
infected with HIV in Blantyre, 
Malawi 
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7 Overview of Chapter 7 
In this chapter I describe an investigation of one of the secondary objectives of my 
PhD.  
To estimate the costs, to individuals and to healthcare providers, and health-
related quality of life of adults who are admitted to the medical wards in 
Queen Elizabeth Central Hospital, Blantyre, Malawi, for the management of 
medical illnesses.  
 
To investigate the relative impact of HIV infection on costs and health-related 
quality of life of adults who are admitted to the medical wards in Queen 
Elizabeth Central Hospital, Blantyre, Malawi, for the management of medical 
illnesses.  
 
As previously mentioned this Chapter is written as a stand-alone study. In this 
Chapter, I follow-up a cohort of adults admitted to the medical wards at Queen 
Elizabeth Central hospital, a teaching hospital in Blantyre, Blantyre. I will investigate 
the health provider, direct non-medical and indirect costs, and societal costs 
associated with managing a range of medical conditions. I will investigate the impact 
of these medical conditions on individual’s health-related quality of life. One of the 
main objectives is to obtain primary economic and health-related quality of life data 
for the final cost-effectiveness modelling study to be presented in Chapter 8.  
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7.1 Introduction 
Hospitals are an essential component of health services, however in sub-Saharan 
Africa there is a lack of understanding of the costs of providing care to inform policy 
or research (Adam and Evans, 2006, Adam et al., 2003, Grimes et al., 2014, Mills, 
1990, Beck et al., 2010). Policy makers and healthcare providers need to understand 
these costs to make budgetary and planning decisions. Importantly, the costs of 
providing hospital care accounts for a large proportion of the total health 
expenditure (Chopra et al., 2009). Providing care in primary health facilities is 
significantly less costly and more equitable than providing care in hospital settings 
(Adam and Evans, 2006, Lombard et al., 1991, Mills et al., 2012).  
 
In the region HIV infection, and the co-morbidities those infected develop, is the 
commonest reason for hospitalisation, with up to three quarters of adults admitted 
for medical reasons HIV positive (SanJoaquin et al., 2013). Moreover, hospital care is 
over twice as costly for individuals infected with HIV as for those who do not have 
HIV (Tshamba et al., 2014, Guinness et al., 2002), with those admitted having poor 
outcomes (SanJoaquin et al., 2013). In comparison to those who are not HIV infected, 
HIV positive individuals often need to stay in hospital longer, and they may require 
more investigations and medications (Hansen et al., 2000). 
 
In resource-rich countries the costs of managing HIV-infected individuals have 
changed over the last decade or two. After the introduction of anti-retroviral therapy 
 
 
258 
(ART) the costs of managing individuals with HIV rose, driven by the high costs of 
anti-retroviral drugs (Rizzardini et al., 2011, Mandalia et al., 2010). However as 
medical care for HIV infected individuals became more effective, and individuals are 
treated earlier in the course of their disease, the need for hospital care and costs fell 
(Rizzardini et al., 2011, Mandalia et al., 2010). This set of changes is likely to occur in 
sub-Saharan Africa over the next 10-20 years with earlier initiation of ART reducing 
the risks of opportunistic and TB disease (Cohen et al., 2011, Group et al., 2015b, 
Group et al., 2015a). Much of the potential cost savings achievable through earlier 
initiation of ART is felt to be through reduced hospitalisation amongst the HIV 
infected population (Munderi et al., 2012, Granich et al., 2012, Meyer-Rath et al., 
2013), however, there is currently a lack of primary economic evidence to support 
this argument (Beck et al., 2010, Adam and Evans, 2006).  
 
In this component of the PhD I investigate the economic impact of hospitalisation 
amongst adults in Blantyre, Malawi, I recruited a cohort of adults admitted to the 
medical wards at Queen Elizabeth Hospital in Blantyre, Malawi. I collected medical 
diagnostic and resource use data, and undertook primary (resource-based) costing 
studies to estimate the costs of managing a range of HIV-related and other illness in 
the hospital. I also investigated the costs incurred by patients and their families as a 
result of the hospitalisations, and evaluated their health-related quality of life 
outcomes.  
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7.2 Methods 
7.2.1 Ethics 
I obtained ethical approval from the College of Medicine Ethics Review Committee, 
University of Malawi; and the University of Warwick Biomedical Research Ethics 
Committee (Appendix I). All participants were provided with an information leaflet 
explaining the study and thereafter informed consent was sought (Appendix XIV and 
XV).  
 
7.2.2 Study overview 
The study was undertaken between June 2014 and December 2014. I recruited 
individuals admitted to the medical wards in Queen Elizabeth Central Hospital 
(QECH), Blantyre.  
 
Participants were asked about their direct non-medical costs, indirect non-medical 
costs and health-related quality of life outcomes during their hospital admission. The 
medical notes were reviewed after discharge to determine the medical reasons for 
admission and the medical resources used during admission. Primary costing studies 
were undertaken to estimate the direct health provider costs. Figure 47 provides an 
overview of the study design. 
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Figure 47: Overview of study design 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7.2.3 Study setting and study population 
QECH is the largest hospital in Malawi, with approximately 1,500 beds and 25,000 
adult inpatients per year (SanJoaquin et al., 2013). The HIV prevalence amongst 
medical inpatients has previously been reported to be as high as 70% (SanJoaquin et 
al., 2013). The hospital has a large emergency department where all new patients 
are triaged and assessed by a medical doctor. The decision is then made on whether 
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the patient needs hospital admission, and to which department they should be 
admitted. The doctor also makes a preliminary medical diagnosis. Patients with 
medical diagnoses are transferred to one of three medical wards: 3A (TB ward); 3B 
(male medical); and 4A (female medical). Patients admitted to either the male or 
female medical ward, and who are then diagnosed and started on TB treatment are 
subsequently transferred to ward 3A (TB ward).  
 
In this study I recruited a cohort of adults (aged>=18years) admitted to these three 
medical wards. A study nurse reviewed the medical admission book on each of the 
three wards. Every fifth participant admitted to each of the three wards was 
recruited into the study during the study period June 2014 and December 2014. In 
addition, all adults who were admitted and had been given a preliminary medical 
diagnosis of less common late stage HIV-related diseases (Pneumocystis Carinii 
Pneumonia; Candidiasis; Cryptococcal Meningitis; or Kaposi’s Sarcoma) were 
recruited. Appendix XVI shows the template of the book designed for each ward to 
record admission information and identify participants eligible for recruitment.  
 
All participants were seen by the field worker on the first working day after their 
admission for recruitment and initial data collection. Participants were subsequently 
also seen by the field worker every three to seven days that followed and on the day 
of discharge. After discharge a doctor working on the ward reviewed the medical 
notes of each participant, and extracted medical associated resource use data. Table 
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39 provides an overview of the data collection, and timing of consent and 
administering questionnaires.    
 
Table 39: Overview of data collection and timing of administering questionnaires 
 1st working 
Day of 
Admission 
Every 3-7 after 
Admission 
(where 
applicable) 
On 
Discharge 
or Death 
After 
discharge 
Individual Interviews – Completed by Field worker with participants 
 
Participant information leaflet:     HTC-500 
Consent:                                             HTC-500X 
Socio-demographic:                         HTC-501 
HRQoL – EQ-5D:                                HTC-QOL 
Participant time and out-of pocket costs:  
                                                             HTC-502 
                                                             HTC-503 
 
✓ 
✓ 
✓ 
✓ 
 
✓ 
 
 
 
 
✓ 
 
 
✓ 
 
 
 
 
✓ 
 
 
✓ 
 
 
Medical data extraction – Completed by Medical doctor reviewing medical notes  
 
Primary and Secondary Diagnosis   HTC-DOC 
HIV +/- ART Status                             HTC-DOC 
Investigations performed                 HTC-DOC 
Procedures performed                     HTC-DOC 
Medications given                             HTC-DOC 
 
 
 
         
 
 
 
 
 
 
✓ 
✓ 
✓ 
✓ 
✓ 
  
 
7.2.4 Medical data extraction  
A medical doctor reviewed the medical notes for each study participant after the 
end of the hospital stay and extracted data on their primary medical diagnosis, HIV 
status and the medical care provided. The doctor recorded the duration of hospital 
admission, and the patient’s outcome (discharged home; transferred to another 
hospital; absconded; or died during hospitalisation). The doctor also recorded their 
HIV status, CD4 count and anti-retroviral drug use. For the CD4 count the doctor 
recorded the CD4 count and the date the CD4 count was measured. For anti-
retroviral drug use, the doctor recorded whether the patient had been initiated prior 
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to hospital admission or initiated during the hospital admission, as well as the drug 
regime patient was prescribed.  
 
The primary medical diagnosis was recorded using two approaches. The first was a 
single-level coding of the diagnosis using one of 22 options (Appendix XVII), 
including one option for ‘other’ and one for ‘not known’. The options were based on 
the internal surveillance system for hospital admission at QECH (SanJoaquin et al., 
2013). The second was a multi-level coding system based on International 
Classification of Diseases, 9th Revision, Clinical Modification (IDC-9-CM) (Elixhauser 
et al., 2014) (Appendix XVIII).  
 
An extensive list of the investigations and procedures, undertaken at QECH was 
derived after discussions with doctors working at the hospital. The doctor recorded 
which investigations and procedures were performed for each patient and how 
many times they were performed. A list of all drugs available at the pharmacy at 
QECH was obtained. The doctor recorded the drug name, dosage, route of 
administration and total number of doses given. Data extraction tools were pilot 
tested by the medical doctors, and adapted after discussions with them. Appendix 
XVII shows the final data extraction tool used by the doctors and Appendix XVII 
shows the medical diagnosis classification codebook.  
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7.2.5 Cost analysis 
7.2.5.1 Direct health provider costs  
THE UNAIDS costing guidelines were used to undertake the primary costing studies 
to estimate the costs for all medical resource outputs used (UNAIDS, 2011). Broadly, 
a list of medical resource outputs (e.g. days of admission; full blood count) was 
identified from the medical data extracted by the doctors. Secondly, interviews were 
conducted with medical and administrative personnel to identify and quantify the 
individual resources required to produce the medical resource outputs. Thirdly, the 
financial data from hospital administration systems, in combination with National 
and International resource data (Frye, 2012, UNAIDS, 2011, WHO-CHOICE), were 
used to value individual resource inputs. Fourthly, the data was used to estimate the 
cost of each medical resource output. Finally, the estimated resource output costs 
were used to estimate the total health provider cost for each study participant. 
 
I used a combination of top-down and bottom-up methods to estimate the relevant 
costs. Figure 48 provides an overview of how the bottom-up approach was used to 
estimate the cost of medical resource outputs. Figure 49 shows how the top-down 
method was used to allocate costs of support services to the medical resource 
outputs.  
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Figure 48: Bottom-up approach to costing resources used 
 
 
Figure 49: Top-down approach to allocating support  
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I undertook interviews with central support services to estimate the total central 
support service costs for running the hospital. This cost was then allocated to each 
department (Medical wards, Laboratory, Radiology and Pharmacy). I used the 
number of staff working in each of these departments divided by the total number 
of staff at the hospital to estimate the proportion of the total central support costs 
consumed by each relevant department. Some central support costs (e.g. catering, 
costs of locum staff) were only allocated to the medical wards, as the other 
departments do not benefit from them. For this we used the number of clinical staff 
working on the medical wards and divided by the total number of clinical staff 
working in the hospital to determine what proportion of the specific form of central 
support cost should be allocated to each medical ward.  
 
For the medical wards, I estimated the cost per day of hospital care. Interviews were 
undertaken with the nurse in charge on the wards to determine the staff who 
worked on the ward and the time they spent on the ward. Information was obtained 
on the consumables used, and the quantity of each consumable used annually. A list 
of all the equipment on the wards was also documented. A unit cost was obtained 
for all consumables and equipment’s. The total average annual cost of running the 
ward was estimated. This compromised the cost of staff, consumables and 
equipment. The cost of central support services was added to these total costs. 
During the study period I also recorded the daily number of patients on each ward, 
and this was used to estimate the total number of patient days of admission per year 
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(Appendix XIX). The total average annual cost for each ward was divided by annual 
patient days to estimate the average cost per patient day of admission.   
 
I repeated the same procedure for the pharmacy department. I estimated the total 
average annual cost of running the pharmacy. This compromised the costs of staff, 
consumables and equipment, in addition to an allocated proportion of the central 
support services. The pharmacy keeps a record of the total drugs supplied per 
annum, broken down by drug formulation and doses given. The total average annual 
cost of running the pharmacy was divided by the total number of drug doses 
supplied to estimate the average cost per dose of drug dispensed by the pharmacy. 
This cost was added to the cost of the drug to estimate the total cost of providing 
the drug to the patient. For the cost of the drugs I used the international market 
price (Health, 2013). The cost of shipping and insurance was excluded from the 
international market price for the drugs.  
 
Figure 50 and Figure 51 compares the costs of drugs obtained from the Malawian 
MoH price catalogue, which includes the cost of shipping and insurance, to the price 
of drugs provided by the International drug price indicator guide, which excludes 
these costs (Health, 2013). For the majority of the drug prices, the prices were 
comparable.  
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Figure 50: Comparison of drug prices between Malawi MoH and international market price (prices< US$0.05)   
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Figure 51: Comparison of drug prices between Malawi MoH and international market price (prices> US$ 0.05) 
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Investigations and procedures are performed through the Laboratory and Radiology 
department at QECH or on the medical wards. For investigations and procedures, I 
estimated the direct cost of performing the investigation and the indirect cost of the 
investigation or procedure. The direct cost of the investigation or procedure 
comprised the attributable cost of personnel, consumables and equipment. I 
undertook interviews with the medical, laboratory and radiology staff to quantify 
each of these items. For equipment and personnel, I recorded the approximate time 
spent in performing the investigation. A unit cost of each item was obtained and the 
total direct cost of the investigation or procedure was estimated. The indirect cost of 
the investigation comprised the cost per test of the department and the cost of the 
central support services. For this I estimated total cost, including the cost of central 
support services, and divided this by the total outputs of the department. For 
investigations and procedures performed in the Laboratory and Radiology 
department, I used the total number of tests performed as the denominator. For the 
Laboratory and Radiology department, I undertook interviews to estimate the 
numbers and grades of staff working in the department, and the consumables and 
equipment used. For all these items I quantified the proportion of the time spent on 
performing investigations or procedures, and the proportion of time spent on 
general duties or activities. For the indirect costs I summed total costs based on 
resources used for activities other than performing a specific investigation or 
procedure.  
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I investigated the validity of the costs estimated for a range of investigations and 
procedures for QECH. For this I compared the costs I estimated from the primary 
costing study to the cash price provided by two different private healthcare 
providers in Malawi (findings described in the results section of this Chapter: Figure 
53 and Figure 54).  
 
I used the estimated direct cost of performing investigations and procedures 
performed on the ward. Some investigations are performed outside QECH. For these 
we used the cost charged to QECH as the total cost of the investigation.  
 
For all the costings, I obtained staff salaries from the QECH Human Resources 
departments and included employer contributions and fringe benefits. The costs of 
consumables and equipment were obtained from the Malawi Ministry of Health 
price catalogue. For costs that were not available in the catalogue, I used the 
international or reference prices (WHO-CHOICE). I first contacted local suppliers to 
obtain costs, and if these were not available, I contacted international suppliers and 
manufacturers. Equipment costs were annuitized over their useful life with an 
annual discount rate of 3%. For large laboratory and imaging equipment, I assumed 
the useful lifetime to be 5 years. This assumption was based on discussions with 
laboratory and radiology staff on time before equipment should be replaced. For all 
other equipment, including general office equipment, I assumed the useful lifetime 
to be 3 years.  
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For all the above interviews to determine resources use by each department I used 
the same data extraction tool developed in Chapter 5 of the PhD that component of 
the study (Appendix XII). 
 
7.2.5.2 Direct non-medical and indirect costs  
A questionnaire was developed to capture the direct non-medical and indirect costs 
incurred by each study participant and their main family member or carer who 
remained with them at hospital during the admission. The direct non-medical costs 
included the cost of transportation, food, drinks, toiletries, clothing and other items 
bought during their hospital admission. For indirect costs, I recorded whether 
participants had taken time off work, and if so, the amount of time, and multiplied 
this by their self-reported income (Pritchard and Sculpher, 2000). Two 
questionnaires (HTC-502 and HTC-503) were developed to estimate these costs and 
are shown in Appendix XXI and XXII.  
 
Table 39 shows when these two questionnaires were administered. A field worker 
interviewed the participant during their hospital admission to complete these 
questionnaires. The first (HTC-502) was administered to participants on the first 
working day after hospital admission (Appendix XXI). All these direct non-medical 
and indirect costs were related the costs incurred on the day of their hospital 
admission. The second (HTC-503) was administered to participants every three to 
seven days after the first questionnaire. This second questionnaire asked 
 
 
273 
participants about direct non-medical and indirect costs for the preceding day they 
were in hospital (Appendix XXII).  
 
The questionnaires were forward translated into Chichewa, the local language of the 
study population, and back translated by two independent bilingual Malawians. The 
questionnaires were then pilot tested, and discussions were held with senior 
Malawian staff working at the Malawi-Liverpool Wellcome Trust Clinical Research 
Programme before the final version was agreed upon.  
 
7.2.5.3 Cost conversions 
As described in preceding chapters, all costs were converted into 2014 US Dollars 
and International Dollars (Drummond et al., 2005b) using data reported by the 
World Bank (Evans et al., 2005). The cost, currency, price year and source country of 
cost were recorded for all items. The costs were adjusted to the year of reporting 
using the Gross Domestic Product (GDP) deflator index, provided by the World Bank. 
The costs were then converted to 2014 US Dollars using the market exchange rate, 
and to 2014 International dollars using purchasing power parity conversion factor 
(Krijnse Locker and Faerber, 1984, Shemilt et al., 2010).   
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7.2.6 Health-related quality of life 
All study participants recruited into the study were asked about their general health 
and their health-related quality of life (HRQoL) as soon as possible after admission, 
and every three to seven days thereafter until final hospital discharge. The 
questionnaire (HTC-QOL) that was administered to participants by the field worker is 
shown in Appendix XXIII. Table 39 shows when the field worker administered this 
questionnaire.  
 
The self-assessed health (SAH) measure was used to ask individuals to rate their 
general health on a five-point Likert scale, with responses coded as: very good; good; 
fair; poor; or very poor. The SAH measure has been found to be a strong predictor of 
future health outcomes in high-income settings (Idler and Benyamini, 1997), and has 
used in resource-constrained settings (Gilbert and Soskolne, 2003, WHO, 2002). 
 
The Chichewa version of the EuroQoL EQ-5D-3L (Dolan, 1997) was used to estimate 
HRQoL of participants recruited into this study. Participants completed both the 
descriptive EQ-5D-3L system and a visual analogue scale at each time point they 
were asked about their HRQoL (EuroQol, 1990). Chapter 4 of the PhD provides a 
more detailed description of the EQ-5D tool, the process used to translate it into 
Chichewa and how EQ-5D utility scores are derived. Briefly, participants are asked to 
respond to the descriptive component of the EQ-5D-3L tool, with the EQ-5D utility 
score derived by using a tariff set.  The tariff sets have been derived from national 
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surveys of the general population, with a subset of the 243 health states being 
valued, most commonly using the time trade-off method (EuroQoL, 1990). The 
remainder of the EQ-5D health states are subsequently valued through the 
estimation of a multivariable model.  As there is no Malawian EQ-5D tariff, I used the 
Zimbabwean EQ-5D tariff set (Jelsma et al., 2003) to derive an EQ-5D utility score for 
each study participant. The visual analogue scale (VAS) is similar to a thermometer, 
and ranges from 100 (best imaginable health state) to 0 (worst imaginable health 
state). Participants record how good or bad their health is on that day by drawing a 
line on the scale.  
 
7.2.7 Statistical analysis 
All analysis was undertaken in Stata version 13.0 (Stata Corporation, Texas, USA). 
Socio-demographic data was collected on all participants recruited into the study. 
This included sex, age marital status, educational attainment, employment status, 
and self-reported income. For socio-economic position, we collected data on 
household assets, nine in total, and information on home environment, for example 
distance to toilet. We undertook principal component analysis was to classify an 
individual’s socio-economic position based on their wealth quintiles (Filmer and 
Pritchett, 2001). Appendix XX shows the questionnaire (HTC-501) used to collect 
individual-level socio-demographic and socio-economic data.  
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The total direct health provider cost was estimated for each study participant. The 
total direct health provider cost per participant was comprised of the cost of the stay 
on the hospital ward, the cost of all investigations and procedures and the cost of all 
drugs given. The cost of stay on the hospital ward was estimated by multiplying the 
average cost per day of admission by the total number of days on the ward. This was 
estimated for each ward the participant was admitted to. The total cost of 
investigations and procedures per participant was estimated by multiplying the cost 
by the number of times they were performed. This was done for all investigations or 
procedures performed and summing the costs.  For drug costs per participant the 
cost of each drug, including the cost of dispensing the drug through the pharmacy 
department, was multiplied by the number of doses given. The total cost of drugs 
per participant was estimated by summing the costs of each individual drug given.  
 
The total direct non-medical and indirect cost per participant was estimated for the 
duration of the hospital admission. This included the total direct non-medical cost 
and indirect costs incurred by the participant and their main family member/carer 
who stayed with them during their hospital admission. For participants who died 
during their hospital admission, this was estimated for the period from admission till 
death. I estimated the total direct non-medical and indirect cost for the day of 
admission, using responses from HTC-502. I estimated the average daily direct non-
medical and indirect cost of each subsequent day of their hospital stay using 
responses from HTC-503. For participants who only had the questionnaire 
administered more than once, the average from each time questionnaire was 
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administered was estimated. The total direct non-medical and indirect cost was 
estimated by adding the costs on the day of admission, to the average daily cost 
multiplied by the total duration of the hospital admission minus one day.  
 
The total societal cost per participant cost was estimated by adding the total direct 
health provider cost, and the total direct non-medical and indirect cost.  
 
I estimated the total health provider costs; the total direct non-medical and indirect 
costs; the total societal cost and the EQ-5D utility score by the primary diagnosis of 
participants. For the primary medical diagnosis, I used the data extracted by the 
doctor on primary reason for the medical admission. The data was recorded from 
the multi-level coding system based on the International Classification of Diseases, 
9th Revision, Clinical Modification (ICD-9-CM) (Elixhauser et al., 2014). For each 
participant, the medical diagnosis was classified up to four-levels.  The classification 
system provides a more specific diagnosis at the higher level, but with the sample 
sizes used, would result in few participants for many of the diagnosis. I therefore re-
coded the primary medical diagnosis to ensure at least five participants had the 
same primary medical diagnosis. I worked iteratively from the higher level to the 
lower levels to ensure that there were at least 5 participants for each of the final 
diagnostic categories.   
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For the EQ-5D utility score and VAS score, I estimated the scores on admission, the 
average score during the hospital admission, the last recorded score prior to 
discharge, and the change in score from admission to the final recorded score. For 
those who died on admission, or after admission, I recorded their utility and VAS 
scores as zero. For the change in EQ-5D utility and VAS scores, I subtracted their last 
recorded score from the first recorded score.  
 
I undertook multivariable analysis to investigate the independent effect of HIV status 
on the total health provider cost and total societal cost. For HIV status, I classified 
individuals as HIV negative; HIV positive and taking anti-retroviral therapy prior to 
hospital admission; HIV positive and started anti-retroviral therapy during hospital 
admission; HIV positive and not on anti-retroviral therapy; and HIV status not known. 
As all participants incurred a cost, and the cost data was skewed, I used generalized 
linear models (GLM) for multivariable analyses of cost data (Barber and Thompson, 
2004). I used the same approach as described in chapter 5 and ran model diagnostics 
to determine the optimal choices for the distributional family and link function 
(Manning and Mullahy, 2001). The Park test, link test, Akaike Information Criterion 
and visual inspection of plots of the deviance residuals were examined to determine 
the optimal choice for the link function and the distributional family. 
 
I also undertook multivariable analysis to investigate the independent effect of HIV 
status on the EQ-5D utility score on hospital admission. EQ-5D utility scores were 
 
 
279 
non-normally distributed, skewed and truncated at 1.0. I used the same approach as 
described in Chapter 5 and evaluated four commonly used estimators to analyse 
these data: ordinary least squares (OLS) regression; Tobit regression, Fractional logit 
(Flogit) regression, and censored least absolute deviations (CLAD) regression (Powell, 
1984, Austin et al., 2000, Papke and Wooldridge, 1996). The mean squared error 
(MSE) and mean absolute error (MAE) statistics were compared between the 
observed EQ-5D utility score and the estimated scores for the whole sample, and for 
sub-groups of the sample based on observed EQ-5D utility scores, to determine the 
choice of preferred estimator.  
 
For all multivariable analyses I ran three alternative models, the first adjusted for HIV 
status, and age and sex. The second model was additionally adjusted for marital 
status, educational attainment, income and socio-economic position (Stangl et al., 
2007). The third model was additionally adjusted for the primary medical diagnosis.  
 
7.2.8 Sensitivity analysis 
I also undertook sensitivity analyses to investigate the impact of using an alternative 
tariff set to determine EQ-5D utility scores. I used the UK York A1 tariff (Dolan et al., 
1996a), which has been found to translate health states with ‘severe’ problems in 
one or more of the five dimensions to a lower EQ-5D utility scores than the 
Zimbabwean tariff (Jelsma et al., 2003).    
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7.3 Results 
7.3.1. Participant characteristics  
1,036 individuals were admitted to the adult medical wards and eligible for 
recruitment during the study period (Figure 52). In total, 822 (79.3%) participants 
were recruited into the study, and medical data extraction was possible for 661 
(80.4%) of these. Table 40 shows the characteristics of those who were and were not 
recruited into the study.  
 
Figure 52: Recruitment of participant 
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Table 40: Characteristics of participants eligible for recruitment   
  Died before 
recruitment 
Absconded/ Discharged 
before recruitment 
Not consented Recruited, medical 
notes not found 
Recruited + 
medical notes 
found 
  n (%) n (%) n (%) n (%) n (%) 
All 88 30 96 161 661 
Sex      
Male 52 (59.1%) 19 (63.3%) 52 (54.2%) 69 (42.9%) 348 (52.7%) 
Female 36 (40.9%) 11 (36.7%) 44 (45.8%) 89 (57.1%) 313 (47.3%) 
Age (years)      
18-24 8 (9.1%) 4 (13.3%) 12 (12.5%) 19 (11.8%) 76 (11.5%) 
25-34 21 (23.9%) 7 (23.3%) 25 (26.0%) 63 (39.1%) 185 (28.0%) 
35-44 31 (35.2%) 4 (13.3%) 27 (28.1%) 39 (24.2%) 189 (28.6%) 
45+ 28 (31.8%) 13 (43.3%) 32 (33.3%) 38 (23.6%) 205 (31.0%) 
Missing 0 (0%) 2 (6.7%) 0 (0%) 2 (1.2%) 6 (0.9%) 
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Table 41 shows the characteristics of participants who were recruited into the study 
and from whom individual-level data was collected on direct non-medical and 
indirect costs and HRQoL, and those for whom I was also able to trace the medical 
notes for data extraction.  
 
Table 42 shows the characteristics, HIV status and outcomes of participants within 
the final analysable sample by the primary medical diagnosis. 52.7% were male, 
31.4% were over the age of 45 years, 69.2% were HIV positive and 21.1% died in 
hospital. The mean duration of hospital admission was 12.1 days (SE: 0.5). 
 
All participants who had a primary diagnosis of Tuberculosis of meninges and central 
nervous system, Candidiasis, Cryptococcal meningitis Pneumocystis Carinii 
Pneumonia and Kaposi’s Sarcoma were HIV positive. Participants with a primary 
medical diagnosis of Tuberculosis of bones and joint had the highest mortality rate 
(60.0%). Participants with a primary medical diagnosis of Tuberculosis in general had 
high rates of mortality (range 27.8% to 60.0%). Participants who were being re-
treated for their Tuberculosis disease had the longest duration of hospital admission 
(41.2 days; SE: 11.8). All participants with a primary medical diagnosis of diabetes 
mellitus, with our without complications, mental health disorders and diseases of 
the musculoskeletal system were discharged home.  
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Table 41: Characteristics of recruited participants   
  Data Collection 
from individuals 
Data 
extraction 
from medical 
notes 
  n (%) n (%) 
All  822 661 
Sex Male 417 (50.7%) 348 (52.6%) 
Female 405 (49.3%) 313 (47.4%) 
Age  (years) 18-24 95 (11.6%) 76 (11.5%) 
25-34 248 (30.2%) 185 (28.0%) 
35-44 228 (27.7%) 189 (28.6%) 
45+ 243 (29.6%) 205 (31.0%) 
Missing 8 (1.0%) 6 (0.9%) 
Marital Status Single (never-married) 90 (10.9%) 73 (11.0%) 
Married/cohabiting 454 (55.2%) 362 (54.8%) 
Separated/divorced 133 (16.2%) 101 (15.3%) 
Widower/widow 107 (13.0%) 92 (13.9%) 
Missing 38 (4.6%) 33 (5.0%) 
Educational 
attainment 
Up to standard 8 463 (56.3%) 368 (55.7%) 
Up to form 6 297 (36.1%) 241 (36.5%) 
University or training college 24 (2.9%) 19 (2.9%) 
Missing 38 (4.6%) 33 (5.0%) 
Income Not working 395 (48.1%) 303 (45.8%) 
Up to 4,000 Kwacha/week 107 (13.0%) 87 (13.2%) 
4,000 to 8,000 kwacha/week 101 (12.3%) 80 (12.1%) 
8,000 to 12,000 kwacha/week 47 (5.7%) 39 (5.9%) 
Over 12,000 kwacha/week 160 (19.5%) 143 (21.6%) 
Missing 12 (1.5%) 9 (1.4%) 
Employment 
status 
Formal employment 148 (18.0%) 131 (19.8%) 
Informal employment/Unemployed 276 (33.6%) 224 (33.9%) 
School/University 37 (4.5%) 31 (4.7%) 
Retired 12 (1.5%) 4 (0.6%) 
Housework 279 (33.9%) 211 (31.9%) 
Sick leave 59 (7.2%) 52 (7.9%) 
Missing 11 (1.3%) 8 (1.2%) 
Socio-economic 
position 
Highest quintile 154 (18.7%) 129 (19.5%) 
2nd highest quintile 157 (19.1%) 123 (18.6%) 
Middle quintile 155 (18.9%) 129 (19.5%) 
2nd lowest quintile 154 (18.7%) 119 (18.0%) 
Lowest quintile 157 (19.1%) 121 (18.3) 
Missing 45 (5.5%) 40 (6.05%) 
HIV Status HIV negative 216 (26.3%) 178 (26.9%) 
 HIV positive 566 (68.9%) 458 (69.3%) 
 Unknown/not disclosed 40 (4.9%) 25 (3.8%) 
Outcome of 
participant 
Discharged home 664 (80.8%) 522 (79.0%) 
Died 158 (19.2%) 139 (21.0%) 
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Table 42: Characteristics of participants by the primary medical diagnosis 
 
Primary Medical Diagnosis  
 
n 
Sex Age (years) HIV Status Days of admission Outcome 
% Male % 18-24 % 25-34 % 35-44 % 45+ % HIV Positive Mean (SE) % Died 
ALL 661 52.7 11.6 28.1 28.9 31.4 69.2 12.1 (0.5) 21.1 
Pulmonary Tuberculosis 55 70.4 7.4 38.9 35.2 18.5 87.0 23.9 (2.9) 27.8 
Tuberculosis of meninges and central nervous system 17 58.8 12.5 12.5 43.8 31.3 100 38.2 (7.2) 47.1 
Tuberculosis of intestines, peritoneum 9 66.7 11.1 11.1 44.4 33.3 77.8 19.3 (7.2) 33.3 
Tuberculosis of bones and joint 5 80.0 0 0 20.0 80.0 40.0 16.0 (5.3) 60.0 
Tuberculosis of other organs 15 66.7 0 20.0 46.7 33.3 80.0 26.0 (9.3) 46.7 
Miliary Tuberculosis 17 64.7 0 52.9 23.5 23.5 82.4 10.7 (1.0) 58.8 
Tuberculosis - Retreatment 6 66.7 16.7 33.3 33.3 16.7 83.3 41.2 (11.8) 33.3 
Septicaemia (except in labour) 60 41.7 24.1 29.3 22.4 24.1 65.0 8.4 (1.0) 18.3 
Candidiasis 6 33.3 0 60.0 20.0 20.0 100 5.7 (1.7) 16.7 
Cryptococcal meningitis 38 73.7 10.5 34.2 47.4 7.9 100 15.8 (1.7) 26.3 
Viral infection 9 55.6 22.2 44.4 11.1 22.2 100 13.9 (3.7) 55.6 
Pneumocystis Carinii Pneumonia 9 44.4 12.5 37.5 37.5 12.5 100 13.4 (1.9) 22.2 
Malaria 13 23.1 30.8 15.4 30.8 23.1 76.9 5.2 (1.6) 7.7 
Kaposi’s Sarcoma 20 80.0 5.0 50.0 35.0 10.0 100 9.1 (1.2) 25.0 
Neoplasms - excluding Kaposi's 8 50.0 25.0 12.5 12.5 50.0 37.5 16.0 (1.7) 12.5 
Diabetes mellitus without complications 5 0 20.0 20.0 0 60.0 0 3.8 (1.2) 0 
Diabetes mellitus with complications 9 55.6 0 0 33.3 66.7 11.1 8.2 (1.2) 0 
Anaemia 35 40.0 11.4 34.3 22.9 31.4 74.3 9.4 (1.3) 17.1 
Mental Health disorders 9 66.7 22.2 22.2 33.3 22.2 22.2 6.6 (1.9) 0 
Meningitis (except that caused by TB or Cryptococcal) 37 29.7 13.5 29.7 27.0 29.7 70.3 9.2 (0.8) 13.5 
Epilepsy; Convulsions 11 45.5 45.5 18.2 9.1 27.3 36.4 5.9 (0.9) 9.1 
Other Neurological Problems 16 75.0 6.3 25.0 43.8 25.0 50.0 10.3 (2.6) 6.3 
Cerebrovascular disease 25 48.0 0 12.5 20.8 66.7 40.0 8.6 (1.1) 8.0 
Hypertension 7 71.4 0 14.3 14.3 71.4 28.6 11.1 (4.4) 28.6 
Congestive heart failure; non-hypertensive 15 40.0 0 0 20.0 80.0 13.3 9.4 (2.1) 33.3 
Other Cardiovascular Problems 13 30.8 15.4 7.7 7.7 69.2 46.2 13.1 (4.5) 15.4 
Pneumonia (except that caused by TB) 93 55.3 7.5 30.9 37.2 24.5 79.8 7.5 (0.9) 13.8 
Other Respiratory Problems 11 27.3 9.1 27.3 9.1 54.6 45.5 9.9 (2.4) 9.1 
Acute - Intestinal Infection 10 100 0 20.0 40.0 40.0 60.0 12.6 (3.5) 10.0 
Chronic - Intestinal Infection 14 35.7 14.3 35.7 21.4 28.6 78.6 6.7 (1.4) 28.6 
Upper gastrointestinal disorders 11 18.2 36.4 18.2 9.1 36.4 72.7 5.7 (0.6) 18.2 
Liver disease 14 57.1 7.1 35.7 28.6 28.6 64.3 10.0 (1.9) 42.9 
Diseases of the genitourinary system 19 42.1 5.3 15.8 31.6 47.4 79.0 7.9 (1.2) 15.8 
Diseases of the musculoskeletal system 6 83.3 0 33.3 0 66.7 33.3 15.0 (4.2) 0 
Other Problems (<5 cases) 14 38.5 30.8 38.5 7.7 23.1 7.7 7.5 (0.9) 7.7 
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7.3.2 Direct health provider unit costs for healthcare resources 
Table 43 to Table 45 shows the unit health provider cost for the investigations and 
procedures performed on participants. For investigations undertaken in either the 
Radiology department (Table 43) or the Laboratory department (Table 44), the total 
cost includes the indirect cost estimated for the department. For the Radiology 
department, the indirect cost per investigation performed was estimated to be 
US$1.68 (INT$4.64). For the Laboratory department, the indirect cost per 
investigation performed was estimated to be US$0.67 (INT$1.86). 
 
Table 46 shows the costs of the Pharmacy department at QECH. The average cost 
per dosage of drug dispensed through the department was estimated to be 
US$0.0058 (INT$0.0162). Table 47 shows the health provider costs of the three 
wards to which participants were admitted. The average health provider cost per 
day of admission was US$14.48, US$15.35 and US$16.17 for wards 3A, 3B, and 4A, 
respectively.  
 
Figure 53 and Figure 54 compares the price of a selection of investigations and 
procedures estimated for QECH from the primary costing study to the prices 
provided by two different private health care providers in Malawi. The prices 
estimated for QECH were lower than the prices charged by the two private 
healthcare providers. 
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Table 43: Mean Health Provider costs  - Radiological and Imaging Investigations 
 
 
 
Investigation 
 
Mean Direct Cost 
 
Mean Total Cost 
 
2014 US 
Dollars 
2014 INT 
Dollars 
2014 US 
Dollars 
2014 INT 
Dollars 
Chest X-Ray 9.05 22.92 10.73 27.56 
Abdominal X-Ray 9.05 22.92 10.73 27.56 
Cervical Spine X-Ray 6.17 17.14 7.85 21.78 
Thoracic Spine X-Ray 6.17 17.14 7.85 21.78 
Lumbar Spine X-Ray 6.17 17.14 7.85 21.78 
Other plain X-Ray 9.05 22.92 10.73 27.56 
Abdominal/ Renal Ultrasound 15.13 42.03 16.81 46.67 
Pelvic Ultrasound 15.13 42.03 16.81 46.67 
Neck Ultrasound 15.13 42.03 16.81 46.67 
Doppler Ultrasound 17.57 48.80 19.25 53.45 
Chest Ultrasound 15.13 42.03 16.81 46.67 
*MRI Head 49.21 63.91 50.89 68.55 
*MRI Spine 49.21 63.91 50.89 68.55 
*CT Head 20.41 56.69 22.08 61.33 
*CT Thorax 20.41 56.69 22.08 61.33 
*CT Abdomen 20.41 56.69 22.08 61.33 
*Service out-sourced to external provider 
MRI: Magnetic resonance imaging 
CT: Computed Tomography 
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Table 44: Mean Health Provider costs  - Laboratory Investigations 
 
Investigation +/- Procedure 
Mean Direct Cost Mean Total Cost 
2014 US 
Dollars 
2014 INT 
Dollars 
2014 US 
Dollars 
2014 INT 
Dollars 
Malaria Film 1.89 5.25 2.56 7.11 
Peripheral blood film 4.26 11.57 4.93 13.43 
Group and X match 12.55 35.00 13.22 36.86 
Full Blood Count (FBC) 4.68 12.41 5.35 14.28 
Erythrocyte sedimentation rate (ESR) 0.80 2.22 1.47 4.08 
*Prothrombin Time 12.24 34.00 12.24 34.00 
Urea + Electrolytes (U+Es)  10.65 29.70 11.33 31.56 
Creatinine 3.27 9.18 3.94 11.04 
Liver Function Tests (LFTs) 8.09 22.57 8.76 24.44 
Lipid Profile 9.77 27.23 10.44 29.09 
Cardiac enzymes 7.52 20.97 8.19 22.83 
Random / Fasting glucose 3.02 8.50 3.69 10.36 
CD4 count 14.81 41.13 15.48 42.99 
HIV Viral Load 26.96 29.18 27.63 31.04 
Hepatitis B surface antigen (Hep B sAg) 2.65 7.36 3.32 9.22 
Hepatitis C antibody (Hep C Ab) 5.21 7.65 5.88 9.51 
VDRL 2.68 7.45 3.35 9.31 
Malaria rapid diagnostic test 2.16 6.00 2.16 6.00 
Blood Culture 33.10 80.31 33.77 82.18 
Urine microscopy 1.73 4.83 2.40 6.70 
Stool microscopy 1.43 3.98 2.10 5.85 
CSF/LP 40.96 112.41 41.63 114.27 
Sputum smear (Microscopy and AFB) 5.19 13.15 5.86 15.01 
Sputum for GeneXpert (rapid TB test) 24.84 58.82 25.51 60.69 
*Sputum culture for Tuberculosis 16.75 46.53 17.42 48.39 
Lymph node aspirate for Micro (AFB, cell count) 7.09 18.34 7.76 20.21 
*Lymph node aspirate for Cytology 29.87 82.98 29.87 82.98 
Lymph node biopsy for Micro (AFB) 6.09 15.70 6.77 17.57 
Lymph node biopsy for Histology 48.86 134.76 49.53 136.63 
Cytology 27.66 76.84 27.66 76.84 
Pregnancy Test 3.26 9.08 3.93 10.94 
**Diagnostic Pleural Tap 4.55 12.63 17.60 47.73 
**Diagnostic Ascitic Tap 4.55 12.63 17.60 47.73 
**Therapeutic and Diagnostic Ascitic Tap 10.55 29.30 23.60 64.40 
**Diagnostic Knee Aspirate 3.00 8.35 16.06 43.45 
**Therapeutic and Diagnostic Pleural Tap 10.55 29.30 23.60 64.40 
*Service out-sourced to external provider 
**Includes cost of procedure 
Urea + Electrolytes (U+Es): Urea, Sodium and Potassium 
Liver Function Tests (LFTs): Total protein, Albumin, Bilirubin, Aspartate aminotransferase (AST), Alanine aminotransferase (ALT) 
Gamma-glutamyl transpeptidase (GGT) and Lactate dehydrogenase (LDH) 
Lipid Profile: Total Cholesterol (TC), Triglyceride (TG), Low-density lipoprotein (LDL), high-density lipoprotein (HDL) 
Cardiac enzymes: Creatine Kinase (CK & CKMD), Lactate dehydrogenase (LD) 
VDRL: Venereal Disease Research Laboratory test for Syphilis  
CSF/LP: Lumbar puncture to obtain cerebrospinal fluid  
AFB: Acid-fast bacilli test for Tuberculosis  
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Table 45: Mean Health Provider costs  - Ward-based Investigations and Procedures 
 
Investigation or Procedure 
 
Mean Total Cost 
2014 US Dollars 2014 INT Dollars 
Urine Dipstick 4.08 11.33 
HIV Test 3.87 10.74 
Electrocardiography (ECG) 2.61 7.24 
Echocardiogram 15.05 41.82 
Therapeutic Pleural Tap 12.88 35.78 
Therapeutic Ascitic Tap 4.55 12.63 
Lymph node aspirate 2.21 6.14 
Insertion of Naso-Gastric tube 3.87 10.74 
Insertion urinary catheter 11.65 32.37 
Incision and drainage 3.40 9.44 
Chest Drain 32.71 88.63 
Therapeutic Lumbar Puncture 8.55 22.13 
*Gastroscopy/Endoscopy/Laryngoscopy 470.70 1307.51 
*Colonoscopy 470.70 1307.51 
*Bronchoscopy 470.70 1307.51 
*Endoscopy +/- Banding 470.70 1307.51 
Laparoscopic Surgery Not costed 
Laparotomy Not costed 
*Not costed, cost obtained from private health provider 
  
 
 
Table 46: Mean Health Provider costs  - Pharmacy department 
 
Cost category 
 
Pharmacy costs 
 
 
2014 US Dollars  2014 INT Dollars % Total* 
Personnel Cost 120,359.32 334,331.44 66.1% 
Consumables 8179.75 21244.10 4.2% 
Rental Space 2256.53 6268.15 1.2% 
Equipment 6571.98 18255.49 3.6% 
Central Support and Overheads 45250.66 125696.29 24.9% 
    
Annual health provider cost 182,618.25 505,795.48  
 
Mean cost per table, vial, ampoule 
dispensed 
 
0.0058 
 
0.0162 
 
*Percentages based on costs estimated in International Dollars 
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Table 47: Mean Health Provider costs  - Ward Stay 
 
 
 
Cost category 
 
Ward 3A (TB ward) 
 
 
Ward 3B (Male Medical) 
 
Ward 4A (Female Medical) 
2014 
US Dollars 
2014 
INT Dollars 
% Total* 2014 
US Dollars 
2014 
INT Dollars 
% Total* 2014 
US Dollars 
2014 
INT Dollars 
% Total* 
Personnel Cost 50,375 139,929 16.6% 66,757 185,437 15.5% 74,922 208,117 18.8% 
Consumables 72,027 199,258 23.7% 154,950 429,102 35.8% 122,792 338,569 30.5% 
Rental space 4,513 12,536 1.5% 4,513 12,536 1.0% 4,513 12,536 1.1% 
Equipment 106,894 296,895 35.3% 119,201 331,082 27.6% 111,102 308,585 27.8% 
Central Support and Overheads 69,334 192,596 22.9% 86,668 240,745 20.1% 86,668 240,745 21.7% 
          
Annual health provider cost 303,142 841,215  432,090 1,198,903  399,997 1,108,551  
          
Mean cost per day of admission 14.48 40.17  15.35 42.58  16.17 44.80  
*Percentages based on costs estimated in International Dollars 
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Figure 53: Comparison of Investigation/Procedure prices between QECH and Private healthcare provider 1 
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Figure 54: Comparison of Investigation/Procedure prices between QECH and Private Healthcare Provider 2 
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7.3.3 Cost analysis  
Table 48 shows the total health provider costs for managing participants by the 
primary medical diagnosis. Across all the participants, the mean total health provider 
cost of the hospital admission was US$314.93 (INT$791.47). The average daily health 
provider cost was US$32.14 (INT$80.74). The ‘hotel’ cost of ward stay accounted for 
the majority of the costs (60.7%). Drugs accounted for approximately 3.6% of the 
total cost of admission for the sample, whilst investigations and procedures 
accounted for 35.9%.  
 
The highest mean total health provider cost was for the management of patients 
with Cryptococcal Meningitis (US$837.92; INT$1568.22), with drugs accounting for 
20.9% of this total health provider cost.  
 
For participants diagnosed with Tuberculosis (TB), the mean total health provider 
cost ranged from US$289.80 (INT$754.21) for Miliary TB to US$741.14 (INT$1943.75) 
for those needing retreatment for TB. The mean total health provider cost of 
managing Pulmonary TB was US$473.11 (INT$1241.09). The mean total health 
provider cost of managing Pneumocystis Carinii Pneumonia was US$325.92 
(INT$850.35). The mean total health provider cost of managing Kaposi’s sarcoma 
was US$231.48 (INT$231.48). 
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Table 48: Total Health Provider costs by primary medical diagnosis 
Primary Medical Diagnosis 
 Total Health Provider Cost Average Daily Cost Mean of Total Heath Provider Cost 
2014 US Dollars 2014 INT Dollars 2014 US Dollars 2014 INT Dollars % Drugs % Investigations & 
Procedures 
% Ward 
stay N (%) Mean (SE) Mean (SE) Mean (SE) Mean (SE) 
ALL 661 314.92 (12.2) 791.47 (27.6) 32.14 (0.9) 80.74 (1.8) 3.6 35.9 60.7 
Pulmonary Tuberculosis 55 473.11 (50.8) 1241.09 (135.2) 23.76 (1.0) 61.37 (2.5) 3.3 26.5 70.6 
Tuberculosis of meninges and central nervous system 17 743.97 (113.1) 1958.77 (297.0) 31.06 (4.9) 82.57 (13.3) 2.7 32.5 65.2 
Tuberculosis of intestines, peritoneum 9 396.14 (104.5 1025.71 (272.6) 26.95 (4.0) 69.93 (10.4) 4.3 37.1 58.7 
Tuberculosis of bones and joint 5 316.08 (102.4) 854.53 (276.5) 19.58 (0.8) 53.14 (1.6) 1.5 19.1 79.7 
Tuberculosis of other organs 15 494.97 (140.0) 1306.25 (384.1) 26.26 (2.7) 67.21 (6.4) 3.8 33.9 62.6 
Miliary Tuberculosis 17 289.80 (25.5) 754.21 (66.9) 28.18 (1.9) 73.29 (4.8) 3.1 35.8 61.5 
Tuberculosis - Retreatment 6 741.14 (203.4) 1943.75 (535.0) 20.24 (2.1) 52.69 (5.4) 3.6 15.4 81.7 
Septicaemia (except in labour) 60 222.95 (17.4) 583.39 (45.7) 33.86 (2.3) 88.30 (5.9) 2.4 40.7 57.2 
Candidiasis 6 153.08 (43.1) 395.98 (113.9) 31.12 (6.0) 77.70 (11.9) 2.8 35.5 62.2 
Cryptococcal meningitis 38 837.92 (97.8) 1568.22 (133.1) 63.71 (9.1) 113.84 (10.4) 20.9 32.6 46.9 
Viral infection 9 273.32 (67.8) 734.24 (185.5) 24.41 (5.1) 64.29 (13.1) 2.0 19.1 79.5 
Pneumocystis Carinii Pneumonia 9 325.92 (28.3) 850.35 (75.5) 26.82 (3.0) 69.63 (7.6) 2.9 30.0 67.3 
Malaria 13 179.01 (36.0) 439.87 (94.3) 44.78 (6.7) 106.46 (14.4) 7.2 44.2 48.8 
Kaposi’s Sarcoma 20 231.48 (25.9) 611.05 (69.7) 29.02 (2.7) 75.65 (6.7) 2.5 35.6 62.4 
Neoplasms - excluding Kaposi's 8 342.16 (42.7) 903.60 (118.8) 22.18 (0.9) 58.20 (2.6) 2.4 22.8 74.9 
Diabetes mellitus without complications 5 161.32 (40.8) 410.83 (107.5) 46.81 (8.9) 118.32 (21.4) 5.4 51.5 43.1 
Diabetes mellitus with complications 9 219.30 (31.2) 580.71 (82.6) 30.82 (4.6) 80.87 (11.3) 3.0 37.5 59.5 
Anaemia 35 252.44 (25.8) 679.83 (70.9) 33.52 (4.2) 89.88 (11.5) 1.7 39.8 58.7 
Mental Health disorders 9 186.64 (38.4) 496.95 (103.3) 33.14 (4.2) 87.91 (10.8) 2.0 44.5 53.5 
Meningitis (except that caused by TB or Cryptococcal) 37 250.94 (17.8) 647.35 (46.0) 30.78 (1.8) 79.27 (4.6) 3.2 37.2 59.8 
Epilepsy; Convulsions 11 186.94 (17.4) 481.81 (44.8) 36.50 (3.9) 93.65 (9.4) 2.6 46.5 51.1 
Other Neurological Problems 16 261.58 (48.6) 682.28 (127.9) 32.85 (3.3) 86.00 (8.5) 1.5 42.1 56.6 
Cerebrovascular disease 25 197.21 (23.7) 523.61 (60.0) 26.09 (1.8) 69.61 (4.7) 2.0 35.0 63.2 
Hypertension 7 235.14 (79.1) 636.56 (212.0) 25.65 (3.5) 68.69 (8.5) 1.6 32.3 66.2 
Congestive heart failure; non-hypertensive 15 240.16 (47.8) 648.29 (132.8) 27.89 (2.7) 74.81 (7.3) 1.4 33.6 65.0 
Other Cardiovascular Problems 13 328.86 (95.2) 852.02 (240.1) 29.42 (2.2) 77.73 (5.9) 2.8 36.7 60.7 
Pneumonia (except that caused by TB) 93 198.61 (14.4) 516.87 (39.5) 30.75 (0.9) 78.88 (2.3) 2.2 40.2 57.9 
Other Respiratory Problems 11 243.27 (56.0) 642.00 (148.2) 25.95 (2.2) 68.06 (5.3) 2.6 29.6 68.0 
Acute - Intestinal Infection 10 251.15 (53.1) 668.58 (147.5) 23.13 (1.8) 60.62 (4.6) 3.3 23.8 73.4 
Chronic - Intestinal Infection 14 249.49 (61.0) 659.38 (166.3) 50.22 (18.8) 133.21 (52.0) 2.7 43.5 54.2 
Upper gastrointestinal disorders 11 193.63 (46.3) 510.05 (130.0) 33.03 (5.0) 86.57 (14.2) 2.1 39.3 58.9 
Liver disease 14 346.30 (103.8) 942.03 (287.4) 31.89 (3.2) 85.93 (8.8) 1.4 42.9 55.9 
Diseases of the genitourinary system 19 209.58 (23.9) 556.56 (65.2) 29.13 (1.6) 76.97 (4.0) 2.0 38.7 59.6 
Diseases of the musculoskeletal system 6 333.96 (79.5) 879.85 (203.9) 23.72 (1.5) 62.77 (4.0) 1.9 28.4 69.8 
Other Problems (<5 cases) 14 209.42 (31.7) 561.10 (85.6) 24.56 (1.4) 65.66 (3.3) 1.7 29.2 69.2 
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Table 49 shows the mean total direct non-medical and indirect costs by primary 
medical diagnosis. For all the participants, the mean total direct non-medical and 
indirect costs incurred during their hospital admission was US$86.93 (INT$241.48).  
 
Tuberculosis of the meninges and central nervous system was associated with the 
highest mean direct non-medical and indirect costs (US$485.95, INT$1349.86). 
Diabetes mellitus without complications was associated with the lowest mean direct 
non-medical and indirect costs (US$21.63, INT$60.07). 
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Table 49: Total direct non-medical and indirect costs   
  
Primary Medical Diagnosis  
 2014 US Dollars 2014 INT Dollars 
n Mean (SE) Mean (SE) 
ALL 660 86.93 (10.0) 241.48 (27.8) 
Pulmonary Tuberculosis 55 133.27 (29.3) 370.21 (81.3) 
Tuberculosis of meninges and central nervous system 17 485.95 (194.3) 1349.86 (539.7) 
Tuberculosis of intestines, peritoneum 9 421.08 (336.8) 1169.68 (935.7) 
Tuberculosis of bones and joint 5 72.35 (32.6) 200.96 (90.4) 
Tuberculosis of other organs 15 299.43 (189.7) 831.74 (526.9) 
Miliary Tuberculosis 17 48.55 (12.6) 134.86 (34.9) 
Tuberculosis – Retreatment 6 174.18 (130.8) 483.83 (363.4) 
Septicaemia (except in labour) 60 36.78 (8.0) 102.16 (22.2) 
Candidiasis 6 25.86 (20.0) 71.84 (55.6) 
Cryptococcal meningitis 38 125.48 (41.9) 348.55 (116.5) 
Viral infection 9 54.68 (29.8) 151.89 (82.8) 
Pneumocystis Carinii Pneumonia 9 69.59 (28.2) 193.30 (78.2) 
Malaria 13 124.91 (116.9) 346.97 (324.7) 
Kaposi’s Sarcoma 20 81.66 (21.5) 226.84 (59.6) 
Neoplasms - excluding Kaposi's 8 57.12 (15.7) 158.66 (43.7) 
Diabetes mellitus without complications 5 21.63 (10.6) 60.07 (29.6) 
Diabetes mellitus with complications 9 220.34 (145.4) 612.05 (404.0) 
Anaemia 35 57.20 (10.5) 158.90 (29.2) 
Mental Health disorders 9 72.97 (30.3) 202.69 (84.1) 
Meningitis (except that caused by TB or Crypto) 37 49.54 (10.3) 137.61 (28.7) 
Epilepsy; Convulsions 11 28.05 (18.1) 77.92 (50.4) 
Other Neurological Problems 16 32.67 (9.2) 90.75 (25.6) 
Cerebrovascular disease 25 42.98 (13.6) 119.39 (37.7) 
Hypertension 7 46.52 (24.1) 129.23 (66.9) 
Congestive heart failure; non-hypertensive 15 28.02 (7.3) 77.83 (20.2) 
Other Cardiovascular Problems 13 49.23 (16.0) 136.76 (44.5) 
Pneumonia (except that caused by TB) 93 33.36 (5.6) 92.65 (15.6) 
Other Respiratory Problems 11 46.70 (18.5) 129.71 (51.4) 
Acute - Intestinal Infection 10 155.70 (53.4) 432.49 (148.3) 
Chronic - Intestinal Infection 14 26.29 (9.6 73.03 (26.7) 
Upper gastrointestinal disorders 11 68.22 (41.2 189.49 (114.5) 
Liver disease 14 56.37 (24.4 156.57 (67.7) 
Diseases of the genitourinary system 19 44.09 (13.3) 122.48 (37.1) 
Diseases of the musculoskeletal system 6 158.44 (93.6) 440.11 (260.1) 
Other Problems (<5 cases) 14 50.22 (15.5) 139.49 (43.1) 
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Table 50 shows the total societal cost of hospital admission by primary medical 
diagnosis. For all participants, the mean total societal cost of hospital admission was 
US$401.53 (INT$1031.93).  
 
Participants diagnosed with TB of the meninges and central nervous system had the 
highest mean total societal cost. The total societal cost for those diagnosed with TB 
of the meninges and central nervous system was US$1229.92 (INT$3308.63). For 
participants diagnosed with Pulmonary TB, the mean total societal cost was 
US$614.46 (INT$1632.92).  
 
The mean total societal cost of managing Cryptococcal Meningitis was US$963.40 
(INT$1916.77). The mean total societal cost of managing Pneumocystis Carinii 
Pneumonia was US$395.51 (INT$1043.65). The mean total societal cost of managing 
Kaposi’s sarcoma was US$313.14 (INT$837.89). 
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Table 50: Total societal cost of hospital admission   
 
Primary Medical Diagnosis  
 2014 US 
Dollars 
2014 INT Dollars 
n Mean (SE) Mean (SE) 
ALL 660 401.53 (18.6) 1031.93 (47.5) 
Pulmonary Tuberculosis 55 614.46 (68.5) 1632.92 (184.7) 
Tuberculosis of meninges and central nervous system 17 1229.92 (267.7) 3308.63 (725.1) 
Tuberculosis of intestines, peritoneum 9 817.22 (437.2) 2195.39 (1196.1) 
Tuberculosis of bones and joint 5 388.43 (130.3) 1055.49 (354.3) 
Tuberculosis of other organs 15 794.40 (321.7) 2137.99 (890.6) 
Miliary Tuberculosis 17 338.35 (30.3) 889.07 (80.2) 
Tuberculosis – Retreatment 6 915.32 (280.4) 2427.58 (744.8) 
Septicaemia (except in labour) 60 259.73 (23.4) 685.55 (62.4) 
Candidiasis 6 178.94 (58.8) 467.81 (156.7) 
Cryptococcal meningitis 38 963.40 (109.0) 1916.77 (197.5) 
Viral infection 9 328.00 (86.2) 886.12 (236.2) 
Pneumocystis Carinii Pneumonia 9 395.51 (50.6) 1043.65 (139.5) 
Malaria 13 303.92 (119.3) 786.85 (328.1) 
Kaposi’s Sarcoma 20 313.14 (43.3) 837.89 (118.5) 
Neoplasms - excluding Kaposi's 8 399.28 (51.1) 1062.26 (143.4) 
Diabetes mellitus without complications 5 182.95 (49.3) 470.91 (131.2) 
Diabetes mellitus with complications 9 439.64 (157.2) 1192.76 (435.2) 
Anaemia 35 309.65 (33.0) 838.73 (90.9) 
Mental Health disorders 9 259.61 (53.0) 699.64 (142.8) 
Meningitis (except that caused by TB or Crypto) 37 300.48 (23.1) 784.96 (61.5) 
Epilepsy; Convulsions 11 214.99 (27.5) 559.74 (73.8) 
Other Neurological Problems 16 294.25 (56.0) 773.03 (148.8) 
Cerebrovascular disease 25 240.19 (33.9) 643.00 (88.1) 
Hypertension 7 281.66 (102.3) 765.79 (276.2) 
Congestive heart failure; non-hypertensive 15 266.34 (49.8) 721.17 (138.0) 
Other Cardiovascular Problems 13 378.09 (107.0) 988.78 (273.3) 
Pneumonia (except that caused by TB) 93 231.59 (18.8) 608.41 (51.9) 
Other Respiratory Problems 11 289.97 (59.7) 771.71 (158.9) 
Acute - Intestinal Infection 10 406.84 (94.3) 1101.07 (262.6) 
Chronic - Intestinal Infection 14 275.78 (64.3) 732.41 (175.6) 
Upper gastrointestinal disorders 11 261.85 (58.2) 699.54 (163.3) 
Liver disease 14 402.67 (104.1) 1098.61 (287.9) 
Diseases of the genitourinary system 19 253.67 (30.3) 679.04 (82.2) 
Diseases of the musculoskeletal system 6 492.40 (111.6) 1319.96 (302.8) 
Other Problems (<5 cases) 14 228.59 (31.4) 613.33 (80.3) 
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Table 51 show the results of the multivariable analysis investigating the independent 
effect of HIV status (incorporating whether the patient on ART) on the mean total 
health provider costs, and Table 52 shows the multivariable analysis investigating the 
independent effect of HIV status on mean total societal costs of hospital admission.  
 
In the multivariable analysis (Table 51), after adjusting for individual characteristics 
(model 2), those who were HIV positive, irrespective of whether they were on ART, 
had an elevated mean total health provider cost compared to those who were HIV 
negative. In the fully adjusted model (model 3), adjusting for individual 
characteristics and the primary medical diagnosis, only those who were HIV positive 
and started on ARVs during their hospital admission had a significantly higher mean 
total health provider cost compared to those who were HIV negative (US$363.81, 
95%CI: US$34.09-693.54). 
 
In the multivariable analysis (Table 52), after adjusting for individual characteristics 
(model 2), those who were HIV positive and not on ART had an elevated mean total 
societal cost of US$97.60 (95%CI: US$9.23-US$185.98) compared to those who were 
HIV negative. In contrast, those who were HIV positive and being treated with ART 
before their hospital admission did not have a significantly higher total societal cost 
of admission (US$64.95, 95%CI: -US$1.98, US$131.89). In all the adjusted models, 
HIV positive individuals who started ART during their hospital admission had an 
elevated mean total societal cost.  
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Table 51: Multivariable analysis exploring relationship between HIV status and anti-retroviral treatment status on the Total Health Provider Costs*     
 
 
 
HIV and Anti-Retroviral therapy status 
Total health provider cost (2014 US Dollars) Total health provider costs (2014 INT Dollars) 
Model 1 
(n=649) 
Model 2 
(n=617) 
Model 3 
(n=617) 
Model 1 
(n=648) 
Model 2 
(n=770) 
Model 3 
(n=626) 
Coef (95% CI) Coef (95% CI) Coef (95% CI) Coef (95% CI) Coef (95% CI) Coef (95% CI) 
HIV negative Ref Ref Ref Ref Ref Ref 
HIV positive + on ART before admission 47.21 (-3.27, 97.70) 
62.21** 
(13.71, 110.72) 
-2.25 
(-38.69, 34.19) 
78.77 
(-44.66, 202.20) 
117.53 
(-3.11, 238.17) 
-12.45 
(-109.26, 84.36) 
HIV positive + started ART in hospital 509.79** (215.67, 803.92) 
465.92** 
(139.06, 792.77) 
363.81** 
(34.09, 693.54) 
1320.32** 
(554.47, 2086.17) 
1222.94** 
(370.90, 2074.97) 
923.45** 
(88.41, 1758.50) 
HIV positive + Not on ART 101.16** (21.40, 180.92) 
105.77** 
(33.34, 178.21) 
31.47** 
(-15.17, 78.10) 
175.72** 
(6.19, 345.26) 
202.97** 
(40.33, 365.61) 
66.38 
(-55.21, 187.96) 
HIV status unknown -131.65** (-181.36, -81.94) 
-138.02** 
(-188.57, -87.47) 
-98.27** 
(-140.33, -56.21) 
-351.63** 
(-483.10, -220.17) 
-368.99** 
(-499.07, -238.90) 
-270.37** 
(-381.58, -159.15) 
Model 1: adjusted for exposure, Age and Sex 
Model 2: additionally adjusted for martial status, educational attainment, income and wealth quintile 
Model 3: additionally adjusted for primary medical diagnosis 
ART: Anti-retroviral therapy 
*Findings from Generalized Linear Model with Poisson distribution and Identity link function  
**p<0.05 
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Table 52: Multivariable analysis exploring relationship between HIV status and anti-retroviral treatment status on the Total Societal costs*    
 
 
 
HIV and Anti-Retroviral therapy status 
Total health societal costs (2014 US Dollars) Total societal costs (2014 INT Dollars) 
Model 1 
(n=649) 
Model 2 
(n=770) 
Model 3 
(n=617) 
Model 1 
(n=800) 
Model 2 
(n=770) 
Model 3 
(n=626) 
Coef (95% CI) Coef (95% CI) Coef (95% CI) Coef (95% CI) Coef (95% CI) Coef (95% CI) 
HIV negative Ref Ref Ref Ref Ref Ref 
HIV positive + on ART before admission 61.20 (-12.27, 134.68) 
64.95 
(-1.98, 131.89) 
-8.83 
(-56.68, 39.02) 
119.61 
(-72.64, 311.86) 
120.51 
(-53.03, 294.06) 
-30.50 
(-158.91, 97.92) 
HIV positive + started ART in hospital 950.71** (206.82, 1694.60) 
517.95** 
(103.68, 932.21) 
404.19** 
(46.06, 762.32) 
2550.15** 
(512.87, 4587.43) 
1366.58** 
(252.12, 2481.04) 
1028.13** 
(111.37, 1944.88) 
HIV positive + Not on ART 116.10** (15.22, 216.98) 
97.60** 
(9.23, 185.98) 
22.63 
(-38.75, 84.00) 
219.83 
(-21.18, 460.84) 
185.20 
(-31.51, 401.91) 
39.55 
(-122.94, 202.04) 
HIV status unknown -170.22** (-235.06, -105.37) 
-170.61** 
(-238.13, -103.09) 
-123.68** 
(-180.76, -66.59) 
-462.02** 
(-636.55, -287.50) 
-461.95** 
(-639.51, -284.40) 
-341.64** 
(-494.57, -188.70) 
Model 1: adjusted for exposure, Age and Sex 
Model 2: additionally adjusted for martial status, educational attainment, income and wealth quintile 
Model 3: additionally adjusted for primary medical diagnosis 
ART: Anti-retroviral therapy 
*Findings from Generalized Linear Model with Poisson distribution and Identity link function 
**p<0.05 
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7.3.5 Health-related quality of life analysis 
Table 53 shows the EQ-5D utility scores on admission, the average EQ-5D utility 
score during the hospital admission, the last recorded EQ-5D utility score prior to 
discharge and the change in EQ-5D utility score from admission to discharge, by 
primary medical diagnosis.  
 
For all participants, the mean EQ-5D utility score on admission was 0.484 (SE: 0.01), 
the average EQ-5D utility score during the hospital admission was 0.498 (SE: 0.01), 
the last recorded EQ-5D utility score was 0.510 (SE: 0.02) and the change in EQ-5D 
utility score from admission to discharge or death was 0.024 (SE: 0.02). The mean 
EQ-5D utility score on hospital admission for those with Pulmonary Tuberculosis was 
0.445 (SE: 0.04), for those with Candidiasis was 0.349 (SE: 0.09), for those with 
Cryptococcal meningitis was 0.483 (SE: 0.04), for those with Pneumocystis Carinii 
Pneumonia was 0.559 (SE: 0.08) and for those with Kaposi’s sarcoma was 0.415 (SE: 
0.06).  
 
Participants with a primary medical diagnosis of Diabetes Mellitus without 
complications experienced the largest improvement in EQ-5D utility score from 
admission to discharge (mean change: 0.222). Participants with a primary medical 
diagnosis of Neoplasm other than Kaposi’s sarcoma experienced the largest 
deterioration in EQ-5D utility score (mean change: 0.260; SE: 0.15). The mean 
change in EQ-5D utility score during hospital admission for those with Pulmonary 
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Tuberculosis was 0.034 (SE: 0.05), for those with Candidiasis was 0.223 (SE: 0.27), for 
those with Cryptococcal meningitis was -0.013 (SE: 0.07), for those with 
Pneumocystis Carinii Pneumonia was -0.058 (SE: 0.16) and for those with Kaposi’s 
sarcoma was -0.018 (SE: 0.07).  
 
Table 54 shows the visual analogue scale (VAS) scores on admission, the mean VAS 
score during the hospital admission, the last recorded VAS score prior to discharge 
and the change in VAS score from admission to discharge by the primary medical 
diagnosis. For all participants, the mean VAS score on admission was 52.8 (SE: 0.8), 
the mean VAS over the course of the hospital admission was 53.8 (SE: 0.8), the last 
recorded mean VAS score was 54.0 (SE: 1.6) with participants experiencing a mean 
improvement in the VAS score of 0.1 (SE: 1.6) during their hospital admission. 
 
Figure 55 compares the EQ-5D utility score, derived from the responses participants 
gave to the EQ-5D five-dimension descriptive system, to the VAS recorded by 
participant on the thermometer. The EQ-5D utility scores show a high degree of 
correlation to the VAS scores. The Pearson’s correlation coefficient between the 
change in EQ-5D utility score and change in VAS was 0.64. 
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Table 53: EQ-5D utility scores by primary medical diagnosis (Zimbabwean Tariff)    
 
Primary Medical Diagnosis 
 
N 
EQ-5D Utility Scores (Zimbabwean Tariff) 
 
n (%) 
On Admission Average during Admission  
n (%) 
Pre-Discharge Mean change 
(SE) Mean (SE) Mean (SE) Mean (SE) 
ALL 661 654 (98.9%) 0.484 (0.01) 0.498 (0.01) 494 (74.7%) 0.510 (0.02) 0.024 
Pulmonary Tuberculosis 55 55 (100%) 0.445 (0.04) 0.465 (0.04) 51 (92.7%) 0.465 (0.04) 0.034 (0.05) 
Tuberculosis of meninges and central nervous system 17 17 (100%) 0.288 (0.08) 0.333 (0.06) 13 (76.5%) 0.333 (0.06) 0.075 (0.15) 
Tuberculosis of intestines, peritoneum 9 9 (100%) 0.524 (0.11) 0.473 (0.09) 8 (88.9%) 0.473 (0.09) -0.106 (0.07) 
Tuberculosis of bones and joint 5 5 (100%) 0.385 (0.09) 0.257 (0.09) 5 (100%) 0.257 (0.09) -0.163 (0.10) 
Tuberculosis of other organs 15 15 (100%) 0.542 (0.08) 0.458 (0.08) 13 (86.7%) 0.458 (0.08) -0.192 (0.11) 
Miliary Tuberculosis 17 17 (100%) 0.393 (0.07) 0.283 (0.06) 15 (88.2%) 0.283 (0.06) -0.236 (0.08) 
Tuberculosis - retreatment 6 6 (100%) 0.577 (0.15) 0.576 (0.15) 5 (83.3%) 0.576 (0.15) -0.039 (0.10) 
Septicaemia (except in labour) 60 60 (100%) 0.514 (0.04) 0.549 (0.04) 37 (61.7%) 0.549 (0.04) 0.093 (0.06) 
Candidiasis 6 6 (100%) 0.349 (0.09) 0.382 (0.09) 2 (33.3%) 0.382 (0.09) 0.223 (0.27) 
Cryptococcal meningitis 38 38 (100%) 0.483 (0.04) 0.498 (0.04) 34 (89.5%) 0.498 (0.04) -0.013 (0.07) 
Viral infection 9 9 (100%) 0.524 (0.11) 0.431 (0.10) 6 (66.7%) 0.431 (0.10) -0.260 (0.15) 
Pneumocystis Carinii Pneumonia 9 8 (88.9%) 0.559 (0.08) 0.528 (0.09) 8 (88.9%) 0.528 (0.09) -0.058 (0.16) 
Malaria 13 13 (100%) 0.521 (0.07) 0.518 (0.07) 4 (30.8%) 0.518 (0.07) -0.021 (0.11) 
Kaposi’s Sarcoma 20 20 (100%) 0.415 (0.06) 0.425 (0.05) 15 (75.0%) 0.425 (0.05) -0.018 (0.07) 
Neoplasms - excluding Kaposi's 8 8 (100%) 0.584 (0.07) 0.484 (0.08) 8 (100%) 0.484 (0.08) -0.262 (0.10) 
Diabetes mellitus without complications 5 5 (100%) 0.682 (0.06) 0.749 (0.04) 3 (60.0%) 0.749 (0.04) 0.222 (0.10) 
Diabetes mellitus with complications 9 9 (100%) 0.405 (0.09) 0.429 (0.06) 6 (66.7%) 0.429 (0.09) 0.057 (0.11) 
Anaemia 35 35 (100%) 0.558 (0.04) 0.590 (0.04) 30 (85.7%) 0.590 (0.04) 0.032 (0.05) 
Mental Health disorders 9 9 (100%) 0.629 (0.08) 0.658 (0.06) 6 (66.7%) 0.658 (0.06) 0.169 (0.12) 
Meningitis (except that caused by TB or Crypto) 37 36 (97.3%) 0.484 (0.04) 0.561 (0.04) 31 (83.8%) 0.561 (0.04) 0.147 (0.06) 
Epilepsy; Convulsions 11 11 (100%) 0.588 (0.11) 0.588 (0.12) 5 (45.5%) 0.588 (0.12) -0.003 (0.10) 
Other Neurological Problems 16 15 (93.8%) 0.506 (0.06) 0.510 (0.06) 10 (62.5%) 0.510 (0.06) 0.027 (0.10) 
Cerebrovascular disease 25 23 (92.0%) 0.359 (0.05) 0.399 (0.06) 12 (48.0%) 0.399 (0.06) 0.150 (0.07) 
Hypertension 7 7 (100%) 0.387 (0.13) 0.419 (0.11) 6 (85.7%) 0.419 (0.11) 0.037 (0.13) 
Congestive heart failure; non-hypertensive 15 15 (100%) 0.569 (0.06) 0.524 (0.06) 15 (100%) 0.524 (0.06) -0.092 (0.09) 
Other Cardiovascular Problems 13 13 (100%) 0.471 (0.08) 0.539 (0.06) 11 (84.6%) 0.539 (0.06) 0.176 (0.12) 
Pneumonia (except that caused by TB) 93 91 (97.8%) 0.501 (0.03) 0.529 (0.03) 57 (61.3%) 0.529 (0.03) 0.084 (0.04) 
Other Respiratory Problems 11 11 (100%) 0.486 (0.08) 0.595 (0.07) 10 (90.9%) 0.595 (0.07) 0.215 (0.09) 
Acute - Intestinal Infection 10 10 (100%) 0.487 (0.10) 0.498 (0.08) 9 (90.0%) 0.498 (0.08) 0.033 (0.11) 
Chronic - Intestinal Infection 14 14 (100%) 0.434 (0.08) 0.443 (0.07) 9 (64.3%) 0.443 (0.07) -0.054 (0.16) 
Upper gastrointestinal disorders 11 11 (100% 0.501 (0.06) 0.487 (0.07) 9 (81.8%) 0.487 (0.07) -0.019 0.13) 
Liver disease 14 14 (100%) 0.436 (0.09) 0.420 (0.09) 11 (78.6%) 0.420 (0.09) -0.040 (0.09) 
Diseases of the genitourinary system 19 19 (100%) 0.536 (0.06) 0.576 (0.06) 15 (78.9%) 0.576 (0.06) 0.080 (0.10) 
Diseases of the musculoskeletal system 6 6 (100%) 0.416 (0.09) 0.326 (0.09) 4 (66.7%) 0.326 (0.09) -0.118 (0.18) 
Other Problems (<5 cases) 14 14 (100%) 0.458 (0.06) 0.502 (0.06) 11 (78.6%) 0.502 (0.502) 0.070 (0.10) 
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Table 54: Visual analogue scale scores by primary medical diagnosis    
 
Primary Medical Diagnosis 
 
N 
Visual Analogue Scores 
 
n (%) 
On Admission Average during Admission  
n (%) 
Pre-Discharge Mean change 
(SE) Mean (SE) Mean (SE) Mean (SE) 
ALL 661 654 (98.9%) 52.8 (0.8) 53.8 (0.8) 494 (74.7%) 54.0 (1.6) 0.1 (1.6) 
Pulmonary Tuberculosis 55 55 (100%) 55.2 (3.0) 55.9 (3.2) 51 (92.7%) 57.5 (5.8) -0.9 (4.8) 
Tuberculosis of meninges and central nervous system 17 17 (100%) 42.9 (6.9) 42.2 (7.2) 13 (76.5%) 53.7 (11.2) -2.5 (11.0) 
Tuberculosis of intestines, peritoneum 9 9 (100%) 50.0 (7.5) 45.9 (7.7) 8 (88.9%) 47.5 (12.4) -8.8 (12.8) 
Tuberculosis of bones and joint 5 5 (100%) 62.0 (8.0) 46.0 (10.6) 5 (100%) 36.0 (22.3) -26.0 (14.7) 
Tuberculosis of other organs 15 15 (100%) 51.0 (6.1) 50.2 (6.4) 13 (86.7%) 40.0 (10.9) -11.2 (12.2) 
Miliary Tuberculosis 17 17 (100%) 38.5 (4.4) 33.4 (4.5) 15 (88.2%) 23.0 (8.4) -20.0 (9.1) 
Tuberculosis - retreatment 6 6 (100%) 73.3 (7.6) 62.0 (9.6) 5 (83.3%) 51.0 (21.2) -23.0 (22.8) 
Septicaemia (except in labour) 60 60 (100%) 53.3 (2.8) 54.8 (2.8) 37 (61.7%) 55.0 (6.0) 1.7 (6.3) 
Candidiasis 6 6 (100%) 48.3 (11.7) 48.9 (11.7) 2 (33.3%) 55.0 (5.0) 5.0 (5.0) 
Cryptococcal meningitis 38 38 (100%) 56.8 (3.2) 55.9 (3.2) 34 (89.5%) 51.9 (6.0) -5.9 (6.6) 
Viral infection 9 9 (100%) 50.0 (10.7) 44.8 (10.5) 6 (66.7%) 42.5 (19.1) -19.2 (16.1) 
Pneumocystis Carinii Pneumonia 9 8 (88.9%) 55.0 (8.0) 53.4 (8.7) 8 (88.9%) 58.8 (13.3) 3.8 (11.0) 
Malaria 13 13 (100%) 53.2 (6.6) 53.5 (6.5) 4 (30.8%) 62.5 (14.9) 2.5 (4.8) 
Kaposi’s Sarcoma 20 20 (100%) 48.3 (3.5) 49.4 (4.4) 15 (75.0%) 48.0 (9.1) -2.3 (9.4) 
Neoplasms - excluding Kaposi's 8 8 (100%) 52.5 (4.5) 46.8 (5.4) 8 (100%) 38.1 (10.3) -20.6 (12.0) 
Diabetes mellitus without complications 5 5 (100%) 73.4 (8.1) 76.9 (8.3) 3 (60.0%) 86.7 (13.3) 11.7 (4.4) 
Diabetes mellitus with complications 9 9 (100%) 54.4 (3.4) 55.1 (4.0) 6 (66.7%) 57.5 (8.3) 4.2 (5.5) 
Anaemia 35 35 (100%) 52.5 (3.2) 56.9 (3.1) 30 (85.7%) 57.0 (6.1) 8.1 (6.2) 
Mental Health disorders 9 9 (100%) 61.1 (4.8) 64.0 (5.0) 6 (66.7%) 69.2 (8.4) 12.5 (4.8) 
Meningitis (except that caused by TB or Crypto) 37 36 (97.3%) 49.9 (3.5) 55.0 (3.7) 31 (83.8%) 60.8 (4.6) 11.0 (4.3) 
Epilepsy; Convulsions 11 11 (100%) 59.1 (6.1) 63.9 (5.5) 5 (45.5%) 64.0 (17.5) 14.0 (9.3) 
Other Neurological Problems 16 15 (93.8%) 55.3 (4.1) 57.1 (4.6) 10 (62.5%) 53.3 (8.7) 3.3 (8.7) 
Cerebrovascular disease 25 23 (92.0%) 50.7 (4.9) 51.9 (4.3) 12 (48.0%) 63.8 (7.5) 7.1 (10.7) 
Hypertension 7 7 (100%) 58.6 (2.6) 56.9 (4.2) 6 (85.7%) 49.2 (16.2) -9.2 (18.7) 
Congestive heart failure; non-hypertensive 15 15 (100%) 57.0 (4.8) 54.1 (5.3) 15 (100%) 49.7 (10.1) -7.3 (10.6) 
Other Cardiovascular Problems 13 13 (100%) 54.6 (4.4) 55.9 (5.4) 11 (84.6%) 60.9 (10.2) 7.3 (9.0) 
Pneumonia (except that caused by TB) 93 91 (97.8%) 53.3 (2.4) 55.6 (2.6) 57 (61.3%) 58.6 (4.4) 5.0 (4.4) 
Other Respiratory Problems 11 11 (100%) 50.5 (5.7) 54.9 (4.0) 10 (90.9%) 56.5 (8.0) 9.0 (9.1) 
Acute - Intestinal Infection 10 10 (100%) 56.0 (7.3) 52.8 (3.8) 9 (90.0%) 48.9 (7.0) -8.9 (12.5) 
Chronic - Intestinal Infection 14 14 (100%) 50.0 (2.5) 48.6 (3.9) 9 (64.3%) 40.6 (12.9) -11.1 (12.8) 
Upper gastrointestinal disorders 11 11 (100% 52.5 (3.7) 55.2 (5.2) 9 (81.8%) 60.1 (12.0) 6.0 (12.9) 
Liver disease 14 14 (100%) 45.0 (5.9) 45.6 (6.7) 11 (78.6%) 45.5 (11.4) -4.5 (10.7) 
Diseases of the genitourinary system 19 19 (100%) 53.2 (4.6) 58.7 (4.5) 15 (78.9%) 56.3 (8.6) 9.0 (8.5) 
Diseases of the musculoskeletal system 6 6 (100%) 47.5 (4.4) 53.3 (3.5) 4 (66.7%) 70.0 (4.1) 21.3 (10.1) 
Other Problems (<5 cases) 14 14 (100%) 52.9 (3.4) 55.4 (3.6) 11 (78.6%) 56.8 (8.0) 8.5 (9.3) 
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Figure 55: Comparison of EQ5D utility Scores to Visual Analogue Scale Scores    
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In the multivariable analysis, the model diagnostics revealed the OLS estimator 
performed as well or better than the other estimators (Table 55 and Table 56). The 
CLAD estimator performed was marginally more efficient for lower observed EQ-5D 
utility scores, but less efficient when observed EQ-5D utility scores ranged from 0.4 
to <1.0, where the majority of observed scores were.  
 
Table 55: Estimated predicted values compared to actual utility scores 
 Model Obs Mean Min Max MSE MAE 
Observed 605 0.503 -0.145 1.000   
 
Model 
OLS 605 0.503 0.242 0.772 0.000 0.199 
TOBIT 605 0.502 0.252 0.759 0.001 0.200 
CLAD* 605 0.489 0.055 1.076 0.015 0.203 
 Flogit 605 0.566 0.347 0.795 0.000 0.200 
OLS: Ordinary Least Squares    MSE: Mean Squared Error 
Flogit: Fractional logit     MAE: Mean Absolute Error 
CLAD: Censored least absolute deviations  *No convergence as median EQ-5D score censored at 1.0 
 
 
 Table 56: MSE and MAE for regression models by utility score range 
 Observed EQ-5D utility score 
  <0 0 to <0.2 0.2 to <0.4 0.4 to <0.6 0.6 to <0.8 0.8 to <1 1 
Obs 29 44 137 149 179 53 14 
  MSE MAE MSE MAE MSE MAE MSE MAE MSE MAE MSE MAE MSE MAE 
OLS 0.495 0.495 0.355 0.355 0.180 0.180 0.003 0.079 0.178 0.179 0.305 0.305 0.433 0.433 
TOBIT 0.500 0.500 0.355 0.355 0.179 0.181 0.002 0.077 0.180 0.180 0.311 0.311 0.415 0.415 
CLAD 0.499 0.499 0.331 0.331 0.147 0.160 0.016 0.100 0.181 0.193 0.326 0.327 0.400 0.400 
Flogit 0.500 0.500 0.355 0.355 0.180 0.181 0.001 0.077 0.179 0.179 0.308 0.308 0.422 0.422 
OLS: Ordinary Least Squares   Flogit: Fractional logit  CLAD: Censored least absolute deviations 
MSE: Mean Squared Error  MAE: Mean Absolute Error 
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Table 57 show the multivariable analysis investigating the independent effect of HIV 
status (incorporating whether on ART) on the EQ-5D utility score on admission, and 
the average EQ-5D utility score during hospital admission.  
 
In the multivariable analysis (Table 57), after adjusting for individual characteristics 
and the primary medical diagnosis (model 3), those who were HIV positive and not 
on ART had a lower adjusted mean EQ-5D utility score on admission of -0.133 
(95%CI: -0.206, -0.060) compared to those who were HIV negative. Those who were 
HIV positive and on ART before their hospital admission had a lower adjusted mean 
EQ05D utility score of -0.083 (95%CI: -0.141, -0.025) compared to those who were 
HIV negative.   
 
In the multivariable analysis (Table 57), the average EQ-5D utility score during the 
hospital admission for those who were HIV positive and not on ART was significantly 
lower than compared to those who were HIV negative (-0.110, 95%CI: -0.180, -0.040). 
Finally, those who were HIV positive and on ART before their hospital admission had 
a lower adjusted ‘average’ mean EQ-5D utility score of -0.085 (95%CI: -0.141, -0.030) 
compared to those who were HIV negative.  
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Table 57: Multivariable analysis exploring relationship between HIV status and anti-retroviral treatment status and the EQ-5D utility scores* derived 
from the Zimbabwean tariff (Primary analysis) 
 
 
 
HIV and Anti-retroviral therapy status 
EQ-5D Utility Score on Admission Average EQ-5D Utility Score during Admission 
Model 1 
(n=646) 
Model 2 
(n=618) 
Model 3 
(n=618) 
Model 1 
(n=646) 
Model 2 
(n=618) 
Model 3 
(n=618) 
Coef (95% CI) Coef (95% CI) Coef (95% CI) Coef (95% CI) Coef (95% CI) Coef (95% CI) 
HIV negative Ref Ref Ref Ref Ref Ref 
HIV positive + on ART before admission -0.068** (-0.118, -0.017) 
-0.073** 
(-0.124, -0.022) 
-0.083** 
(-0.141, -0.025) 
-0.069** 
(-0.118, -0.020) 
-0.076** 
(-0.126, -0.027) 
-0.085** 
(-0.141, -0.030) 
HIV positive + started ART in hospital -0.034 (-0.235, 0.168) 
-0.031 
(-0.244, 0.182) 
-0.018** 
(-0.206, 0.205) 
-0.038 
(-0.232, 0.157) 
-0.056 
(-0.260, 0.149) 
-0.063 
(-0.275, 0.149) 
HIV positive + Not on ART -0.099** (-0.165, -0.032) 
-0.114** 
(-0.181, -0.047) 
-0.133** 
(-0.206, -0.060) 
-0.082** 
(-0.146, -0.017) 
-0.095** 
(-0.160, -0.031) 
-0.110** 
(-0.180, -0.040) 
HIV status unknown 0.014 (-0.138, 0.109) 
-0.035 
(-0.155, 0.084) 
-0.039 
(-0.165, 0.088) 
-0.010 
(-0.129, 0.109) 
-0.029 
(-0.144, 0.086) 
-0.055 
(-0.175, 0.065) 
Model 1: adjusted for exposure, Age and Sex 
Model 2: additionally adjusted for martial status, educational attainment, income and wealth quintile 
Model 3: additionally adjusted for primary medical diagnosis 
ART: Anti-retroviral therapy 
*Findings from OLS estimator 
**p<0.05 
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7.3.5 Findings from sensitivity analysis  
Table 58 shows the findings from the sensitivity analysis where the UK tariff was 
used to estimate the EQ-5D utility scores by the primary medical diagnosis.  Using 
the UK tariff, the mean EQ-5D utility score on admission was 0.267 (SE: 0.02), the 
mean EQ-5D utility score during the hospital admission was 0.325 (SE: 0.01), the last 
recorded mean EQ-5D utility score was 0.406 (SE: 0.02) and the mean change in EQ-
5D utility score was 0.154.  
 
Figure 56 compares the EQ-5D utility scores derived from the Zimbabwean and UK 
tariffs. The EQ-5D utility scores estimated using the UK tariff was lower than the EQ-
5D utility scores estimated from the Zimbabwean tariff. Figure 56 shows the 
Pearson’s correlation coefficient was >0.9 when the two EQ-5D tariffs were 
compared. 
 
Table 59 shows the findings from the multivariable analysis investigating the 
independent effect of HIV status on the EQ-5D utility score on admission, and the 
average EQ-5D utility score during hospital admission where the EQ-5D utility scores 
were derived from the UK tariff. The multivariable analysis revealed comparable 
findings to when the Zimbabwean tariff was used, but with the adjusted EQ-5D 
utility scores estimated using the UK tariff being systematically lower.  
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Table 58: Sensitivity analysis: EQ-5D utility scores from UK Tariff by primary medical diagnosis    
 
Primary Medical Diagnosis 
 
 
N 
EQ-5D Utility Scores 
 
n (%) 
On Admission Average during admission  
n (%) 
Pre-Discharge Mean change 
(SE) Mean (SE) Mean (SE) Mean (SE) 
ALL 661 654 (98.9%) 0.267 (0.02) 0.325 (0.01) 494 (74.7%) 0.406 (0.02) 0.154 (0.02) 
Pulmonary Tuberculosis 55 55 (100%) 0.205 (0.05) 0.289 (0.04) 51 (92.7%) 0.402 (0.05) 0.190 (0.06) 
Tuberculosis of meninges and central nervous system 17 17 (100%) 0.070 (0.10) 0.173 (0.06) 13 (76.5%) 0.314 (0.10) 0.223 (0.18) 
Tuberculosis of intestines, peritoneum 9 9 (100%) 0.384 (0.14) 0.339 (0.09) 8 (88.9%) 0.373 (0.11) -0.059 (0.10) 
Tuberculosis of bones and joint 5 5 (100%) 0.089 (0.12) 0.028 (0.09) 5 (100%) 0.100 (0.06) 0.011 (0.09) 
Tuberculosis of other organs 15 15 (100%) 0.324 (0.10) 0.287 (0.10) 13 (86.7%) 0.314 (0.12) -0.017 (0.10) 
Miliary Tuberculosis 17 17 (100%) 0.156 (0.10) 0.091 (0.07) 15 (88.2%) 0.112 (0.06) -0.093 (0.11) 
Tuberculosis - retreatment 6 6 (100%) 0.412 (0.22) 0.470 (0.19) 5 (83.3%) 0.509 (0.21) 0.167 (0.12) 
Septicaemia (except in labour) 60 60 (100%) 0.306 (0.05) 0.389 (0.05) 37 (61.7%) 0.484 (0.07) 0.270 (0.07) 
Candidiasis 6 6 (100%) 0.073 (0.07) 0.126 (0.05) 2 (33.3%) 0.450 (0.26) 0.403 (0.47) 
Cryptococcal meningitis 38 38 (100%) 0.244 (0.06) 0.318 (0.05) 34 (89.5%) 0.359 (0.07) 0.122 (0.08) 
Viral infection 9 9 (100%) 0.399 (0.10) 0.326 (0.10) 6 (66.7%) 0.421 (0.19) -0.117 (0.12) 
Pneumocystis Carinii Pneumonia 9 8 (88.9%) 0.382 (0.13) 0.381 (0.11) 8 (88.9%) 0.392 (0.17) 0.010 (0.21) 
Malaria 13 13 (100%) 0.338 (0.09) 0.332 (0.10) 4 (30.8%) 0.472 (0.25) -0.037 (0.12) 
Kaposi’s Sarcoma 20 20 (100%) 0.145 (0.07) 0.204 (0.05) 15 (75.0%) 0.262 (0.09) 0.110 (0.07) 
Neoplasms - excluding Kaposi's 8 8 (100%) 0.453 (0.12) 0.292 (0.12) 8 (100%) 0.134 (0.18) -0.295 (0.15) 
Diabetes mellitus without complications 5 5 (100%) 0.610 (0.09) 0.701 (0.05) 3 (60.0%) 0.858 (0.07) 0.301 (0.16) 
Diabetes mellitus with complications 9 9 (100%) 0.148 (0.14) 0.184 (0.13) 6 (66.7%) 0.243 (0.14) 0.057 (0.14) 
Anaemia 35 35 (100%) 0.355 (0.07) 0.442 (0.06) 30 (85.7%) 0.464 (0.07) 0.160 (0.07) 
Mental Health disorders 9 9 (100%) 0.416 (0.12) 0.489 (0.10) 6 (66.7%) 0.669 (0.11) 0.236 (0.21) 
Meningitis (except that caused by TB or Crypto) 37 36 (97.3%) 0.294 (0.06) 0.423 (0.05) 31 (83.8%) 0.525 (0.07) 0.261 (0.09) 
Epilepsy; Convulsions 11 11 (100%) 0.426 (0.17) 0.444 (0.18) 5 (45.5%) 0.480 (0.31) 0.112 (0.18) 
Other Neurological Problems 16 15 (93.8%) 0.308 (0.10) 0.324 (0.09) 10 (62.5%) 0.191 (0.10) 0.090 (0.13) 
Cerebrovascular disease 25 23 (92.0%) 0.087 (0.08) 0.151 (0.09) 12 (48.0%) 0.482 (0.14) 0.264 (0.10) 
Hypertension 7 7 (100%) 0.132 (0.19) 0.179 (0.14) 6 (85.7%) 0.314 (0.16) 0.133 (0.16) 
Congestive heart failure; non-hypertensive 15 15 (100%) 0.371 (0.10) 0.388 (0.09) 15 (100%) 0.416 (0.10) 0.045 (0.10) 
Other Cardiovascular Problems 13 13 (100%) 0.270 (0.11) 0.386 (0.09) 11 (84.6%) 0.524 (0.11) 0.330 (0.15) 
Pneumonia (except that caused by TB) 93 91 (97.8%) 0.296 (0.04) 0.366 (0.03) 57 (61.3%) 0.492 (0.05) 0.222 (0.06) 
Other Respiratory Problems 11 11 (100%) 0.236 (0.12) 0.425 (0.10) 10 (90.9%) 0.594 (0.12) 0.410 (0.13) 
Acute - Intestinal Infection 10 10 (100%) 0.292 (0.15) 0.303 (0.12) 9 (90.0%) 0.257 (0.10) 0.044 (0.15) 
Chronic - Intestinal Infection 14 14 (100%) 0.170 (0.12) 0.246 (0.10) 9 (64.3%) 0.250 (0.14) 0.162 (0.18) 
Upper gastrointestinal disorders 11 11 (100% 0.286 (0.10) 0.292 (0.09) 9 (81.8%) 0.423 (0.13) 0.055 (0.16) 
Liver disease 14 14 (100%) 0.229 (0.11) 0.264 (0.09) 11 (78.6%) 0.374 (0.11) 0.098 (0.11) 
Diseases of the genitourinary system 19 19 (100%) 0.299 (0.08) 0.417 (0.07) 15 (78.9%) 0.522 (0.12) 0.269 (0.13) 
Diseases of the musculoskeletal system 6 6 (100%) 0.131 (0.10) 0.011 (0.10) 4 (66.7%) 0.069 (0.16) -0.150 (0.22) 
Other Problems (<5 cases) 14 14 (100%) 0.185 (0.10) 0.298 (0.09) 11 (78.6%) 0.360 (0.13) 0.323 (0.11) 
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Figure 56: Comparison of EQ-5D utility scores estimated from Zimbabwean and UK tariffs 
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Table 59: Multivariable analysis exploring relationship between HIV status and anti-retroviral treatment status on EQ-5D utility scores derived from the 
UK tariff (Sensitivity analysis)*     
 
 
 
HIV and Anti-Retroviral therapy status 
EQ-5D Utility Score on Admission Average EQ-5D Utility Score during Admission 
Model 1 
(n=646) 
Model 2 
(n=617) 
Model 3 
(n=617) 
Model 1 
(n=646) 
Model 2 
(n=617) 
Model 3 
(n=617) 
Coef (95% CI) Coef (95% CI) Coef (95% CI) Coef (95% CI) Coef (95% CI) Coef (95% CI) 
HIV negative Ref Ref Ref Ref Ref Ref 
HIV positive + on ART before admission -0.100** (-0.173, -0.027) 
-0.114** 
(-0.192, -0.037) 
-0.122** 
(-0.209, -0.034) 
-0.085** 
(-0.149, -0.021) 
-0.103 
(-0.171, -0.036) 
-0.116** 
(-0.192, -0.041) 
HIV positive + started ART in hospital -0.072 (-0.362, 0.218) 
-0.065 
(-0.386, 0.257) 
-0.053 
(-0.390, 0.283) 
-0.119 
(-0.375, 0.136) 
-0.149** 
(-0.429, 0.130) 
-0.177 
(-0.466, 0.113) 
HIV positive + Not on ART -0.163** (-0.259, -0.067) 
-0.189** 
(-0.290, -0.088) 
-0.210** 
(-0.321, -0.100) 
-0.116** 
(-0.200, -0.031) 
-0.141** 
(-0.229, -0.053) 
-0.162** 
(-0.257, -0.067) 
HIV status unknown 0.025 (-0.202, 0.153) 
-0.038  
(-0.290, 0.142) 
-0.048 
(-0.238, 0.142) 
-0.032 
(-0.188, 0.125) 
-0.042 
(-0.199, 0.115) 
-0.078 
(-0.241, 0.086) 
Model 1: adjusted for exposure, Age and Sex 
Model 2: additionally adjusted for martial status, educational attainment, income and wealth quintile 
Model 3: additionally adjusted for primary medical diagnosis 
ART: Anti-retroviral therapy 
*Findings from OLS estimator 
**p<0.05 
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7.4 Discussion 
In this component of the PHD I estimated the total health provider costs, the total 
societal costs and the EQ-5D utility scores for a range of medical diagnoses for 
individuals admitted to the medical wards at Queen Elizabeth Central Hospital 
(QECH).  
 
The study undertaken in this Chapter demonstrates the high health provider costs of 
managing patients in hospitals and the high costs incurred by those admitted to 
hospital. Additionally, I show the poor health-related quality of life amongst those 
admitted to hospital. For example in Chapter 6 of the PhD, I estimated the health 
provider cost of managing an HIV positive individual on anti-retroviral therapy at the 
HIV clinic for one year to be approximately 2014 US$166. In this Chapter, I estimated 
the average health provider cost of managing an adult on the medical ward during a 
hospitalisation episode to be approximately 2014 US$ 315.  In Chapter 6 of the PhD, I 
found that over the first year of accessing anti-retroviral therapy, the total direct 
non-medical and indirect costs were approximately 2014 US$9. In this chapter, I 
found the total direct non-medical and indirect cost during a hospitalisation episode 
was approximately 2014 US$87. In Chapter 6 of the PhD I found the mean EQ-5D 
utility score amongst HIV positive individuals attending the HIV clinic to be assessed 
for initiation of anti-retroviral therapy to be approximately 0.841. Amongst adults 
admitted to the QECH the mean EQ-5D utility scores was found to be 0.484.  
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In this study, the average health provider cost of managing individuals in hospital 
was approximately US$314.93. This cost is comparable to previous estimates of 
health provider costs of providing hospital care in sub-Saharan Africa. In a previous 
study in Kenya, the average health provider costs was found to be US$163  (in 2000 
prices) (Guinness et al., 2002). In Zimbabwe, the average health provider cost of 
hospital admission was estimated to range from US$40 for HIV negative individuals 
in a district hospital to US$316 for HIV positive individuals in a central hospital (in 
2000 prices) (Hansen et al., 2000). In this study I found the cost of the ward stay 
(including clinical staff salaries) accounted for approximately 60% of the total health 
provider cost, whilst the cost of procedures accounted for approximately 35% of the 
total health provider costs.  
 
Table 60 shows the findings from previous hospital costing studies and the 
proportion of the total health provider costs accounted for by different resources. 
The high proportion of the total costs accounted for by investigations and 
procedures could possibly reflect the fact that this study was undertaken in the main 
teaching hospital in Malawi. Queen Elizabeth Central hospital (QECH) provides a 
wider range of laboratory services than district level hospitals in Malawi. 
Alternatively it may reflect the gradual increase in availability of diagnostic services 
in the region. Of the three studies shown in Table 60, the most recent study found 
investigations and procedures accounted for nearly half of the total health provider 
costs (Tshamba et al., 2014).  The relatively lower proportion of the total cost 
accounted for by drugs is likely to reflect increasing availability of medicines in Africa, 
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and the work done by International Organisations like the World Heath Organisation 
(WHO). Since 2001, the WHO has implemented the prequalification of medicines 
programme that aims to ensure high quality drugs enter the African healthcare 
markets at reasonable prices (WHO, no date-b). The service allows many of the 
National and International healthcare providers working the region bulk purchase 
medicines at reduced costs.     
 
Table 60: Distribution of costs by cost category amongst hospitalised medical patients 
from previous hospital costing studies in the region. 
 
 
 
Guinness et al 
(Guinness et al., 
2002) 
 
Hongoro and 
McPake(Hongoro and 
McPake, 2003) 
 
Tshamba et al 
(Tshamba et al., 
2014) 
 
Year of Data Collection 1997 1999 2010 
Country of Study Kenya Zimbabwe Dr Congo 
HIV Status of sample Positive Mixed Positive 
 
Proportion of total hospital cost 
 
Hotel/Staff Costs 68% 89% 19% 
Investigations/procedures 21% 10% 46% 
Medications 11% 1% 35% 
 
 
In this study, I found the average health provider cost per day of hospital admission 
to be approximately 2014 US$32, with patients spending on average 12 days in 
hospital to receive inpatient care. Table 61 shows the average duration of hospital 
stay found in previous studies investigation hospital care in Africa. The higher 
duration of hospital admission in this study could also reflect that fact that QECH is a 
teaching hospital and consequently is caring for those with more complex medical 
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conditions, or the gradual improvement in inpatient care available in the region that 
necessitates longer admissions.  
 
Table 61: Comparison of duration of hospital admission 
  
Guinness et al 
(Guinness et al., 2002) 
 
Hongoro 
and 
McPake 
(Hongoro 
and 
McPake, 
2003) 
 
de 
Cherif 
et al 
(de 
Cherif 
et al., 
2009) 
 
Olukoga 
(Olukog
a, 2007) 
 
 
McCarthy 
et al 
(McCarth
y et al., 
2006) 
 
 
Janson 
et 
al(Jans
on et 
al., 
2012) 
 
Tshamba 
et al 
(Tshamb
a et al., 
2014) 
 
Year of Data Collection 1997 1997 1999 2002 2002 2008 2008 2010 
Country of Study Kenya Kenya Zimbabwe South 
Africa 
South 
Africa 
South 
Africa 
South 
Africa 
Dr Congo 
HIV Status Positive Negative Mixed Positive Mixed Positive Mixed Positive 
 
 
Average days of admission by Clinical diagnosis 
Acute Gastroenteritis  3.5 4.5       
Acute Pneumonia 6.0 4.0       
Tuberculosis 8.0 8.0 4-10   9.7 9.7  
Clinical enteric illness 10.5 6.5       
Diabetes 4.0 4.0       
Malaria 4.0 3.0 3-6      
Bacterial meningitis  7.0 9.0       
Cryptococcal meningitis      10   
All 7 6  8-9 3-9   7 
 
 
In this study, the health provider costs were highest for those diagnosed with 
Cryptococcal Meningitis (US$837.92), where 20% of the total health provider cost 
was due to the cost of drugs. In QECH, these individuals received treatment with 
Amphotericin B and Flucytosine, both of which are very costly drugs. A recent study 
in Uganda estimated the health provider cost of managing Cryptococcal Meningitis 
with Amphotericin B with Flucytosine to be approximately US$467.48 (in 2012 
prices) (Rajasingham et al., 2012). However, the study did not involve primary data 
collection from individuals and primary costing of health services, and consequently 
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may explain their slightly lower estimate. In comparison, the health provider costs of 
managing Candidiasis, Pneumocystis Carinii Pneumonia and Kaposi’s sarcoma, all of 
which are also occur with late-stage HIV disease, was comparable to or lower than 
the average health provider costs of managing inpatients at QECH. In comparison to 
the average inpatient at QECH, where 3.6% of the total cost of care was for drugs, 
inpatients with Candidiasis, Pneumocystis Carinii Pneumonia and Kaposi’s sarcoma, a 
smaller proportion of the total health provider cost was spent on drugs. This may 
reflect the lack of available medicines to care for this patient group in the setting.  
 
Tuberculosis remains one of the commonest reasons for hospital admission and this 
study highlights the high health provider costs of managing affected individuals 
(US$316.08 to US$743.97). The majority of TB patients in the study were HIV positive, 
a high proportion of them died, and very few had improvements in health-related 
quality of life during admission. Previous studies have highlighted the high costs 
incurred by patients affected by TB needing hospital admission (Floyd et al., 1997, 
Moalosi et al., 2003, Schnippel et al., 2013). In this study, patients diagnosed with TB 
had high mean direct non-medical and indirect costs during their hospital admission 
(US$73.35 to US$485.95). The long duration of hospitalisation would explain the high 
costs, especially for those requiring re-treatment for TB. These costs may be 
unavoidable after developing TB disease, considering the severity of the illness, but 
the findings highlight the importance of improving uptake of TB preventative therapy 
and TB case detection, especially amongst those infected with HIV.  
 
 
318 
In Malawi, hospital care is provided free but users will inevitably incur some costs in 
accessing care, ranging from transportation to hospital, to loss of income. The 
average direct non-medical and indirect costs was approximately US$86.93. The 
majority of Malawians live on less than $2 a day (World Bank), highlighting the 
catastrophic impact of a hospitalisation on the finances of Malawians. Whilst 
preventing illness will have a major impact on reducing this burden, decentralising 
hospital care could avert much of these costs. QECH is the main teaching hospital in 
Malawi and therefore likely to provide more intensive care than the rural district 
hospitals where the majority of the population live. Patients may need to spend 
more money travelling long distances to access care, need a family or carer to 
accompany them and take more time off from income generating activities than if 
hospitalised closer to their primary residence. However, the shortage of medical 
personnel in Malawi and the rest of Africa, and the high cost of laboratory services, 
impedes the decentralisation of hospital care.  
 
Previous studies have highlighted the impact of HIV on the costs of hospital care and 
the burden it places on individuals (Guinness et al., 2002, Hansen et al., 2000, 
Menzies et al., 2012, Hongoro and McPake, 2003, Goudge et al., 2009). In this study, 
approximately 70% of patients were HIV positive, a finding comparable to previous 
estimates from a study undertaken in the same hospital (SanJoaquin et al., 2013). 
HIV status was found to be independently associated with the total health provider 
and total societal costs of admission. However, after adjusting for the primary 
medical diagnosis, the association was no longer statistically significant. The findings 
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would suggest it is the illnesses that HIV causes, specifically the illness associated 
with late stage HIV disease that places the greatest financial burden on health 
providers and society.  Timely entry into HIV care and initiation of anti-retroviral 
therapy has been shown to reduce the burden of late-stage HIV diseases (Brinkhof et 
al., 2007, May et al., 2010a, Sterne et al., 2009), and therefore would likely reduce 
this financial burden.  
 
The health-related quality of life (HRQoL) of hospitalised individuals in the study was 
poor. The average EQ-5D utility score amongst inpatients during their hospital 
admission was 0.498, this compares poorly with the average EQ-5D utility score 
observed amongst HIV testers in Chapter 5 and HIV positive individuals accessing HIV 
care in Chapter 6. Of more concern was the minimal improvement in HRQoL from 
admission to discharge. HIV infection seems to be the main driver of this poor HRQoL, 
with HIV status being independently associated with the EQ-5D utility scores, even 
after adjusting for the medical diagnosis.  Of note, individuals started onto ART 
tended to have better HRQoL than HIV positive individuals not yet started therapy, 
even after adjusting for the primary medical diagnosis.  
 
Previous studies have highlighted the lack of health utility data in the region for the 
purposes of undertaking cost-utility analyses (Robberstad and Olsen, 2010, Beard et 
al., 2009). This study provides an extensive catalogue of health utility scores to 
inform cost-utility analyses for a range of interventions, not just limited to HIV (Guo 
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et al., 2009, Organization, 2010, Dabhadkar et al., 2011). The findings of this study 
also suggest the EQ-5D measure provides health state utility scores that correlates to 
individuals own perception of their health-related quality of life derived from the 
VAS. The utility scores derived from the 5-dimensions of the descriptive questions 
individuals answer (on their pain, mobility, self-care, usual activities and 
anxiety/depression), using the Zimbabwean tariff show a high degree of correlation 
to the visual analogue scores derived from individuals rating their health on a scale 
ranging from 0 to 100 (Figure 55). This high correlation was also seen when I 
examined the change in the EQ-5D utility score and the change in the VAS score.  
 
Of interest is the choice of tariffs used to convert the descriptive responses provided 
by participants to the EQ-5D measure. In the sensitivity analysis, I examined the EQ-
5D utility scores derived using the UK York A1 tariff and compared them to the EQ-
5D utility scores derived from the Zimbabwean tariff. The UK York A1 tariff results in 
systematically lower utility scores than the Zimbabwean tariff, with the change in 
utility scores found with the two tariffs being greater when the UK tariff was used. 
The average change in EQ-5D utility score for all participants, measured by the UK 
tariff was 0.154, whilst using the Zimbabwean tariff was 0.024. As highlighted 
previously, the UK York A1 tariff translates health states with ‘severe’ problems in 
one or more of the five dimensions to lower EQ-5D utility scores than the 
Zimbabwean tariff.  This has important implications for this study where I used a 
tariff set not derived from the population I was studying. If the Malawian population 
valued health states more comparably to the UK population than the Zimbabwean 
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population, then I would potentially undervalue potential gains from interventions 
improving the health status of those with more severe diseases. Putting this in 
context, if HIV self-testing were to increase timely uptake of HIV testing amongst 
those infected with the virus, and consequently reducing the risk of progressing to 
advanced HIV disease and HIV-associated illness with early initiation of ART, the 
incremental cost-effectiveness ratio (ICER) estimated using the Zimbabwean tariff 
set would be higher. In Chapter 8 of the PhD where I estimate the ICER from 
implementing HIVST, I will explore the impact of using EQ-5D utility scores derived 
from the UK tariff in the sensitivity analysis.  
 
The findings from this study are primarily limited by the relatively small number of 
participants recruited for a few of the medical conditions, and the fact that the study 
was undertaken in a large central teaching hospital which limits generalisability to 
smaller district hospital settings. In addition the findings may be potentially biased 
by the high attrition rate (only 80% of eligible participants consented to participate 
and had their medical notes found). For the majority of these participants it was 
because their medical notes could not be found. This is a common issue with doing 
research in resource-poor settings where medical records are not computerised or 
patients may take them on discharge.  
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7.5 Summary of Chapter 7 
In this chapter I undertook primary data collection from individuals admitted to 
hospital in Blantyre, Malawi. I collected data on the costs of providing care and 
health-related quality of life of patients admitted with a range of HIV-related 
illnesses. In addition, I estimated the total societal costs of medical illnesses needing 
inpatient management.  
 
In this study I found that approximately 70% of adults admitted to the hospital for 
the management of medical condition were HIV positive. I show the high mortality 
rates amongst this cohort, especially amongst those HIV positive. This study 
highlights the significant financial burden HIV poses on healthcare providers and 
individuals needing hospital inpatient medical care in Malawi. The high costs of 
hospital care and the detrimental effects on their health-related quality of life 
highlight the benefits of early and timely entry into HIV care. Many of the illnesses 
seen in this study would be potentially avoidable with early uptake of HIV testing 
and initiation of anti-retroviral therapy.  
 
In the next chapter the economic data collected as part of this study will be used to 
inform the decision-analytic modeling of the cost-effectiveness of HIV self-testing.  
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CHAPTER 8: Cost-utility analysis of 
providing HIV self-testing in 
addition to facility-based HIV 
testing and counselling in Blantyre, 
Malawi 
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8 Overview of Chapter 8 
In this chapter I will aim to investigate the primary objective of my PhD and thereby 
answer the primary research question. 
 
To undertake a decision-analytic modelling based cost-utility analysis to 
estimate the incremental cost per quality-adjusted life year (QALY) gained 
with the provision of HIV self-testing in conjunction with traditional facility-
based HIV testing and counselling services in Blantyre, Malawi.  
 
I will provide a brief introduction to the topic, and describe in detail the methods 
used in undertaking the decision-analytic modeling. I will describe the model 
structure and the data used to parameterise the model. I will present the findings of 
the model analysis, including the sensitivity analysis. I will provide a brief discussion 
of the findings in this Chapter, with a more detailed discussion of findings in the 
main discussion (Chapter 9).   
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8.1 Introduction 
HIV remains a global health problem, and sub-Saharan Africa has been 
disproportionately affected by the epidemic (UNAIDS, 2014b). Recent advances in 
HIV treatment and prevention offers promise (Cohen et al., 2011, Gray et al., 2007a, 
Group et al., 2015a, Group, 2015b), however for them to be effective individuals will 
need to be aware of their current HIV status (Granich et al., 2009). Efforts are 
currently being made to increase provision of HIV testing amongst Africans (UNAIDS, 
2014a), with HIV self-testing high on the agenda (WHO, 2015).  
  
HIV self-testing (HIVST) has been found to be a safe and effective strategy for 
increasing the uptake of HIV testing, and can be delivered by trained health 
volunteers, with individuals accurately testing themselves (Choko et al., 2015a). 
Individuals found to be HIV positive are willing to link into HIV treatment services 
(Choko et al., 2015a, MacPherson et al., 2014). HIVST can be delivered at costs 
comparable to facility-based HTC; potentially at lower costs should the price of the 
HIV self-test kits fall (Chapter 5). HIVST saves users significant time and money, 
which may in part explain the high levels of uptake (Chapter 5). The cost of managing 
HIV positive individuals identified through HIVST is comparable to those identified 
through facility-based HIV testing and counseling (HTC), with potential savings during 
the assessment for ART eligibility (Chapter 6). Additionally, HIVST identifies HIV 
positive individuals earlier in their disease progression than facility-based HTC 
(Choko et al., 2015b, Rosen and Fox, 2011), potentially averting some of the cost and 
health consequences of HIV associated illnesses (Chapter 7).   
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However, policy makers will need to be aware of the value for money of offering 
HIVST, if they are to consider prioritising its implementation over other health 
technologies. Economic evaluations allow us to investigate this issue and provide 
useful information to policy makers wishing to scale-up HIV self-testing services in 
their region. Whilst there is a range of approaches to undertaking an economic 
evaluation, a cost-utility analysis has the advantage of providing economic evidence 
to policy makers on the value of implementing interventions whilst allowing direct 
comparisons to be made with intervention targeting other disease areas.  
 
The main aim of the study undertaken was to investigate the cost-effectiveness of 
providing HIVST in addition to facility-based HTC in Malawi. I used decision-analytic 
modeling to simulate the costs and health consequences of implementing HIVST, 
and to estimate the incremental cost per quality-adjusted life gained. I populated 
the models with primary cost and health-related quality of life data collected from 
Malawi, and epidemiology data extracted from the literature. I undertook the 
evaluation from both the health provider and societal perspectives. The findings will 
help inform policy on the cost-effectiveness of implementing HIVST.  
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8.2 Methods 
8.2.1 Study overview  
Decision-analytic modeling was undertaken to perform a cost-utility analysis 
(Drummond et al., 2005b) to estimate the incremental cost-effectiveness of the 
HitTB HIV self-testing intervention. In the model I compare the costs and 
consequences of providing only facility-based HIV testing to providing HIV self-
testing (HIVST) in addition to facility-based HIV testing and counseling (HTC). The 
model examines the costs and consequences for hypothetical adults (aged>15 years) 
living in Blantyre, Malawi.  
 
The analysis was undertaken from both the health provider and societal perspectives 
(Drummond et al., 2005b). The primary health outcome was measured in quality-
adjusted life years (QALYs). Costs are represented in 2014 US dollars and 2014 
International Dollars, and a discount rate of 3% was applied to both costs and health 
effects (WHO, 2003a). An individual sampling model (Barton et al., 2004)  was used, 
with a one month cycle length, and was run over a time horizon of 20 years in the 
primary analysis. The model was also run over shorter (10 years) and longer (40 
years) time horizons. The model is a static model and assumes there is no interaction 
between individuals being modeling. The model was built in TreeAge Pro 2015 
(TreeAge Software, Williamstown, Massachusetts) and probabilistic sensitivity 
analysis (PSA) was carried out using Monte Carlo simulation.  
 
 
328 
8.2.2 Model description  
8.2.2.1 Model overview  
An individual sampling model (ISM) (Barton et al., 2004) was used to project the 
health consequences and costs incurred as individuals accessed either modality of 
HIV testing, accessed HIV care or were admitted to hospital for the management of 
an HIV associated illness.  
 
An individual sampling model (ISM), which is often referred to as a microsimulation 
model in the literature (Barton et al., 2004), is comparable to a Markov model but 
overcomes the Markovian assumption that does not allow transition probabilities 
and rewards assigned to a health state to be conditional on either the time spent in 
the health state or characteristics of individuals entering the health state (Barton et 
al., 2004). Additionally in comparison to a cohort model, the ISM simulates the 
transitions through the health states in the model for a single individual. Taken 
together an ISM provided the flexibility needed to model the evaluation of HIV 
testing and counseling strategies where likelihood of HIV testing depends on past 
history of HIV testing, and risk of health events, whilst eligibility for anti-retroviral 
therapy (ART) on an individuals’ HIV disease stage.   
 
The model projects the costs and consequences of offering HIVST as provided in the 
HitTB intervention. The characteristics of the population modeled and the costs and 
impact on HRQoL reflect the HiTTB study population. In the model HIV negative and 
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HIV positive individuals both access HIV testing services, but only HIV positive 
individuals may be linked into HIV treatment and start anti-retroviral therapy. In the 
model HIVST is only available in the intervention strategy. HIV positive individuals 
may suffer from one of the HIV-associated co-morbidities. HIV negative individuals 
are not at risk of suffering from one of the HIV associated co-morbidities, but may 
acquire HIV infection. In the model, eligibility for initiation of ART is based on 
Malawian National HIV guidelines (MoH, 2014). Figure 57 provides a broad overview 
of the model structure. The model had 4 main health states; (1) HIV negative; (2) HIV 
positive and not on ART; (3) HIV-associated co-morbidity; (5) HIV positive and on ART.  
In addition, all individuals are at risk of dying, resulting in them entering death - an 
absorbing health state.  
 
In the model there are three modules: (1) HIV disease progression module (Figure 
58); (2) HIV testing and linkage module (Figure 59); and (3) HIV treatment module 
(Figure 60). The modules simulate individuals’ HIV disease progression, uptake of HIV 
testing, entry into HIV care and admission to hospital for the management of an HIV 
associated illness. The model records and tracks the characteristics of the individuals 
and these are used to determine likelihood of a range of events. The model tracks 
the CD4 count and the WHO stage of HIV positive individuals to determine eligibility 
for ART after HIV testing. The model uses the individual’s CD4 count to determine 
the risk of death, the risk of hospitalisation for a severe HIV associated illness and 
health outcomes on ART. The model records history of HIV testing to determine 
uptake of re-testing. The model tracks duration on ART or in pre-ART care to 
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determine likelihood of retention in care, and the costs and HRQoL changes whilst in 
care.   
 
Figure 57: Overview of HIV model structure 
 
 
 
8.2.2.2 Individual simulation in the model   
At the beginning of the simulation, individuals are assigned to either the HIV 
negative health state or the HIV positive and not on ART health states. Individuals 
who are HIV negative are at risk of acquiring HIV infection. HIV positive individuals 
are assigned a CD4 count on entry into the model and also after acquiring HIV 
infection. The CD4 count assigned determines whether the individual is assigned to 
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one of five health states; CD4 count >500 cells/μl; CD4 count 351-500 cells/μl; CD4 
count 201-350 cells/μl; CD4 count 51-200 cells/μl; or CD4 count =< 50 cells/μl. The 
CD4 count assigned to individuals was randomly chosen between these ranges, with 
the exception for those assigned to the health state with a CD4 count >500 cells/μl.  
 
There is very little certainty in the literature around actual CD4 counts during the 
early phase on HIV infection, as very few individuals will know precisely when they 
acquired HIV and therefore unlikely to have had their CD4 count measured soon 
after infection (Lodi et al., 2011). Therefore, individuals entering the CD4 count >500 
cells/μl were assigned a CD4 count of 501 cells/μl and the literature was used to 
determine the monthly probability of their CD4 count falling to below 500 cells/μl, at 
which stage they were assigned a CD4 count of 500 cells/μl.  
 
Figure 58 provides an overview of the HIV disease progression module. After an 
individual is assigned a CD4 count (on entry into the model or after acquiring HIV 
infection), the model simulates their HIV disease progression over time with monthly 
decrements in their CD4 count. Individual’s transition to the health state with the 
lower CD4 count strata if their CD4 count falls below the defined range.  
 
Every month individuals are also at risk of death and risk of suffering from one of the 
severe HIV associated co-morbidities. The risk of death and severe HIV associated co-
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morbidities depends on their CD4 count. In the CD4 count defined health states 
individuals do not incur any costs, but their HRQoL changes.  
 
If an individual suffers from one of the severe HIV associated co-morbidities, they 
temporarily transition into those health states incurring additional costs and changes 
in their health-related quality of life. As the findings in Chapter 7 highlights the 
majority of hospitalised patients undergo HTC, it was assumed that everyone has an 
HIV test. However, as I found very few subsequently initiated ART, I assumed 
everyone would be initiated onto ART if they attended the HIV clinic, and assumed 
the likelihood of linking into HIV care was comparable to the likelihood of linking into 
HIV care after facility-based HTC.  
 
In the model there are nine health states representing the severe illnesses that HIV 
positive individuals are potentially at risk of and that result in hospitalisation 
(Chronic Diarrhoea; Oesophageal Candidiasis; Severe Bacterial infection; Pulmonary 
Tuberculosis; Extra-Pulmonary Tuberculosis; Severe Malaria; Malignancy; 
Pneumocystis Carinii Pneumonia; Cryptococcal meningitis). 
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Figure 58: Overview of HIV disease progression module 
 
 
 
Every month HIV positive and HIV negative individuals may access HIV testing. HIVST 
is only available in the intervention strategy, whilst facility-based HTC is available in 
both strategies being investigated. Figure 59 shows the HIV testing and linkage 
module in the model. HIV negative individuals who access HIV testing will test HIV 
negative and therefore are not in need of linkage into HIV care. Individuals who test 
HIV negative are assumed to not re-test for another year in accordance with the 
WHO’s HIV testing guidelines (WHO, 2015). In the HiTTB HIVST intervention, HIVST 
was only offered to individuals once a year (Choko et al., 2015a), and the model 
replicates this. HIV positive individuals who test may then link into HIV care or not 
link into HIV care. If they do not link into HIV care they return to the HIV disease 
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progression module. If they link into HIV care they enter the HIV treatment module 
(Figure 60). 
 
Figure 59: Overview of HIV Testing and Linkage module 
 
 
 
 
Figure 60 provides an overview of the HIV treatment module. Individuals who access 
HIV are assessed for eligibility for ART; this involves measuring their CD4 count and 
clinical assessment of their HIV disease stage. Individuals whose CD4 count is below 
350 cells/μl are started onto anti-retroviral therapy. Individuals whose CD4 count is 
greater than 350 cells/μl and who have advanced HIV disease (WHO stage 3 or 4) are 
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started onto ART. Individuals whose CD4 counts are greater than 350 cells/μl but do 
not have advanced disease (WHO stage 3 or 4) enter pre-ART care.  
 
As individuals access ART or pre-ART care they incur costs and their HRQoL may 
change. In addition, every month individuals are at risk of dying or not returning to 
continue with their HIV treatment. If they fail to return to continue their HIV 
treatment (attrition form ART) they re-enter the HIV disease progression module. 
Individuals on ART are also at risk of suffering from the nine severe HIV associated 
illnesses that result in hospitalisation. 
 
There are four health states within the HIV treatment module, each defined by the 
CD4 count on entering HIV treatment. Whilst on treatment their CD4 count may 
increase and if it does the model updates their CD4 count. If they do not return to 
continue their HIV treatment, the updated CD4 count determines which health state 
in the HIV disease progression module they re-enter.  The updated CD4 count 
determines the monthly risk of dying or from suffering one of the severe HIV 
associated illnesses. However, the CD4 count on entry into ART is used to determine 
the cost associated with HIV treatment and associated health-related quality of life 
(to reflect the primary data used in the model). Individuals who enter pre-ART may 
return for repeat assessment for ART eligibility, incurring additional cost, and 
potentially becoming eligible for treatment. As they are not on ART, their CD4 count 
is assumed to continue falling at the same rate.  
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Figure 60: Overview of HIV treatment module 
 
 
 
8.2.3 Model parameters  
8.2.3.1 Overview of model parameter synthesis 
On entry into the model, the characteristics of the individuals’ modeled (HIV status 
and CD4 count) were chosen to reflect the HitTB study population. At the time of 
submitting my PhD, the HitTB study was in the process of completing the post-
intervention prevalence survey. The HitTB post-intervention prevalence survey was 
being undertaken in a randomly sampled population of both the intervention and 
control clusters, and is collecting data on HIV status, ART coverage and CD4 counts. 
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Once this data becomes available, some of the model parameters will be updated 
prior to publication of the cost-effectiveness findings. 
 
I used primary data collected during the PhD (Chapters 5, 6 and 7) to define the costs 
and health utility scores for all the health states in the model. I undertook targeted 
literature reviews to synthesise transition parameters that were not available from 
the HitTB study or from primary studies undertaken as part of my PhD. I undertook 
the targeted literature searches in Pubmed and reviewed the references to 
determine the appropriateness of the data for this model. A targeted literature 
search provided an efficient approach to obtaining the relevant data (Moher et al., 
2007). Where there was more than one data source found I used the inverse 
variance weight approach (fixed-effects meta-analysis) to pool the data to estimate a 
weighted mean and standard error of the weighted mean for parameter inputs. The 
data extracted were all converted to monthly transition probabilities (Briggs et al., 
2006).  
 
The primary analysis involves a probabilistic sensitivity analysis and therefore 
probability distributions were fitted to the parameters used in the model to reflect 
the underlying uncertainty in the estimates (Briggs et al., 2012b). The beta 
distribution was fitted to transition probabilities and health state utilities, and the 
gamma distribution for costs (Briggs et al., 2006). For the mean monthly decline in 
CD4 count I fitted the normal distribution. To fit the beta distribution, either the 
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primary observed data (numbers experiencing the event and not experiencing the 
event) was used to determine the alpha (events) and beta (non-events) values, or 
the method of moments was used estimate the alpha and beta values from the 
mean and standard errors (Briggs et al., 2006). The method of moments approach 
was also used to determine the alpha and beta values to fit the gamma distribution 
for the cost parameters (Briggs et al., 2006). To fit the normal distribution the mean 
and standard error was used. When primary data from outputs of a multivariable 
analysis was used, I took into account the covariance between regression 
coefficients in determining the standard errors (Briggs et al., 2006, Briggs et al., 
2012b).   
 
Table 62 to Table 67 show the parameters used in the primary analysis. The low and 
high values reflect the 95% confidence intervals (CIs) for the parameters in the 
model, and are provided for transparency in the data utilised and replication of 
model analysis (Briggs et al., 2012b, Eddy et al., 2012). The 95% CIs are presented for 
ease of understanding parameters used, and reflect either the primary data, or are 
from 5000 simulations of the applied probability distributions. The following sections 
provide a more detailed description of how the model parameters were obtained.  
  
8.2.3.2 Initial characteristics of individuals modeled.  
The impact of HIV testing is only on those who are HIV negative and on those who 
are HIV positive and not on ART. Therefore on model entry individuals are assigned 
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one of two health states (HIV negative; HIV positive not on ART). The proportion of 
those already on ART was not taken into account, as it does not impact on the 
proportion of those who are HIV negative (see equations below). I used the HIV 
prevalence observed in the Blantyre study population (Choko et al., 2011) to 
determine the likelihood of which of these two health states to assign an individual 
to.  
 
pHIV negative  =1 - (pHIV positive*(1-pOnART)) - (pHIV positive*pOnART) 
pHIV negative =1 - pHIVpositive + pHIV positive*pOnART - pHIV positive*pOnART 
  =1 - pHIVpositive 
 
A targeted literature search was undertaken to identify the appropriate parameter 
values to determine the CD4 count of HIV positive individuals living in sub-Saharan 
Africa not yet receiving ART (Table 68).  A previous literature review and modeling 
study had been undertaken in 2006 that investigated the CD4 counts of populations 
in HIV prevalent countries in sub-Saharan Africa (Williams et al., 2006). These studies 
were excluded as the large-scale introduction of anti-retroviral therapy at the 
population level will impact on the CD4 count distribution amongst HIV positive 
individuals not on ART as those with lower CD4 counts are more likely to be receiving 
treatment. Three studies were identified that investigated the CD4 count amongst a 
randomly sampled population in a sub-Saharan African country (Kranzer et al., 2013, 
Maman et al., 2015, Malaza et al., 2013). The data presented in these studies were 
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incomplete and therefore the authors of the studies were contacted; data was 
subsequently obtained from only one study (Kranzer et al., 2013). This data was used 
to determine whether individuals had a: CD4 count >500 cells/μl; CD4 count 351-500 
cells/μl; CD4 count 201-350 cells/μl; CD4 count 51-200 cells/μl; or CD4 count =< 50 
cells/μl; on entry into the model. The CD4 count assigned to individuals was 
randomly chosen between these ranges. Table 62 shows the parameters used to 
determine the initial characteristics of individuals modeled.   
 
8.2.3.3 Transition probabilities   
8.2.3.3.1 HIV incidence  
Evidence from the literature highlights that the risk of an HIV positive individual 
transmitting their infection to uninfected individuals (predominantly through 
unprotected sexual contact in sub-Saharan Africa) depends mainly on the stage of 
their infection (Powers et al., 2011b), gender (Glynn et al., 2001), whether 
circumcised (Gray et al., 2007a) and whether on anti-retroviral therapy (Cohen et al., 
2011). The model was a static model and therefore does not take into account the 
changing risk of HIV negative individuals acquiring HIV infection through increased 
population ART coverage (Granich et al., 2009).  I therefore undertook a targeted 
search of the literature to identify studies that have estimated the HIV incidence in 
African population since the introduction of ART (Table 68).   
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Of the nine studies identified, one study was undertaken before or in the early 
stages of scale-up of ART in Africa (Rehle et al., 2010) and another study undertaken 
in a population sub-group (women) and not representative of the general population 
(Karim et al., 2011). One study was a systematic review of 12 modeling studies 
investigating impact of ART on HIV incidence (Eaton et al., 2012), with a further five 
modeling studies identified that were undertaken after the publication of the 
systematic review (Alsallaq et al., 2013, Mossong et al., 2013, Cori et al., 2014, 
Shafer et al., 2014, Murray et al., 2014). One study was an observation study 
undertaken in a cohort of 16,667 HIV negative individuals in South Africa and 
examined risk of HIV infection during a period of comparable ART coverage to 
Malawi (Table 63) (Tanser et al., 2013).  
 
8.2.3.3.2 Changes in CD4 counts amongst those not on ART 
I undertook targeted literature searches to obtain the necessary data to quantify the 
monthly decrements in individuals’ CD4 counts, the risk of suffering from one of the 
nine severe HIV-associated co-morbidities and the risk of death at differing CD4 
counts (Table 68).   
 
The evidence in the literature suggests that the CD4 count falls rapidly after HIV 
seroconversion and then decreases linearly over time (Williams et al., 2006). On 
searching the literature I found seven studies describing changes in CD4 counts in 
HIV positive individuals living in Africa who had not started ART. One study only 
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provided a description of modeling approaches to estimate changes in CD4 counts 
(Williams et al., 2006) and two studies provided mean changes in CD4 counts for the 
entire sample not disaggregated by CD4 count strata (Mboto et al., 2009, 
Katubulushi et al., 2005). Consequently the data from these three studies were not 
utilised. One study investigated the time from HIV infection to the CD4 count falling 
below 500 cells/μl (Lodi et al., 2011) and three studies provided relevant information 
on changes in CD4 counts (Martinson et al., 2014, May et al., 2009, Holmes et al., 
2006). The data provided in the three studies (Martinson et al., 2014, May et al., 
2009, Holmes et al., 2006) were pooled using inverse variance weight (Sutton et al., 
2000) to determine monthly decrements in CD4 counts (Table 63).  
 
8.2.3.2.3 Risk of mortality and HIV associated co-morbidities  
A targeted literature search revealed four studies that investigated mortality 
amongst HIV positive individuals before starting anti-retroviral therapy by their CD4 
count (Anglaret et al., 2012, Badri et al., 2006a, Jaffar et al., 2004, Geng et al., 2013). 
Only one study provided detailed mortality rates disaggregated by the multiple CD4 
count strata used in the model (Anglaret et al., 2012). The data used to model the 
risk of death for those on ART are shown in Table 63. For the risks of co-morbidities 
two studies were found in the literature (Anglaret et al., 2012, Holmes et al., 2006), 
with one providing the detailed risks of illnesses by CD4 counts (Anglaret et al., 2012). 
In addition this study was also used to determine HIV associated mortality and the 
risk of progression to WHO stage 3 or 4 amongst HIV positive individuals (Anglaret et 
al., 2012). The parameters used in the model to estimate the risk of HIV associated 
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co-morbidities and overall likelihood of progression to WHO stage 3 or 4 estimated 
from this study is shown in Table 64. I did not apply distributions (for the PSA) for the 
risk of these events. For readability (as the risks are very low) I have provided the 
monthly probability used in the model as percentages.  
 
Four published studies were found that estimated the mortality rate amongst adults 
in Malawi from non-HIV associated reasons (Jahn et al., 2008, Streatfield et al., 2014, 
Glynn et al., 2014, Chihana et al., 2012). All these studies were undertaken in the 
Karonga district in Malawi where a large sample of the community is actively 
followed as part of a demographic surveillance site. The data presented in the 
studies are all from the same source and therefore the most recent data and the 
data that allowed estimation of non-HIV associated mortality rate was used (Chihana 
et al., 2012).   
 
8.2.3.2.3 Uptake of HIV testing and linkage  
The Malawian HIV programme data was used to determine likelihood of accessing 
facility-based HTC (MoH, 2014). For the intervention strategy, the likelihood of 
accessing HIVST was based on observed data from the HiTTB study (Choko et al., 
2015a). The model recorded when individuals had accessed either modality of HIV 
testing. Chapter 5 of the PhD thesis suggested that HIVST is complimentary to 
facility-based HTC; I assumed that individuals might access either modality of HIV 
testing.    
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A prospective cohort study was undertaken in the two main health facilities serving 
the HitTB study population before the introduction of HIVST (MacPherson et al., 
2012a). The study estimated the proportion of facility-based HIV testers linking into 
HIV care, and consequently this data was used to estimate the probability of linkage 
after facility-based HTC. Of note a systematic review was recently undertaken that 
estimated linkage into HIV care after facility-based HTC in sub-Saharan Africa (Rosen 
and Fox, 2011). In the review, they estimated approximately 59% (range 35% to 88%) 
of facility-based HIV testers linked to the HIV clinic for assessment for ART eligibility 
(Rosen and Fox, 2011), comparable to the estimate from the study in Malawi 
(MacPherson et al., 2012a).  
 
The probability of linking into HIV care after HIVST was based on observed data from 
the HiTTB study (Choko et al., 2015a). In that study, which I co-authored, there were 
two estimates of linkage into HIV care after HIVST. The first estimate (524 of the 930 
sampled individuals linked into HIV care) excluded those who were already on anti-
retroviral therapy. The second estimate (524 of the 1257 sampled individuals linked 
into HIV care) included those already on ART. As the model simulates linkage after 
HIV positive individuals not on ART access HIVST, I used the first estimate in the 
base-case analysis (Table 63) and investigate the impact of a lower rate of linkage 
(the second estimate) in the sensitivity analysis.  
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8.2.3.2.4 Outcomes of HIV care 
I undertook a targeted literature search to identify studies that had investigated 
retention in care amongst those who are not eligible for ART. In the literature a 
systematic review of this topic had recently been published (Plazy et al., 2015). I 
reviewed the papers in the review (Clouse et al., 2013, Hassan et al., 2012, Honge et 
al., 2013, Kranzer et al., 2010, Lessells et al., 2011, Namusobya et al., 2013), 
excluding those undertaken amongst pregnant women. Two additional papers not 
included in the review were found (Geng et al., 2013, Larson et al., 2010) to obtain 
the probability of individuals in pre-ART care returning for repeat assessment for 
ART eligibility.   
 
Since the population scale-up of anti-retroviral therapy in the region, large cohorts of 
individuals in different countries in sub-Saharan Africa have been followed up as part 
of the International Epidemiologic Databases to Evaluate AIDS (IeDEA) collaboration 
(formerly called ART-Linc) (IeDEA, no date). The collaboration has published several 
publications on the outcomes of HIV positive individuals on ART. The publications 
will often use the same cohorts, with longer follow-up, to provide an updated 
understanding of outcomes for ART patients. Their database of publications relating 
to Southern Africa was reviewed to obtain the most recent publication (relating to 
the most recent data), with the longest follow-up and with data on mortality 
disaggregated by CD4 count.  
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The data obtained to estimate the probability of death by CD4 count was obtained 
from one of the studies undertaken using multiple cohorts in South Africa (Hoffmann 
et al., 2013). The study excluded pregnant women and provided data on the risks on 
mortality in the first three years after starting ART disaggregated by the current CD4 
count (Hoffmann et al., 2013). In addition, the study estimated the increase in CD4 
count whilst on ART (Hoffmann et al., 2013). A recent systematic review and meta-
analysis was found in the literature that examined the retention rates in HIV 
treatment for those who initiated ART (Fox and Rosen, 2010). The data was used to 
estimate the monthly probability of loss to follow-up from HIV treatment (Table 63).   
 
A literature search did not reveal any studies that provided the risks of severe HIV 
associated illnesses by CD4 counts for those started on ART. However, a study in 
South Africa compared the risk of hospitalisations amongst those on ART and those 
not on ART (Badri et al., 2006b). The study provided odds ratios for the risk of 
hospitalisations amongst HIV positive patients on ART relative to HIV positive 
patients not receiving ART. I therefore multiplied the derived probability from the 
odds ratios (Table 63) by the associated risks estimated for those not on ART (Table 
64) to determine likelihood of being admitted to hospital for the nine severe HIV-
associated illnesses in the model.  
 
The model does not take into account the impact of ART treatment failure amongst 
HIV positive individuals on ART. A recent analysis of HIV positive patients on anti-
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retroviral therapy in 16 countries in sub-Saharan Africa, with a total of 297 825 
patients with 782 412 person-years of follow-up, found only 3% switched to a 
second-line anti-retroviral therapy regimen (Haas et al., 2015).    
 
8.2.3.4 Health provider and societal costs 
All cost estimates used in the model were derived from the primary studies 
undertaken as part of the PhD. The cost of facility-based HTC and HIVST were 
derived from the study undertaken in chapter 5 of the PhD. The cost of assessing 
individuals fro ART eligibility and the cost of providing ART were derived from 
Chapter 6 of the PhD.  
 
The cost of hospitalisation for the nine severe HIV associated illnesses modeled in 
the cost-utility analysis were derived from Chapter 7 of the PhD. Table 65 shows the 
cost parameters (in 2014 US and INT Dollars) used in the model for analysis from the 
health provider perspective. Table 66 shows the cost parameters used in the model 
for analysis from the societal perspective.  
 
8.2.3.5 Health state utility scores 
The health utility scores for the health states in the model were derived from the 
studies undertaken in the PhD. The utility score for the HIV positive individuals not 
yet on ART were derived from the pre-ART observation period in the study 
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undertaken in Chapter 6 of the PhD. The health utility scores for those who start ART 
and the change in utility scores with time on ART were derived from the ART 
observation period in the study undertaken in Chapter 6 of the PhD.  
 
The health utility scores for those who suffered from one of the nine severe HIV 
associated illnesses were derived from Chapter 7 of the PhD. Table 67 shows the 
utility parameters, derived from the EQ-5D measure using the Zimbabwean tariff, 
that were used in the primary analysis.  
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Table 62: Parameters used to determine baseline characteristics of individuals in model 
 Parameters to determine Individual characteristics on entry into model  
Base case Low High Distribution Reference 
      
HIV Prevalence 0.185 0.140 0.234 Beta (Choko et al., 2011) 
       
 
CD4 count on entry into model 
amongst HIV positive 
individuals 
 
 
>500 cells/μl 0.363 0.292 0.439 Beta 
(Kranzer et al., 2013) 
351-500 cells/μl 0.244 0.182 0.312 Beta 
201-350 cells/μl 0.263 0.201 0.332 Beat 
51-200 cells/μl 0.107 0.065 0.157 Beat 
=< 50 cells/μl 0.024 0.006 0.051 Beat 
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Table 63: Monthly transition probabilities in model 
Parameter Parameter Values Distribution Reference 
Base case Low High 
HIV incidence 0.00219 0.00208 0.00231 Beta (Tanser et al., 2013) 
Probability of CD4 count falling to 500 cells/μl 0.011 0.009 0.011 Beta (Lodi et al., 2011) 
Monthly fall in CD4 count (cells/μl) 351-500 cells/μl 2.37 2.12 2.61 
Normal (Martinson et al., 2014, May et al., 2009, Holmes et al., 2006) 201-350 cells/μl 1.74 1.45 2.03 
51-200 cells/μl 4.42 3.98 4.86 
Mortality for HIV positive and not on ART >500 cells/μl 0.0005 0.0001 0.0017 
Beta (Anglaret et al., 2012) 
350-500 cells/μl 0.0013 0.0007 0.0025 
200-349 cells/μl 0.0035 0.0023 0.0047 
100-199 cells/μl 0.0142 0.0109 0.0177 
50-99 cells/μl 0.0266 0.0219 0.0394 
<50 cells/μl  0.0563 0.0454 0.0670 
Uptake of Facility-based HIV Testing and counselling  0.0256 0.0254 0.0257 Beta (MoH, 2014) 
Uptake of HIV Self-testing  0.143 0.138 0.149 Beta (Choko et al., 2015a) 
Linkage into HIV care Facility-based HTC 0.5070 0.4505 0.5642 Beta (MacPherson et al., 2012a) 
HIV self-testing 0.5633 0.5322 0.5945 Beta (Choko et al., 2015a) 
Retention in care for Pre-ART 0.57 0.56 0.58 Beta 
(Clouse et al., 2013, Geng et al., 2013, Hassan et al., 2012, 
Honge et al., 2013, Kranzer et al., 2010, Larson et al., 
2010, Lessells et al., 2011, Namusobya et al., 2013, Plazy 
et al., 2015) 
Mortality on ART by CD4 count on 
initiation of treatment 
>350 cells/μl 0.00117 0.00101 0.00133 
Beta (Hoffmann et al., 2013) 201-350 cells/μl 0.00208 0.00188 0.00229 101-200 cells/μl 0.00416 0.00387 0.00446 
<=100 cells/μl 0.01159 0.01119 0.01200 
Weekly increase in CD4 count on ART (cells/μl) 1.3 1.1 1.5 Normal (Hoffmann et al., 2013) 
Lost to follow-up from ART  Months 0 to 6 0.0246 0.0222 0.0275 
Beta (Fox and Rosen, 2010) Months 7 to 12 0.0101 0.0085 0.0113 Months 13 to 24 0.0035 0.0023 0.0048 
After month 24 0.0032 0.0024 0.0043 
Probability multiplier for risk Severe HIV associated illness on 
ART 0.2248 0.1870 0.2647 Beta 
(Badri et al., 2006b) 
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Table 64: Monthly risk of Severe HIV associated illness and HIV disease progression by current CD4 count 
 
Monthly risk by current CD4 count  
>500 cells/μl 350-500 cells/μl 200-349 cells/μl 100-199 cells/μl 50-99 cells/μl <50 cells/μl Ref 
Chronic Diarrhoea 0.00% 0.00% 0.01% 0.03% 0.10% 0.18% 
(Anglaret et 
al., 2012) 
 
 
 
 
 
Oesophageal candidiasis 0.00% 0.00% 0.01% 0.03% 0.10% 0.17% 
Invasive bacterial diseases 0.20% 0.18% 0.52% 0.97% 1.07% 0.96% 
Pulmonary TB 0.03% 0.03% 0.11% 0.26% 0.40% 0.13% 
Extra-pulmonary TB 0.02% 0.02% 0.10% 0.09% 0.16% 0.09% 
Malaria  0.09% 0.14% 0.19% 0.26% 0.30% 0.40% 
Malignancy (KS/Lymphoma) 0.00% 0.00% 0.01% 0.01% 0.03% 0.05% 
Pneumocystis Pneumonia 0.00% 0.00% 0.03% 0.05% 0.05% 0.67% 
Cryptococcal Meningitis 0.00% 0.00% 0.03% 0.04% 0.18% 0.54% 
Overall monthly progression to 
WHO stage 3 
0.61% 0.66% - - - - 
(Anglaret et 
al., 2012) Overall monthly progression to 
WHO stage 4 
0.02% 0.12% - - - - 
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Table 65: Health provider costs for model (2014 US and INT Dollars) 
 
Cost Parameter 
Health Provider Costs Distribution 
2014 US Dollars  2014 INT Dollars 
Base case Low High  Base case Low High  
HIV testing at Health Facility 8.90 7.53 10.57  20.44 20.25 25.18  
HIV self-testing  8.78 7.78 10.46  17.25 14.25 22.42  
Assessment for ART eligibility after facility HTC (CD4 >350 cells/μl ) 31.91 26.10 33.44  80.77 26.10 33.44  
Assessment for ART eligibility after facility HTC (CD4 <350 cells/μl ) 22.03 19.85 24.22  59.79 54.34 65.24  
Assessment for ART eligibility after HIVST (CD4 >350 cells/μl ) 23.63 18.24 29.03  60.90 49.07 72.74  
Assessment for ART eligibility after HIVST (CD4 <350 cells/μl ) 21.51 19.04 23.97  57.78 51.74 63.82  
HIV treatment: Month 1 after Facility HTC 19.51 17.71 21.31  33.03 28.78 37.28  
Cost of ART: Month 2 onwards after Facility HTC 14.41 13.17 15.65  19.22 16.53 21.91 Gamma 
Cost of ART: Month 1 after HIVST 16.23 13.99 18.48  25.04 20.31 29.76  
Cost of ART: Month 2 onwards after HIVST 13.84 12.49 15.19  18.28 15.32 21.25  
 
 
 
 
Cost of hospital admission for 
severe HIV associated illness 
Chronic Diarrhoea 233.06 99.08 367.04  609.07 243.19 974.94  
Oesophageal candidiasis 153.08 69.03 237.13  395.98 170.12 621.84  
Invasive bacterial diseases 226.88 203.64 250.13  591.03 529.02 653.05  
Pulmonary TB 438.99 341.45 536.53  1151.13 891.00 1411.25  
Extra-pulmonary TB 492.25 390.55 593.95  1288.55 1027.30 1549.79  
Malaria 199.63 111.34 287.93  488.44 256.78 720.09  
Malignancy (KS/Lymphoma) 243.35 195.28 291.41  638.36 517.23 759.49  
Pneumocystis Pneumonia 325.92 270.34 381.50  850.35 700.83 999.88  
Cryptococcal Meningitis 837.92 651.27 1024.57  1568.22 1299.65 1836.79  
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Table 66: Societal costs for model (2014 US and INT Dollars) 
 
Cost Parameter 
Societal Costs Distribution 
2014 US Dollars 2014 INT Dollars 
 Base case Low High Base case Low High 
HIV testing at Health Facility 10.68 9.91 11.45 26.78 24.94 28.63  
 
 
 
 
 
 
 
 
 
Gamma 
HIV self-testing  8.85 7.97 9.72 17.62 15.09 20.16 
Assessment for ART eligibility after facility HTC (CD4 >350 cells/μl ) 36.27 30.52 42.02 92.44 78.50 106.39 
Assessment for ART eligibility after facility HTC (CD4 <350 cells/μl ) 23.04 20.19 25.89 62.39 54.98 69.80 
Assessment for ART eligibility after HIVST (CD4 >350 cells/μl ) 24.96 16.71 33.21 64.19 44.40 83.98 
Assessment for ART eligibility after HIVST (CD4 <350 cells/μl ) 22.36 18.49 26.23 59.81 49.77 69.85 
Cost of ART: Month 1 after Facility HTC 21.40 19.10 23.69 38.26 32.49 44.03 
Cost of ART: Month 2 onwards after Facility HTC 14.39 12.84 15.95 19.17 15.46 22.88 
Cost of ART: Month 1 after HIVST 17.87 14.85 20.89 29.60 22.24 36.95 
Cost of ART: Month 2 onwards after HIVST 13.93 12.18 15.69 18.54 14.26 22.82 
 
 
 
 
Cost of hospital admission for 
severe HIV associated illness 
Chronic Diarrhoea 260.90 117.88 403.93 686.42 288.95 1083.89 
Oesophageal candidiasis 178.94 57.65 300.24 467.81 149.47 786.16 
Invasive bacterial diseases 268.80 237.55 300.04 707.46 619.21 795.71 
Pulmonary TB 580.78 433.99 727.58 1545.00 1160.15 1929.85 
Extra-pulmonary TB 764.94 524.73 1005.14 2046.00 1400.56 2691.43 
Malaria 358.45 53.43 663.47 929.60 137.93 1721.27 
Malignancy (KS/Lymphoma) 317.45 241.01 393.89 844.20 638.28 1050.12 
Pneumocystis Pneumonia 395.51 291.58 499.44 1043.65 761.95 1325.35 
Cryptococcal Meningitis 963.40 746.68 1180.12 1916.77 1541.48 2292.06 
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Table 67: EQ-5D Utility scores for model (Zimbabwean and UK tariff) 
 
Utility Parameters 
Utility scores  Distribution 
Main analysis (Zimbabwean Tariff) Sensitivity analysis (UK Tariff) 
 Base case Low High Base case Low High 
HIV Negative individuals 1.000 1.000 1.000 1.000 1.000 1.000  
 
 
 
 
 
 
Beta 
HIV positive not on 
ART 
 
CD4>200 cells/μl 0.897 0.816 0.977 0.855 0.737 0.973 
CD4 51 to 200 cells/μl 0.850 0.768 0.931 0.796 0.676 0.916 
CD4 count <=50 cells/μl 0.668 0.565 0.771 0.481 0.329 0.633 
Monthly improvement on Anti-retroviral therapy 0.008 0.007 0.010 0.011 0.009 0.012 
 
 
 
Hospital admission for 
severe HIV associated 
illness 
Chronic Diarrhoea 0.476 0.318 0.634 0.213 0.036 0.466 
Oesophageal candidiasis 0.349 0.168 0.530 0.073 0.001 0.282 
Invasive bacterial diseases 0.495 0.454 0.536 0.283 0.224 0.343 
Pulmonary TB 0.426 0.346 0.505 0.175 0.069 0.281 
Extra-pulmonary TB 0.391 0.306 0.477 0.167 0.061 0.273 
Malaria 0.567 0.411 0.722 0.403 0.205 0.602 
Malignancy (KS/Lymphoma) 0.420 0.321 0.520 0.159 0.028 0.289 
Pneumocystis Pneumonia 0.559 0.399 0.718 0.382 0.125 0.638 
Cryptococcal Meningitis 0.483 0.399 0.568 0.244 0.114 0.373 
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Table 68: Targeted literature search findings for synthesis of parameters in model 
HIV incidence 
Search strategy  (((HIV incidence[Title/Abstract]) AND Africa[Title/Abstract]) AND antiretroviral therapy 
Publications identified 44 
Relevant publications 9 
Population CD4 count 
distribution 
Search strategy  ((HIV[Title/Abstract]) AND CD4[Title/Abstract]) AND Africa[Title/Abstract] 
Total references 1802 
Relevant publications 4 
CD4 count decline  
Search strategy  ((HIV[Title/Abstract]) AND CD4[Title/Abstract]) AND Africa[Title/Abstract] 
Total references 1802 
Relevant publications 7 
HIV mortality before 
starting anti-retroviral 
therapy 
Search strategy  (((HIV[Title/Abstract]) AND Africa[Title/Abstract]) AND death[Title/Abstract]) 
Total references 1182 
Relevant publications 4 
 
 
 
 
 
 
 
 
356 
8.2.4 Model validation  
The model was validated using three broad approaches: (1) face validity; (2) model 
verification; and (3) external validity (Eddy et al., 2012). The face validity of the 
model was undertaken by reviewing the literature around economic evaluation of 
HIV interventions (Chapter 4 of PhD) to determine best practices and approaches to 
modeling HIV interventions. Discussion with experts in the field of HIV were 
undertaken to determine appropriate clinical pathways for HIV disease progression 
and outcomes of undergoing HIV testing and HIV treatment.   
 
I undertook model verification and examined the external validity of the model by 
examining components of the model and comparing outputs from the model with 
findings in the literature. I evaluated the model predicted uptake of both facility HTC 
and HIVST, and the HIV prevalence amongst HIV testers to findings from the HiTTB 
study and published findings from the region. I compared the model outputs 
pertaining to linkage into HIV treatment and outcomes of those on HIV treatment to 
previous studies to ensure the calculations being undertaken in the model reflect 
real world findings. Model verification was also used to make modifications to the 
model structure and pathways in the model (Briggs et al., 2012b). As previously 
mentioned the model verification will be repeated once the observed findings from 
the HiTTB study become available. This will allow the model to be calibrated to 
reflect the outcomes of the HiTTB study. The findings were not available at the time 
of PhD submission, but will be utilised prior to publication of findings in peer-
reviewed journals.  
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8.2.5 Sensitivity analysis  
A range of sensitivity analyses was undertaken to evaluate the effects of alternative 
plausible parameter input on the findings of the model. I undertook sensitivity 
analyses to evaluate the impact on alternative model parameter values on the 
primary outcome, namely the incremental cost-effectiveness ratio (ICER).  The range 
of sensitivity analyses undertaken included: 
 
I. Utilising the EQ-5D utility scores derived from the UK tariff set (data shown in 
Table 67).  
II. Alternative discount rates: 0% and 6% (WHO, 2003a) 
III. Lower HIV prevalence: 10% and 5%  
IV. Higher cost of providing HIVST: 50% higher; 25% lower; 50% lower 
V. Lower rates of linkage into HIV treatment after HIVST: 50% lower 
VI. Lower cost of providing HIV treatment: 25% lower 
VII. Impact of rate of HIV disease progression (measured by CD4 count) for those 
not yet receiving ART: 50% faster and 50% slower monthly rate of decline 
VIII. Lower uptake of HIVST in those who are HIV positive but not yet aware of 
their infection: 20% lower uptake 
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8.2.6 Alternative model scenarios  
The WHO now recommends that HIV positive individuals are started onto ART when 
their CD4 count falls to 500 cells/μl (WHO, 2014). The Malawian MoH has not yet 
adopted this practice, and during the HitTB study individuals were started onto ART 
when their CD4 count fell below 350 cells/μl (or WHO stage 3 or 4). In addition, 
there is emerging evidence that suggest HIV positive individuals would benefit with 
initiation of ART as soon as they are aware of their HIV status (Group, 2015a, Group, 
2015b). As either of these changes may soon become practice, I evaluated the cost-
effectiveness of offering HIVST in addition to facility-based HTC under these 
scenarios (Table 69).  
 
 
Table 69: Alternative model scenarios evaluated 
 
Current 
scenario 
 
 
Facility HTC + ART initiation at CD4 350 cells/μl or WHO stage 3 or 4 
 
 
 
 
 
Alternative 
scenario 
 
Facility HTC + ART initiation at CD4 500 cells/μl or WHO stage 3 or 4 
 
Facility HTC + Immediate ART initiation  
 
 
 
HIVST + Facility HTC + ART initiation at CD4 350 cells/μl or WHO stage 3 or 4 
 
HIVST + Facility HTC + ART initiation at CD4 500 cells/μl or WHO stage 3 or 4 
 
HIVST + Facility HTC + Immediate ART initiation  
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8.2.6 Decision rules 
The WHO suggests that interventions where the ICER is less that the GDP per capita 
should be interpreted as very cost-effective, whilst interventions that are less than 
three times the GDP per capita should be interpreted as cost-effective (WHO, 2001, 
WHO, 2003a). The World Bank estimates for the GDP per capita in Malawi is 
approximately $250. These decision rules were applied in my analyses. 
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8.3 Results 
8.3.1 Findings from model validation  
Table 70 and Table 71 show the findings from the model validation checks. Table 70 
shows that in the model simulations, the proportion of the total population who 
access facility-based HTC over the first three years was 22.9% to 28.1%, and 
comparable to that observed in the study population prior to implementing HIV self-
testing (22.6%). In the model simulations, the uptake of HIVST in the model over the 
first year (77.4%) was comparable to that observed in the HiTTB HIV self-testing 
study (76.5%). The uptake of HIVST in the model simulations over the subsequent 
years were higher than that observed in the HITTB HIV self-testing study. The model 
simulation shows the HIV prevalence amongst facility HTC clients was comparable to 
that observed in the study population. In the model simulation, the HIV prevalence 
amongst HIV self-testers was higher than that observed in the HiTTB study. 
 
Table 71 shows the model validation checks on the CD4 count at initiation of 
antiretroviral therapy simulated by the model and that observed in the real world. 
The model predicts the CD4 count of facility HIV testers and HIV self-testers that link 
into HIV treatment services to be marginally higher than that observed in Blantyre, 
and in the HiTTB study.  
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Table 70: Findings from model validation for outcomes of offering HIV testing 
Findings from model simulation Data from Blantyre, Malawi  
 Study Observed data 
Annual uptake of Facility HTC  
(Current strategy) 
Year 1: 28.1% 
Year 2: 23.4% 
Year 3: 22.9% 
Choko et al (2011) 22.6%  
Proportion of population ever tested  
(Current strategy) 
After Year 1: 28.1% 
After Year 2: 51.0% 
After Year 3: 58.8% 
Choko et al (2011) 
MacPherson et al (2012) 
61.8% (Population) 
37.1% (HTC clients) 
Population uptake of HIVST  
(Intervention strategy) 
Year 1: 77.4% 
Year 2: 58.4% 
Year 3: 51.6% 
Choko et al (2015) 
 
Year 1: 76.5% 
Year 2: 74.4% 
HIV prevalence amongst Facility HTC  
(Current Strategy) 
Year 1: 18.8% 
Year 2: 20.1% 
Year 3: 20.7% 
MacPherson et al (2012) 
 
18.5% 
HIV prevalence amongst HIVST  
(Intervention strategy) 
Year 1: 18.4% 
Year 2: 12.0% 
Year 3: 12.3% 
Choko et al (2015) 
 
Year 1: 10.1% to 11.8% 
Year 2: 6.8% to 7.3% 
CD4 count amongst Facility HTC Clients at ART assessment 
(Current Strategy) 
Median: 417 cells/μl 
Mean: 369 cells/μl 
MacPherson et al (2012) Median: 294 cells/μl (All) 
Median: 240 cells/μl (men and non-
pregnant women) 
CD4 count amongst HIVST Clients at ART assessment 
(Intervention strategy) 
Median: 445 cells/μl 
Mean: 388 cells/μl 
Choko et al (2015) 
 
Median: 250 cells/μl  
 
Proportion of HIV positive Facility HTC clients starting ART 
(Current Strategy) 
Year 1: 22.8% 
Year 2: 22.3% 
Year 3: 21.3% 
MacPherson et al (2012) 31.1% 
Proportion of HIV positive HIVST clients starting ART 
(Intervention strategy) 
Year 1: 26.2% 
Year 2: 13.1% 
Year 3: 9.9% 
Choko et al (2015) 
 
29.6% (HIVST clients attended clinic and 
had CD4 count <350 cells μl 
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Table 71: Findings from model validation for outcomes on Anti-retroviral therapy 
  Percentage of those Initiated who die in the first year 
CD4 count at ART initiation Model simulation Observed data (May et al., 2010b) 
>=200 cells/μl 2.3% 5.1% 
100-199 cells/μl 7.3% 5.5% 
50-99 cells/μl 13.6% 8.7% 
25-49 cells/μl 20.7% 16.6% 
<25 cells/μl  16.4% 21.4% 
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8.3.2 Primary findings  
Table 72 shows the discounted costs in 2014 US dollars, effectiveness estimate and 
ICER estimate of offering HIVST and facility-based HTC versus offering just facility-
based HTC over a 20-year time horizon (primary analysis).  
 
The projected mean discounted incremental cost per person over the 20-year time 
horizon from implementing HIVST was US$167.03 and US$175.14 from the health 
provider perspective and societal perspectives, respectively. The model estimated a 
mean discounted health gain of 0.53 QALYs per person over the 20-year time 
horizon. When the model was run over a 20-year time horizon the ICER from the 
health provider perspective was US$316.18 per QALY gained. The ICER from the 
societal perspective was US$332.05 per QALY gained. Table 73 shows the findings 
when the costs were estimated in 2014 International Dollars.  
 
Figure 61 and Figure 62 shows the cost-effectiveness plane for the model 
simulations from the health provider and societal perspective, respectively. Figure 
63 and Figure 64 shows the cost-effectiveness acceptability curves (CEAC) for the 
primary analysis from the health provider and societal perspective, respectively. At a 
willingness to pay (WTP) threshold of three times the GDP for Malawi (<US$750 per 
gain in QALY), the intervention would be considered cost-effective from both the 
health provider and societal perspectives.  
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The model predicts the probability of the intervention being cost-effective at a WTP 
threshold of US$ 250 per gain in QALY to be 0.09 and 0.08 from the health provider 
and societal perspectives, respectively. The CEAC shows that all model simulations 
predict the ICER to be below US$670 from the health provider perspective, and 
below US$610 from the societal perspective.  
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Table 72: Cost-effectiveness findings from primary analysis (2014 US Dollars) 
 
 
Perspective 
 
 
Strategy 
Discounted Mean costs and QALYS per person ICER  
2014 US Dollars QALYs 
Mean Cost Incremental 
cost 
Mean Effectiveness Incremental 
Effectiveness 
 
(2014 US$ per QALY) 
Health Provider Facility HTC 435.34 - 13.85 -  
HIVST + Facility HTC 602.36 167.03 14.38  0.53 316.18 
       
Societal Facility HTC 491.68 - 13.85 -  
HIVST + Facility HTC 666.82 175.14 14.38 0.53 332.05 
 
 
 
 
 
 
Table 73: Cost-effectiveness findings from primary analysis (2014 INT Dollars) 
 
 
Perspective 
 
 
Strategy 
Discounted Mean costs and QALYS per person ICER  
2014 INT Dollars QALYs 
Mean Cost Incremental 
cost 
Mean Effectiveness Incremental 
Effectiveness 
 
(2014 INT$ per QALY) 
Health Provider Facility HTC  811.64 - 13.85 -  
HIVST + Facility HTC  1077.89   14.38  0.53  502.36 
       
Societal Facility HTC 976.09 - 13.85 -  
HIVST + Facility HTC 1265.03 288.94 14.38 0.53 549.06 
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Figure 61: Cost-effectiveness plane showing incremental costs and effectiveness of offering HIVST (Health provider perspective) 
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Figure 62: Cost-effectiveness plane showing incremental costs and effectiveness of offering HIVST (Societal perspective) 
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Figure 63: Cost-effectiveness acceptability curve – Health provider perspective   
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Figure 64: Cost-effectiveness acceptability curve – Societal perspective 
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8.3.3 Findings over different time horizons 
Table 74 shows the findings from the health provider perspective and costs in 2014 
US Dollars when the model was run over a 10-year and 40-year time horizon. The 
projected mean discounted incremental cost per person was US$90.44 and 
US$269.39 over a 10-year and 40-year time horizons, respectively. The model 
estimated a mean discounted health gain of 0.15 QALYs and 1.77 QALYs per person 
over a 10-year and 40-year time horizon, respectively.  When the model was run 
over a short time horizon of 10 years, the ICER was US$ 598.56 per QALY gained. 
When the model was run over a longer time horizon of 40 year, the ICER was 
US$ 151.81 per QALY gained. Over a longer time-horizon of 40 years, the model 
predicts the probability of the intervention being cost-effective at a WTP threshold 
of US$ 250 per gain in QALY to be 0.998 from the health provider perspective (Table 
75).  
 
8.3.3 Sensitivity analysis  
Figure 65 shows ICERs for the different scenarios investigated in the sensitivity 
analysis undertaken. Table 75 shows incremental costs in 2014 US dollars from the 
health provider perspective, incremental effectiveness estimate, ICER estimate, and 
the probability of offering HIVST and facility-based HTC being cost-effective at the 
two willingness to pay thresholds of one times the GDP and three times the GDP per 
capita of Malawi. All the scenarios investigated suggest that the intervention would 
remain cost-effective is our willingness to pay for a gain in QALY was below three 
times the GDP of Malawi.  
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Table 75 shows that in comparison using a discount rate of 3%, discounting costs and 
health benefits at a rate of 6%, results in a lower incremental cost, higher 
incremental effectiveness, with the probability of implementing HIVST being cost-
effective at a willingness to pay threshold of US$ 250 per gain in QALY was higher at 
0.895.  
 
In comparison to using the Zimbabwean tariff to derive the EQ-5D utility scores, 
using the UK tariff results in the probability of implementing HIVST being cost-
effective at a willingness to pay threshold of US$ 250 per gain in QALY to be higher 
at 0.115 (Table 75). If the HIV prevalence in the population offered HIVST was lower 
at 5% or 10%, the sensitivity analysis shows the ICER estimate to be higher at 
US$ 476.04 per QALY gained and US$394.25 per QALY gained.   
 
The sensitivity analysis shows that if the cost of an HIV self-test episode was 25% or 
50% lower the probability of the intervention being cost-effective at the lower 
willingness to pay threshold of US$ 250 per gain in QALY to be 0.220 and 0.496, 
respectively (Table 75). The sensitivity analysis shows that if the cost of delivering 
HIVST was 50% higher, providing HIVST would still be considered cost-effective.   
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Table 74: Cost-effectiveness findings from primary analysis over different time horizons (2014 US Dollars) 
 
 
Perspective 
 
 
Time Horizon 
 
 
Strategy 
 Discounted Mean costs and QALYS per person ICER  
2014 US Dollars QALYs 
Mean Cost Incremental 
cost 
Mean 
Effectiveness 
Incremental 
Effectiveness 
 
(2014 US$ per QALY) 
Health Provider 10 years Facility HTC 170.63  - 8.09 -  
 HIVST + Facility HTC  261.07 90.44  8.24  0.15  598.56 
        
Health Provider 20 years Facility HTC 435.34 - 13.85 -  
 HIVST + Facility HTC 602.36 167.03 14.38  0.53 316.18 
 
Health Provider 
 
40 years 
 
Facility HTC 
 
928.61 
 
- 
 
22.29 
 
- 
 
  HIVST + Facility HTC 1198.00 269.39 24.06 1.77 151.81 
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Figure 65: Tornado diagram showing findings from sensitivity analysis 
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Table 75: Findings from sensitivity analysis and different time horizons, including probability of intervention cost-effective 
  
  
Incremental cost 
(2014 US Dollars) 
Incremental 
effectiveness 
(QALYs) 
ICER 
(2014 US$ per 
QALY) 
Probability cost-effective 
1X 
GDP/capita 
3 X 
GDP/capita 
Base Case Scenario - 20 year time horizon 167.03 0.53 316.18 0.087 1.000 
Base Case Scenario - 40 year time horizon 269.39 1.77 151.81 0.998 1.000 
Base Case Scenario - 10 year time horizon 90.44 0.15 598.56 0.000 0.807 
Discount rate 0% 224.64 0.37 600.73 0.000 0.778 
Discount rate 6% 129.52 0.62 208.41 0.895 1.000 
EQ-5D - UK Tariff 166.80 0.54 306.92 0.115 1.000 
Faster CD4 decline amongst HIV positive individuals not on ART 
(50% faster) 177.45 0.65 271.50 0.292 1.000 
Slower CD4 decline amongst HIV positive individuals not on ART 
(50% slower) 155.68 0.39 397.75 0.006 0.995 
HIV prevalence in population: 5% 130.78 0.27 476.04 0.000 0.967 
HIV prevalence in population: 10% 143.87 0.36 394.25 0.004 0.998 
Uptake of HIVST amongst HIV positive - 20% Lower 160.44 0.49 326.67 0.053 1.000 
Linkage after HIVST - 50% lower 122.35 0.33 366.21 0.034 0.994 
Higher cost of HIVST - 50% higher 198.59 0.52 382.18 0.003 0.999 
Lower cost of HIVST - 25% lower 150.78 0.52 288.08 0.220 1.000 
Lower cost of HIVST - 50% lower 134.23 0.53 255.42 0.496 1.000 
Lower cost of providing HIV Treatment - 25% lower 141.86 0.53 268.77 0.318 1.000 
ICER: Incremental cost-effectiveness ratio 
GDP: Gross Domestic Product 
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8.3.4 Public health impact of offering HIVST 
Table 76 shows the potential public health impact of providing HIVST over the 20 
years the model was run. Provision of HIVST would result in a 284.6% increase in the 
number of HIV testing episodes and a 143.2% increase in the months of ART 
provided. There would potentially be a 47.3% reduction in the number of 
hospitalisations amongst HIV positive individuals for Pneumocystis Pneumonia, and a 
73.7% reduction in admission for pulmonary Tuberculosis. There would potentially 
be 79.2% fewer HIV infected individuals dying over the 20 years after HIVST was 
implemented.  
 
Table 76: Public health Impact of implementing HIV self-testing 
  Percentage change over 20 
years of providing HIVST 
HIV testing episodes 284.6% 
Months of ART provided 143.2% 
 
 
 
Hospitalisations  
Chronic Diarrhoea 55.1% 
Oesophageal candidiasis 62.4% 
Invasive bacterial diseases 77.3% 
Pulmonary TB 73.7% 
Extra-pulmonary TB 69.1% 
Malaria 82.8% 
Malignancy (KS/Lymphoma) 63.9% 
Pneumocystis Pneumonia 47.3% 
Cryptococcal Meningitis 47.5% 
HIV related deaths 79.2% 
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8.3.4 Alternative scenarios – Earlier initiation of ART 
Table 77 shows the incremental costs in 2015 US dollars, incremental effects and 
ICERs for the cost-effectiveness analysis of HIVST under alternative thresholds for 
eligibility for ART initiation. Figure 66 shows the cost-effectiveness plane comparing 
the alternative strategies to the current strategy of providing facility-based HTC and 
initiation of ART when individuals CD4 count falls below 350 cells/ul (or WHO Stage 3 
or 4).  
 
Table 77 shows that in comparison to the current strategy of providing only facility-
based HTC and ART, the ICER for providing HIVST and immediate of ART was 
US$ 345.85 per QALY gained and would be a cost-effective strategy for Malawi.  
 
The strategies for earlier initiation of ART with only providing facility-based HTC were 
dominated by strategies for earlier initiation of ART with the additional provision of 
HIVST. In addition, providing HIVST under current guidelines for ART initiation were 
dominated by strategies with earlier initiation of ART with the additional provision of 
HIVST.  Figure 67 shows the cost-effectiveness acceptability frontier (CEAF) with the 
optimal strategies by increasing willingness to pay thresholds. The current strategy 
remains optimal up to a WTP threshold of US$310 per QALY gained. At WTP 
thresholds above US$310 per QALY gained, providing HIVST and earlier initiation of 
ART are the optimal strategies.   
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Table 77: Cost-effectiveness findings for alternative scenario from the health provider perspective (20 year time horizon) 
 
 
 
 
 
 
 
 
 
 
HIV Testing strategy 
 
 
ART Initiation Strategy 
 
Discounted Mean costs and QALYS per person 
 
 
ICER 
 
2014 US Dollars QALYs 
Mean  
Cost 
Incremental 
cost 
Mean 
Effectiveness 
Incremental 
Effectiveness 
 (2014 US$ per 
QALY gained) 
Facility HTC CD4 <=350 cells/μl or WHO stage 3 or 4 434.38  13.87    
Facility HTC CD4 <=500 cells/μl or WHO stage 3 or 4 490.26 55.89 14.04 0.17 329.17 
Extended 
dominance 
Facility HTC Immediate ART initiation (Test and Treat) 591.14 156.76 14.26 0.39 402.43 
Extended 
dominance 
Facility HTC + HIVST CD4 <=350 cells/μl or WHO stage 3 or 4 603.75 169.38 14.39 0.53 322.34 
Extended 
dominance 
Facility HTC + HIVST CD4 <=500 cells/μl or WHO stage 3 or 4 684.43 250.05 14.66 0.79 316.63  
Facility HTC + HIVST Immediate ART initiation (Test and Treat) 823.45 389.07 14.99 1.12 345.85  
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Figure 66: Cost-effectiveness plane showing incremental costs and effectiveness for alternative scenarios (Health provider perspective) 
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Figure 67: Cost-effectiveness acceptability frontier for alterative scenarios (Health provider perspective) 
 
 
 
380 
8.4 Discussion 
In this chapter of the PhD, I found that implementing HIVST would be a cost-effective 
health strategy for Malawi, potentially very cost-effective if the decision was 
considered over a longer time horizon of 40 years. Additionally, I found the 
implementing HIVST would have a significant public health impact by reducing the 
burden of HIV associated illnesses that require hospital care. Implementing HIV self-
testing would result in an increase in spending from the health provider but also a 
gain in quality adjusted life years. The analysis over the shorter (10-year) and longer 
(40-year) time horizons suggests that much of the additional costs would be incurred 
in the first few years of implementing HIVST, and much of the health benefits would 
not be realised till later. The ICER estimate was considerably lower when future costs 
and health gains were not discounted, and considerably higher when they were 
discounted at a higher rate of 6%.  
 
The cost of providing HIVST and HIV treatment were important drivers of costs and 
cost-effectiveness. HIVST would remain cost-effective if the cost of delivering self-
testing was higher. However, the ICER estimates would be lower if the cost of 
providing HIVST or HIV treatment were lower, increasing the likelihood the strategy 
would be considered very cost-effective, whilst making implementation more 
affordable. These scenarios could be achieved through market-based strategies to 
increase the competition and reduce barriers to market access for HIV self-test kits 
and generic anti-retroviral drugs. The former is currently being investigated through 
a large UNITAID grant that I am involved in, and involves working with healthcare 
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providers and manufacturers of HIV self-test kits to investigate alternative lower cost 
approaches to delivering HIVST, and providing regulatory support for current and 
future manufactures of HIV self-test kits to enter the African market. One of the aims 
of the project is to bring down the price of the Oral HIV self-test kit (US$4.80 
including shipping) to a price comparable to the rapid finger prick HIV test kits used 
in health facilities (US$0.69). This would potentially lower the cost of delivering 
HIVST by 25-50%. Further cost reductions could be achieved if alternative 
approaches to delivering HIVST prove effective. The cost of providing HIV treatment 
has historically fallen, as HIV programmes grew in size and matured, and the prices 
for anti-retroviral drugs fell (Menzies et al., 2012, Tagar et al., 2014). It is possible 
this trend will continue with earlier initiation of ART in HIV positive individuals.  
 
The HIV prevalence in Malawi varies, with higher prevalence reported in the urban 
cities and lower in rural villages (Chihana et al., 2012, MoH, 2014, WHO, no date-a). 
In addition, the HIV prevalence in other countries in sub-Saharan Africa has also 
been reported as lower than the 18.5% assumed in the primary model analysis 
(UNAIDS, 2013a). The findings from the CUA suggest that implementing HIVST would 
remain a cost-effective strategy if the HIV prevalence in the population offered the 
service were lower. However, implementing HIVST in other settings may be 
associated with higher or lower costs than that estimated in Blantyre. This should be 
taken into account, and further work is needed before the findings can be 
generalised.  
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The incremental cost-effectiveness ratio (ICER) of implementing HIVST estimated 
from the societal perspective was comparable to that estimated from the health 
provider perspective. In Chapters 5-7 I found the direct non-medical and indirect 
costs were considerable. Although HIVST is associated with minimal direct non-
medical and indirect costs, accessing HIV treatment is not. HIVST will increase the 
number of HIV positive individuals accessing HIV treatment and thereby placing 
additional costs on them. Moving HIV testing closer to individual’s homes saves 
users time and money, and this may also possible with HIV treatment. Assessing 
individuals for initiation of ART and providing HIV treatment in people’s homes have 
proved effective (Jaffar et al., 2009, MacPherson et al., 2014, Wringe et al., 2010), 
but will come at a cost but may still to be cost-effective for healthcare providers.  
 
In the cost-effectiveness analysis undertaken I have assumed the incidence of HIV 
amongst HIV-negative individuals would remain constant over time and would not 
differ across the two strategies examined. Implementing HIVST will increase the 
proportion of HIV-positive individuals on ART, and may reduce the HIV incidence 
over time. This would have a beneficial impact on health outcomes and costs of 
providing HIV care, as fewer and fewer individuals would become infected with HIV 
and need costly treatment with anti-retroviral drugs. Taking into account the impact 
on HIV transmission would likely result in a lower ICER.  
 
In the study I undertook a range of model validation checks to compare the outputs 
of the model to outcomes observed in the real world. For this I predominantly used 
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findings observed in the study population from which the majority of my model 
parameter estimates were derived from. The validation checks suggest the model 
could be further optimised and this will be possible once the findings from HiTTB 
cluster randomised trial become available. Two potential issues found from the 
model validation related to the HIV prevalence amongst HIV self-testers in the model 
were higher than that found in the HiTTB study, and the higher CD4 counts observed 
amongst both HIV self-testers and facility-based testers who link into HIV treatment 
services. The sensitivity analysis suggests that the ICER estimate remained 
comparable if we assumed a lower uptake of HIVST amongst those who were HIV 
positive but not yet aware of their status, and if we assumed a faster decline in CD4 
counts amongst HIV positive individuals not on ART.   
 
In Chapters 5, 6 and 7 I found the EQ-5D utility scores derived from the UK tariff 
were systematically lower than the scores derided in the primary analysis using the 
Zimbabwean tariff. In the sensitivity analysis in this chapter I found the ICER 
estimate was only marginally lower when the EQ-5D utility scores derived from the 
UK tariff was used to populate the model. This would suggest that if Malawians were 
to value health in a comparable way to the UK population, placing lower values for 
health states associated with ‘severe problems’ in one or more of the five 
dimensions of health enquired in the EQ-5D measure, the conclusions around cost-
effectiveness would not change. However, as the model shows more gains when run 
over a 40-year time horizon, it may still be valuable to consider deriving an EQ-5D 
tariff set for Malawi.   
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8.5 Summary of Chapter 8 
In this chapter, I undertook a cost-utility analysis to investigate my primary research 
question. I used decision-analytic modelling and provide a description of the 
modelling approach and structure of the model. I describe the parameters used to 
populate the model and the sensitivity analysis undertaken. I found implementing 
HIVST would be a cost-effective option for Malawi, potentially very cost-effective. I 
show that this conclusion would not change if we used alternative parameters in the 
model or a shorter time horizon. I provide a brief discussion of the findings.  
 
In the final chapter (Chapter 9) I will provide a more detailed discussion of the 
findings from the PhD, the implications for policy and research, and the strengths 
and limitations of the analyses undertaken in the PhD.  
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CHAPTER 9: Discussion of Findings 
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9 Overview of Chapter 9 
In this chapter I provide a final discussion of my PhD thesis. I begin by summarising 
the primary issues relating to HIV and HIV testing in sub-Saharan Africa and Malawi. I 
then summarise the main findings of my PhD; how my findings relate to previous 
findings in the area; and the strengths and limitations of the PhD. I summarise the 
implications of my findings for policy, and the original contribution to research made 
by this PhD. I discuss potential areas for future research relating to HIVST, reflect on 
the research training and experiences during the course of my study, and finish with 
a brief conclusion to the thesis.   
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9.1 Introduction 
HIV self-testing (HIVST) is a potential solution to help increase awareness of HIV 
status amongst Africans (Choko et al., 2015b), promote timely access to anti-
retroviral therapy (ART) and biomedical prevention strategies, and consequently 
limit a regional epidemic (Granich et al., 2009, Gray et al., 2007a, Cohen et al., 2011, 
Grant et al., 2010). However, for policy makers to consider implementation, 
evidence is needed on the cost and cost-effectiveness of HIVST used within a 
regional context.  
 
In 2014, over 35 million people were living with HIV, with over 2 million people 
becoming infected every year and nearly 2 million people dying from the infection 
(UNAIDS, 2014b). Sub-Saharan African has been worst hit by the epidemic, 
accounting for nearly three quarters of the global burden (UNAIDS, 2014b). In 
Malawi there are approximately one million adults living with HIV, and despite of 
efforts to increase the provision of HIV testing and treatment services, less than half 
of adults are aware of their HIV status, and less than half of those in need of ART are 
receiving therapy (UNAIDS, 2013a, MoH, 2014, Staveteig et al., 2013, UNAIDS, 2015).  
 
In Africa, HIV testing and counselling (HTC) has traditionally been provided through 
health facilities. Individuals either access them voluntarily or are offered the option 
when accessing other forms of medical care. Facility-based HTC has been found to 
be unpopular amongst Africans, especially amongst men (Hensen et al., 2012, 
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Jurgensen et al., 2012, Kalichman and Simbayi, 2003, Macpherson et al., 2012c, 
Weiser et al., 2006). Health facilities offering HTC often lack privacy and 
confidentially and may require individuals to take time of work or incur other 
personal costs (Kalichman and Simbayi, 2003, Wolff et al., 2005, Morin et al., 2006, 
Wringe et al., 2009, Angotti et al., 2009, Kwapong et al., 2014, Musheke et al., 2013). 
As a consequence HIV positive individuals have been found to enter HIV treatment 
services late; reducing survival, increasing burden of HIV associated illnesses and 
increasing the risk of transmission to their sexual partners.  
 
Community-based HIV testing strategies, including home-based and mobile HTC, 
have been found to be popular offering those wishing to test privacy and 
convenience (Suthar et al., 2013, Sabapathy et al., 2012). In comparison to facility-
based HTC, the cost of community-based HTC is high (Menzies et al., 2009, Grabbe et 
al., 2010), but economic evaluations suggest they are cost-effective (Smith et al., 
2015, Bassett et al., 2014). However, in sub-Saharan African very few healthcare 
providers have implemented them (Staveteig et al., 2013), with concerns over their 
cost and human resource needs of scaling them up (Sabapathy et al., 2012). 
 
HIVST involves individuals using an oral self-test kit to test in private and provides a 
potential approach for delivering community-based HTC services (WHO, 2013b, 
WHO, 2015, UNAIDS, 2013b). HIVST can be safely delivered by trained volunteers, 
achieving high rates of HIV testing and re-testing, reaching hard-to-reach groups like 
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men, and achieves high rates of linkage into HIV treatment services amongst those 
testing HIV positive (Choko et al., 2011, Choko et al., 2015b, MacPherson et al., 
2014).  
 
Economic evaluation provides a rigorous approach to comparing the costs and 
consequences of alternative health technologies, with the evidence informing policy 
on how to best use limited resources (Drummond et al., 2005b). In resource-
constrained settings like Malawi this information can be extremely useful. There has 
been an increase in the number of economic evaluations in Africa (Creese et al., 
2002, Walker, 2003, Scotland et al., 2003b, Uthman et al., 2010, Galarraga et al., 
2009, Gomez et al., 2013, Sweeney et al., 2012, Johri and Ako-Arrey, 2011, Remme 
et al., 2014, Santa-Ana-Tellez et al., 2011), with development of guidelines for their 
undertaking (UNAIDS, 2011, WHO, 2003a). However, there are concerns about the 
methodologies used (Galarraga et al., 2009, Walensky et al., 2010a, Loubiere et al., 
2010, Uthman et al., 2010, Beck et al., 2010) and data used (Galarraga et al., 2009, 
Kahn et al., 2011, Creese et al., 2002, Beck et al., 2010, Meyer-Rath and Over, 2012). 
This has potentially hindered their use in informing policy making (Beck et al., 2010).    
 
The main objective of this PhD was to undertake a cost-utility analysis (CUA) from 
the health provider and societal perspective to estimate the incremental cost per 
quality-adjusted life year (QALY) when providing HIVST in addition to current 
approaches to providing facility-based HIV testing. Three observational studies were 
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conducted to collect primary cost and health-related quality of life data from HIV 
testers, individuals accessing HIV treatment and HIV positive individuals admitted to 
hospital for the management of HIV associated diseases. A decision-analytic 
modelling framework was used to undertake a CUA. Decision models were 
parameterised with the economic data collected and data extracted from the 
scientific literature.    
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9.2 Main findings of PhD 
The main finding from the PhD was that implementing HIVST is a cost-effective 
strategy in Blantyre, Malawi. The CUA estimated the incremental cost per QALY 
gained from implementing HIVST in addition to the current strategy of facility-based 
provision of HTC to be 2014 US$316.18 (2014 INT$502.36) and 2014 US$332.05 
(2014 INT$549.06) over a 20-year time horizon from the health provider and societal 
perspectives, respectively. When the decision was evaluated over a longer time 
horizon of 40 years, the incremental cost-effectiveness ratio (ICER) from the health 
provider perspective was 2014 US$151.81 per QALY gained. The World Health 
Organization (WHO) interprets interventions where the ICERs are below one times 
the gross domestic product (GDP) per capita to be very cost-effective and 
interventions below three times the GDP per capita to be cost-effective. The GDP per 
capita in Malawi is approximately US$250. Depending on the time horizon HIVST is 
cost-effective or very cost-effective. Additionally, taking into account the impact of 
increased coverage of HIV testing and HIV treatment amongst HIV-positive 
individuals through the implementation of HIVST will likely result in a lower ICER. 
This will result in implementation being more cost-effective that that found in this 
analysis.  
 
The sensitivity analysis found that implementing HIVST would still be considered 
cost-effective if the decision was considered over a shorter time horizon of 10 years, 
if the cost of a HIV self-test episode was higher, if there was lower rates of linkage 
into HIV treatment services after HIVST, if the HIV prevalence in the general 
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population offered HIVST or in those who self-tested was lower, and if future costs 
and health outcomes were undiscounted.  
 
Implementing HIVST will result in increased healthcare spending by Malawian 
healthcare providers. However, HIVST could be provided at a cost comparable to 
facility-based HTC (Chapter 5). The cost of per individual tested through HIVST was 
estimated to be approximately 2014 US$8.78, comparing favourably to facility-based 
HTC (2014 US$7.53 to US$10.57). In the sensitivity analysis undertaken in Chapter 8, 
I found that as the cost per HIVST episode was lowered by 25% and 50%, the 
probability of the intervention being very cost-effective (ICER<US$250 per QALY) 
improved from 0.09 to 0.220 and 0.496, respectively. The sensitivity analysis 
suggests that the cost of providing HIVST is an important driver of cost-effectiveness.    
 
One of the main consequences of providing HIVST is the increased numbers of HIV 
positive individuals entering HIV treatment services and therefore needing life-long 
anti-retroviral therapy (ART). In Chapter 6 I estimated that it costs approximately 
2014 US$27.28 to assess an individual for eligibility to initiate ART, and for those 
who start treatment, approximately 2014 US$166.20 per annum to provide care 
through a health facility. Over the next 20 years of implementing HIVST, there will be 
approximately 1.5-fold increase in the provision of ART (Chapter 8). The annual cost 
of providing ART is twenty times as much as the cost of an episode of HIV testing (in 
the model individuals were limited to one HIV test episode per annum). If the cost of 
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providing HIV treatment (including anti-retroviral drugs) were 25% lower, the 
probability the intervention would be considered very cost-effective would increase 
to 0.318 (Chapter 8). The findings highlight the impact the cost of providing HIV 
treatment on the cost-effectiveness of implementing HIVST.  
 
An interesting finding was the lower health provider cost per patient identified 
eligible for ART through HIVST when compared to facility-based HTC. However users 
of the two services may not be entirely comparable. Some facility-based HIV testers 
may have been seeking medical care for other medical reasons, related to 
progressive HIV disease, having been referred by the health provider for HIV testing 
under the umbrella of provider-initiated testing and counselling (PITC). Importantly, 
the health provider and societal cost of providing HIV treatment after initiating ART 
was not associated with the modality of HIV testing received. 
 
In the PhD I used the EuroQoL EQ-5D-3L measure to ask participants about their 
HRQoL. Those accessing HIVST reported better HRQoL than those accessing facility-
based HTC (Chapter 5); whilst amongst those who accessed HIV treatment those 
with more advanced HIV disease (measured by CD4 count) reported poorer HRQoL 
(Chapter 6). I found there was a significant relationship between utility scores and 
HIV disease stage, measured by CD4 count (Chapter 6). HIV positive individuals with 
lower CD4 counts had lower mean adjusted EQ-5D utility scores. For HIV positive 
individuals, utility scores increased after starting ART, with the majority of 
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participants recruited in the study reporting perfect health (EQ-5D utility score of 
1.0) after being on ART for one year. The findings highlight the beneficial impact of 
timely initiation of ART on an individual’s HRQoL and support the importance of 
taking into account HRQoL in economic evaluations. Individuals who started ART 
were also found to have a gradual improvement in their EQ-VAS scores (Chapter 6). 
The VAS score reflects self-reported HRQoL, with individuals rating their own health 
on a scale between zero and hundred. The findings suggest that individuals 
themselves report improvements in HRQoL once they start ART.  Importantly, I did 
not find that the EQ-5D utility scores amongst HIV positive individuals varied 
significantly either before or after starting ART according to the method of HIV 
testing used.   
 
A questionnaire was developed to ask participants about the direct non-medical 
costs they incurred and their loss of income as a consequence of accessing medical 
care. HIVST was found to be associated with lower direct non-medical and indirect 
costs than facility-based HTC (2014 US$2.93 lower), however, implementing HIVST 
increases the numbers of HIV positive individuals entering HIV treatments services. 
The total direct non-medical and indirect costs associated with a HIV positive 
individual accessing HIV treatment in the first year was approximately 2014 US$8.98. 
Thus the ICERs estimated from health and societal perspectives were similar.  
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The decision-analytic model shows the impact of implementing HIVST, reducing the 
risk of hospitalisations for HIV associated illnesses (Chapter 8). Many of these 
illnesses are seen exclusively (e.g. Cryptococcal meningitis, Pneumocystis 
Pneumonia) or predominantly (e.g. Tuberculosis) in those who are HIV positive. 
Approximately 70% of adults admitted to Queen Elizabeth Central hospital (QECH) 
are HIV positive (Chapter 7), with high mortality rates and poor HRQoL amongst 
hospitalised patients, and high health provider, direct non-medical and indirect costs 
of hospitalisation. Approximately one in five adults admitted to QECH for medical 
reasons died during their hospitalisation, the mean EQ-5D utility score amongst 
hospitalised patients was 0.484 and the mean total health provider cost was 2014 
US$314.92. By comparison, the mean EQ-5D utility score amongst those who started 
ART (Chapter 6) was 0.845 and the mean annual health provider cost of managing a 
HIV positive individuals in a primary health facility (including providing anti-retroviral 
drugs) was 2014 US$166.20.  
 
In September 2015, the WHO released a press statement advising immediate 
initiation of ART in all those infected with HIV. The Malawi Ministry of Health (MoH) 
is in the progress of reviewing these guidelines and planning to implement them in 
2016. In the CUA (Chapter 8) I investigated implementing HIVST in the context of 
earlier (CD4 falls below 500 cells/μl) and immediate initiation of ART. Earlier 
initiation of ART only providing facility-based HTC was extended dominated by 
earlier initiation of ART with the additional provision of HIVST. Extended dominance 
means that the ICER for earlier ART initiation with only facility-based HTC is higher 
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than for earlier initiation of ART with the provision of both facility-based HTC and 
HIVST, but the latter comes at greater cost. A move towards earlier initiation of ART, 
would provide better money for value if additionally implementing HIVST. Earlier 
initiation of ART would result in a further reduction in HIV incidence at the 
population level, improving the cost-effectiveness of implementing HIVST.  
 
The CUA suggests that in comparison to ART initiation when CD4 falls below 350 
cells/ul with the provision of only facility-based HTC, immediate ART initiation with 
the additional provision of HIVST would be a ‘cost-effective’ option for Malawi. The 
estimated ICER from the health provider perspective was US$345.85 per QALY 
gained.  
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9.3 Comparison to previous findings 
The findings from the PhD suggest that implementing HIVST would be a cost-
effective strategy in Malawi. A recent economic evaluation of HIVST in Zimbabwe 
found HIVST would be cost-effective, potentially cost saving (Cambiano et al., 2015). 
In addition, recent economic evaluations of home and mobile HIV testing, using 
finger-prick rapid HIV testing providing by HIV counsellors, would be a cost-effective 
strategy for South Africa (Bassett et al., 2014, Smith et al., 2015).   
 
The recent economic evaluation of HIVST in Zimbabwe investigated a range of 
hypothetical scenarios relating to the cost of implementing HIVST, uptake of HIVST, 
linkage into HIV treatment services, and ART eligibility criteria on the incremental 
cost-effectiveness on implementing HIVST (Cambiano et al., 2015).  The analysis was 
undertaken prior to availability of real-world outcome data relating to HIVST. 
Similarly to findings presented in this thesis, the cost of delivering HIVST was a major 
determinant of cost-effectiveness (Cambiano et al., 2015), although the authors 
found that implementing HIVST would be cost saving if it could be delivered at a cost 
of US$3, and only cost-effective at ICER thresholds above US$10,000 per DALY 
averted if the cost of providing each episode was above US$9 (their estimate of 
facility HTC was US$9/subject). In the analysis, ART was initiated once individuals 
CD4 count fell below 500 cells/μl and a transmission dynamic model was used 
undertake the modelling. This may in part explain the differences in the findings. 
Using a transmission model to undertake the cost-effectiveness analysis will capture 
additional health gains and cost savings through potential reductions in HIV 
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incidence. Initiating HIV-positive individuals earlier onto ART will reduce HIV 
transmission, and result in additional health gains and cost saving over time.    
 
In South Africa implementing mobile HTC, in addition to facility-based HTC, was 
associated with an ICER of 2012 US$2,400 per year of life saved (Bassett et al., 2014), 
whilst implementing home-based HTC (counsellor provided finger-prick HTC) was 
associated with an ICER of 2014 US$1090 per DALY averted (Smith et al., 2015). The 
higher estimates are likely to reflect the higher cost of goods in South Africa, and the 
fact HIV care is doctor-led.  The similar ICER estimates would suggest that 
community-based provision of HTC is cost-effective.  
 
The advantage HIVST offers is the lower cost of delivering HIV testing in the 
community. I estimated the cost of testing an individual through HIVST to be 
approximately 2014 US$8.78. This compares favourably to previous estimates of 
community-based HIV testing strategies (US$7.77 to US$33.54 in 2012 prices) that 
utilised standard finger-prick RDT kits (Chapter 3) (Suthar et al., 2013). In the 
previous economic evaluations of home-based and mobile HTC, the cost per 
individuals tested used in the model analysis was over US$20.  
 
In the CUA, I found the ICER for changing eligibility for ART initiation from  <=350 
cells/μl to <=500 cells/μl, with only provision of facility-based HTC, to be 
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approximately 2014 US$329.16 per QALY gained. Previous studies have estimated 
the ICER to be 2012 $273 to $1691 per DALY averted in South Africa, and 2012 $749 
per DALY averted in Zambia (Eaton et al., 2014). Additionally, I found the ICER for 
moving to immediate ART initiation, with only provision of facility-based HTC, to be 
approximately 2014 US$402.43 per QALY gained. Previous studies have estimated 
the ICER to range from 2012 US$170 per life year saved (Hontelez et al., 2013) to 
2013 US$408 per QALY gained (Alistar et al., 2014). The comparability of findings 
would suggest external validity in the ICERs estimated in the PhD.   
  
The cost of providing HIV treatment was an important determinant of cost-
effectiveness. I found that the yearly cost of providing anti-retroviral drugs and HIV 
care (US$166.20) was comparable with recent estimates in Malawi (US$136 in 2011 
prices), Kenya (US$230 to US$288 in 2009 prices), Zambia (US$198 to US$278 in 
2011 prices), Ethopia (US$186 to US$216 in 2011 prices), Rwanda (US$232 in 2011 
prices) and Lesotho (US$261 to US345 in 2010 prices) (Larson et al., 2013, Johns et 
al., 2014, Scott et al., 2014, Tagar et al., 2014, Bratt et al., 2011, Jouquet et al., 2011). 
In comparison to previous studies, I did not find the cost of providing HIV care, 
including anti-retroviral drugs, to be associated with the HIV disease stage of 
individuals when they entered care (Leisegang et al., 2009, Harling and Wood, 2007). 
This is likely because in estimating HIV treatment costs I only included the costs of 
medical resources used directly during an individual’s visit to the HIV clinic.  
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In the PhD I found the HRQoL was poorer amongst those with more advanced HIV 
disease and in those suffering from HIV-associated illnesses requiring hospital 
admission. Additionally I found HRQoL improved in HIV positive individuals who 
initiated anti-retroviral therapy. Like previous studies, I found HRQoL was poorer 
amongst those with more advanced HIV disease, and much of the improvement in 
HRQoL occurred in the first few months after starting ART (Pitt et al., 2009, Jelsma et 
al., 2005, Stangl et al., 2007, Beard et al., 2009). However, only a few studies 
undertaken in sub-Saharan Africa have used the EQ-5D tool to measure HRQoL in 
HIV infected individuals (Beard et al., 2009, Robberstad and Olsen, 2010, Bhargava 
and Booysen Fle, 2010, Gow et al., 2013), and even fewer have used the tool to 
investigate the impact of HIV associated illness (like Tuberculosis) (de Grass et al., 
2015). A potential barrier to the use of the EQ-5D tool in sub-Saharan Africa is the 
limited number of population tariff sets for countries in the region from which to 
derive EQ-5D utility scores. However, the EQ-5D tool has been found to demonstrate 
reliability, discriminative validity and responsiveness to change in HIV infected 
individuals, including after initiation of ART (Tran et al., 2012, Tran et al., 2015).  
 
In the PhD I found the direct non-medical and indirect costs associated with 
accessing HIV testing, HIV care and hospital care were high. Previous studies have 
highlighted the direct non-medical costs of accessing HIV care (Rosen et al., 2007, 
Bisson et al., 2006, Chimbindi et al., 2015), or that these costs are barriers to 
individuals accessing HIV services (Fox et al., 2010, Hardon et al., 2007, Tuller et al., 
2010, Zachariah et al., 2006). 
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9.4 Strengths and limitations of PhD 
In the PhD I undertook three observational studies to collect primary cost and 
HRQoL data relating HIV testing and HIV management. I undertook a CUA using 
decision-analytic modelling to estimate the incremental cost-effectiveness of 
implementing HIVST in addition to current facility-based provision of HTC. The 
research undertaken in the PhD has several strengths and limitations.  
 
The main strength of the PhD are that the research question was answered by 
undertaking a CUA, with the analysis undertaken from both the societal and health 
provider perspective, incorporating a wide range of costs and consequences from 
accessing the two different approaches to HIV testing, with the costs adjusted and 
presented to a common price year and currency, and the economic data 
prospectively collected and driven by the modelling needs (Drummond et al., 2005b, 
Briggs et al., 2008, Petrou and Gray, 2011b).  
 
A CUA offers a systematic approach to comparing the costs and consequences of 
implementing new health technologies, aiding policy decisions concerned with 
allocative efficiency (Drummond et al., 2005b). Measuring health outcomes in QALYs, 
allows consideration of the impact of implementing HIVST on both mortality and 
morbidity (Mehrez and Gafni, 1989, La Puma and Lawlor, 1990, Loomes and 
McKenzie, 1989, Weinstein et al., 2009).  
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I undertook decision-analytic modelling to investigate the cost-effectiveness of 
implementing HIVST. HIVST was being provided in Blantyre as part of a randomised 
controlled trial, and it might be considered a missed opportunity not to ‘piggy back’ 
an economic analysis onto the trial (Petrou and Gray, 2011a, Glick et al., 2014). 
However, in this instance, I consider this as one of the strengths of the PhD. The 
HitTB study was a cluster-randomised trial with the intervention provided over two 
years and follow-up assessed linkage into HIV treatment and mortality outcomes. 
Under this scenario I considered decision-analytic modelling unavoidable (Buxton et 
al., 1997). Decision-analytic modelling allowed me to consider all the cost 
implications and health outcomes of implementing HIVST at a population level, 
including long-term costs and consequences of accessing HIV treatment and impact 
on suffering HIV associated illnesses. The findings from the trial are yet to be 
published, and it is likely the cost-effectiveness findings from the PhD will be 
published around the same time, aiding timely dissemination for research and policy.  
 
The structure of the decision-analytic model was influenced by previous evaluations 
of HIV interventions (Chapter 4) and by clinical doctors working in HIV (Roberts et al., 
2012). The cost and HRQoL data were collected to meet the model requirements and 
not vice-versa (Caro et al., 2012). The studies undertaken in Chapters 5, 6 and 7 were 
designed and undertaken in such a way as to provide relevant cost and HRQoL data 
to parameterise the model, including recruiting participants who were residents of 
the HitTB study. The transition probabilities used in the model were obtained either 
from the HitTB study, or from undertaking targeted literature searches and fixed-
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effects meta-analysis to pool data (Caro et al., 2012). The model underwent standard 
validation checks, and probabilistic sensitivity analysis was undertaken to reflect the 
uncertainty in the estimates used to parameterise the model (Briggs et al., 2012b, 
Eddy et al., 2012). Sensitivity analysis was also undertaken to investigate the impact 
of using alternative model parameters on conclusions drawn, including implications 
of changes in costs of delivering HIVST and HIV treatment.   
 
The analysis was undertaken from the health provider and societal perspectives, 
thereby allowing consideration of the allocative efficiency of implementing HIVST at 
both the health provider and societal levels (Drummond et al., 2005b, Johannesson 
and O'Conor, 1997a). I undertook primary observational studies to estimate the 
direct health provider cost, and the direct non-medical and indirect costs. This 
provided estimates from both the health provider and societal perspectives for use 
in the CUA.  
 
In Chapter 5 I estimated the cost of providing HIVST in Africa, the first time this has 
been done. In Chapter 6 I estimated the costs of providing HIV care, including ART, to 
HIV positive individuals with findings comparable to previous estimates from Malawi 
and regionally (Tagar et al., 2014, Scott et al., 2014, Bikilla et al., 2009, Menzies et al., 
2012, Marseille et al., 2012). In Chapter 7 I estimated the costs of managing a range 
of health conditions in adults needing hospital admission, and used medical doctors 
to extract medical resource use data from the medical notes after discharge. In all 
 
 
404 
these three studies I prospectively collected healthcare use at the patient level, and 
undertook primary costing of the resources used to estimate the direct health 
provider costs. I followed international costing guidelines to cost the healthcare 
resources (UNAIDS, 2011), with the same methods used across all three 
observational studies. I interviewed key personnel at each of the healthcare 
organisations, and collecting the same categories of resource inputs (e.g. Staff 
salaries and training, consumables, equipment) (NICE, 2008). The use of a 
combination of a top-down and bottom-up costing methodology depending on the 
healthcare resource being costed, provided efficiency and accuracy (Beck et al., 
2012). Collecting prospectively at the patient level reduces the risk of bias.  
 
I followed standard guidelines for annuitization of equipment costs (WHO, 2003a), 
and presented costs in both US and International dollars and adjusted to a common 
price year (WHO, 2003a, Drummond et al., 2009, Drummond et al., 2005a). Providing 
estimates in both US and International dollars, as advocated by the WHO (WHO, 
2003a), aids interpretation of findings in Malawi and Internationally by taking into 
account differences in purchasing power parity between countries (Shemilt et al., 
2010).  
 
In order to estimate the direct non-medical and indirect costs, I developed and pilot 
tested data collection tools, and prospectively collected economic data from 
participants. The direct non-medical costs considered were adapted to the setting 
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and population interviewed (e.g. for hospitalised patients I additional considered 
costs incurred from overnight stay). The comparability in the methods, and items 
considered across the three studies provides rigour, and aides their use in the cost-
effectiveness analysis. Importantly, these costs have been considered important 
deterrents to accessing HIV care in Africa, but have rarely been fully quantified.  
 
In order to undertake the CUA I collected primary HRQoL data directly from 
participants exposed to the intervention. I used the Chichewa version of the EQ-5D 
tool that had undergone the EuroQol group’s translation and validation process 
(EuroQol, no date). As there was a lack of a Malawian tariff set to derive the EQ-5D 
utility scores, I used the Zimbabwean tariff set to derive the EQ-5D utility scores. This 
is a potential limitation, however, in the sensitivity analysis of all the studies 
(Chapters 5-8) I investigated the impact of using the UK tariff set to derive EQ-5D 
utility scores. The UK tariff set equates poor health states to lower EQ-5D utility 
scores than the Zimbabwean tariff. In the studies described in Chapter 5, 6 and 7 I 
found the EQ-5D utility scores lower but these did not impact on the multivariable 
analysis undertaken in the respective chapters. Additionally, using the UK tariff to 
derive EQ-5D utility scores for the cost-utility analysis did not impact on my final 
conclusion regarding the cost-effectiveness of implementing HIVST. I also showed 
that the EQ-5D tool seems to be performing well in this setting, correlating well with 
the VAS and responses to self-assessed health. 
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There are five important limitations of the cost-effectiveness analysis and modelling 
approach used. Firstly, I did not consider the impact of HIV transmission. Secondly, 
the model was parameterised by predominantly observational data. Thirdly, I did not 
consider the impact of individuals failing to suppress their HIV infection on anti-
retroviral drugs. Fourthly, I only considered the impact of HIV associated illnesses 
that required hospitalisations, and did not take into account the other illnesses that 
are managed in the community or at primary health clinics. Fifthly, I did not consider 
the impact of adverse drug reactions to ART. In the following text I interpret the 
potential implications of each of thee limitations.  
 
Implementing HIVST will potentially increase the proportion of HIV positive 
individuals on ART, increasing the proportion of HIV positive individuals whose HIV 
viral load is suppressed by the anti-retroviral drugs, reducing HIV incidence within 
the population (Tanser et al., 2013). This beneficial effect on HIV incidence will be 
greater through implementing HIVST. As fewer individuals will acquire HIV, there will 
be additional cost savings and reduced mortality and morbidity, potentially making 
HIVST more cost-effective than found in my analysis. I used an individual sampling 
model (ISM) to undertake the decision-analytic modeling. In previous analysis 
undertaken in HIV, researchers using ISM have either used a constant risk of HIV 
transmission/acquisition (Hallett et al., 2011) or not incorporated the impact on HIV 
transmission (Losina et al., 2009, Walensky et al., 2012, Walensky et al., 2009, 
Walensky et al., 2010b, Walensky et al., 2011, Goldie et al., 2006, Bendavid et al., 
2011, Bendavid et al., 2008, Gray et al., 2007b). An alterative modelling approach 
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that incorporates changes in HIV incidence over time would be through the use of 
transmission dynamic modelling or discrete event simulation (Barton et al., 2004). A 
disadvantage of using a transmission dynamic model would be that I would not have 
been able to model events based on individual level characteristics and keep the 
number of health states to a manageable quantity (Barton et al., 2004). Discrete 
event simulation would have allowed this, but with added computational burden. 
The primary model simulation took approximately twelve hours to run.  
 
Previous economic evaluations of community-based HIV testing strategies have used 
both transmission dynamic modelling (Cambiano et al., 2015, Smith et al., 2015) and 
individual sampling models (Bassett et al., 2014). However, they found that National 
guidelines determining the CD4 count threshold at which individuals were eligible for 
ART initiation which drove the beneficial impact on HIV incidence (Smith et al., 2015, 
Cambiano et al., 2015). HIV positive individuals not receiving ART are at highest risk 
of transmitting HIV to an uninfected sexual partner in the first six months to a year 
after they become infected, when their HIV viral load is high (Hollingsworth et al., 
2008, Powers et al., 2011a, Blaser et al., 2014). Increasing uptake of HIV testing and 
entry into HIV treatment through HIVST is unlikely to have major impact HIV 
incidence, and therefore cost-effectiveness, under current ART initiation threshold of 
CD4 count <=350 cells/μl. In the context of immediate initiation of ART in HIV 
infected individuals, there will potentially be a significant beneficial impact on HIV 
incidence (Granich et al., 2009).  
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The findings are also limited by the fact that the cost and HRQoL data used to 
parameterise the model were obtained from observational studies and therefore are 
potentially vulnerable to bias. In addition, some of the transition probabilities used 
in the decision-analytic model were also extracted from observational studies. In the 
studies undertaken in Chapters 5 and 6 I recruited a convenience sample of HIV 
testers and HIV positive individuals, respectively. There is a potential risk of selection 
bias, with recruited participants not representing the HitTB study population 
(Cochran, 2007). In the study undertaken in Chapter 7, I recruited one in five adults 
admitted to the medical wards at QECH, in addition to those who had a preliminary 
medical diagnosis of the rarer HIV associated illnesses I was interested in obtaining 
economic data to parameterise the model. Additionally there was considerable 
attrition from initial recruitment into the hospital cohort after hospital admission, to 
the medical data extraction stage in the study. These all could potentially bias the 
findings from each of the studies, and the final ICER estimate. In the studies in 
Chapters 5 and 6 I undertook multivariable analysis to adjust for individual-level 
characteristics, but the sample sizes in the study undertaken in Chapter 7 did not 
allow for this. I also represented the uncertainty in the parameter estimates by 
incorporating the standard errors of the estimated sample means in fitting the 
distributions, and took into account possible correlations (Briggs et al., 2008). 
Despite these procedures, there may still be potential biases in the final ICER 
estimates, and whether they result in the ICER being underestimated or 
overestimated is not predictable (Philips et al., 2004). 
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The findings are also limited by the fact that I did not consider the impact of 
individuals failing ART in the cost-effectiveness analysis. Individuals on ART are often 
monitored at regular intervals to detect whether the anti-retroviral drugs they are 
prescribed are suppressing their HIV viral load. If anti-retroviral drugs fail to suppress 
the HIV viral load their HIV disease will progress. This will increase their risk of HIV 
associated mortality and morbidity. Incorporating HIV viral load monitoring and 
switching anti-retroviral drug regimens if individuals fail therapy will increase the 
costs of providing HIV treatment. Individuals would require additional visits to the 
HIV clinic, second-line anti-retroviral drug regimens are more costly, and the cost of 
performing HIV viral load assessments is high (estimated to be US$26.96 in Chapter 
7). Consequently it is possible the ICER for implementing HIVST would be higher as 
this strategy would result in more individuals on ART, increasing the additional costs 
of providing HIV treatment. At the time of undertaking the analysis and collection of 
data in the primary observational study described in Chapter 6, the Malawi health 
service had not implemented routine monitoring of HIV viral load for patients on 
ART, and therefore primary healthcare resource use relating to monitoring ART 
failure was not possible. Additionally, a recent study that observed nearly 300,000 
Africans on ART, with over 780,000 person-years of follow-up, found that only 3% 
were switched onto a second-line anti-retroviral drug regime (Haas et al., 2015). 
Importantly, there is some evidence that suggests delayed ART initiation is 
associated with higher likelihood of failing first-line anti-retroviral drug regimes 
(Vanobberghen et al., 2015, Tran et al., 2014).  Implementing HIVST is likely to result 
in more timely ART initiation.  These issues would suggest the likely impact of 
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considering failure of ART would have been minimal, especially as most of the costs 
would be incurred in the future.  
 
The CUA did not consider the impact of implementing HIVST on the costs and 
consequences of suffering HIV associated illness that are managed in primary health 
clinics or in the community. Previous economic evaluations of HIV interventions have 
also predominantly focussed on HIV associated illnesses requiring hospitalisation 
without considering impact on other illnesses that do not require hospitalisation 
(Badri et al., 2006b, Bendavid et al., 2011, Goldie et al., 2006, Hamers et al., 2012, 
Walensky et al., 2011, Waters et al., 2011, Walensky et al., 2013). HIV positive 
individuals are at risk of a range of co-morbidities that require medical care, many of 
these do not require hospital admission.  Considering this issue in the economic 
analysis would potentially result in HIVST being more cost-effective. HIVST will 
increase the proportion of HIV positive individuals accessing HIV treatment and 
initiating ART, thereby reducing their risk of suffering from these co-morbidities and 
the cost of managing them.   
 
The findings are also limited by the fact that I did not consider the impact of adverse 
drug reactions to anti-retroviral drugs in the CUA. Individual’s prescribed anti-
retroviral drugs are at a significant risk of adverse drug reactions including 
lipodystrophy, peripheral neuropathy and liver damage (Eluwa et al., 2012, 
Subbaraman et al., 2007). These may potentially impact on the ART adherence and 
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HRQoL of those treated (Duval et al., 2004, Colebunders et al., 2005). In the CUA, I 
incorporated the beneficial impact of timely entry into HIV treatment through 
implementing HIVST. The negative impact of adverse drug reactions to ART will likely 
reduce the incremental cost-effectiveness of HIVST.   
 
Taken overall the summary effect of these limitations is difficult to gauge. However 
in many respects they are likely to underrepresent the cost-effectiveness of HIVST. In 
addition they give useful pointers for future research which could be undertaken in 
this area.  
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9.5 Policy implications 
The findings from the PhD imply that implementing HIVST in Malawi will be a cost-
effective, and potentially a very cost-effective strategy for the Ministry of Health. 
Policy makers in Malawi have already show a keen interest in HIVST, being one of 
the first countries in sub-Saharan Africa to investigate the legal and policy issues 
relating to the provision of HIV self-testing (SAT, 2015), and supporting several 
research studies in the area. The evidence from research studies highlights that 
HIVST can be delivered safely; users accurately learn their HIV status and there is a 
major impact on increasing population coverage of HIV testing and linkage into HIV 
services for those testing positive (Choko et al., 2011, Choko et al., 2015b, 
MacPherson et al., 2014, Pant Pai et al., 2013, Mavedzenge et al., 2015, Ngure et al., 
2014).  The findings from the PhD add to this growing evidence by highlighting that 
implementing HIVST is a cost-effective intervention in Malawi, with the cost of 
provision comparable to current facility-based HIV testing.   
 
In the PhD, I estimated the incremental cost per additional quality-adjusted life year 
gained from implementing HIVST in addition to facility-based HTC. In interpreting 
whether this strategy was cost-effective, I compared this estimate to thresholds 
commonly used to conclude cost-effectiveness in international health economics 
and policy (WHO, 2001, WHO, 2003a). However, this does not necessary imply the 
intervention offers the most efficient use of resources or that it should be 
implemented. Policy decisions will take into account other issues including whether 
implementation is equitable, affordable or feasible. An intervention that is cost-
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effective may not be equitable, as it may benefit certain individuals more than 
others.  An intervention that is cost-effective may not be affordable or feasible, as it 
may require financial, human or capital resources that may not be available in 
countries like Malawi. Interpretation of cost-effectiveness in resource-constrained 
settings may also be complicated by the lack of cost-effectiveness data for other 
interventions to make comparisons against. In addition, healthcare in countries like 
Malawi receives significant funding from external donors, often provided vertically 
for specific healthcare services, and therefore thresholds of cost-effectiveness may 
vary depending on the health service being considered. Policy makers will also need 
to consider these other issues when interpreting whether implementing HIVST is a 
cost-effective strategy.  
 
The World Health Organisation (WHO) and the United Nations Programme on 
HIV/AIDS (UNAIDS) both support the implementation of HIV self-testing in sub-
Saharan Africa (Johnson et al., 2014, WHO, 2015, UNAIDS, 2013b). The majority of 
countries in East and Southern Africa face comparable HIV disease burdens, poor 
uptake of HIV testing and sub-optimal population coverage of ART (UNAIDS, 2014b, 
UNAIDS, 2015). In the region, international and national policy makers are aiming to 
increase awareness of HIV status, ensuring that at least 90% of those HIV positive 
are aware of their infection, and 90% of HIV positive individuals are being treated 
with anti-retroviral therapy, potentially bringing an end to the HIV epidemic in the 
region by 2030 (UNAIDS, 2014a). HIVST offers a potential solution to achieving these 
goals, and the findings in the PhD (ICER: 2014 INT$549.06 per QALY gained) suggest 
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that HIVST would be potentially cost-effective in these other countries, especially as 
the majority have larger HIV budgets and stronger economies.   
 
HIV testing has been offered in health facilities for over a decade but uptake remains 
low (Staveteig et al., 2013). Community-based HIV testing strategies have been 
found to be popular and cost-effective but not widely implemented. They require 
trained healthcare professions, operating during standard working hours and 
extensive resources to transport equipment and consumables to the community in 
order to deliver the service (Suthar et al., 2013). HIVST offers a potential solution to 
increasing the feasibility of delivering community-based HIV testing. It can be 
delivered by trained volunteers, with users accessing the service at times that are 
convenient to them and delivered with minimal infrastructure and service delivery 
support. One of the main deterrents to accessing facility and community HIV testing 
services, especially by men, is the lack of privacy and confidentially offered an HIV 
testing process that requires another person to communicate the result. HIVST does 
not require this. Policy makers in the region will need to seriously take on board this 
issue and the potential solution HIVST offers if they are to increase uptake of HIV 
testing and re-testing.    
 
The cost of HIV self-test kits remains high in comparison to the rapid finger-prick test 
kits used in health facilities. Additionally, I found the price of delivering HIV self-
testing had an impact on its cost-effectiveness. Lowering the cost of HIVST kits would 
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also make implementation more affordable option for policy makers in the region. 
Over 100 million HIV tests are performed every year in Africa (WHO, 2011), the 
potential market for HIV self-test kits is large. Manufacturers of HIV self-test kits 
need to be aware that bringing easily useable and disposal kits into the market, at 
prices comparable to current finger-prick test kits, could have massive potential. 
Alternatively, International donors may need to consider subsidising the costs of HIV 
self-test kits or negotiating lower prices from manufactures through bulk 
procurement for low- and middle-income countries. If the cost of HIV self-test kits 
were 50% lower, the cost of delivering HIVST would fall to US$6.72 per individual 
tested. The cost-effectiveness of HIVST would improve, and the cost of 
implementing the service will increase substantially.  
 
Policy makers wishing to implement HIVST will need to be aware of the knock-on 
effects on HIV treatment services, with more individuals needing anti-retroviral 
therapy. Considering the financial implications of HIV testing without taking into 
account the impact on HIV treatment services would have grave consequences. 
Overcrowded, poorly functioning and poor quality HIV treatment services could in 
the long term have negative effects on individuals desire to learn their HIV status, 
since desire to learn one’s HIV status will be in part driven by awareness of HIV 
services available. Of more concern could be the negative consequences of poorly 
provided HIV treatment services that could potentially impact on adherence and 
response to ART, potentially resulting in increased numbers defaulting treatment 
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after initiation and therefore at increased risk of developing resistance to the few 
anti-retroviral drug regimens available in the region.  
 
Not all policy makers in sub-Saharan Africa support the provision of HIVST (Napierala 
Mavedzenge et al., 2011).  There are concerns that without healthcare professionals 
being directly involved in the counselling and consenting before offering HIV testing, 
some individuals, especially women, may be coerced into testing, or that individuals 
may test but not link into HIV treatment services (Napierala Mavedzenge et al., 2011, 
Walensky and Bassett, 2011). HIVST is a relatively novel technology, and healthcare 
providers are still learning how to implement the service in Africa. Further work is 
needed to consider these issues, and whether alternative service delivery models 
may reduce potential risks whilst still being cost-effective. It is likely that as 
healthcare professionals become more experienced with HIVST, and if less restricted 
distribution models with HIV counselling provided through alternative approaches 
(e.g. mobile telephones) prove safe and effective, the costs of providing HIVST could 
also be substantially lower. 
 
Awareness of HIV status is currently low in Malawi and in the other countries in the 
region. Implementing HIVST would increase awareness, but in the long-term would 
reduce the yield of HIV positives identified through an HIV self-testing service. As 
much of the benefit comes from detecting HIV positive individuals and timely entry 
into HIV treatment, the cost-effectiveness of HIVST will fall over time. Also over time 
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healthcare providers who implement HIVST will need to consider approaches to 
targeting their services to ensure that higher-risk and never previously tested 
individuals are reached.  
 
HIVST is not intended to replace facility-based HTC strategies. Facility-based HTC will 
continue to be an important route to offering HTC, primarily because health facilities 
are attended by sicker populations (e.g. TB patients) and pregnant women (Hensen 
et al., 2012), who require access to HTC. The need to undertake confirmatory HIV 
testing and to link individuals into HIV treatment and prevention services (Choko et 
al., 2015a, MacPherson et al., 2014) suggests the optimal role of HIVST is to detect 
HIV infection earlier and to bring individuals into treatment before they are affected 
by an HIV associated illness like Tuberculosis (UNAIDS, 2013b, WHO, 2013b). HIVST 
could also complement facility-based HTC by improving uptake of testing amongst 
health facility attendees or utilising them as a route for reaching higher risk 
individuals, both of which are poorly done at present (MacPherson et al., 2012b, 
Byamugisha et al., 2011). 
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9.6 Original contribution to research from PhD 
My PhD makes several important contributions to research. This is the first economic 
evaluation of HIVST undertaken in Malawi. In addition this is the first analysis of 
HIVST that uses real world health outcome and cost data. In the PhD I estimated the 
cost-effectiveness of implementing HIVST, undertook primary costing studies to 
estimate the real-world costs of providing HIVST and investigated the HRQoL of 
those who underwent HIV testing.   
 
My PhD involved the development of a Chichewa version of the EuroQol EQ-5D tool. 
Chichewa is the predominant language in Malawi, and the development of a 
language appropriate tool will allow further cost-utility analyses to be undertaken in 
the region. In addition, I estimated a catalogue of EQ-5D utility scores for individuals 
affected by HIV and other medical conditions for use in cost-utility analysis, 
something that is currently lacking.   
 
In the PhD I estimated the health provider costs of managing a range of health 
conditions in Queen Elizabeth Central hospital, Malawi. There has been no previous 
hospital costing study undertaken in the region. The estimates will be valuable for 
health economists wishing to undertake cost-effectiveness studies relating to a wide 
range of health conditions that result in hospital admission.  The cost estimates from 
the PhD and data collection tools developed to extract medical resource use have 
been and are being used in a range of economic evaluation in Malawi.  
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9.7 Recommendations for future research 
HIV self-testing is a new health technology globally and in sub-Saharan Africa. There 
is on going research in Malawi, which I am involved in, and in sub-Saharan Africa 
investigating alternative models of delivering HIVST, targeting specific populations 
(e.g. sex workers, sexual partners of antenatal clinic attendees) or exploring 
alternative approaches to increasing linkage into HIV treatment (e.g. financial 
incentives). These models could potentially deliver HIVST at lower costs, more 
effectively reach HIV positive individuals who are not aware of their HIV status, be 
associated with higher rates of linkage into HIV treatment services, or offer linkage 
into HIV prevention services (e.g. voluntary male medical circumcision) amongst 
those who test HIV negative. These alternative models will need to undergo cost-
effectiveness analysis, and in some scenarios, will need to be compared to the HIVST 
delivery model evaluated in this PhD.  
 
The majority of the HIVST research has been undertaken in Malawi, and further 
research is needed in other African countries. There are concerns regarding 
generalising the cost-effectiveness findings from one country to another (Drummond 
et al., 2009). Countries in East and Southern Africa have been most affected by the 
HIV epidemic and face comparable disease burdens. HIV services in the region, with 
the exception of South Africa, are delivered in comparable approaches and face 
similar financial and human resource constraints to those which Malawi faces. 
However, the populations may differ in their willingness to access HIVST, link into 
HIV treatment and prevention services or in the costs of delivering services. In 
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addition, policy makers may have differing willingness to pay thresholds for gains in 
health. Economic evaluations, along with research into effectiveness and impact on 
social harms, of HIVST may be needed in other countries in the region to better 
inform policy makers on the implications of implementing HIVST in their country.  
 
Primary costing studies are often a necessity in resource-poor settings. National 
healthcare providers in sub-Saharan Africa often do not have the resources to 
undertake costing studies or the financial systems in place to provide cost estimates 
for policy making or researchers looking at undertaking economic evaluations. The 
WHO provides cost estimates for a range of healthcare resource use inputs from 
which economic evaluations can be performed (WHO-CHOICE). However, healthcare 
services are continually changing and newer health technologies are becoming 
increasingly available in the region. UNAIDS provides costing guidelines to assist 
researchers planning to cost HIV services (UNAIDS, 2011). In the PhD I estimated the 
unit costs for a range of healthcare resources, but further research is needed to 
estimate other health resources and to be done in different healthcare and country 
settings. This will allow further consideration of developing cost databases that could 
potentially be updated at regular intervals. Importantly, costing health resources 
requires further research to investigate whether services are being provided 
efficiently. A range of research methods is available to investigate the cost efficiency 
of healthcare provision, investigating the links between resource inputs and 
healthcare outputs. These will also have added value in provision of health services. 
For example in the studies undertaken in the PhD I make the assumption that 
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services are being provided in the most efficient manner. However, it is possible 
there may be financial gains for healthcare providers from economies of scale and 
scope. The next 10 years will see a large increase in the numbers of HIV positive 
individuals on anti-retroviral therapy, and the number of individuals who will have 
been on treatment for several years. Further research is needed to investigate how 
to provide these services at either lower cost or at higher quality. This may positively 
impact on the cost-effectiveness of implementing HIVST.  
 
Health interventions should aim to tackle mortality and improve quality of life. There 
are increasing resources available to measure and monitor quality of life outcomes. 
The EQ-5D tool is one such measure and is one of the more widely used tools in the 
region. It has already been translated and approved by the EuroQol group for use in 
over 5 African languages. However its use in economic evaluations in the region is 
still limited. One reason is the lack of population tariff sets from which to derive EQ-
5D utility scores from responses given by individuals to the descriptive component of 
the tool. A local population tariff set has the advantage that it reflects the 
preferences of the population who will ultimately benefit from the decisions 
regarding what health services to implement. There is no current Malawian 
population tariff set and undertaking research to develop one is a research priority. 
Importantly, it may encourage health economists and grant funders to increase the 
number of economic evaluations that are performed in the country. Additionally 
having additional tariff sets for countries in the region will allow investigation of 
whether populations in the region value health outcomes in similar ways. If so, it 
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might suggest that a regional tariff, or the use a tariff set performed in another 
country would be fit for use in a country that lacks a tariff set (Norman et al., 2009).  
 
The realisation that there is a link between individual treatment and population 
transmission risks (Tanser et al., 2013) and that link depends on the strategy 
employed at the individual-level (Granich et al., 2009) necessitates further 
examination of optimal modelling approaches to incorporate both the individual and 
population consequences of different strategies.  Dynamic transmission models will 
often show that interventions are more cost-effective when targeting communicable 
diseases than static models. This is mainly because dynamic models represent the 
impact on reduction of future infections more thoroughly (Jit and Brisson, 2011). 
They will capture the additional health gains and cost savings through reductions in 
the future incidence of the infection. In sub-Saharan Africa where resources are 
especially limited, representing this reduction of future infections is essential to aid 
optimal use of resources. The management of HIV in sub-Saharan Africa has entered 
a new phase with optimism surrounding the potential role of anti-retroviral drugs to 
treat individuals, and to prevent transmission (Cohen et al., 2011). In order to 
provide policy makers with robust estimates of an increasing number of potential 
strategies HIV cost-effectiveness modelling approaches need to incorporate all 
possible recent evidence on costs and consequences of these different interventions.   
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9.8 Reflection of research training during PhD 
The PhD allowed me to develop a range of research skills including experience in 
undertaking public health and health economics research in resource-poor settings, 
managing a research team consisting of nine personnel, and further developing my 
research skills in writing, oral presentation, econometrics and decision-analytic 
modelling.  
 
During the PhD I managed a team of nine Malawian staff for two years. They were 
responsible for recruitment and follow-up of research participants, including 
interviewing participants to complete data collection tools. I gained experience in 
training and managing research personnel. In addition, I developed and piloted a 
range of data collection tools (shown in Appendix).  An important lesson I learned 
was that I could have undertaken the research at lower cost and more efficiently. 
The significant proportion of the data collected had little value in answering the 
objectives of the PhD. In addition I could have undertaken the study with fewer 
research personnel.     
 
One of the most important lessons learned during the PhD was the need to be 
adaptive. The hospital cohort study presented in Chapter 7 of the PhD was not part 
of the original PhD research objectives. Initially I had planned to collect hospital 
resource use data from the HIV treatment cohort (Chapter 6) but the small sample 
sizes meant there would be too few occurrences of these events to obtain 
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meaningful data. Additionally, non-medical personnel asking participants detailed 
questions about their hospital admission was not found reliable. The hospital cohort 
study was developed to resolve these two issues, and resulted in more precise 
estimates of hospital care.  
 
An important lesson learned about undertaking research in resource-poor settings 
related to the difficulty of following up participants in the community.  The HIV 
treatment cohort (described in Chapter 6) was recruited at the primary health clinics 
and seen on each visit to the clinic. Of those who started ART, 33% were lost to 
follow-up and 7% had their care transferred to another clinic. In the study I recorded 
a number of contact details for participants, and made three attempts to contact 
them. The high attrition rate for community-based studies in Malawi is unavoidable 
because the population are mobile, often for employment and unemployment 
reasons. In retrospect I probably would have recruited a larger sample for the study 
to ensure more individuals had at least one year of follow-up on ART.   
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9.9 Conclusion 
In conclusion I found implementing HIV self-testing in Malawi is a cost-effective 
strategy, supporting other research showing it to be an effective approach to 
increasing uptake of HIV testing and timely entry into HIV care. I found HIVST to be 
delivered at comparable cost to facility-based HTC. I estimated the costs of providing 
HIV treatment and found that overall there were no differences between those who 
had previously accessed HIVST and those who had accessed facility-based HTC. I 
found that individuals with advanced HIV disease report poorer quality of life, and 
that individuals improve once they start anti-retroviral therapy. I also demonstrate 
the high costs of providing hospital care and the poor quality of life in HIV positive 
individuals suffering HIV associated illnesses. The cost-effectiveness findings of the 
PhD provide valuable information to policy makers in Malawi, and potentially in sub-
Saharan Africa, on the value of implementing HIVST, and indicate a number of areas 
for on-going research.  
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WHO Clinical Staging, 2007 
 
CDC 
Clinical Stage 1 
-Asymptomatic 
-Persistent generalized lymphadenopathy 
    + 
Either 
-CD4+ T-lymphocyte count of >500 cells/µL  
-CD4+ T-lymphocyte % of total lymphocytes of >29 
Category A 
-Asymptomatic 
-Acute HIV 
-Persistent Generalised Lymphadenopathy 
Clinical Stage 2 
-Moderate unexplained weight loss (<10% of body weight) 
-Recurrent respiratory infections  
-Herpes zoster 
-Angular cheilitis 
-Recurrent oral ulceration 
-Papular pruritic eruptions 
-Seborrheic dermatitis 
-Fungal nail infections 
    + 
Either 
-CD4+ T-lymphocyte count of 200--499 cells/µL  
-CD4+ T-lymphocyte % of total lymphocytes of 14--28. 
Category B 
-Bacillary angiomatosis 
-Oropharyngeal candidiasis  
-Vulvovaginal candidiasis, persistent or resistant 
-Pelvic inflammatory disease (PID) 
-Cervical dysplasia/cervical carcinoma in situ 
-Hairy leukoplakia, oral 
-Herpes zoster involving two or more episodes or at least 
one dermatome 
-Idiopathic thrombocytopenic purpura 
-Constitutional symptoms, such as fever (>38.5ºC) or 
diarrhea lasting >1 month 
-Peripheral neuropathy 
Clinical Stage 3 
-Unexplained severe weight loss (>10% of body weight) 
-Unexplained chronic diarrhea for >1 month 
-Unexplained persistent fever for >1 month  
-Persistent oral candidiasis (thrush) 
-Oral hairy leukoplakia 
-Pulmonary tuberculosis (current) 
-Severe presumed bacterial infections  
-Acute necrotizing ulcerative stomatitis, gingivitis, periodontitis 
-Unexplained anemia 
-Neutropenia  
-Chronic thrombocytopenia 
Category C 
-Bacterial pneumonia, recurrent 
-Candidiasis of the bronchi, trachea, or lungs 
-Candidiasis, esophageal 
-Cervical carcinoma, invasive, confirmed by biopsy 
-Coccidioidomycosis, disseminated or extrapulmonary 
Cryptococcosis, extrapulmonary 
-Cryptosporidiosis, chronic intestinal (>1 month in duration) 
-Cytomegalovirus disease (other than liver, spleen, or 
nodes) 
-Encephalopathy, HIV-related 
-Herpes simplex: chronic ulcers (>1 month in duration), or 
bronchitis, pneumonitis, or esophagitis 
-Histoplasmosis, disseminated or extrapulmonary 
-Isosporiasis, chronic intestinal (>1-month in duration) 
-Kaposi sarcoma 
-Lymphoma, Burkitt, immunoblastic, or primary central 
nervous system 
-Mycobacterium avium complex (MAC) or Mycobacterium 
kansasii, disseminated or extrapulmonary 
-Mycobacterium tuberculosis, pulmonary or extrapulmonary 
-Mycobacterium, other species or unidentified species, 
disseminated or extrapulmonary 
-Pneumocystis jiroveci (formerly carinii) pneumonia (PCP) 
-Progressive multifocal leukoencephalopathy (PML) 
-Salmonella septicemia, recurrent (nontyphoid) 
Toxoplasmosis of brain 
-Wasting syndrome 
 
Clinical Stage 4 
-HIV wasting syndrome 
-Pneumocystis pneumonia 
-Recurrent severe bacterial pneumonia 
-Chronic herpes simplex infection 
-Esophageal candidiasis  
-Extrapulmonary tuberculosis 
-Kaposi sarcoma 
-Cytomegalovirus infection  
-Central nervous system toxoplasmosis 
-HIV encephalopathy 
-Cryptococcosis, extrapulmonary (including meningitis) 
-Disseminated nontuberculosis mycobacteria infection 
-Progressive multifocal leukoencephalopathy 
-Candida of the trachea, bronchi, or lungs 
-Chronic cryptosporidiosis (with diarrhea) 
-Disseminated mycosis 
-Recurrent nontyphoidal Salmonella bacteremia 
-Lymphoma (cerebral or B-cell non-Hodgkin) 
-Invasive cervical carcinoma 
-Atypical disseminated leishmaniasis 
-Symptomatic HIV-associated nephropathy 
-Symptomatic HIV-associated cardiomyopathy 
-Reactivation of American trypanosomiasis 
 
OR 
CD4+ T-lymphocyte count of <200 cells/µL   
 
OR 
CD4+ T-lymphocyte percentage of total lymphocytes of <14 
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Abstract
Background
Home-based HIV testing and counselling (HTC) achieves high uptake, but is difficult and
expensive to implement and sustain. We investigated a novel alternative based on HIV self-
testing (HIVST). The aim was to evaluate the uptake of testing, accuracy, linkage into care,
and health outcomes when highly convenient and flexible but supported access to HIVST
kits was provided to a well-defined and closely monitored population.
Methods and Findings
Following enumeration of 14 neighbourhoods in urban Blantyre, Malawi, trained resident
volunteer-counsellors offered oral HIVST kits (OraQuick ADVANCE Rapid HIV-1/2 Anti-
body Test) to adult (!16 y old) residents (n = 16,660) and reported community events, with
all deaths investigated by verbal autopsy. Written and demonstrated instructions, pre- and
post-test counselling, and facilitated HIV care assessment were provided, with a request to
return kits and a self-completed questionnaire. Accuracy, residency, and a study-imposed
requirement to limit HIVST to one test per year were monitored by home visits in a system-
atic quality assurance (QA) sample.
Overall, 14,004 (crude uptake 83.8%, revised to 76.5% to account for population turn-
over) residents self-tested during months 1–12, with adolescents (16–19 y) most likely to
test. 10,614/14,004 (75.8%) participants shared results with volunteer-counsellors. Of
1,257 (11.8%) HIV-positive participants, 26.0% were already on antiretroviral therapy, and
524 (linkage 56.3%) newly accessed care with a median CD4 count of 250 cells/μl
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(interquartile range 159–426). HIVST uptake in months 13–24 was more rapid (70.9%
uptake by 6 mo), with fewer (7.3%, 95% CI 6.8%–7.8%) positive participants. Being “forced
to test”, usually by a main partner, was reported by 2.9% (95% CI 2.6%–3.2%) of 10,017
questionnaire respondents in months 1–12, but satisfaction with HIVST (94.4%) remained
high. No HIVST-related partner violence or suicides were reported. HIVST and repeat HTC
results agreed in 1,639/1,649 systematically selected (1 in 20) QA participants (99.4%), giv-
ing a sensitivity of 93.6% (95% CI 88.2%–97.0%) and a specificity of 99.9% (95% CI
99.6%–100%). Key limitations included use of aggregate data to report uptake of HIVST
and being unable to adjust for population turnover.
Conclusions
Community-based HIVST achieved high coverage in two successive years and was safe,
accurate, and acceptable. Proactive HIVST strategies, supported and monitored by com-
munities, could substantially complement existing approaches to providing early HIV diag-
nosis and periodic repeat testing to adolescents and adults in high-HIV settings.
Introduction
Sub-Saharan Africa is still disproportionately affected by the HIV epidemic, accounting for
71% (24.7 million) of people living with HIV globally; in 2013, 71% of the 2.1 million global
new infections, and 73% of the 1.5 million HIV-related deaths, occurred in the region [1].
Despite major investments in HIV testing, treatment, and prevention programmes, only one-
quarter of adult Africans have had a recent HIV test, and half of people living with HIV in sub-
Saharan Africa do not know they are HIV positive [1–3].
Barriers to HIV testing and counselling (HTC) and initiation of antiretroviral therapy
(ART) include overly busy health facilities, concerns about lack of confidentiality and privacy,
and high out-of-pocket costs [4–6]. Community-based HTC approaches, including home-
based and mobile services, can overcome some of these problems, achieving high population
uptake of HTC [7–10]. Compared to facility-based approaches, community-based HTC pro-
vides earlier HIV diagnosis and increases uptake of couples testing [4,5]. Nevertheless, evalua-
tion of community-based HTC and HIV services has raised concerns about cost and
sustainability [11,12], especially for delivering services to more rural settings [12,13]. For
example, despite community-based HTC being national policy in Malawi and Zimbabwe,
only 2% of Malawians and 4% of Zimbabweans in 2010 were reached by mobile or door-to-
door services [3].
HIV self-testing (HIVST), defined as an individual performing and interpreting his/her own
HIV test [14], has the potential to be implemented at a wide scale with a minimal requirement
for trained health-workers. As such, HIVST could improve population coverage of regular
HTC, recognised as being a critical component of all strategies to further intensify HIV preven-
tion and care in countries with generalised HIV epidemics. We have previously demonstrated
very high uptake and accuracy of HIVST in a small feasibility study [7]. However, critical, unan-
swered questions that need to be addressed before considering large-scale interventions based
on HIVST include the following: what levels of HIVST uptake and accuracy can be achieved
with population-wide implementation, and do safety concerns, including the potential for coer-
cive testing, suicide, and gender-based violence, preclude implementation [15–17]?
Community-Based HIV Self-Testing and Linkage into Care in Malawi
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We, therefore, investigated the uptake, accuracy, and outcomes of implementation of com-
munity-wide HIVST delivered by trained resident volunteer-counsellors in Blantyre, Malawi
[18]. A delivery system based on service provision from the houses of volunteer-counsellors
was designed. The aim was to evaluate uptake, accuracy, linkage into care, and health outcomes
when highly convenient and flexible but supported access to HIVST kits was provided to a
well-defined and closely monitored population. HIVST services were flexibly provided, with
facilitated access to HIV care for those willing to share positive results. Participants could opt
for support ranging from standard provider-conducted HTC to HIVST at home either in com-
plete privacy or assisted by an attendant volunteer-counsellor.
Methods
Ethical Statement
Ethical approval was obtained from the College of Medicine Ethics Review Committee, Univer-
sity of Malawi; London School of Hygiene & Tropical Medicine; and Liverpool School of Trop-
ical Medicine. All participants opting for HIVST provided written (or witnessed thumbprint)
informed consent.
Study Design
This study was a prospective study nested within a cluster-randomised trial
(ISRCTN02004005) comparing health outcomes between 14 clusters randomised to HIVST
and 14 clusters randomised to routine (facility-based) HTC [18]. The data reported here relate
only to the 14 clusters where HIVST was provided. HIVST was provided for a 2-y period in
any given cluster, starting between February and May 2012; active surveillance for harms con-
tinued for 4–6 mo after the 2-y HIVST period.
Study Setting and Study Population
The study took place in three high-density informal residential settlements in urban Blantyre, as
described elsewhere [10,18]. In brief, neighbourhood clusters were defined on the basis of exist-
ing community health worker catchment areas and enumerated between April and June 2011.
In clusters randomised to the intervention arm, community-based HIVST was available for all
adults (!16 y). Services were provided by two resident volunteer-counsellors in each cluster of
~1,200 adults; the volunteer-counsellors were identified using participatory methods [19] and
were paid a monthly stipend similar to that of Malawi Ministry of Health community health
workers. Volunteer-counsellors received Malawi Ministry of Health HTC training and study-
specific HIVST and protocol training. Targets within each cluster were to reach>80% of adult
residents each year through promoting HIVST door to door and leafleting. Participants could
opt to test at home, with or without the volunteer-counsellor present to provide help as needed.
HIV Self-Testing Kit Provision
Participants (individuals or couples) received pre-test counselling, received instructions on per-
forming HIVST, and were asked to demonstrate understanding using a cotton bud and vial of
water in place of the kit itself. An anonymous self-completed questionnaire (SCQ) was provided
with an opaque envelope for return of the used kit and SCQ, either to the volunteer-counsellor
or into a locked “ballot” box kept at the volunteer-counsellor’s house (S1 Questionnaire). The
test kit used was OraQuick ADVANCE Rapid HIV-1/2 Antibody Test (OraSure Technologies).
User instructions were modified and included pictures. The ten-item SCQ included questions
about the self-read HIVST result, satisfaction indicators, and the results of the individual’s most
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recent previous HIV test, if applicable. The question “If you were forced to test, who forced
you?” was used to define coercion. Residents were asked to limit HIVST to one test in each
12-mo time period. Post-test counselling was recommended, but not required. All participants
received a “self-referral card” allowing them to directly access one of two study clinics, but were
encouraged to share results with their resident volunteer-counsellor for standard results-based
post-test counselling and referral. A modified counselling protocol (including written informa-
tion on all local HIV care options) was used for participants unwilling to share their results.
Within seven of the 14 study clusters, a second cluster-randomised controlled trial was con-
ducted that investigated the effect of optional home-based initiation of HIV care (ART eligibil-
ity assessment and 2 wk of treatment including ART if indicated) on uptake of ART [10]. This
intervention was extended to all 14 HIVST clusters from January 2013 onwards.
At health facilities, a study nurse provided confirmatory HIV testing (Determine HIV-1/2,
Alere; and Uni-Gold Recombigen HIV, Trinity Biotech), CD4 count measurement (Cyflow SL-
3 platform, Partec), tuberculosis screening (with isoniazid preventive therapy for those eligible
[20]), WHO clinical staging, and cotrimoxazole. Participants who met national ART eligibility
criteria (CD4 count< 350 cells/μl or WHO stage 3 or 4 or breastfeeding or pregnant) were reg-
istered for ART.
Ascertainment of Outcomes
Volunteer-counsellors recorded each individual/couple with nature of support provided for the
test, age, and sex of the individual(s), and whether they had tested before. Estimates of linkage
into care were based on the number of participants who disclosed positive results to counsellors
during the first 12 mo compared to the number of participants accessing study clinic confirma-
tory testing and HIV care over the same time period. Confirmation of participation in the
study was based on presentation of the self-referral card.
Recording Social Harms
In each cluster, four community members (key informants) provided weekly reports of all
deaths and any known episodes of intimate partner violence. Study nurses conducted verbal
autopsies for all reported deaths, including temporal relatedness to HIVST.
Quality Assurance
A systematic sample of HIVST participants was selected for home visit by study nurses, aiming
for minimum 5% coverage. Nurses selected from participants tested in the previous week using
counsellors’ HIVST logs that recorded one participant or couple per row, with 20 rows per
page. A random number between 1 and 20 was generated on a weekly basis and provided to
nurses on the day of use. Nurses selected the corresponding row number (e.g., each row 11 par-
ticipant if the number 11 had been supplied that week). If the selected number exceeded the
number of participants on any given page, then the nurses continued counting out from row 1
of the same page until that week’s number was reached. Checks during the home visit included
age, confirmation of residency, whether or not HIVST kits had been used, and self-read result,
with offer of confirmatory testing (finger-prick blood parallel testing with Determine HIV-1/2
and Uni-Gold Recombigen HIV).
Statistical Analysis and Sample Size
Stata version 13.0 (StataCorp) and R version 2.15.3 (R Foundation for Statistical Computing)
were used for analyses. The sample size for the parent cluster-randomised trial was determined
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by the primary outcome (cluster-level tuberculosis case notification rates) and not by HIVST
uptake or linkage. Of note, however, primary outcome assumptions were that population
uptake of HIVST would be!70% per year [7,8], with!80% linkage into HIV care [21] and
HIVST accuracy of!90% [7].
The proportion of residents accepting HIVST was estimated both overall and within sex,
age, and neighbourhood strata, using population denominators from the study census (i.e.,
proportions were calculated using a fixed denominator that was determined before the start of
the study, rather than as cumulative incidence, which would have required individual cohort
follow-up for all residents) conducted in the year preceding the rollout of the intervention.
Since crude uptake in some sex-age-neighbourhood subgroups exceeded the population
denominators from the study census, the number of residents accepting HIVST within any sin-
gle sex-age-neighbourhood subgroup was capped at the census denominator for that subgroup
to provide an adjusted uptake.
The first estimate of linkage into care was calculated with the number of participants who
presented at a study clinic with a volunteer-counsellor-provided self-referral card as the
numerator and the number of participants who disclosed a positive HIV result to the volun-
teer-counsellor as the denominator. The second estimate was calculated after adjusting for a
proportion assumed to be already aware of their positive HIV status and in care.
Participant characteristics in months 1–12 and months 13–24 were compared using design-
based F-tests calculated by applying the second-order Rao and Scott correction [22,23] to the
usual Pearson chi-squared test statistic for two-way tables to allow for the clustered sampling
design. The accuracy of self-reported HIVST results in quality assurance (QA) participants was
assessed using finger-prick rapid diagnostic test results to calculate sensitivity, specificity, and
exact binomial 95% confidence intervals. Univariate and multivariate random effects logistic
regression models accounting for clustering at the neighbourhood level were fitted in order to
obtain odds ratios (ORs) and 95% CIs for associations between prespecified exposures of inter-
est (age, sex, previous testing, testing alone/with partner, self-read HIVST result) and reported
coercion. A substantial proportion of SCQ participants had missing data for at least one of the
exposures of interest. Comparison of characteristics of participants with and without complete
data showed no significant differences, and, therefore, findings from complete case analysis are
presented [24]. Sensitivity analysis was undertaken using multiple imputation methods to han-
dle missing data.
Results
Uptake of HIVST
In 2011, 16,660 adults (16 y or older) were enumerated in the 14 HIVST clusters. During
months 1–12 and months 13–24, a total of 14,004 (84.1%) and 13,785 (82.7%) participants
accessed the HIVST service, respectively (Figs 1 and 2). Compared to months 1–12, the second
year saw higher proportions of men (46.1% versus 43.8%; p = 0.057), adolescents (24.7% versus
22.2%; p< 0.001), participants with a sexual partner (59.3% versus 37.5%; p< 0.001), and par-
ticipants who had tested for HIV ever (82.2% versus 64.9%, and for testing within the last 12
mo, 61.2% versus 27.3%; p< 0.001 for both) (Table 1).
The estimated uptake of HIVST, based on study census denominators, was 84.1% and
82.7% in months 1–12 and months 13–24, respectively. Crude uptake in some age-sex-neigh-
bourhood subgroups (notably among adolescent women [aged 16–19 y]) exceeded population
denominators from the census conducted in the year preceding the study (Table 2). Capping
uptake in any single age-sex-neighbourhood subgroup at 100% led to revised uptake estimates
of 76.5% and 74.4% in months 1–12 and months 13–24, respectively. With both approaches,
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there was significantly higher uptake each year amongst women than men, and for progres-
sively younger age groups (p< 0.001 for both).
The time course of HIVST uptake within each annual period for which HIVST was
restricted to a single test per person (Methods and QA results) is shown by time point, sex, and
age group in Fig 3. In comparison to months 1–12, uptake during the second year of availability
was more rapid, with a higher proportion accessing services soon after they became available
(Fig 3), notably so for adolescents (aged 16–19 y).
Fig 1. Flow of study participants in months 1–12 of HIV self-testing.
doi:10.1371/journal.pmed.1001873.g001
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HIV Prevalence in HIVST Participants and Linkage into Care
In the first year of HIVST, HIV prevalence in participants sharing results with volunteer-coun-
sellors was 11.8% (95% CI 11.2%–12.5%), similar to the estimate from the rereading of
returned kits (10.1%, 95% CI 9.6%–10.7%) (Fig 1). These estimates, however, were substantially
higher than the respective figures from months 13–24, which were 6.8% (95% CI 6.3%–7.2%)
and 7.3% (95% CI 6.8%–7.8%). HIV prevalence among self-testing participants (shown sepa-
rately for men and women in Fig 4) was highest in the age group 40–49 y, with a pooled
Fig 2. Flow of study participants in months 13–24 of HIV self-testing.
doi:10.1371/journal.pmed.1001873.g002
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prevalence of 22.5% (95% CI 19.4%–25.8%) in months 1–12; the pooled rate in participants
aged 16–19 y (2.5%, 95% CI 1.9%–3.2%) was much lower.
In total, 75.8% (95% CI 75.1%–76.5%; 10,614/14,004) of participants who underwent
HIVST in months 1–12 reported their result to a volunteer-counsellor, with 1,257 (11.8%, 95%
CI 11.2%–12.5%) reporting a positive result. During this same time period, 524 participants
presented for HIV care, with all presenting cards identifying them as having been directly
Table 1. Characteristics of HIV self-testing participants in the first and second years of HIV self-testing availability.
Characteristic Uptake of HIVST p-Value1
Month 1–12(n = 14,004) Month 13–24(n = 13,785)
n Percent n Percent
Sex
Male 6,124 43.8 6,339 46.1 0.057
Female 7,868 56.2 7,415 53.9
Age group
<20 y 3,107 22.2 3,399 24.7 <0.001
20–29 y 6,375 45.6 6,381 46.3
30–39 y 2,995 21.4 2,806 20.4
40–49 y 897 6.4 730 5.3
!50 y 597 4.3 431 3.1
Able to read and write?
No 742 5.3 366 2.7 0.002
Yes 13,124 94.7 13,090 97.3
Ever previously tested for HIV?
No 4,893 35.1 2,427 17.8 <0.001
Yes 9,040 64.9 11,205 82.2
Tested for HIV in last 12 mo?
No 10,034 72.7 5,217 38.8 <0.001
Yes 3,771 27.3 8,227 61.2
Ever self-tested for HIV before?
No 13,509 97.9 7,508 55.9 <0.001
Yes 290 2.1 5,931 44.1
Tuberculosis symptoms?2
No 13,301 96.8 13,357 98.7 <0.001
Yes 434 3.2 178 1.3
Who initiated testing?3
Client 5,405 38.8 3,163 23.1 0.075
Counsellor 8,543 61.2 10,506 76.9
Have a sexual partner?
No 6,826 62.5 3,520 40.7 <0.001
Yes 4,098 37.5 5,128 59.3
1p-Value from design-based F-test allowing for clustering by neighbourhood of residence.
2Having any of the following: cough of any duration, fever, night sweats, or weight loss.
3The client was considered to have initiated testing if the client visited the community counsellor explicitly to request an HIVST kit; the counsellor was
considered to have initiated testing if the community counsellor visited the client at the client’s home either by prior arrangement or during door to door
rounds.
doi:10.1371/journal.pmed.1001873.t001
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referred in by a volunteer-counsellor (Fig 5). Thus, our first estimate of linkage is 41.7% (524 of
1,257 self-testing positive). However, in a subset of 3,016 participants in months 1–12, 2,380
(78.9%; 95% CI 77.4%–80.4%) responded to a question about ART. Of these, 219 (9.2%, 95%
CI 8.1%–10.4%) were HIV positive, and 57 (26.0%, 95% CI 20.3%–32.4%) of these individuals
stated that they were already on ART, consequently increasing our estimate of linkage to 56.3%
(524/930). The median CD4 count from 415 participants (72.9% of those attending care) was
Table 2. Age-sex distribution of study population and study participants with and without adjustment by study censusmaximum denominators in
age-sex-neighbourhood subgroups.
Characteristic Study Census Crude Uptake1 Revised Uptake2
HIVST Uptake Percent p-Value HIVST Uptake Percent p-Value
Months 1–12 of HIVST
Total 16,660 14,004 84.1 — 12,751 76.5 —
Men
16–19 y 1,196 1,223 102.3 <0.001 1,068 89.3 <0.001
20–29 y 3,326 2,686 80.8 2,646 79.6
30–39 y 2,462 1,491 60.6 1,477 60.0
40–49 y 926 412 44.5 412 44.5
!50 y 733 299 40.8 299 40.8
Women
16–19 y 1,306 1,884 144.3 <0.001 1,306 100.0 <0.001
20–29 y 3,487 3,682 105.6 3,313 95.0
30–39 y 1,872 1,502 80.2 1,458 77.9
40–49 y 627 484 77.2 461 73.5
!50 y 510 297 58.2 297 58.2
Either sex or age missing 215 44 20.5 14 6.5
Months 13–24 of HIVST
Total 16,660 13,785 82.7 — 12,396 74.4 —
Men
16–19 y 1,196 1,382 115.6 <0.001 1,104 92.3 <0.001
20–29 y 3,326 2,892 87.0 2,828 85.0
30–39 y 2,462 1,448 58.8 1,412 57.4
40–49 y 926 364 39.3 348 37.6
!50 y 733 235 32.1 232 31.7
Women
16–19 y 1,306 2,010 153.9 <0.001 1,301 99.6 <0.001
20–29 y 3,487 3,475 99.7 3,270 93.8
30–39 y 1,872 1,354 72.3 1,331 71.1
40–49 y 627 363 57.9 353 56.3
!50 y 510 195 38.2 190 37.3
Either sex or age missing 215 67 31.2 27 12.6
1For each sex-age group, the number of people in that group who tested through HIVST (years: 2012–2014) is the numerator, and the total number of
people in that sex-age group at the time of census (2011) is the denominator. Uptake estimate may exceed 100% due to population turnover.
2For each sex-age group, the numerator is the number of people in that group who tested through HIVST (years: 2012–2014) but now capped at the
census denominator for that sex-age group for those age-sex groups where the number of testers exceeded the number of people in that group in the
census. The denominator is the total number of people in that sex-age group at the time of census (2011).
3Chi-squared test for HIVST yes/no.
doi:10.1371/journal.pmed.1001873.t002
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Fig 3. Cumulative uptake of HIV self-testing by sex, age group, and time point. (A) Cumulative uptake of HIVST during the first 12 mo of availability
among all HIVST cluster residents by age and time point among men and women. HIVST uptake increased with time, rising to close to 100% by 12 mo in
adolescents (age group 16–19 y); uptake for men was lower than for women at every time point. (B) Cumulative uptake of HIVST during months 13–24 of
HIVST availability among all cluster residents by age and time point. Uptake defined as an individual having collected an HIVST kit from a community
counsellor. Since crude uptake of HIVST exceeded 100% in some age-sex-neighbourhood subgroups, likely explained by migration, revised estimates were
calculated where uptake in any single age-sex-neighbourhood subgroup was censored at 100%; study census data were used for denominators.
doi:10.1371/journal.pmed.1001873.g003
Community-Based HIV Self-Testing and Linkage into Care in Malawi
PLOSMedicine | DOI:10.1371/journal.pmed.1001873 September 8, 2015 10 / 21
250 cells/μl (interquartile range [IQR] 159–426), with 66.3% (275/415) of CD4 counts being
below 350 cells/μl.
Accuracy
A total of 2,361 (8.5%) of 27,789 HIVST participants were included in QA tracing (shown for
separate years in Figs 1 and 2). Only 54 (2.3%) were found not to be cluster residents, while
1,649 (69.8%) agreed to confirmatory HIV testing. Results were positive in 141 (8.6%, 95% CI
7.2%–10.0%). Compared to stated HIVST results, there were 9/1,508 (0.6%) false negatives
(including four participants already on ART) and 1/133 false positives, giving agreement of
Fig 4. HIV prevalence in self-testing participants who returned used test kits by sex and age group and time of HIV self-testing availability. This
figure shows HIV prevalence in HIVST participants for men (A) and women (B), stratified by time of HIVST availability. Bars show HIV prevalence (percent);
error bars show 95% confidence intervals. Estimates are based on denominators determined through enumeration. Numerators were based on a reread of
used and returned HIVST kits by a laboratory technician within 2 wk of use. Individuals were asked to test only once within each 12-mo time period, and
retesting in people already aware of their positive HIV status was discouraged.
doi:10.1371/journal.pmed.1001873.g004
Community-Based HIV Self-Testing and Linkage into Care in Malawi
PLOSMedicine | DOI:10.1371/journal.pmed.1001873 September 8, 2015 11 / 21
1,639/1,649 (99.4%, 95% CI 98.9%–99.7%), sensitivity of 93.6% (95% CI 88.2%–97.0%), and
specificity of 99.9% (95% CI 99.6%–100%) (Table 3).
Acceptability of Self-Testing and Social Harms, Including Reported
Coercive Testing
During months 1–12, 81.1% (95% CI 80.5%–81.8%; 11,359/14,004) participants returned a SCQ
to the counsellor, with 7,014 (61.7%) completing all key fields including self-read HIVST result,
coercion, and acceptability indicators (S1 Questionnaire). There was acceptable internal consis-
tency (Cronbach’s alpha = 0.64) for the four variables relating to acceptability: overall satisfac-
tion with HIVST, whether or not they would recommend HIVST to friends and family, how
hard it was to self-test, and whether or not they trusted the results of an oral test [25].
Fig 5. Linkage into HIV care after HIV self-testing (months 1–12).
doi:10.1371/journal.pmed.1001873.g005
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Acceptability indicators were high in all age group and sex strata, with 94.6% (1,446/1,635)
reporting that they were “highly satisfied” with the HIVST process and 97.1% (6,683/6,883)
reporting they would “definitely recommend HIVST to their friends and family”. These indica-
tors did not vary significantly by self-reported HIV status, with those testing positive having
OR 0.60 (95% CI 0.34–1.05) and OR 0.92 (95% CI 0.56–1.50) relative to HIV-negative partici-
pants for being “very satisfied” with the HIVST process and for “definitely” recommending
HIVST to friends and family, respectively.
In total, 288/10,017 participants (2.9%, 95% CI 2.6%–3.2%) reported having been coerced
into participating in HIVST. Notably, however, satisfaction indicators in the group reporting
coercion were high, with 94.4% (252/267) stating that they would recommend HIVST to
friends and family, and 92.2% (130/141) reporting that they were highly satisfied with HIVST.
In the univariate analysis, men and participants who self-tested with their partner were signifi-
cantly more likely to report having been coerced into HIVST (Table 4). In multivariate analysis,
male sex (adjusted OR [aOR] 1.83, 95% CI 1.38–2.43) and having tested with a partner (aOR
3.86, 95% CI 2.82–5.29) remained significantly associated with reported coercion. There was
no significant difference in reporting of coercion by reported HIVST result to volunteer-coun-
sellors (aOR 1.00, 95% CI 0.59–1.71). The findings were comparable when multiple imputation
methods were used to handle missing data (S1 Table).
A total of 132 adult deaths were reported through the community liaison system during the
first 12 mo of follow-up, including one suicide in an individual who had not self-tested and
four murders, none of which had any known or close temporal relationship to self-testing. No
intimate partner violence episodes were reported through the community liaison system.
Discussion
The main finding of this study was the high population uptake of HIVST and retesting during
2 y of highly decentralised service provision in an urban community in Malawi. HIVST was
safe and accurate, with uptake highest among adolescents, and with acceptable linkage into
HIV care services using a delivery model based on trained volunteers. No suicides or other seri-
ous unintended consequences related to HIVST were detected by an active community surveil-
lance system, including systematic death reporting and verbal autopsies. Feeling coerced into
self-testing (usually by a main partner) was common (2.9% respondents), but was nonetheless
associated with a high satisfaction rating for HIVST for all but a small minority of respondents.
This model of HIVST is potentially scalable to other low-income settings where annual repeat
HIV testing is recommended.
Table 3. Summary of quality assurance process and accuracy results.
Self-Reported HIV Self-Test Result Index Test*
Positive Negative Total
Positive 132 1 133
Negative 9** 1,507 1,516
Total 141 1,508 1,649
Concordance: 99.4% (95% CI 98.9%–99.7%); sensitivity: 93.6% (95% CI 88.2%–97.0%); speciﬁcity: 99.9%
(95% CI 99.6%–100.0%).
*Parallel testing with two rapid ﬁnger-prick blood tests by a trained nurse.
**Includes four participants later found to be already on ART.
doi:10.1371/journal.pmed.1001873.t003
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HIV testing needs in Africa have changed dramatically in the last decade due to the massive
scale-up of ART services and an increasing focus on early diagnosis and treatment of HIV for
prevention [26,27], as well as other biomedical HIV prevention strategies [28,29]. Population
surveys and qualitative studies report high readiness to test, but there exist substantial barriers
to accessing free clinic-based HIV testing services [30–33].
The high acceptability and ease of distribution of oral test kits makes HIVST of special inter-
est in high-HIV settings, where the aim is to achieve affordable universal coverage and regular
repeat testing [34]. Here we report considerable complementarity of this model of HIVST with
existing strategies. Although our urban population was already served by free facility-based ser-
vices, 35% of participants in the first 12 mo had never previously tested, and uptake was high in
two important hard-to-reach groups: men and adolescents. Our estimates of adolescent popula-
tion uptake (~100% for women aged 16–19 y and ~90% for men aged 16–19 y) are in stark con-
trast with reported adolescent HTC uptake in African DHS surveys [3]. Ideally, HIVST services
would capitalise on high acceptability among key populations, facilitating linkage into HIV pre-
vention programmes, such as pre-exposure prophylaxis and voluntary medical male circumci-
sion, as well as ensuring prompt linkage into HIV care [14]. The per-episode costs of providing
HIVST compared to the costs of facility-based testing will be reported fully elsewhere.
Our data from the second year of HIVST availability (participants were asked to test only
once in each year) show high readiness to retest, as well as reduced numbers of first-time testers
and new positive HIV diagnoses, which is consistent with the high coverage reported from the
Table 4. Factors associated with reported coercion duringmonths 1–12 of HIV self-testing (n = 7,014).
Characteristic Number Coerced into HIVST/Total Percent OR1 95% CI1 aOR1 95% CI1
Women 91/4,138 2.2 1 1
Men 112/2,868 3.9 1.81 1.36–2.39 1.83 1.38–2.43
Age group
16–19 y 44/1,470 3.0 1 1
20–29 y 102/3,276 3.1 1.04 0.73–1.49 1.05 0.73–1.50
30–39 y 47/1,499 3.1 1.05 0.69–1.59 1.01 0.66–1.53
40–49 y 6/446 1.4 0.44 0.19–1.04 0.44 0.18–1.03
!50 y 4/315 1.3 0.42 0.15–1.17 0.39 0.14–1.10
Ever tested before 159/5,361 3.0 1 1
Never tested before 44/1,645 2.7 0.90 0.64–1.26 0.86 0.60–1.23
Self-tested alone 136/6,157 2.2 1 1
Self-tested with partner 67/849 7.9 3.8 2.80–5.13 3.86 2.82–5.29
Self-test self-read result
Negative 182/6,299 2.9 1.00 1
Positive 16/649 2.5 0.85 0.51–1.43 1.00 0.59–1.71
Don’t know 5/58 8.6 3.2 1.25–8.03 3.17 1.22–8.22
Highly satisﬁed with HIVST
Yes 84/1,581 5.3 1.00 ND ND
No 5/54 9.3 1.82 0.71–4.68 ND ND
Would recommend HIVST to friends and family
Yes 188/6,763 2.8 1.00 ND ND
No 12/120 10.0 3.89 2.10–7.18 ND ND
1ORs for age and sex were adjusted for each other only; ORs for all other variables were adjusted for age, sex, and each other.
ND, not done.
doi:10.1371/journal.pmed.1001873.t004
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first year. Importantly, population uptake in the second year was faster, suggesting that under
programmatic conditions, experienced volunteer-counsellors could cover larger populations as
soon as communities have been familiarised with HIVST concepts.
Optimum systems for linking clients into HIV care/prevention programmes are not well
established in Africa [35–38] but are critical to the public health impact and cost-effectiveness
of HTC [39]. Here we estimate a timely linkage into confirmatory testing and HIV care follow-
ing HIVST of 56%, which compares favourably with many other approaches [40] and is well
within the expected range for African HTC services [35,36]. This linkage estimate, however,
reflects that, in addition to HIVST, participants were asked to attend post-test counselling and
were advised to share their HIVST results. Facilitated HIV care assessment and initiation was
provided following a successful trial in the first 6 mo of this study [10]. Despite reluctance to be
tested by a volunteer-counsellor who is a neighbour, willingness to take kits and to share results
was high. Although at first seemingly paradoxical, other studies have also reported that learn-
ing one’s HIV status demands a moment of complete privacy, but that being able to turn to
someone familiar can then make the next steps of accessing HIV care less daunting [41].
Some of the benefits of community-based HTC are reaching HIV-positive individuals ear-
lier [42], improving survival [43], and reducing costs [44] and onward transmission. A recent
meta-analysis has found that when CD4 measurement was offered in tandem with home-based
HIV testing, approximately 60% of those who tested HIV positive had CD4 counts greater
than 350 cells/μl [9]. Here we report a CD4 count profile below this ideal (median 250 cells/μl,
IQR 159–426) for HIVST participants who subsequently attended care, but still considerably
higher than that of HIV care attendees diagnosed from our study clusters following standard
non-study HTC (median 154 cells/μl, IQR 116–249) [10].
Concerns about the potential impact of user error on diagnostic accuracy from HIVST
[45,46] have been widely discussed [14]. Here we report an HIVST accuracy (93.6% sensitivity,
99.9% specificity) very similar to that of unobserved HIVST using the OraQuick ADVANCE
Rapid HIV-1/2 Antibody Test in American participants [47]. We have previously reported
97.9% sensitivity and 100% specificity for a small observed/controlled-setting study in Blantyre
[7]. In the HIVST model evaluated, users were given a short simple demonstration by trained
lay volunteers, and this may have been a key factor in maintaining high accuracy in this rela-
tively low literacy setting. Both accuracy and uptake of services post-testing will need revalua-
tion if different test kits or less supportive models are considered, for example, over-the-
counter or vending machine sales.
Also of note, a much higher than anticipated proportion (26%) of our HIV-positive HIVST
participants were on ART already, as were two of our four participants found to have false-nega-
tive results. ART is known to reduce sensitivity especially for oral fluid-based rapid diagnostic
tests [48]. In Malawi, faith healing, whereby HIV is considered curable through prayer, is widely
preached and may prompt ART patients to reconsider their status and need for ART if they get
a negative test result via HIVST [49]. Based on our experience, we would recommend careful
messaging about retesting while on ART in HIVST package inserts and education campaigns.
Coercion was reported by 3% of our SCQ respondents and was the major social harm, with
no suicides or intimate partner violence attributed to HIVST despite active surveillance. Com-
parable data suggest that feeling coerced affects other modalities of HTC, with an estimated 7%
of HTC episodes in Africa occurring without consent [50]. Both pregnant women and their
male partners commonly report feeling coerced into testing by health professionals [51].
Among our participants, men and those who tested with their partners were more likely to
report coercion. HIVST programmes need to anticipate and guard against coercive and man-
datory testing, and to ensure that information about rights is disseminated and that systems for
reporting social harms are in place.
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Study limitations include uncertainty around our linkage and uptake estimates, and use of
aggregate-level data reporting rather than individual cohort follow-up. Population turnover,
typically high in urban slums, was not factored into our population denominators, and may in
part explain why our crude uptake estimates for adolescent women were>100%. Importantly,
our QA programme results ruled out a major contribution to our findings from HIVST offered
to non-eligible individuals (non-residents and individuals taking multiple tests). Estimates of
linkage into care always have a wide uncertainty (Fig 5), but as disclosure of positive HIVST
results was voluntary, even our precise denominators are unknown. Furthermore, we under-
appreciated the extent of retesting while already on ART, adding to the uncertainty around
numbers of newly identified HIV-positive participants. However, these sources of imprecision
are unlikely to have affected our overall messages.
In summary, community-level HIVST service provision along with supportive post-test ser-
vices resulted in high and rapid uptake of accurate HIVST, with very low incidence of major
social harms, and acceptable linkage into HIV care. The continued high uptake in the second
year suggests that scaling up HIVST could have a sustained impact on the coverage of HIV test-
ing and care in Africa, especially for men and adolescents.
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Editors' Summary
Background
Every year, about 2.1 million people (70% of whom live in sub-Saharan Africa) are newly
infected with HIV, the virus that causes AIDS, and 1.5 million people (again, mainly in
sub-Saharan Africa) die as a result. HIV, which is usually transmitted through unprotected
sex with an infected individual, gradually destroys CD4 lymphocytes and other immune
system cells, leaving HIV-positive individuals susceptible to other serious infections and to
unusual cancers. HIV is diagnosed by looking for antibodies to HIV in blood or saliva.
After diagnosis, the progression of HIV infection is monitored by regularly counting the
number of CD4 cells in the blood. Initiation of antiretroviral therapy—a combination of
drugs that keeps HIV replication in check but that does not cure the infection—is recom-
mended when an individual’s CD4 count falls below 500 cells/μl or when he or she devel-
ops an AIDS-defining condition.
WhyWas This Study Done?
HIV-positive individuals need to know their status so that they can take steps to avoid
transmitting the virus to other people (for example, by always using a condom during sex-
ual intercourse) and so that they can begin treatment. Treatment helps to keep HIV-posi-
tive individuals healthy but also reduces their chances of transmitting the virus to their
sexual partners. Unfortunately, many HIV-positive individuals are unaware of their status.
The situation is particularly bad in sub-Saharan Africa, where, despite major investments
in facility-based and community-based HIV testing and counseling (HTC) programs, only
a quarter of adults have had a recent HIV test, and only half of the people living with HIV
know they are HIV positive. Barriers to facility-based HTC include concern about lack of
confidentiality and fears of stigmatization. Home-based HTC avoids some of these barriers
and can achieve high uptake of testing, but doubts have been expressed about the sustain-
ability of this approach to testing. Here, the researchers evaluate an alternative to home-
based HTC—HIV self-testing (HIVST)—by undertaking a community-based prospective
study of HIVST in Blantyre, Malawi. HIVST involves individuals performing and inter-
preting their own HIV test and has the potential to be widely implemented with minimal
involvement of trained healthcare workers.
What Did the Researchers Do and Find?
Trained resident volunteer-counselors offered one oral HIVST kit (a kit that measures
HIV in saliva) per year for a two-year period to 16,660 adult residents in 14 neighborhoods
in urban Blantyre. All the participants received instructions on how to use the kits, pre-
and post-counseling, and, for participants self-testing HIV positive, a referral card to
attend an HIV care clinic. The residents also completed a questionnaire about their experi-
ence of HIVST. Three-quarters of the residents self-tested in the first and second year of
the study. HIVST uptake was more rapid in the second year than in the first year and was
high among men and adolescents, two hard-to-reach populations. Three-quarters of the
residents who self-tested during the first year of the study shared their results with a volun-
teer-counselor. Of the 1,257 participants who discovered they were HIV positive during
the first year of the study, more than half accessed HIV care. Importantly, 94.4% of the
participants reported that they were happy with HIVST even though 2.9% reported being
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forced to take the test, usually by a main partner; no HIVST-related partner violence or
suicides were reported by the study’s community surveillance system. Finally, HIVST and
repeat HTC results agreed in 99.4% of participants selected as a quality assurance sample
(one in 20 of the participants).
What Do These Findings Mean?
These findings show that, in urban neighborhoods in Malawi, coverage with community-
based HIVST was high (particularly among adolescents and men) in two successive years
and that HIVST was safe, accurate, and acceptable. Importantly, HIVST using a delivery
model based on trained volunteers led to acceptable linkage into HIV care services, and
the approach had a very low incidence of major social harms such as partner violence.
Uncertainty about estimates of uptake and linkage to care and other aspects of the study
design may limit the accuracy of these results. Nevertheless, these findings suggest that
scaling up HIVST could complement existing strategies for providing early HIV diagnosis
and periodic repeat testing and could thus have a sustained impact on the coverage of HIV
testing and care in Africa and on the control of the HIV/AIDS epidemic.
Additional Information
This list of resources contains links that can be accessed when viewing the PDF on a device
or via the online version of the article at http://dx.doi.org/10.1371/journal.pmed.1001873.
• Information is available from the US National Institute of Allergy and Infectious Dis-
eases on all aspects of HIV infection and AIDS, including testing and diagnosis
• NAM/aidsmap provides basic information about HIV/AIDS, summaries of recent
research findings on HIV care and treatment, and personal stories about living with
HIV/AIDS
• Information is available from Avert, an international AIDS charity, on many aspects of
HIV/AIDS, including HIV testing, HIV/AIDS treatment and care, and HIV prevention,
and on HIV/AIDS in Malawi and in sub-Saharan Africa; Avert also provides personal
stories about living with HIV/AIDS
• TheWorld Health Organization provides information on all aspects of HIV/AIDS (in
several languages), including its new consolidated guidelines on HIV testing
• The UNAIDS Fast-Track Strategy to End the AIDS Epidemic by 2030 provides up-to-
date information about the AIDS epidemic and efforts to halt it; UNAIDS also provides
detailed region-specific information and policy news.
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IMPORTANCE Self-testing for HIV infectionmay contribute to early diagnosis of HIV, but
without necessarily increasing antiretroviral therapy (ART) initiation.
OBJECTIVE To investigate whether offering optional home initiation of HIV care after HIV
self-testing might increase demand for ART initiation, compared with HIV self-testing
accompanied by facility-based services only.
DESIGN, SETTING, AND PARTICIPANTS Cluster randomized trial conducted in Blantyre, Malawi,
between January 30 and November 5, 2012, using restricted 1:1 randomization of 14
community health worker catchment areas. Participants were all adult (!16 years) residents
(n = 16 660) who received access to home HIV self-testing through resident volunteers. This
was a second-stage randomization of clusters allocated to the HIV self-testing group of a
parent trial.
INTERVENTIONS Clusters were randomly allocated to facility-based care or optional home
initiation of HIV care (including 2 weeks of ART if eligible) for participants reporting positive
HIV self-test results.
MAIN OUTCOMES ANDMEASURES The preplanned primary outcome compared between
groups the proportion of all adult residents who initiated ARTwithin the first 6months of HIV
self-testing availability. Secondary outcomes were uptake of HIV self-testing, reporting of
positive HIV self-test results, and rates of loss from ART at 6months.
RESULTS A significantly greater proportion of adults in the home group initiated ART
(181/8194, 2.2%) compared with the facility group (63/8466, 0.7%; risk ratio [RR], 2.94, 95%
CI, 2.10-4.12; P < .001). Uptake of HIV self-testing was high in both the home (5287/8194,
64.9%) and facility groups (4433/8466, 52.7%; RR, 1.23; 95% CI, 0.96-1.58; P = .10).
Significantly more adults reported positive HIV self-test results in the home group (490/8194
[6.0%] vs the facility group, 278/8466 [3.3%]; RR, 1.86; 95% CI, 1.16-2.97; P = .006). After 6
months, 52 of 181 ART initiators (28.7%) and 15 of 63 ART initiators (23.8%) in the home and
facility groups, respectively, were lost from ART (adjusted incidence rate ratio, 1.18; 95% CI,
0.62-2.25, P = .57).
CONCLUSIONS AND RELEVANCE AmongMalawian adults offered HIV self-testing, optional
home initiation of care compared with standard HIV care resulted in a significant increase in
the proportion of adults initiating ART.
TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT01414413
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I n 2012, an estimated 35 million individuals were infectedwith the human immunodeficiency virus (HIV).1 Antiret-roviral therapy (ART) substantially reduces the risk of on-
ward HIV transmission as well as greatly reducing morbidity
andmortality,2,3 raising hopes that highuptake of annualHIV
testing and early initiation of ART could improveHIVpreven-
tion as well as care.4,5
Achieving high coverage of HIV testing is a major chal-
lenge. Surveys in 15 sub-Saharan African countries between
2009 and 2012 show that only 20.0% of women and 20.5% of
men were tested for HIV in the previous year.6 Once tested,
individuals need to access care and prevention services to
maximize the individual and public health benefits of knowl-
edgeofHIVstatus.However,onlyone-fifthofpatients link into
care without any periods of loss to follow-up.7-9
Self-testing for HIV infection is a novel approach that is
highly acceptable in Malawi and the United States.10,11 Self-
testing forHIVhasbeendefinedas individualsperformingand
interpretingtheirHIVtest inprivate,12 aprocess thatcouldover-
comebarriers to conventional facility-based and community-
based HIV testing, which lack privacy and convenience.13,14
However, no studies in high HIV prevalence settings have in-
vestigated linkage into HIV care after HIV self-testing. Home
initiationofHIV carehasnot previously been investigated, al-
thoughhome continuation ofARTwasnoninferior to facility-
based services in a Ugandan trial.15
We therefore tested the hypothesis that offering optional
home initiation of HIV care after HIV self-testing might in-
crease population-level uptake of ART and increase willing-
ness to test and to report positive results compared with HIV
self-testing accompanied by facility-based services only.
Methods
This was a second-stage randomization of clusters allocated
to the HIV self-testing group of a parent study, which was a
cluster randomized trial comparing health outcomes
achieved under HIV self-testing vs standard-of-care HIV
testing (with 14 vs 14 clusters in each group of the parent
trial).16 The present study was a cluster randomized trial
using the 14 community health worker catchment areas
allocated to receive HIV self-testing in the parent trial.
These 14 clusters underwent restricted randomization into 2
groups: HIV self-testing followed by optional home initia-
tion of HIV care or HIV self-testing accompanied by facility-
based HIV care.
Participants and Study Setting
There are 26 administrativewards in Blantyre,Malawi. Three
wards (Ndirande, Likhabula, andChilomoni)were selected as
the study site. They were all located in the northwest area of
the city and comprised high-density urban neighborhoods.
Comprehensive HIV care (including ART) was only available
at 3 health facilities (Ndirande and Chilomoni Health Centres
and Queen Elizabeth Central Hospital).
Between April and June 2011, 14 of a possible 73 commu-
nity health worker catchment area clusters (5 in Ndirande,
6 in Likhabula, and 3 in Chilomoni) (Figure 1) were selected
purposely to ensure sufficient distance and separation
between cluster boundaries to reduce risk of con-
tamination.17 Clusters that were delineated by natural bound-
aries (rivers, roads, forests, etc) were preferentially selected.
Boundaries of selected clusters were defined by study
research assistants and Ministry of Health community health
workers walking the boundary of each community health
worker’s catchment area recording coordinates with global
positioning satellite receivers (eTrex Legend HCx, Garmin
International). All households within clusters were enumer-
ated by research assistants recruited from clusters, and a
sociodemographic questionnaire was performed with the
head of each household, or if unavailable, an adult household
representative.
The research ethics committees of the College of Medi-
cine, University of Malawi, Liverpool School of Tropical
Medicine, and London School of Hygiene and Tropical Medi-
cine approved the study. All participants provided written
informed consent (or a witnessed thumbprint if illiterate) for
HIV self-testing and separately for home initiation of care.
Interventions
Twovolunteercounselors fromeachcluster, selectedusingpar-
ticipatorymethods,18were trained inHIV testing. Prior toHIV
self-testing availability, counselors in all 14 clusters pro-
moted the availability ofHIV self-testing bydoor-to-door vis-
its and leafleting. Between January 30, 2012, and November
5, 2012, oralHIV test kits (OraQuickAdvanceRapidHIV-1/2 an-
tibody test, OraSure Technologies) were distributed to adult
residents requesting HIV self-testing from the counselors’
home (1 kit per resident per year), with pretest information
about HIV self-testing, counseling, and demonstration of kit
use. Participantswere asked to self-test in the privacy of their
Figure 1. Location of Study Clusters and Allocation
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ownhouseand to return theused testkit inperson to thecoun-
selor in a sealed envelope. Participants were not required to
report self-test results to the counselor; if they declined to do
so, they receivedgenericposttest counseling.Participantswho
reported self-test results received results-based counseling.
Counselors recorded numbers of HIV self-test kits distrib-
uted and positive results.
All participants who had positive results on self-testing
could self-refer or be referred by counselors to study clinics
where study nurses performed confirmatory HIV testing, tu-
berculosis (TB) screening (and provided isoniazid preventive
therapy [IPT] if eligible), World Health Organization (WHO)
staging, and CD4 cell counts; provided cotrimoxazole; and
made onward referral for ART initiation (routine ART clinics
within the same facility) if eligible (CD4 cell count <350/μL,
WHO stage 3 or 4, pregnant, or breastfeeding).19
In the 7 clusters allocated to the home group, at the same
timeduringwhichHIVself-testingwasbeingpromoted, coun-
selors additionally promoted (verbally and with leaflets) the
availability of home services during the door-to-door visits.
The counselors provided a second leaflet and verbal informa-
tiononhomeservices toparticipantswhenattending thecoun-
selor’s home to request HIV self-testing. Counselors orga-
nized homevisits by study nurses for participants reporting a
positiveHIV self-test result and requesting home initiation of
care. Nurses visited each participant twice (first visit within 3
days and second visit within 7 days) to carry out confirma-
tory HIV testing, WHO staging, CD4 cell count (venous blood
for laboratory testing), and TB screening (with IPT if eligible)
and to provide 2 weeks of ART if the participant was eligible.
Participants were provided with completed ART registration
cards and a follow-up appointment at their nearest HIV care
clinic.
Adult ART initiations during the study period were
ascertained by (1) recording home ART initiations and (2)
interviewing all adults who initiated ART at any of the 3 clin-
ics serving the study population and using printed satellite
maps marked with cluster boundaries and local landmarks,
followed if necessary by a home visit, to establish cluster
residence.20 Data from clinic registers and treatment cards
were extracted for the 6 months following ART initiation in
all identified study residents, without reference to group.
Self-reported adherence was assessed by questionnaire at 3
points after ART initiation (at 2-4 weeks, 3 months, and 6
months) using the AIDS Clinical Trials Group adherence
questionnaire.21
Outcomes
The primary outcome compared between groupswas the cu-
mulative incidence of ART initiation among all adult cluster
residents (regardless of HIV status, ART eligibility, site of HIV
testing, orART initiation)during the first 6monthsofHIV self-
testingavailability.Thesecondaryoutcomescompared thecu-
mulative incidence of taking an HIV self-testing kit (regard-
less ofwhether used), reporting a positiveHIV self-test result
to counselors, and loss from ART by 6 months (with partici-
pants recorded as still taking ART or transferred out to an-
other clinic classified as retained).
Sample Size
We assumed that adult HIV prevalence was 18.5%,10 50% of
HIV-positive self-testing adults would report a positive result
to counselors, and 5% of the adult population would initiate
ARTover 6months in the facility group.Amean cluster popu-
lation of 1200 adults in 14 clusters provided 80% power at a
5% level of significance to detect a risk ratio (RR) of 1.5 be-
tween groups of the adult populationwho initiatedART,with
a coefficient of variation k = .20.17
Randomization andMasking
Clusters were randomized at a public meeting after restrict-
ing possible allocations to ensure that for each of the 3wards,
thedifference in thenumberof clustersallocated toeachgroup
wouldbenomore than2 (providing2100uniqueallocationpat-
terns). Community representativesdrewcoloredballs froman
opaque bag held above eye level to select the distribution of
clusters and group allocation. Counselors and residents were
notmasked to the intervention, but investigator blindingwas
maintained until the final analysis.
Statistical Methods and Cost Analysis
For the primary and secondary outcomes, analysis was done
by intention to treat. CONSORT guidelines were followed in
reporting preplanned study outcomes (eMethods 1 in the
Supplement).22 The cluster-level proportions of residents
who initiated ART, took an HIV self-test kit, and reported a
positive HIV self-test result in each intervention group were
compared using the t test, with the unadjusted RR calculated
as the ratio of cluster-averaged means using the method
described by Hayes andMoulton.17 The analysis was adjusted
for death reported in households in the year preceding enu-
meration. Because data on these outcomes were not linked to
individuals and were collected and analyzed at the cluster
level, there were no missing data to take into account in the
analysis.
A separate analysis was used to assess rates of loss from
ART with the denominator being adult residents who initi-
ated ART. The ART initiators whose treatment records indi-
cated that theywere still taking ART or had transferred to an-
other ART clinic were classified as retained on ART. The ART
initiatorswhose treatment records indicated that theyhaddied
or defaulted fromARTwere classified as lost toART.23NoART
initiatorshadmissingdata forARToutcome.Cluster-level rates
of loss fromART ineachgroupwere comparedusing the t test,
with theunadjusted rate ratio calculatedas the ratioof cluster-
averagedmeans andwith subsequent adjustment for sex, age,
pregnancy status, CD4 cell count strata, andWHO stage. The
3 of 244participants (1.2%) forwhomWHOstagewasmissing
were not included in this adjusted analysis. Under national
treatmentguidelines,CD4cell countwasnot indicatedforpreg-
nantwomen and individuals inWHO stage 3 or 4 andwas not
measuredprior toART initiation in facilities. Therefore, for the
69 of 244 individuals (28.3%) without CD4 cell count results,
a category for missing was constructed.
Characteristics of ART initiators were compared between
groups using χ2 tests for categorical characteristics and
Kruskal-Wallis tests for continuous characteristics. Differ-
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ences in adherence between the 2 groups were compared
using χ2 tests. Tests were 2-sided and a P value of ≤.05 was
considered significant. Stata version 12.1 (StataCorp) was
used for analysis.
A partial cost analysis was undertaken of the home ART
initiation service fromaprogrammatic perspective (eMethods
2 in the Supplement).24 The cost estimates do not include the
costs of facility-based assessment and initiation or down-
stream HIV care costs.
Results
The 14 clusters enumerated between April and June 2011 had
a combined adult population of 16 660,with 8194 adults resi-
dent in 3213 households in the home group and 8466 adults
resident in 3397 households in the facility group (Figure 2).
Characteristics were well balanced between groups (Table 1),
apart from reported household deaths in the previous year
(home group: 131/8194, 4.1%; facility group: 81/8466, 2.4%).
Primary Outcome
Between January 30, 2012, andNovember 5, 2012, 244 cluster
resident adults initiated ART during 6 months of HIV self-
testing availability. The cumulative incidence of ART initia-
tionwassignificantlyhigher in thehomegroup (181/8194, 2.2%
of residents) comparedwith the facility group (63/8466, 0.7%
of residents;RR, 2.94; 95%CI, 2.10-4.12;P < .001) (Table 2). Af-
ter adjusting for reportedhouseholdmortality at baseline, the
effect of availability of home care initiation remained statis-
tically significant (adjusted RR, 2.44; 95% CI, 1.61-3.68;
P < .001).
Of the 181 residents initiating ART in the home group, 116
(64.0%) initiated at home and 65 (36%) initiated at 1 of the 3
health facilities. Thedifference betweengroups inART initia-
tionwasmaintained throughout theanalysisperiod (Figure3).
Secondary Outcomes
During the 6 months of availability, a total of 9720 of 16 660
adult residents (58.3%) took anHIV self-test kit. Therewasno
significant difference in uptake between the home (5278/
8194, 64.9%) and facility groups (4433/8466, 52.7%; RR, 1.23;
95%CI,0.96-1.58;P = .10).Participants in thehomegroup(490/
8194, 6.0%)were significantlymore likely to report a positive
HIV self-test result than facility group participants (278/
8466, 3.3%; RR, 1.86; 95% CI, 1.16-2.97; P = .006).
HomeART initiators had significantly highermedianCD4
cell counts compared with facility initiators (eTable 1 in the
Supplement):medianCD4cell countatARTinitiationwashigh-
est among home initiators in the home group (219/μL, inter-
quartile range [IQR], 135-305) compared with facility initia-
tors in the home group (154/μL, IQR, 116-249) and the facility
group (187/μL, IQR, 100-256; P = .04).
Loss FromARTOver 6Months
After 6 months, 52 of 181 participants (28.7%; 30/116 [25.9%]
home initiators and 22/65 [33.8%] facility initiators) who ini-
tiatedART in thehomegroupand 15of 63participants (23.8%)
in the facility group were lost from ART. Treatment records
showed that 5 of 181 (2.8%) and 1 of 63 (1.6%) ART initiators in
the home and facility groups died, respectively. In unad-
justed analysis, the rate of loss from ART was higher in ART
initiators in the home group (63.4/1000 person-months; 95%
CI, 42.7-84.1) than in the facility group (53.5/1000 person-
Figure 2. Flowchart of HIV Self-testing and ART Initiation inMalawi
28 Clusters in parent trial
14 Clusters allocated to HIV self-testing
14 Randomized
7 Clusters included in analyses
8194 Participants included in
primary analysis
0 Participants excluded from
primary analysis
181 Participants included in
secondary analysis (ART initiators)
8013 Participants excluded from
secondary analysis (did not
initiate ART)
7 Randomized to home group
8194 Participants in 7 clusters (mean
cluster size, 1179; median, 1203;
range, 923-1416)
7 Received home option as
randomized
7 Randomized to facility group
8466 Participants in 7 clusters (mean
cluster size, 1209; median, 1209;
range, 1075-1276)
7 Received facility-based treatment
as randomized
7 Clusters included in analyses
8466 Participants included in
primary analysis
0 Participants excluded from
primary analysis
63 Participants included in
secondary analysis (ART initiators)
8403 Participants excluded from
secondary analysis (did not
initiate ART)
0 Clusters discontinued intervention 0 Clusters discontinued intervention
ART indicates antiretroviral therapy.
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months; 95% CI, 23.7-83.4), although not significant (inci-
dence rate ratio [IRR], 1.18; 95% CI, 0.67-2.10). Adjusting for
risk factors had little effect (adjusted IRR, 1.18; 95% CI, 0.62-
2.25).
There were 201 ART initiators (82.4% of all ART initia-
tions and 91.0% of initiators who returned for a subsequent
clinic appointment) who completed the adherence question-
naire 2 to 4 weeks after ART initiation, 145 (59.4% of all ART
initiators and82.9%of individuals retained in care)who com-
pleted thequestionnaire at 3months, and119 (48.8%ofallART
initiators and67.2%of individuals retained in care)who com-
pletedquestionnaires at 6months.Overall, of thosewithdata
available, 19 of 164 (11.6%) and 3 of 60 (5.0%)ART initiators in
thehomeand facility groups, respectively, self-reportedmiss-
ing at least 1 dose of ART in the past 4 days at any assessment
point (P = .14).
Cost Analysis
The total cost of the home-based ART service was US
$20 005.24 (45 809.16 international dollars) (eTable 2 in the
Supplement). The average cost per participant assessed was
US $97.11 (222.37 international dollars), and the average cost
per participant who initiated ART through the home service
was US $172.46 (394.91 international dollars).
Discussion
Themainfindingof thiscluster randomizedtrialwas thatpopu-
lation-level ART initiations were significantly increased (RR,
2.94;95%CI,2.10-4.12)byavailabilityofhomeinitiationofcare.
To our knowledge, this is the first study to investigate the ef-
fects of a comprehensive home-based HIV testing, eligibility
Table 1. Baseline Characteristics
Home Group Facility Group
No. of clusters 7 7
No. of households 3213 3397
No. of adults (aged ≥16 y) 8194 8466
Cluster Characteristics
Adults per cluster, mean (range), No. 1179 (923-1416) 1209 (1075-1276)
Population density per cluster, persons per m2, mean (range) 0.016 (0.009-0.030) 0.024 (0.010-0.044)
Household Characteristics
Adults per household, mean (SD), No. 2.55 (1.26) 2.48 (1.17)
Children per household, mean (SD), No. 1.96 (1.58) 1.93 (1.54)
Household wealth quintile, No. (%)a
1 (poorest) 730 (23.3) 806 (24.3)
2 (poorer than average) 656 (21.0) 703 (21.2)
3 (average) 599 (19.2) 696 (21.0)
4 (wealthier than average) 602 (19.2) 589 (17.8)
5 (least poor) 540 (17.3) 518 (15.6)
Death in household in year preceding enumeration, No. (%) 131 (4.1) 81 (2.4)
Individual Characteristics (Adults Only)
Age, mean (SD), y 30.4 (11.8) 30.2 (11.4)
Age group, y, No. (%)
16-19 1312 (16.1) 1227 (14.5)
20-29 3312 (40.5) 3556 (42.1)
30-39 2113 (25.9) 2267 (26.8)
40-49 785 (9.6) 788 (9.3)
50-59 363 (4.4) 355 (4.2)
≥60 285 (3.5) 255 (3.0)
Male, No. (%)b 4252 (52.5) 4399 (52.6)
Marital status, No. (%)c
Married or cohabiting 5031 (62.8) 5293 (64.4)
Never married 2441 (30.5) 2403 (29.2)
Widowed, separated, or divorced 535 (6.7) 524 (6.4)
Ever lost a spouse, No. (%)d 378 (4.7) 373 (4.5)
Highest level of education, No. (%)e
No schooling 217 (2.7) 237 (2.9)
Primary 3168 (39.7) 3214 (38.7)
Secondary, no MSCE 2389 (30.0) 2863 (34.5)
Secondary with MSCE 1564 (19.6) 1465 (17.6)
Higher 635 (8.0) 520 (6.3)
Abbreviation: MSCE: Malawi
secondary certificate of education.
a Missing values: home group: 86,
facility group: 85.
bMissing values: home group: 7,
facility group: 79.
c Missing values: home group: 163,
facility group: 228.
dMissing values: home group: 180,
facility group: 224.
e Missing values: home group: 197,
facility group: 149.
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assessment, and treatment initiation strategy. The uptake of
HIV self-testing during the first 6 months of availability was
high in both groups (58% overall). At a time when universal
test and treat approaches to controlling the HIV epidemic are
being considered,4 home initiation of HIV care shows high
promise as a simple strategy to improve uptake of ART when
HIV self-testing is carried out at home.
The absolute difference between groups was 1.5%
(2.2% − 0.7%) or, assuming adult HIV prevalence was 18.5%
in both groups10 and 76% of adults eligible for ART under
2010 WHO guidelines were taking ART at baseline,1 an
additional 7.9 per 100 HIV-infected adult residents (181/
[8194 × 18.5%] − 63/[8466 × 18.5%]) and 33.0 per 100 ART-
eligible HIV-infected adults (181/[8194 × 18.5% × 24%] − (63/
[8466 × 18.5% × 24%]) initiated ART when both HIV self-
testing and home initiation of HIV care were offered
(detailed calculations in eTable 3 in the Supplement). We
attribute this increase to removal of existing barriers to ini-
tial linkage to ART, including mistrust of routine clinic-
based services and the intense pressure of time related to
extreme poverty.13,25 Reassuringly, offering the option of
home initiation of HIV care did not simply shift ART initia-
tions from health facilities to home: the rate of facility ART
initiations was maintained between groups, while home ini-
tiations provided extra numbers.
AlthoughHIVself-testinghasbeenavailable formore than
20 years,26 it has only recently been considered for use in na-
tionalHIV testingprograms.27FollowingUSFoodandDrugAd-
ministration approval for over-the-counter sale of anoralHIV
self-test kit in 2012,28 and 2 pilot studies from Kenya29 and
Malawi10showinghighacceptabilityanduptake, therehasbeen
Figure 3. Cluster Resident ART Initiations During 6Months
of HIV Self-testing Availability
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Table 2. Primary and Secondary Trial End Pointsa
Home Group Facility Group
Risk or Rate
Ratio
(95% CI) P Value k0
No./Total
No.
% or Rate per 1000
Person-Months
(95% CI)
No./Total
No.
% or Rate per 1000
Person-Months
(95% CI)
Primary trial outcome:
ART initiations
Unadjustedb 181/8194c 2.2% 63/8466 0.7% 2.94 (2.10-4.12) <.001 .15
Adjusted 2.44 (1.61-3.68) <.001
Secondary trial
outcomes
HIV self-tests 5287/8194 64.9% 4433/8466 52.7% 1.23 (0.96-1.58) .10 .23
Reporting of HIV
positive self-test
results
490/8194 6.0% 278/8466 3.3% 1.86 (1.16-2.97) .006 .50
Loss from ART if
initiated ART
Unadjusted 52/181 63.4 (42.7-84.1) 15/63 53.5 (23.7-83.4) 1.18 (0.67-2.10) .52
Adjusted 1.18 (0.62-2.25) .57
Abbreviations: ART, antiretroviral therapy; k0, intracluster coefficient of
variation in facility group; WHO,World Health Organization.
a For ART initiation, HIV self-tests, and reporting of positive HIV self-test results,
denominators are total number of adult residents. For loss from ART,
denominator is all adult cluster residents who initiated ART (regardless of site
of HIV testing, or site of ART initiation) during first 6months of HIV self-testing
availability. Unadjusted proportions of adult residents initiating ART, taking
HIV self-testing kits, and reporting positive HIV self-testing results were
compared using the t test with the risk ratio calculated as the ratio of
cluster-averagedmeans. Ninety-five percent CIs were calculated based on the
t distribution and using a Taylor approximation to estimate the standard error
of the log risk ratio. The analysis was adjusted for reported household death in
the previous year using a logistic regressionmodel to estimate cluster-specific
predicted prevalence of the outcome (risk residuals), which were compared
using the t test with the risk ratio calculated as the ratio of cluster-averaged
risk residuals. For this adjusted analysis, 95% CIs and P values were calculated
from the cluster-specific residuals based on the t distribution and using a
Taylor approximation to estimate the standard error of the log risk ratio.
Unadjusted rates of loss from ART among ART initiators were compared using
the t test, with the rate ratio calculated as the ratio of cluster-averagedmeans.
The analysis was adjusted for sex, age, pregnancy status, WHO clinical stage
(1/2 or 3/4), and CD4 cell count strata (>350/μL, 201-350/μL,!200/μL, or
missing [n = 69]) at ART initiation using a Poisson regressionmodel to
estimate cluster-specific prevalence of covariates (rate residuals), which were
compared using the t test with the rate ratio calculated as the ratio of
cluster-averaged rate residuals. For this adjusted analysis, 95% CIs and
P values were calculated from the cluster-specific residuals based on the
t distribution and using a Taylor approximation to estimate the standard error
of the log rate ratio. Three individuals who hadmissing data for WHO clinical
stage were excluded from this adjusted analysis.
b Includes all ART initiations among cluster resident adults during the first 6
months of HIV self-testing availability, regardless of site of ART initiation
(home or facility).
c Of the 181 residents initiating ART in the home group, 116 (64.0%) initiated at
home and 65 (36%) initiated at 1 of the 3 health facilities.
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renewed interest in HIV self-testing as a strategy for comple-
mentingexistingHIVtestingservices.27AdvantagesofHIVself-
testing include increasedconvenienceandconfidentialitycom-
pared with facility-based HIV testing.10
Economic analysis found the cost of homeassessmentper
participant tobeUS$97.11 (222.37 internationaldollars) and the
cost per individual initiatedwithART tobeUS$172.46 (394.91
international dollars). This compares favorablywith commu-
nity-based HIV testing programs (US $7.77-$126.48 per indi-
vidual tested)11 and the annual costs of providing ART in fa-
cilities (US $857.84-$1165.47).30 Patient costs were not
considered in this analysis. However, home initiation of care
will likely have savings for individuals who would otherwise
incur substantial transport and opportunity costs. The costs
of the HIV self-testing service, costs of facility-based initia-
tion of care, and the differences in downstreammanagement
costs were not considered. The home-based service identi-
fiedparticipantsat significantlyhighermedianCD4cell counts,
which will likely affect cost-effectiveness through prolonged
survival,31 reduced early HIV management costs,32 and in-
creased lifetime HIV treatment costs.
Loss fromARTover6monthswasworse in thehomegroup
than in the facility group, although the differences were not
statistically significant, andoverall numbers of initiatorswere
small, limitingpower to identify anythingother than largedif-
ferences. Pooled across study groups, 72.5% of ART initiators
were still taking ART at 6 months. This is below national HIV
program estimates for Malawi (80% retained at 12months33),
although still within the range seen in other programs.34 The
study setting, with recruitment from urban slums, may have
led to inclusion of a greater proportion of highlymobile indi-
viduals compared with other areas of the country. The trend
toward poorer outcomes among ART initiators in the home
group means that careful monitoring and treatment support
should be provided for home ART initiators in future studies
to avoid losing the initial populationbenefits of homeART ini-
tiation.
Perceived lackof confidentiality (whichcouldbemorepro-
nounced in smaller or rural communities) has been cited as a
potential barrier to uptake when HIV interventions are of-
fered in the home, although in a previous trial of home con-
tinuationofARTafter facility initiation, dropoutdue to stigma
wasextremelyuncommon.15Weovercame thesepotential dif-
ficulties by developing a partnership with the community
(through volunteer counselors and community representa-
tive groups) and with participants by giving pretest informa-
tionabout thepotential advantagesanddisadvantagesofhome
initiation of HIV care. Regular meetings were held with com-
munity stakeholders where concerns could be raised and ad-
dressed. No incentives (financial or otherwise) were pro-
vided to participants or providers.
Limitations of the study include the need to use all adult
cluster residents (not people living with HIV or ART-eligible
adults) as our denominator. This reflects the lack of available
cluster-level HIV prevalence and CD4 cell count data. How-
ever, ART initiation remained statistically significantly
increased in the home group after adjusting for household
mortality in the previous year, which could have been
indicative of differences in HIV prevalence or ART coverage
between study groups. To maintain privacy and confidenti-
ality, individual HIV self-testing participants were not fol-
lowed up as a cohort; reporting results was optional and not
required. Therefore, we cannot estimate overall linkage into
care after positive HIV self-testing or examine any given step
of the HIV care pathway. Total numbers of ART initiations
were small, meaning that larger studies are required to fully
evaluate the possible trends toward worse retention of ART
in the home initiation group. Initiators of ART were followed
up for only a short period (6 months) and default from ART
was not followed up by active tracing. Clinical outcomes of
ART initiators (including causes of death) were not assessed
at 6 months. Because HIV self-testing was implemented
through neighborhood volunteers living close to partici-
pants, home initiation of HIV care was a highly feasible
option in this situation andmay not apply to other models of
HIV self-testing delivery. Other models for encouraging link-
age may need to be developed and ideally directly compared
for effectiveness.
Conclusions
Among Malawian adults offered HIV self-testing, optional
home initiation of care compared with standard HIV care re-
sulted in a significant increase in the proportion of adults ini-
tiating ART.
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APPENDIX V: Literature search 
strategy to review cost-
effectiveness studies of HIV 
interventions  
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Literature search strategy employed:   
 
1. For HIV related terms 
MESH headings for HIV related terms were combined with searching terms in 
title/abstract/keywords. The searches were then combined with ‘OR’. 
 
1 HIV/ or Anti-HIV Agents/ or HIV-2/ or HIV-1/ or HIV Infections/ 
2 Acquired Immunodeficiency Syndrome/ 
3 Antiretroviral Therapy, Highly Active/ 
4 (human immunodeficiency virus or human immunedeficiency virus or human immuno-
deficiency virus or human immune-deficiency virus or human immun*)).ab,kw,ti. 
5 (acquired immunodeficiency syndrome or acquired immunedeficiency syndrome or acquired 
immunodeficiency syndrome or acquired immune-deficiency syndrome or acquired human 
immun*).ab,kw,ti. 
6 (HAART or highly active antiretroviral therapy or highly active anti-retroviral therapy or highly 
active antiretroviral treatment or highly active anti-retroviral treatment or antiretroviral or 
anti-retroviral).ab,kw,ti. 
7 1 or 2 or 3 or 4 or 5 or 6 
 
 
2. For restricting publication relating to sub-Saharan Africa 
MESH headings relating to sub-Saharan Africa were combined with searching for list 
of countries and regions in sub-Saharan Africa in title/abstract/keywords and 
country of publication or affiliation.  The searches were then combined with ‘OR’. 
8 (angola or benin or botswana or burkina faso or burundi or cameroon or cape verde or 
central african republic or chad or comoros or congo or cote d’ivoire or democratic republic 
of the congo or Djibouti or ethiopia or Eritrea or equatorial guinea or gabon or gambia or 
ghana or guinea or guinee bissau or guinea-bissau or ivory coast or kenya or Lesotho or 
Liberia or madagascar or malawi or mali or mozambique or Namibia or niger or nigeria or 
rwanda or (sao tome and principe) or senegal or sierra leone or somalia or south africa or 
south sudan or sudan or Swaziland or tanzania or togo or uganda or zaire or zambia or 
Zimbabwe or sub-Saharan Africa or East Africa or Southern Africa or West Africa).ab,cp,kw,ti. 
9 exp "Africa South of the Sahara"/ 
10 1 or 2 
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3. For restricting studies relating to economic evaluations 
To restrict searches to economic evaluations the University of York Centre for 
Reviews and Dissemination (CRD) search filter was used. This component was not 
included when searching the Cochrane Library and the CRD as the databases are 
restricted to economic evaluation studies. 
(http://www.york.ac.uk/inst/crd/intertasc/nhs_eed_strategies.html). 
11 Economics, Pharmaceutical/ or Economics, Behavioral/ or Economics, Medical/ or 
Economics/ or Economics, Hospital/ or Economics, Dental/ or Economics, Nursing/ 
12 exp "Costs and Cost Analysis"/ 
13 (economic$ or cost or costs or costly or costing or price or prices or pricing or 
pharmacoeconomic$).ti,ab. 
14 (expenditure$ not energy).ti,ab. 
15 value for money.ti,ab. 
16 budget$.ti,ab. 
17 or/11-16 
18 ((energy or oxygen) adj cost).ti,ab. 
19 (metabolic adj cost).ti,ab. 
20 ((energy or oxygen) adj expenditure).ti,ab. 
21 or/18-20 
22 17 not 21 
 
 
4. Finalising search 
The three broad searches described above were combined with ‘AND”. References 
that are letters, editorials and historical articles were subsequently removed. 
References of animal only studies were also removed. The final search restricted 
references to those published in English and to publication date from 1st Jan 2000 
onwards.  
23 7 and 10 and 22 
24 letter.pt. 
25 editorial.pt. 
26 historical article.pt.  
27 Or/24-26 
28 23 not 27 
29 Animals/ 
30 Humans/ 
31 29 not (29 and 30) 
32 28 not 31 
33 Limit 29 to English language 
34 Limit 28 to yr=”2000-current” 
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Appendix VI: Participant 
information leaflet (English version) 
– HIV testing and HIV cohort studies 
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Principal Investigator: Dr Hendramoorthy Maheswaran 
Malawi-Liverpool-Wellcome Trust Clinical Research Programme 
PO Box 30096, Chichiri, Blantyre 3, Malawi 
Tel +265 187 6444, Fax +265 187 5774 
www.mlw.medcol.mw  
Chairman of CoMREC: Prof JM Mfutso-Bengo 
The College of Medicine of Malawi 
PO Box 360, Chichiri, Blantyre 3, Malawi 
Tel +265 9999 57805 
www.medcol.mw!
Study!Title:!! Cost/effectiveness!of!Home/based!HIV!Testing!and!Counselling!in!
Blantyre,!Malawi!
!
Introduction,
Good!Day,!my!name!is!_______________________,!I!am!working!for!the!Malawi/Liverpool/Wellcome!
Clinical!Research!Programme.!We!are!doing!research!on!HIV,!which!is!very!common!in!this!country.!We!
are!undertaking!a!study!to!evaluate!the!costs!and!benefits!of!delivering!HIV!testing!in!homes!and!
through!health!facilities!in!Blantyre,!Malawi.!There!may!be!some!words!that!you!do!not!understand.!
Please!ask!me!to!stop!as!we!go!through!the!information!and!I!will!take!time!to!explain.!A!decision!of!
whether!or!not!you!want!to!participate!will!not!affect!your!right!to!access!these!services.!
!
Purpose,of,this,study?,
HIV!testing!allows!individuals!to!learn!their!HIV!status.!Those!diagnosed!as!HIV!positive!can!then!seek!
care!from!health!facilities!to!improve!their!health.!In!Malawi,!many!people!do!not!learn!their!HIV!status!
early!enough.!If!people!who!are!HIV!positive!learn!their!HIV!status!earlier,!they!may!be!less!likely!to!
suffer!from!poor!health!or!die.!This!will!improve!their!survival!and!quality!of!life.!It!may!also!save!them!
money,!as!they!do!not!have!to!go!to!the!clinic!or!hospital!as!often,!or!take!time!of!work!because!of!poor!
health.!It!will!also!save!the!Ministry!of!Health!money,!which!they!could!spend!on!other!health!services.!
!
In!Malawi,!most!people!have!an!HIV!test!at!their!local!clinic.!Recently,!a!new!service!has!been!
introduced,!where!individuals!can!have!a!HIV!test!in!their!homes.!We!want!to!see!if!providing!HIV!testing!
in!peoples!homes!allows!them!to!learn!their!HIV!status!earlier,!and!what!the!impact!of!this!is!on!their!
health.!We!want!to!carry!out!a!questionnaire!study!with!people!who!get!an!HIV!test!through!their!local!
clinic!and!in!their!homes.!We!want!to!compare!what!the!impact!of!using!these!services!is!on!your!quality!
of!life,!your!costs,!and!the!care!you!receive!after!learning!your!HIV!status.!!
!
Procedures!!!
Duration:!The!study!takes!place!over!approximately!18!months!in!total.!!
!
What,will,be,asked,of,you:!We!will!ask!individuals!aged!16!and!over!who!agree!to!participate!in!this!
study!a!set!of!questions!aimed!at!soliciting!information!on!the!following:!their!background,!HIV!testing!
services!used,!HIV!test!result,!costs!of!attending!health!facilities,!their!quality!of!life,!and!health!services!
used.!We!would!also!like!to!meet!with!you!again.!This!will!depend!on!whether!you!are!HIV!positive!or!
HIV!negative.!!
!
!
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If,you,are,HIV,negative,we!would!like!to!meet!with!you!at!your!local!clinic!after!about!1!year!for!brief!
interview.!At!the!follow/up!interview!we!will!ask!whether!you!have!re/tested!for!HIV.!We!will!also!offer!
you!an!HIV!test!if!you!wish!to!be!tested.!!
!
If,you,are,HIV,positive!we!would!like!to!meet!with!you!each!time!you!attend!the!HIV!clinic!for!about!1!
year.!On!each!visit!we!will!ask!a!set!of!set!of!questions!aimed!at!soliciting!information!on!the!following:!
costs!of!attending!the!clinic,!your!quality!of!life,!the!medical!care!provided!at!the!clinic,!and!any!other!
medical!care!you!used!since!the!last!visit.!These!interviews!will!last!approximately!15!minutes.!At!the!
beginning!and!the!end!of!the!study,!we!will!ask!your!clinic!nurse!will!take!a!small!amount!of!blood.!This!
blood!will!be!used!to!test!how!well!your!body!is!coping!with!the!HIV!infection.!This!is!often!done!as!part!
of!routine!care!in!the!clinic.!If!you!are!HIV!positive!and!you!do!not!return!to!the!clinic!for!more!than!3!
months!we!would!like!to!meet!with!you!for!a!brief!interview.!We!will!also!ask!that!you!go!to!your!clinic!
to!see!the!HIV!nurse.!!
!
Participation,is,voluntary:!You!may,withdraw!from!the!study!at!any!time!without!giving!a!reason!and!
without!any!penalty.!!!
!
Cost,,Risks,and,Discomforts:!You!will!be!asked!about!your!HIV!status.!You!may!feel!uncomfortable!to!
discuss!this!topic.!You!do!not!have!to!inform!us!of!your!HIV!status,!you!may!refuse!to!participate,!and!
may!withdraw!from!the!interview!at!any!time.!If!you!withdraw!from!the!interview!you!will!still!be!able!to!
access!HIV!services.!Taking!part!in!this!study!will!not!cost!you!anything.!
!
Benefits:!There!will!be!no!direct!benefit!to!you!from!participation.!!However,!the!information!you!
provide!may!help!improve!HIV!testing!services!in!your!community.!!
!
Reimbursement:!You!will!be!provided!with!refreshments!during!the!interview.!Those!who!have!been!
specifically!asked!to!attend!the!clinic!for!an!interview!will!be!reimbursed!their!travel!costs.!!
!
Confidentiality:!We!will!not!be!sharing!the!identity!of!those!participating!in!the!research!with!anyone.!
The!information!that!we!collect!from!this!research!project!will!be!kept!confidential.!Information!about!
you!that!will!be!collected!during!the!research!will!not!be!identified!by!your!name!but!by!a!number.!Only!
the!researchers!will!know!what!your!number!is!and!they!will!lock!that!information!up!with!a!lock!and!
key.!The!knowledge!that!we!get!from!doing!this!research!will!be!shared!with!you.!There!will!be!small!
meetings!in!the!community!and!these!will!be!announced.!If!information!from!the!study!is!published!or!
presented!at!scientific!or!public!meetings,!your!name!and!other!personal!information!will!not!be!used.!!
!
Approval,for,the,study:,The!College!of!Medicine!Research!Ethics!Committee,!Blantyre,!Malawi!and!the!
University!of!Warwick!Biomedical!Research!Ethics!Committee,!Warwick,!UK!has!approved!this!study.!!
!
Questions:!If!you!have!any!further!questions!about!the!study,!you!may!call!Dr!Hendramoorthy!
Maheswaran!(Principal!Investigator,!Tel:!XXXXXXXXXX) or COMREC chairperson (Tel: 09999 57805) 
!
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!(
Principal Investigator: Dr Hendramoorthy Maheswaran 
Malawi-Liverpool-Wellcome Trust Clinical Research Programme 
PO Box 30096, Chichiri, Blantyre 3, Malawi 
Tel +265 187 6444, Fax +265 187 5774 
www.mlw.medcol.mw  
Chairman of CoMREC: Dr Getrude Chapotera Kalanda 
The College of Medicine of Malawi 
PO Box 360, Chichiri, Blantyre 3, Malawi 
Tel +265 9999 57805 
www.medcol.mw!
Dzina!la!kafukufuku:!Kusalowa!mthumba!kwa!ntchito!yoyeza!HIV!komanso!kupereka!
uphungu!pakhomo!ku!Blantyre,!Malawi!
!
Malonje((
Mwaswela! bwanji,! dzina! langa! ndi! ______________________,! ndimagwira! ntchito! ku! Malawi&Liverpool&
Wellcome0Trust0Clinical0Research0Programme.!Tikupanga!kafukufuku!wa!HIV,!yomwe!!yafala!mu!dziko!muno.!
Tikuchita!kafukufukuyu!pofuna!ku!unika!!mitengo!ndi!phindu!lopereka!ndondomeko!zoyeza!HIV!m’makomo!
komanso! kudzera! ku! zipatala! ! za! ku! Blantyre,! Malawi.! Pakhoza! kupezeka! mau! ena! oti! ! simungathe!
kuwamvesetsa.! Chonde! ndifunseni! kuti! ndiime! kaye! pamene! tikukamba! za! uthengawu! ndipo! ndidzatenga!
nthawi!kufotokozera.! !Chiganizo! chanu!pakufuna!kutenga!mbari!mukafukufukuyu!kapena!ayi! sichizakhudza!
ufulu!wanu!pofuna!kupeza!mwayi!wofuna!kupeza!thandizoli.!
!
Cholinga(cha(kafukufukuyu?(
Kuyezetsa!HIV!kupeleka!mwayi!kwa!anthu!kudziwa!ngati!ali!ndi!HIV!kapena!ayi.!!Onse!amene!angapezeke!ndi!
HIV,!ali!ndi!mwayi!olandira!!chisamaliro!kudzera!ku!ntchito!za!umoyo!pofuna!kukonza!thanzi!la!moyo!wawo..!
Kuno!ku!Malawi,!anthu!ambiri!safuna!kudziwa!mwamsanga!ngati!ali!ndi!HIV!kapena!ayi.!Ngati!anthu!amene!
ali!ndi!HIV!angathe!kudziwa!mwamsanga,!akhoza!kukhala!osadwalaKdwala!komanso!atha!kupewa! imfa! .! Izi!
zidzathandizila! kuti! akhale! ndi!moyo!wautali! komanso! kutengulira!moyo!wawo.! Zikhozanso! kuwathandizila!
kuti! asawononge! ndalama,! popeza! sayenera! kupita! ku! chipatala! cha! ching’ono! kapena! chachikulu! pafupiK
pafupi,! kapena! kujomba! ku!ntchito! chifukwa! chodwalala.! Zimenezi! zizathandiziranso!unduna!wa! za!umoyo!
kuti!usaononge!ndalama,!zimene!zingathe!kugwira!ntchito!zina!za!umoyo.!!
!
Ku!Malawi,!anthu!ambiri!amakayezetsa!HIV!ku!zipatala!zazing’ono!za!mdela!lawo.!Posachedwapa,!thandizo!la!
tsopano! lakhazikitsidwa,! limene! anthu! angathe! kuyezetsa! ! HIV!m’makomo!mwawo.! ! Tikufuna! kuona! ngati!!
ndondomeko!!yoyeza!HIV!m’makomo!mwa!anthu,!ikuthandiza!!anthu!!kudziwa!mwamsanga!!ngati!ali!ndi!HIV!
kapena!ayi,!komanso!gwero! limene!ndondomekoyi! ! liri!nalo!pa!thanzi! lawo.!Tikufuna!tipange!dongosolo! ! lo!
funsa! ! anthu! amene! ayezetsa! HIV! ku! zipatala! zazing’onoKzing’ono! za! mdela! lawo! ! komanso! m’makomo!
mwawo.! Tikufuna! tisiyanitse! gwero! limene! lingakhalepo! pa! thanzi! lawo! chifukwa! chogwiritsa! ntchito!
thandizoli,ndalama!zimene!amagwiritsa!ntchito,!komanso!chisamaliro!chimene!alandira!atadziwa!kuti!ali!ndi!
HIV.!
!
Ndondomeko(!
Nthawi(yotalika(bwanji:!kafukufukuyu!atenga!nthawi!yotalika!pafupifupi!!miyezi!18!yonse!pamodzi.!!
(
Kodi(mudzafunsidwa(chani:!!Tidzafunsa!anthu!amene!ali!ndi!zaka!16!kupita!mtsogolo,!amene!angavomereze!
kutenga!nawo!mbari!mukafukufukuyu,!kudzera!mu!gulu!la!mafunso!ndi!cholinga!chofuna!kupeza!mayankho!
pa!nkhani!monga:!chiyambi!chawo,njira!zoyezera!!HIV!zimene!agwiritsapo!ntchito,!zotsatira!!za!kuyezetsa!HIV!
kwao,! ndalama! zimene! amagwiritsa! ntchito! ! akamapita! ku! zipatala,! m’mene! moyo! wawo! uliri,! komanso!
thandizo!la!za!umoyo!lomwe!agwiritsa!ntchito.!Tidzafuna!kukumananso!nanu!kachiwiri.!Izi!zidzatengera!ngati!
muli!ndi!HIV!kapena!mulibe.!!
Kusalowa(Mthumba(kwa(ntchito(yoyeza(ndi(Kupereka(uphungu(wa(HIV(((((( (((((((((
HTC>101:(Kalataya(uthenga(kwa(otenga(nawo(mbari(((Chichewa(Version)(
Participant Information Leaflet (English Version) v2.0 Last Modified: 16/12/2012 – Page 2 of 2 
!
(
Ngati(mulibe(HIV(tidzafuna!kuti!tikumane!nanu!kudzera!ku!chipatala!cha!mdela!lanu!pakatha!chaka!chimodzi!
kuti!tidzakufunseni!mafunso!mwa!chidule.!Pa!nthawiyi!tidzafuna!kudziwa!ngati!munayezetsanso!HIV!komanso!
tidzakupatsani!mwayi!oti!muyezetse!HIV,!ngati!mungafune!kutero.!!
!
Ngati(muli(ndi(HIV(tidzafuna!kukumana!nanu!nthawi!zonse!mukapita!ku!chipatala!kokalandira!thandizo!la!HIV!
kwa! chaka! chimodzi.! Nthawi! zonse! tikakumana! nanu! tidzakufunsani! mafunso! ofuna! kupeza!mayankho! pa!
nkhani! izi:! ndalama! zimene!mwagwiritsa! ntchito! ! popita! ku! chipatala,! thanzi! la!moyo!wanu!m’mene! liriri,!
mtundu! wa! chisamaliro! chimene! mumalandira! ku! chipatalako,! ndi! zisamaliro! zina! zimene! munalandirapo!
kuchokera! nthawi! imene! tinakumana! ! komaliza.! Ndondomeko! ya! mafunsoyi! idzatitengera! pafupiKfupi!
mphindi!15.!Poyambilira!komanso!pamapeto!a!kafukufukuyu,! tidzapempha!namwino!wa!kuchipatala!chanu!
kuti! akutengeni! magazi! pang’ono.! ! Magaziwa! adzagwiritsidwa! ntchito! kuyeza! m’mene! thupi! lanu!
likuthanilana!ndi! tizilombo!ta!HIV.! ! Izi! zimachitika!monga!mbali! imodzi!ya!chisamaliro!cha!masiku!onse!cha!
kuchipata.! Ngati!muli! ndi! HIV! ndipo! simunabwelenso! ku! chipatala! koposela!miyezi! 3,! tidzafuna! kukumana!
nanu! kuti! tikufunseni! mafunso! mwachidule.! Tidzakupemphaninso! kuti! mudzapite! ku! chipatala! chanu! kuti!
mudzakakumane!ndi!namwino!amene!amakhudzana!ndi!ndondomeko!za!HIV.!!
!
Kutenga( nawo(mbaliku( ndi( kozipereka:! !mukhoza! kutuluka!mukafukufukuyu! nthawi! ina! iriyonse! popanda!
kupereka!chifukwa!chirichonse!komanso!popanda!kulipira!chindapusa!china!chirichonse.!!!
!
Mtengo(,(chiopsyezo(ndi(Nkhawa:!mudzafunsidwa!zokhudzana!ndi!m’mene!mthupi!mwanu!muliri.!!Mukhoza!
kukhala!osamasuka!kukambirana!za!!nkhaniyi.!simukuyenera!kutidziwitsa!za!m’mene!mthupi!mwanu!muliri,!
mukhoza! kukana! kutenga! nawo! mbari,! komanso! kutuluka! mu! kafukufukuyu! nthawi! ina! iriyonse.! Ngati!
mungfune! ! kutuluka!mukafukufukuyu!mudzakhalabe! ndi!mwayi! opeza! chithandizo! cha! HIV.! ! Simudzalipira!
chirichonse!chifukwa!choti!mwatenga!nawo!mbari!mukafukufukuyu.!!
!
Phindu:!sipadzakhala!phindu!lina!lirilonse!looneka!kwa!inu,!mukalora!!kutenga!nawo!mbari,!Komabe,!mfundo!!
zimene!mutapereke,!zikhoza!kukonza!mwatsopano!ntchito!za!ku!yezetsa!HIV!!mu!dela!lanu.!!
!
Kubwezeredwa( ndalama:! mudzapatsidwa! za! kumwa! zoziziritsa! kukhosi! pa! nthawi! ya! mafunsoyi.! Anthu!
amene!afunsidwa!kuti!apite!ku!chipatala!kuti!akafunsidwe!mafunso!azabwezeredwa!ndalama!zawo!zimene!
anga!gwiritse!ntchito!pa!mayendedwe.!!!
!
Chinsinsi:!!sitidzagawana!za!maina!a!anthu!otenga!nawo!mbari!mukafukufukuyu!!!ndi!wina!aliyense.!Mfundo!!
zomwe!zidzapelekedwe!!kuchokera!ku!kafukufukuyu!!zidzasungidwa!mwa!!chinsinsi.!Nkhani!!yokhudzana!ndi!
inu! imene! tidzakambirane! !nthawi! imene!kafukufukuyu!azidzachitika! siidzadziwika!ndi!dzina! lanu!koma!ndi!
nambala.!Ndi!anthu!ochititsa!kafukufukuyu!okhawo!amene!angazadziwe!!kuti!nambala!yanu!ndi!chani,!ndipo!
adzatsekera! uthengawo! ndi! loko! komanso! kiyi.! Tidzagawana! nanu! nzeru! zimene! tingapeze.! kudzera!
mukafukufukuyu.! Kudzachitika! ! timisonkhano! ting’onoKting’ono! m’madelamwanumo! potsatira!
kulengezedwa.! Ngati! mfundo! zochokera! mukafukufukuyu! ziti! zizalembedwe! kapena! kufalitsidwa!
m’misokhano!!dzina!lanu!kapena!khani!ina!iriyonse!yokamba!zainu!!sizidzagwiritsidwa!ntchito.!
!!
Chilorezo(chobvomereza(kuti(kafukufukuyu(achitikee:( (komiti! yoyang’anira! za!makafukufuku!ya!College&of&
Medicine& Research& Ethics,! ku! Blantyre,! Malawi! ndi! komiti! ya! university! ya! Warwick! Biomedical! Research,!
Warwick,!ku!UK!yavomereza!kafukufukuyu.!!
!
Mafunso:( Ngati! mungakhale! ndi! mafunso! ena! okhudzana! ndi! kafukufukuyu,! mukhoza! kuyimbira! foni! Dr!
Hendramoorthy! Maheswaran! (mkulu! woyendetsa! kafukufukuyu! pa! nambala! iyi:! 0996151939) kapena wa 
pampando wa COMREC  pa nambala iyi: 09999 57805 
!
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Appendix VIII: Consent form 
(English version) – HIV testing and 
HIV cohort studies 
 
 
 
 
 
 
 
 
 
 
Cost%effectiveness,of,HIV,Testing,and,Counselling,,, ,,,,,,,,,,,,
!
HTC%102:,Consent,Form,(English,version),,
Consent Form (English Version) v1.0 Last Modified: 03/12/2015 – Page 1 of 1 
!
!,
Principal Investigator: Dr Hendramoorthy Maheswaran 
Malawi-Liverpool-Wellcome Trust Clinical Research Programme 
PO Box 30096, Chichiri, Blantyre 3, Malawi 
Tel +265 187 6444, Fax +265 187 5774 
www.mlw.medcol.mw  
Chairman of CoMREC: Prof JM Mfutso-Bengo 
The College of Medicine of Malawi 
PO Box 360, Chichiri, Blantyre 3, Malawi 
Tel +265 9999 57805 
www.medcol.mw!
Study!Title:!! Cost/effectiveness!of!Home/based!HIV!Testing!and!Counselling!in!
Blantyre,!Malawi!
!
• I!have!been!invited!to!participate!in!this!study!comparing!the!costs!and!benefits!of!HIV!testing!through!home!
and!clinic!based!services!
• I!have!received,!read!and!understood!the!written!information!(Participant!Information!Leaflet)!regarding!the!
study!
• I!understand!that!it!will!involve!follow/up!interviews!!
• I!have!been!informed!that!the!risks!are!minimal!!
• I!am!aware!that!there!may!be!no!benefit!to!me!personally!and!that!I!will!not!be!compensated!beyond!travel!
expenses!and!refreshments.!
• I!may,!at!any!stage,!without!prejudice,!withdraw!my!consent!and!participation!in!the!study.!
• I!have!been!provided!with!the!name!of!a!researcher!(Dr!Hendramoorthy!Maheswaran)!who!can!be!easily!
contacted!using!the!number!and!address!I!was!given!for!that!person.!
• I!have!had!sufficient!opportunity!to!ask!questions!and!(of!my!own!free!will)!declare!myself!prepared!to!
participate!in!the!study.!!
!!
____________________________!!!!!!!!!!!_____________________________!!!!!!!!!___________________!
Participant’s!name!(print)! ! !!!!!!!!!Participant’s!signature!! ! !!!!!!!!!!!!!!!Date!
!
!
I!have!accurately!read!or!witnessed!the!accurate!reading!of!the!consent!form!to!the!potential!
participant,!and!the!individual!has!had!the!opportunity!to!ask!questions.!I!confirm!that!the!individual!has!
given!consent!freely."
_____________________________!!!!!!!!!_____________________________!!!!!!!!!!__________________!
Name!of!staff!member!(print)! !!!!!! !!!!!!!!!!!Staff!member’s!signature! !! !!!!!!!!!!!!!!!Date!
who!administered!consent!
!
IF!ILLITERATE,!a!literate!witness!must!sign.,
,
I!have!witnessed!the!accurate!reading!of!the!consent!form!to!the!participant,!and!the!individual!has!had!
the!opportunity!to!ask!questions.!I!confirm!that!the!individual!has!given!consent!freely.!
______________________________!!!!!!______________________________!!!!!!!!!!!!________________!
Witness’!name! !(print)!!! !!!!!!!!!!!!!!!!!!!!!!!!!!!!Witness’!signature! ! !!!!!!!!!!!!!!!Date!
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Appendix IX: Consent form 
(Chichewa version) – HIV testing 
and HIV cohort studies 
 
 
 
 
 
 
 
 
 
 
Kusalowa(mthumba(kwa(ntchito(yoyeza(ndi(Kupereka(uphungu(wa!HIV( ((
HTC=102:(Kalata(ya(chilolezo((Chichewa Version)(((
Kalata ya chilolezo (Yotanthauzira kuchokera ku  chingerezi) v2.0 Last Modified: 03/12/2015 – Page 1 of 1 
!
!(
Principal Investigator: Dr Hendramoorthy Maheswaran 
Malawi-Liverpool-Wellcome Trust Clinical Research Programme 
PO Box 30096, Chichiri, Blantyre 3, Malawi 
Tel +265 187 6444, Fax +265 187 5774 
www.mlw.medcol.mw  
Chairman of CoMREC: Dr Getrude Chapotera Kalanda 
The College of Medicine of Malawi 
PO Box 360, Chichiri, Blantyre 3, Malawi 
Tel +265 9999 57805 
www.medcol.mw!
Mutu!wa!kafukufuku:!! Kusalowa!mthumba!kwa!ndondomeko!yoyezetsa!!HIV!!
ndikulandira!uphungu!pakhomo!!ku!Blantyre,!Malawi!
!
• Ndaitanidwa!kudzatenga!nawo!mbari!mukafukufuku!ofuna!kusiyanitsa!kuipa!ndi!ubwino!wa!pakati!poyezetsa!
HIV!ku!nyumba!ndi!!ku!chipatala!!
• Ndalandira,!ndawerenga!ndi!kumvesetsa!bwino!uthenga!olembedwawu!(Kalatayla!uthenga!wa!otenga!nawo!
mbari)!okhudzana!ndi!kafukufukuyu!
• Ndamvesetsa!kuti!padzakhala!!ndondomeko!yo!yankha!mafunso!motsatana!
• Ndadziwitsidwa!kuti!!chiopsyezo!kwa!ine!pakutenga!nawo!mbali!pakafukufukuyu!!ndi!chochepa!!
• Ndikudziwa!kuti!palibe!phindu!lirilonse!kwa!ine,!!komanso!sindidzapatsidwa!ndalama!ina!kupatula!ndalama!yo!
yendera!!ndi!zakumwa!zoziziritsa!ku!khosi.!
• !Ndikhoza,nthawi!iriyonse,!popanda!kusalidwa,!kukaniza!chilorezo!changa!!komanso!kukana!kutenga!nawo!
mbari!mukafukufukuyu.!
• Ndapatsidwa!dzina!la!opangitsa!kafukufukuyu!(Dr!Hendramoorthy!Maheswaran)!!amene!angathe!
kulumikizidwa!mosavuta,!pogwiritsa!ntchito!nambala!ndi!adilesi!imene!ndinapatsidwa,!ya!munthuyu.!
• Ndakhala!ndi!mwayi!okwanira!oti!ndifunse!mafunso!komanso!(mwakufuna!kwanga)!ndikuvomereza!kuti!ndine!
okonzeka!kutenga!nawo!mbari!mukafukufukuyu.!!
!!
____________________________!!!!!!!!!!!_____________________________!!!!!!!!!___________________!
Dzina!la!otenga!nawo!mbari!(zilembo!zikulizikulu)! !!!!!Sayini!!ya!otenga!nawo!mbari!! ! !!Tsiku!
!
!
Ndawerenga!kapena!kuonelera!!kuwerenga!koyenelera!kwa!kalata!ya!chilolezo!kwa!otenga!nawo!mbari!
moyenelera,!ndipo!munthuyu!anali!ndi!mwayi!ofunsa!mafunso.!Ndikuvomereza!kuti!munthuyu!
wapereka!chilolezo!mwaufulu."
"
_____________________________!!!!!!!!!_____________________________!!!!!!!!!!__________________!
Dzina!la!munthu!ogwira!ntchito!(zilembo!za!zikulu)! !!!sayini!ya!munthu!ogwira!ntchito!!!!!!!!!!!!!!!!!!!!!!!!!!Tsiku!!!!!!!!!
amene!anatsogolera!!ndondomeko!ya!chilolezo!!!!!!!!!!!!!!!!!!
!
NGATI!SATHA!KULEMBA!NDI!KUWERENGA!,!amene!amatha!asayinire!ngati!mboni.(
(
Ndaonelera! kuwerenga! koyenelera! kwa! kalataya! chilolezo! kwa! otenga! nawo!mbari,! ndipo!munthuyu!
anali!ndi!mwayi!ofunsa!mafunso.!Ndikuvomereza!kuti!!munthuyu!wapereka!chilolezochi!mwa!ufulu.!
!
______________________________!!!!!!______________________________!!!!!!!!!!!!________________!
Dzina!la!Mboni! !(zilembo!za!zikulu)!! ! sayini!!ya!mboni! !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!Tsiku!
Study!ID!Barcode!
!
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Appendix X: HTC-103 Baseline 
socio-demographics questionnaire – 
HIV testing and HIV cohort studies 
 
 
 
 
 
  
 
 
 
  d        d          m      o     n            y        y      y       y
Cost-effectiveness of HIV Testing and Counselling
HTC-103: Baseline Questionnare
P01 HHBAR Participant
Barcode
P02 HHID Interviewer ID CLUSIDP03 Cluster ID
P04 SIT Place of interview 1. Participant Home
2. Chilomoni Clinic
3. Queens Hospital
4. Ndirande Clinic
DOIP05 2  0  1
P06 NAM Physical
Address
P08 TEL Telephone number of Participant (1st)
P12 DOB Tsiku lobadwa
Date of Birth
AGEP13 Age
P14 SEX Sex 1. Male 2. Female
P15 PREG Ngati ndinu mkazi, kodi muli ndi pakati?
If female, are you pregnant?
1. Yes
2. No
99. N/A
P16 PREGM Kodi mwakhala ndi pakati kwa miyezi ingati?
Months pregnant Write 99 if Not Applicable
P17 MARSTC Kodi muli pa banja?
What is your marital status?
(TICK ONE)
1. Married
2. Polygamous marriage
3. Living together as married
4. Never Married
5. Separated
6. Widower/Widow
7. Divorced
Years
PLACE ID
BARCODE HERE
Date of interview
Version no: 1.0 Last modified by HM 02/28/2013 Page 1 of 4
  d        d          m      o     n            y        y      y       y
P09 TEL2 Telephone number of Participant (2nd)
P10 TEL3 Telephone number of Partner,Spouse,or Family Member
P11 TEL4 Telephone number of Family Member at
participants home village
P07 NAM2 Draw Map
to Home
Mapbook Reference: Page Grid
Write Participants Barcode
3827066923
Kodi pakhomo pano muli ndi zinthu izi?
Does your household own any of the following (please tick all that apply)?
P21 FRIDG Fridge?
Car?
Bed?
Television?
Motorcycle?
Watch?
Phone?
Koloboyi?
Radio?
P22 HHCARM1
P23 BED
P24 TELEV
P25 HHCARM2
1. Yes 2. No
1. Yes 2. No
1. Yes 2. No
1. Yes 2. No
1. Yes 2. No
1. Yes 2. No
1. Yes 2. No
1. Yes 2. No
1. Yes 2. No
P26 WATCH
PHONP27
P28 KOLO
RADIOP29
P30 LAND Kodi alipo m'modzi wam'banja limeneli amene ali ndi malo olima?
Does any member of your household own any agricultural land?
1. Yes
2. No
P31 SHFOOD M'mwezi wathawu, mwakhalapo ndi mavuto pakapezedwe ka chakudya
mowilikiza bwanji?
During the past month, how often have you had
problems getting the food you need?
1. Never
2. Sometimes
3. Often
4. Always
P32 SKPML M'sabata ziwiri zapitazi alipo munthu wankulu pakhomo pano amene sanadye kapena kudya
mopelewera ndi cholinga choti ana akhale ndi chakudya chokwanira?
In the past two weeks, has an adult in your house skipped a meal
or ate less in order for there to be enough for the children?
1. Yes
2. No
P33 HROOM Kodi mnyumba mwanu muli zipinda zingati kuphatikiza makitchni?
How many rooms,including kitchens, are there in your home?
P34 HWAT Kodi madzi ogwiritsa ntchito pakhomo pano
mumatunga kuti?
At your home, in which way do you
obtain water for domestic use
(TICK ONE)?
1. Piped water inside the dwelling
2. Piped water inside the yard
3. Piped water at kiosk
4. Borehole/well
5. River/Stream
6. Other
HWATDP35 Kodi komwe mumakatunga madzi mungati ndi kotalika bwanji?
At your home,what is the distance to the
closest water access point?
1. Less than 200m
2. Between 200m & 500m
3. Between 500m & 1km
4. More than 1km
Specify,if other
HTC-103: Baseline Questionnare
Version no: 1.0 Last modified by HM 02/28/2013 Page 2 of 4
P19 TOGYRS Kodi mwakhala limodzi ndi okondedwa anu kwa nthawi yayitali bwanji?
How long have you been together with your
spouse/partner? Months
Years
P20 SCH Kodi maphuziro anu munafika nawo pati?
What is the highest level of formal
schooling you have ever attended? PRESCHO = 00
STAND 1 = 01
STAND 2 = 02
STAND 3 = 03
STAND 4 = 04
STAND 5 = 05
STAND 6 = 06
STAND 7 = 07
STAND 8 = 08
UNIVE 4 = 18
UNIVE 3 = 17
UNIVE 2 = 16
UNIVE 1 = 15
FORM 6 = 14
FORM 5 = 13
FORM 4 = 12
FORM 3 = 11
FORM 2 = 10
 FORM 1 = 09
ABOVE = 19
TRAIN COL
TCYR 1 = 20
TCYR 2 = 21
TCYR 3 = 22
TCYR 4 = 23
P18 PARTNER Ngati simuli pabanja kodi muli ndichibwenzi
If NOT MARRIED, do you have a partner
at the moment?
1. Yes
2. No
99. N/A
ID
5030066921
Kodi pamasabata anayi apitawa munalembedwapo
ntchito yolipidwa?
1. Yes, Formal Work
2. No, Informal Work
3. On Sick Leave
4. Retired
5. At School, University
6. Housework
7. Other, Specify
Over the last 4 weeks have you been
formally employed(TICK ONE)?
P40 EMPL
P41 MASAL Pa ntchito yanu yeni yeni, kodi ndi chani cheni cheni chimene mumachita kumalo anu antchito?
In your MAIN JOB, what is the main activity at the place of work? (TICK ONE)
99. Not Applicable
1. Agriculture, Forestry, Fishing
2. Mining and Quarrying
3. Manufacturing
4. Electricity, Water, Other Utilities
5. Construction
6. Wholesale and Retail Marketing, Hotel/ Restaurants
7. Transport and Communication
8. Finance and Business
9. Social and Community Services
10. Other, Specify
P42 MAHOU Pa ntchito yanu yeni yeni, kodi ndi maola angati amene mumagwira pa sabata?
In your MAIN JOB, how many hours do you work a week?
Specify,if other
Specify,if other
HTC-103: Baseline Questionnare
Version no: 1.0 Last modified by HM 02/28/2013 Page 3 of 4
P38 HLIT Kodi pakhomo pano mumagwiritsa
ntchito chiyani powunikira?
At your home, what is your
main source of lighting
(TICK ONE)?
1. Collect firewood
2. Buy firewood
3. Batteries
4. Paraffin
5. Animal waste
6. Electricity
7. Candles
8. Charcoal
9. Crop residue/Grass
10. Saw dust
P39 PINC Pa masabata anayi apitawa, kodi ndi ndani amene
wakhala wopeza ndalama weni weni m'banjali?
Over the last 4 weeks, who has been
the primary income earner in the
household (TICK ONE)?
1. I  Have
2. Husband/Wife
3. Father
4. Mother
5. Son
6. Daughter
7. Extended Family
8. Other, Specify
Specify,if other
P43 PINCOM Kodi mumapeza ndalama zingati kuwerengera zonse PAMODZI pa
sabata? (asanachotse msonkho/ kapena china chili chonse) MKWhat is your TOTAL estimated income per week from
all sources (Before tax/deductions)
P36 HTOL Kodi pakhomo pano mumagwilitsa ntchito chimbudzi
cha mtundu wanji?
At your home, what is the MAIN type of
toilet facility available for use by
your household? (TICK ONE)
1. Flush toilet
2. Ventilated pit latrine (VIP)
3. Non-Ventilated pit latrine
4. None
P37 HTOLSH Kodi mumagwiritsa ntchito chimbuzi chimenechi ndi mabanja ena? 1. Yes
2. NoDo you share this toilet facility with other households?
Hours
ID
9242066920
HOH
Mafunso osatirawa ndi okhuza anthu amene mumakhala nawo m'banja mwanu. Amenewa ndi anthu
amene nthawi zambiri mumakhala nawo ndikudyera limodzi zakudya m'banja mwanu.
The following questions are about members of your household. These are individuals who
normally live and share meals in your household.
P44 HHNA Limodzi ndi inuyo, kodi mnyumba mwanu mumakhala anthu aakulu angati (azaka
zobadwa khumi zisanu ndi zitatu kapena kuposera pamenepa)?
Including yourself, how many adults (aged 18 years and
over) live in the household?
P45 HHNC Kodi mnyumbamu mumakhala ana angati (azaka zobadwa zosapitirira zakubadwa
khumi zisanu ndi zitatu)?
How many children (aged under 18 years of age) live in the
household?
P46 Kodi inu ndinu mwini/mkulu wa banja limeneli?
Are you the head of the household?
1. Yes
2. No
P47 HOUSINC
What is the combined TOTAL household income per
week from all sources? (Ask participant to include
the income of all members of the household
including themselves)
Write '888888' if participant does not know
Kodi zonse pamodzi pakhomo pano mumapeza ndalama zingati kuchoka
kulikonse? (Funsani wotenga nawo mbali kuti aphatikize ndalama
zomwe onse pakhomopo amapeza kuphatikizapo iwo eni)
MK
DATA OFFICE USE ONLY
Data Officer  IDDIDP48 P49 DDATE Date formchecked 2  0  1
  d        d          m      o     n         y        y      y       y
Version no: 1.0 Last modified by HM 02/28/2013 Page 4 of 4
HTC-103: Baseline Questionnare ID3698066929
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Appendix XI: HTC-104 Post HIV 
testing questionnaire: Patient costs 
and health-related quality of life – 
HIV testing and HIV cohort studies 
 
 
 
 
 
 
 
 
 
Cost-effectiveness of HIV Testing and Counselling
HTC-104: Post HIV Testing and Counselling
Q01 HHBAR Participant
Barcode
Q02 HHID Interviewer ID CLUSIDQ03 Cluster ID
Q04 SIT Place of interview
1. Participant Home
2. Chilomoni Clinic
3. Queens Clinic
4. Ndirande Clinic
DOIQ05
Q06 DOT
Q07 LOC
Where did you have your recent HIV test?
Q08 RES Zotsatila zoyezetsa HIV
HIV test result
Q09 COU Kodi munayezetsa limodzi ndi okondedwa anu?
Did you test as a Couple? (Couples Testing)
Does not necessarily have to be husband/wife
PLACE ID
BARCODE HERE
Date of interview
Version no: 1.0 Last modified by HM 02/28/2013 Page 1 of 6
Tsiku limene anayezedwa HIV (lembani tsiku
lalero ngati ayezedwa lero)?
Date of HIV Test (Write todays
date if tested today)
Kodi kunali kuti kumene munakayezetsa HIV posachedwapa?
1. At Home: Oral Self-testing in presence of counsellor
2. At Home: Oral Self-testing in Private
3. At Home: Finger Prick VCT (not from Hit-TB Study)
4. HIV Testing Clinic: Refered by Antenatal clinic (ANC)
5. HIV Testing Clinic: Refered by TB clinic
6. HIV Testing Clinic: Refered by health professional(not TB, not ANC)
7. HIV Testing Clinic: Went solely to learn my HIV status
8. Mobile Testing Service
9. Private healthcare provider
10. Other, Specify
1. Positive
2. Negative
3. Not disclosed
4. Invalid/indeterminate
5. Not done
Q10 COUYR Ngati ndi choncho, kodi patha zaka zingati
chiyezetsereni limodzi ndi okendedwa anu?
If yes, years together as a couple?
1. Less than 1yr
2. Between 1 and 5yrs
3. More than 5yrs
4. NOT APPLICABLE
  d        d          m      o     n             y        y      y       y
2  0  1
  d        d          m      o     n             y        y      y       y
2  0  1
Q11 COURES  Zotsatira za kuyezetsa HIV kwa munthu
amene anayezetsa ngati banja?
HIV test result of individual
who tested as couple with you?
1. Positive
2. Negative
3. Not disclosed
4. Invalid/indeterminate
5. Not done
99. NOT APPLICABLE
Specify,if other
Write Participant Barcode
1. Yes
2. No
0717593035
HTC-104: Post HIV Testing and Counselling
Q12 TRA
Q13 TRAT
Q14 WAIT
How long did you spend at the clinic in TOTAL (from
arriving to leaving)? For home self-testing, total time
spent waiting at counsellors home
Q17 WORK Kodi munayeneka kupempha nthawi yopuma kuntchito kuti mukayezedwe?
Did you have to take time off work to get tested?
1. Yes
2. No
Kodi munatenga nthawi yayitali bwanji kuti mukafike kumalo oyezetsera HIV?
(Pankhani yoziyeza nokha panyumba, muwerengere limodzi ndi nthawi imene
anatenga kuti akafike kwa wopereka uphungu wammudzi kuti akatenge
chipangizo choziyezera)
How long did it take you to get to HIV testing
site?(For home self-testing, include time taken to
visit counsellor to pick up test kit) One-way travel
Write '0' if tested at home
Kodi munatenga nthawi yayitali bwanji kuti muthandizidwe (pamene munafika
kufikira nthawi yimene munathandizidwa)?
Q18 WORK2 Ngati ndi choncho, kodi munapempha masiku/maola kapena masiku
angati kuntchito?
IF YES, how many days/hours did you take off?
Write '0' if did not take time of work
Write '88' if not working
Kodi munayenda bwanji kukafika kumalo oyezetsera HIV?
How did you get to the HIV testing site?(For
home self-testing, how did participant travel
to community counsellor to pick up test kit)
1. Tested in my home
2. Walked
3. Public transport
4. Own transport
5. Other, Specify
Mafunso amenewa akukhuza zomwe munakumana nazo poyezetsa HIV chapompano
These questions refer to your recent HIV testing experience
Q15 TRAM Kodi munagwiritsa ntchito ndalama yina yiriyonse pamayendedwe kuti mukafike kumalo
oyezetsera?
Did you spend any money on transportation to get there/here?
(including for petrol/diesel)
Q16 TRAM2 Ngati munagwiritsa ntchito ndalama pamayendedwe, kodi munagwiritsa
ntchito ndalama zingati?
If you did spend money on transportation, how much
did you spend?(Cost for one-way travel)
Write '0' if did not spend any money
MK
Hours
Days
1. Yes
2. No
Hours
Minutes
Minutes
Hours
ID
Version no: 1.0 Last modified by HM 02/28/2013 Page 2 of 6
Specify,if other
If you did spend money on food/drinks, how much
did you spend?
Write '0' if did not spend any money
Ngati munagwiritsa ntchito ndalama pa chakudya kapena zakumwa,
kodi munagwiritsa ntchito ndalama zingati?
FOOD2Q20
MK
Did you spend any money on food/drinks whilst waiting
to be seen?
Kodi lero munagwiritsa ntchito ndalama yina yiliyonse pa chakudya kapena
zakumwa panthawi imene mumadikira kuti muonedwe?
FOOD1Q19 1. Yes
2. No
9625593032
Q27 FAM3
How much money did they spend on transportation to
accompany you?(Cost for one-way travel)
Write '0' if did not spend any money
Write '99999' if question not applicable
Kodi iwowo anagwiritsa ntchito ndalama zingati pamayendedwe kuti
akuperekezeni inuyo?
Kodi m'bale wanu kapena mzanu wina aliyense anakuperekezani kuti mukayezetse HIV?
Q28 FAM4 Kodi iwowo anagwiritsa ntchito ndalama zingati pachakudya kapena zakumwa
chifukwa choti anakuperekezani inuyo kuti mukayezetse HIV?
How much money did they spend on food/drinks whilst
waiting with you?
Write '0' if did not spend any money
Write '99999' if question not applicable
Did any family member or friend accompany you to get your
HIV test done?
1. Yes
2. No
Q24 FAM
Ngati ndi choncho, kodi iwowo anapempha masiku/maola kapena matsiku opuma
kuntchito angati kuti akuperekezeni?
If yes, how many days/hours did they take off work to
accompany you?
Write '0' if did not take time off work
Write '99' if question not applicable
Write '88' if not working
Q25 FAM1
MK
MK
Hours
Days
MK
Kodi munagwiritsa ntchito ndalama zingati pa chinthu chimenechi?
How much did you spend on this?
Write '99999' if question not applicable
OTH3Q23
Specify what you
spent money on?
Tchulani chinthu chimene
munagwiritsirapo ntchito
ndalama?
OTH2Q22
Did you spend any money on anything else as a result of
going to get the HIV test done?
Kodi munagwiritsa ntchito ndalama yina yiriyonse pachinthu chirichonse china chifukwa
chopita kuti mukayezetse HIV?
OTH1Q21 1. Yes
2. No
ID
HTC-104: Post HIV Testing and Counselling
Version no: 1.0 Last modified by HM 02/28/2013 Page 3 of 6
MKHow much money did they spend on this?
Write '0' if did not spend any money
Write '99999' if question not applicable
Kodi zinali ndalama zingati zimene anagwiritsa ntchito pachinthu chimenechi?FAM7Q31
Specify what they
spent money on
Tchulani chinthu chimene
iwowo anagwiritsirapo
ntchito ndalama
FAM6Q30
Q29 FAM5 Kodi iwowo anagwiritsa ntchito ndalama yina yiriyonse pachinthu chirichonse
china chifukwa choti anakuperekezani inuyo kuti mukayezetse HIV?
Did they spend any money on anything else as a result
of accompanying you to get the HIV test done?
1. Yes
2. No
Q26 FAM2
If they work, how much do they normally earn per
day?
Write '99999' if question not applicable
Write '88888' if participant does not know
Ngati amagwira ntchito, kodi amapeza ndalama zochuluka bwanji pa tsiku?
MK
4363593036
HTC-104: Post HIV Testing and Counselling
Nkhawa/Khumudwa? (Osasangalala)Q37 ANX
Q36 PAIN Ululu/kuphwanya m'thupi kusowetsa mtendere?
1. Ndilibe ululu kapena sindikumva kuphwanya m'thupi
2. Ndimakhala ndi ululu kapena kumva kuphwanya m'thupi mwapakatikati
3. Ndimakhala ndi ululu kapena kumva kuphwanya m'thupi kwambiri
1. Sindikuda nkhawa kapena kukhumudwa
2. Ndimakhala oda nkhawa kapena okhumudwa mwapakatikati
3. Ndimakhala oda nkhawa kapena okhumudwa kwambiri
ID
1. Ndilibe mavuto ali onse pogwira ntchito zanga za nthawi zonse
2. Ndili ndi mavuto ena pang'ono pogwira ntchito za nthawi wonse
3. Ndimalephera kugwira ntchito zanga za nthawi zonse
Zochitika za tsiku ndi tsiku (monga kugwira ntchito, kuwerenga,ntchito za pakhomo, za m'banja
kapena kuchita zimene zimandisangalatsa)
USUALQ35
1. Ndilibe vuto podzisamalira ndekha
2. Ndimakhala ndi mavuto ena posamba kapena podziveka ndekha
3. Ndimalephera kusamba kapena kudziveka ndekha
Kudzisamalira ndekha(mwachitsazo kusamba ndi kudziveka ndekha)SELFQ34
1. Ndilibe vuto lina lililonse poyenda
2. Ndimakhala ndi mavuto ena poyenda
3. Ndimangobindikira pa kama
MayendedweMOBQ33
Chongani mu gulu lilironse pansipa, chonde sonyezani mfundo
zimene zikufotokoza bwino za umoyo wanu.
Q32 GEN Kodi munganene kuti umoyo wanu uli bwanji?
How would you rate your general
health?
1. Bwino kwambiri
2. Wabwino
3. Bwino pang'ono
4. Si uli bwino
5. Si uli bwino mpang’ono pomwe
Version no: 1.0 Last modified by HM 02/28/2013 Page 4 of 6
Mafunso amenewa akukukhuza ulendo uwuwu
These questions refer to this visit
3490593036
Kuti tithandize anthu
kunena za umoyo wawo,
tajambula mlingo woyesela
(chofanana ndi choyesela
kuzizila/kutentha kwa
m'thupi) womwe umoyo
wabwino wayerekezedwa ndi
chizindikiro cha 100
ndipo umoyo woipa
wayelekezedwa ndi
chizindikiro cha 0
Tikufuna mutisonyeze pa
mlingowu mmene umoyo
ulili lero kuti uli
bwino kapena suli bwino
mmene inu mukuganizira.
Lembani mzere kuchokera
pa bokosi pansipa kupita
pa mlingo woyesera umene
ukufotokoza za ubwino
kapena kuipa kwa mmene
umoyo wanu ulili lero.
Mmene
umoyo wanu
ulili lero
Q38 VAS Write Participants Score Below:
9     0
8      0
7      0
6      0
5       0
4       0
3       0
2      0
1      0
100
Kuyerekezedwa kuti 
umoyo si uli bwino
0
Kuyerekezedwa kuti umoyo 
uli bwino kwambiri
HTC-104: Post HIV Testing and Counselling ID
Version no: 1.0 Last modified by HM 02/28/2013 Page 5 of 6
3124593030
HTC-104: Post HIV Testing and Counselling
Q41 FAILT Pamene munalephera kuyezetsa
kotsiriza, ndi chifukwa ninji
munalephera kuyezetsa HIV?
For that most recent
failed attempt, why did
you not get the HIV
test done?
1. I changed my mind
2. Clinic/facility closed
3. No HIV counsellor
4. No HIV testing equipment
5. I was told I should wait for the 'Window period"
6. NOT APPLICABLE
9. Other, Specify
Q40 FAIL Mumiyezi khumi ndi iwiri yapitayi, ndikangati munayesa kuyezetsa HIV koma simunathe
kuyezetsa HIV?
Over the last 12 months, how many times have you tried to get
a HIV test, but did not end up having the HIV test? (Failed
Attempt)
ID
Version no: 1.0 Last modified by HM 02/28/2013 Page 6 of 6
Specify,if other
Q39 PAST Mumiyezi khumi ndi iwiri yapitayi, ndi kangati mwayezetsapo HIV mpakana kulandira
zotsatira za kuyezetsako? (Osaphatikizapo kuyezetsa HIV mwapangitsa posachedwapa)
Over the last 12 months, how many times have you had a HIV
test where you completed the HIV test?(Not including this
most recent HIV test)
Have you been to the primary health care
clinic over the last 6 months (Excluding
for TB, Malaria or Trauma)?
Kodi munagonekedwapo kuchipatala chaching'ono miyezi isanu
ndi umodzi yapitayi pa zifukwa zina (kupatula chifukwa cha TB)?
PHCQ44
1. Yes
2. No
IF YES, COMPLETE
HTC-PHC
QUESTIONNAIRE
1. Yes
2. NoHave you been admitted to hospital overthe last 12 months?(Excluding for TB,
Malaria or Trauma)
Kodi munagonekedwapo mchipatala pamiyezi khumi ndi iwiri
yapitayi?
HOSQ43 IF YES, COMPLETE
HTC-HOP
QUESTIONNAIRE
Have you had Tuberculosis in the last 12
months?
Kodi munadwalapo chifuwa chachikulu cha TB pamiyezi khumi
ndi iwiri yapitayi?
TBQ42 1. Yes
2. No
IF YES, COMPLETE
HTC-TB
QUESTIONNARE
Q45 DID Data Officer  ID
DATA OFFICE USE ONLY
Q46 Date form
checked 2  0  1
  d        d          m      o     n         y        y      y       y
DDATE
2463593035
 
 
506 
Appendix XII: Resource use data 
extraction tool 
 
 
 
 
 
 
  
 
 
 
 
Cost%HTC:)Resource)use)data)extraction)tool)
!
!
The!objective!of!this!case!report!form!is!to!collect!information!from!each!of!the!clinics!will!be!done!by!interviewing!a!senior!member!of!staff!in!the!
respective!clinic,!and!listing!all:!
!
• staff!who!work!in!the!department,!including!their!position!
• consumables,!equipment!etc!used!on!the!ward!!
!
The!information!requested!needs!to!completed!in!detail!and!systematically,!obtaining!as!much!information!as!possible!to!ensure!costs!can!be!applied!to!
each!item.!!!!
!
!
)
Clinic/Department:)
)
!
)
Interviewer)Name:)
)
!
)
Information)obtained)from)
(Name,)Mobile)and)Email):)
)
!
)
Date)of)Interview:)
)
!
!
!
!
Page)
Number)
)
Form)to)complete)
3) Staff!and!Personnel!
6) Consumables!(items!lasting!<1!year)!
9) Equipment!(items!lasting!>1!year)!
12) Other!Recurrent!Items!!
15) Other!Capital!Items!
18) Glossary!
20) Additional!forms!!
!
!
!
!
!
1. Staff/Personnel)
!
No.) Staff)Name/Initial) Description/Position)of)Staff))
(e.g.)Dr;)Nurse;)HSW;)Pay)grade;)job)title))
%)FTE)in)
department)
Notes)
1) !
!
! ! !
2)
) !
!
! ! !
3) !
!
! ! !
4) !
!
! ! !
5) !
!
! ! !
6) !
!
! ! !
7) !
!
! ! !
2. Consumables)
!
No.) Name)of)Consumable/Item) Detailed)Description)
(e.g.)Brand;)Make;)Model;)Number)in)package)etc.)))
How)much)used)per)
MONTH/YEAR)
Additional)Notes)
1) !
!
! ! !
2) !
!
! ! !
3) !
!
! ! !
4) !
!
! ! !
5) !
!
! ! !
6) !
!
! ! !
7) !
!
! ! !
8) !
!
! ! !
!
3. Equipment)
!
No.) Name)of)Equipment/Item) Detailed)Description)
(e.g.)Brand;)Make;)Model)etc.))
%)Use)by)Service)
Center))
Additional)Notes)
1) !
!
! ! !
2) !
!
! ! !
3) !
!
! ! !
4) !
!
! ! !
5) !
!
! ! !
6) !
!
! ! !
!
4. Other)Recurrent)Items)(Not)included)in)‘Consumables’))
!
!
No.) Name)of)Recurrent)Item)
)
Detailed)Description)
(e.g.)Brand;)Make;)Model;)Number)in)package)etc.)))
How)much)used)per)
MONTH/YEAR)
Additional)Notes)
1) !
!
! ! !
2) !
!
! ! !
3) !
!
! ! !
4) !
!
! ! !
5) !
!
! ! !
6) !
!
! ! !
!
5. Other)Capital)Items)
!
No.) Name)of)Capital)Item) Detailed)Description)
(e.g.)Brand;)Make;)Model)etc.))
%)Use)by)Service)
Center))
Additional)Notes)
1) !
!
! ! !
2) !
!
! ! !
3) !
!
! ! !
4) !
!
! ! !
5) !
!
! ! !
!
Glossary)
!
!
Staff/Personnel) 1. General)Guidance))
a. All!staff!!
b. For!staff!who!provide!services!to!more!than!one!service!center,!record!proportion!of!time!to!this!service!center!
c. Remember!to!include!Senior!management!staff!(e.g.!Nurse!Manager!etc.…)!
d. For!unpaid!people,!record!staff!position!appropriate!to!the!tasks!they!perform,!rather!than!their!experience/!qualifications.!
e. For!students,!only!include!them!if!they!are!involved!in!providing!a!service!to!department!!!
!
2. Bank/Locum)Staff)
a. Place!these!costs!in!“recurrent!Items”!
b. Either!consider!the!total!expenditure!of!locum!staff!over!time!period,!or!note!level!and!average!usage!
!
Consumables)
)
)
)
)
)
)
)
1) Only)items)with)a)lifespan)of)less)than)one)year)should)be)counted)as)consumables)–)Longer'lasting'items'should'be'classified'as'
‘Equipment’'
!
2) General)guidance)
a. Identify!all!consumables!used!by!the!service!centre!(Medical!and!nonTMedical)!
b. Quantify!how!much!of!item!is!used!in!an)Average)Month!
c. Provide!sufficient!information:!Brand/Manufacturer!+/T!description!of!item!!
!
3) Laboratory)
a. Any!consumables,!such!as!test!reagents,!used!within!the!laboratory!centre!should!be!identified.!If!a!cost!for!each!type!of!test!is!
calculated,!the!consumables!specifically!used!for!each!different!type!of!test!should!be!identified.!
!
4) Other)Service)centers)
a. Remember!to!include!Furniture,!stationery,!paper,!detergents,!cleaning!materials.!!
!
!
!
Equipment) 1. General)guidance)
a. List!all!equipment!used!in!service!center!
b. Include!both!medical!and!nonTmedical!equipment!!
i. Medical!equipment!includes!both!diagnostic!and!therapeutic!items!
ii. NonTmedical!items!include!beds!and!chairs!for!patients!or!staff!members.!!
c. Record!!
i. Manufacturer!and!model!of!equipment!
ii. In!case!item!is!not!commercially!available,!record!the!material,!measurements!and!use!of!item!in!detail!!
d. Record!number!of!all!pieces!in!service!center!
e. If!item!is!shared!with!other!service!centres:!record!proportion!of!use!by!relevant!service!center!
!
2. Laboratory)and)Radiology)
a. Any!equipment!used!in!performing!tests!should!be!listed.!!
b. If!a!cost!for!each!type!of!test!is!being!calculated,!the!amount!of!time!each!piece!of!equipment!is!used!for!performing!each!
test!also!needs!to!be!measured!and!the!total!expressed!as!a!proportion!of!a!full!day’s!use.!
!
3.)Other)support)centers)
c. Consider!all!equipment!!
i. This!may!include!washing!and!drying!machines!for!cleaning!services!
ii. Office!equipment,!such!as!computers,!printers!and!telephones!
iii. Storage!units,!including!filing!cabinets!
iv. Relevant!security!equipment.!!
!
Recurrent)inputs)
)
)))))))))))OR)
)
Capital)inputs)
• Estimation!should!be!made!whether!the!input!was!used!within!a!single!year!(recurrent'input)!or!during!multiple!years!(capital'
input).!!
!
• An!example!of!recurrent!input!would!be!an!expert!consultation!led!by!an!external!doctor!on!a!single!occasion,!and!capital!input!
might!include!staff!training.!
!
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Cost-effectiveness of HIV Testing and Counselling
HTC-105: Follow-up Questionnaire
R01 HHBAR Participant
Barcode
R02 HHID Interviewer ID CLUSIDR03 Cluster ID
R04 SIT Place of interview 1. Participant Home
2. Chilomoni Clinic
3. Queens ART Clinic
4. Ndirande Clinic
DOIR05
R10 FOLL What is the reason participant
is here at clinic today?
R11 WHO WHO Clinical stage
R12 WHODAT Date of when participant
had WHO Clinical Stage?
R14 CD4DAT Date when this CD4 count was done?
PLACE ID
BARCODE HERE
Date of interview
Version no: 1.0 Last modified by HM 02/28/2013 Page 1 of 8
Questions to be completed by reviewing HIV patient Cards
R13 CD4 Last CD4 count
1. Assessment for ART Elgibility
2. Collection of CD4 result
3. Group Counselling
4. Initiation of ART
5. Entry into Pre-ART care
6. Collection of ART +/- IPT/CPT
7. Collection of IPT/CPT (Pre-ART Care)
8. Traced after Loss to follow-up
9. Other, Specify
1. WHO Stage I
2. WHO Stage II
3. WHO Stage III
4. WHO Stage IV
2  0  1
  d        d          m      o     n         y        y      y       y
2  0  1
  d        d          m      o     n             y        y      y       y
2  0  1
Specify,if other
R07 FTEL Telephone number of Participant (1st)
R08 FTEL2 Telephone number of Participant (2nd)
R09 FTEL3 Telephone number of Partner, Spouse
or Family Member
R06 HTC104 Did participant complete HTC-104 at same interview? 1. Yes 2. No
Write Participant Barcode
5698457082
HTC-105: Follow-up Questionnaire
R17 ARTSID
R18 ARTTB TB Status (Current)
CPT: Number of tablets given?R21 ARTCTX
R19 ARTPILL ARVs: Pill count?
R20 ARTPMIS ARVs: Doses missed
R22 ARTFAM Family Planning: Depot given?
Has the patient experienced any side
effects (current)-in the last month?
(Tick all that apply)
1. Not on ARV Drugs
2. No Side Effects
3. Peripheral neuropathy
4. Hepatitis
5. Skin Rash
6. Lipodystrophy
7. NOT APPLICABLE
8. Other, Specify
1. TB Not suspected
2. TB suspected
3. TB confirmed but not yet on treatment
4. TB Confirmed and currecntly taking treatment
5. Other, Specify
1. Yes 2. No
R16 ARTSTA Date ART initiated (Write todays
date if initiating today)
1. Regimen 1a
2. Regimen 2a
3. Regimen 3a
4. Regimen 4a
5. Regimen 5a
6. Regimen 6a
7. Regimen 7a
8. Regimen 8a
9. Not Started ARV Drugs
10. Defaulted ARV Drugs
11. Other, Specify
If on ART, which ART
regime is participant
receiving?
R15 ART
Specify,if other
Specify,if other
Specify,if other
Version no: 1.0 Last modified by HM 02/28/2013 Page 2 of 8
ID
R24 ARTVIR
1. Yes
2. No
Viral Load sample taken?
R23 ARTCON Number of condoms given?
R25 ARTVIR2 Result of Viral Load?
  d        d          m      o     n             y        y      y       y
0470457085
HTC-105: Follow-up Questionnaire
Chongani mu gulu lililonse pansipa , chonde sonyezani mfundo
zimene zikufotokoza bwino za
R27 MOB Mayendedwe
R28 SELF Kudzisamalira ndekha (mwachitsazo kusamba ndi kudziveka ndekha)
1. Ndilibe vuto lina lililonse poyenda
2. Ndimakhala ndi mavuto ena poyenda
3. Ndimangobindikira pa kama
1. Ndilibe vuto podzisamalira ndekha
2. Ndimakhala ndi mavuto ena posamba kapena podziveka ndekha
3. Ndimalephera kusamba kapena kudziveka ndekha
Zochitika za tsiku ndi tsiku (monga kugwira ntchito, kuwerenga,ntchito za pakhomo, za
m'banja kapena kuchita zimene zimandisangalatsa)
USUALR29
1. Ndilibe mavuto ali onse pogwira ntchito zanga za nthawi zonse
2. Ndili ndi mavuto ena pang'ono pogwira ntchito za nthawi wonse
3. Ndimalephera kugwira ntchito zanga za nthawi zonse
Nkhawa/Khumudwa? (Osasangalala)R31 ANX
R30 PAIN Ululu/kuphwanya m'thupi kusowetsa mtendere?
1. Ndilibe ululu kapena sindikumva kuphwanya m'thupi
2. Ndimakhala ndi ululu kapena kumva kuphwanya m'thupi mwapakatikati
3. Ndimakhala ndi ululu kapena kumva kuphwanya m'thupi kwambiri
1. Sindikuda nkhawa kapena kukhumudwa
2. Ndimakhala oda nkhawa kapena okhumudwa mwapakatikati
3. Ndimakhala oda nkhawa kapena okhumudwa kwambiri
Mafunso amenewa akukukhuza ulendo uwuwu
These questions refer to this visit
R26 GEN Kodi munganene kuti umoyo wanu uli bwanji?
How would you rate your general
health?
ID
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1. Bwino kwambiri
2. Wabwino
3. Bwino pang'ono
4. Si uli bwino
5. Si uli bwino mpang’ono pomwe
0723457086
Kuti tithandize anthu
kunena za umoyo wawo,
tajambula mlingo woyesela
(chofanana ndi choyesela
kuzizila/kutentha kwa
m'thupi) womwe umoyo
wabwino wayerekezedwa ndi
chizindikiro cha 100
ndipo umoyo woipa
wayelekezedwa ndi
chizindikiro cha 0.
Tikufuna mutisonyeze pa
mlingowu mmene umoyo
ulili lero kuti uli
bwino kapena suli bwino
mmene inu mukuganizira.
Lembani mzere kuchokera
pa bokosi pansipa kupita
pa mlingo woyesera umene
ukufotokoza za ubwino
kapena kuipa kwa mmene
umoyo wanu ulili lero.
Mmene
umoyo wanu
ulili lero
R32 VAS Write Participants Score Below:
9     0
8      0
7      0
6      0
5       0
4       0
3       0
2      0
1      0
100
Kuyerekezedwa kuti 
umoyo si uli bwino
0
Kuyerekezedwa kuti umoyo 
uli bwino kwambiri
IDHTC-105: Follow-up Questionnaire
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0479457084
R34 TRAT Kodi munatenga nthawi yayitali bwanji kuti mukafike kuchipatala chaching'ono
choyang'ana za HIV lero?
How long did it take to get to the HIV clinic today?
(One-way travel)
R37 TRAM2 Ngati munagwiritsa ntchito ndalama pamayendedwa, kodi munagwiritsa
ntchito zingati?
If you did spend money on transportation, how much
did you spend?(One-way travel)
Write '0' if did not spend any money
R33 TRA Kodi munayenda bwanji kuti mufike kuchipatala chaching'ono lero?
How did you get to the HIV clinic today?
Hours
Minutes
ID
1. Walked
2. Public Transport
3. Own Transport
4. Other
1. Yes
2. NoDid you spend any money on transportation to get here?(including for petrol/diesel)
Kodi munagwiritsa ntchito ndalama yina yiliyonse pamayendedwe kuti mufike kuno?TRAMR36
MK
R35 WAIT
Minutes
Hours
Did you have to time off work to attend Clinic today?
Kodi munayeneka kutenga nthawi yakuntchito kuti mubwere kuchipatala chaching'ono lero?WORKR38 1. Yes
2. No
If yes how many days/hours did you take off work today?
Write '0' if did not take time off work
Write '88' if not working
Ngati ndi choncho, kodi ndi masiku/maola kapena mphindi zingati zantchito
zimene munatenga lero?
WORK2R39
Hours
Days
Kodi lero munagwiritsa ntchito ndalama yina yiliyonse pa chakudya kapena zakumwa
panthawi imene mumadikira kuti muonedwe?
Did you spend any money on food/drinks, whilst waiting to be
seen today?
FOOD1R40 1. Yes
2. No
R41 FOOD2 Ngati munagwiritsa ntchito ndalama pa chakudya kapena zakumwa, kodi
munagwiritsa ntchito zingati?
If you spent money on food/drinks how much did you
spend?
Write '0' if did not spend any money
MK
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R43 OTH2 Tchulani chinthu chimene
munagwiritsirapo ntchito
ndalama
Specify what you
spent money
R42 OTH1 Kodi lero munagwiritsa ntchito ndalama yina yiliyonse pa chinthu china chilichonse
chifukwa chobwera kuchipatala chaching'ono lero?
Did you spend any money on anything else as a result of
attending the clinic today ?
R44 OTH3 Kodi munagwiritsa ntchito ndalama zingati pa chinthu chimenechi?
How much did you spend on this?
Write '0' if did not spend any money
Write '99999' if question not applicable
1. Yes
2. No
MK
How long did you spend at the clinic in TOTAL (from
arriving to leaving)?
Kodi munatenga nthawi yayitali bwanji kuti muthandizidwe (pamene munafika
kufikira nthawi yimene munathandizidwa)?
2756457084
ID
R45 FAM Kodi m'bale wanu kapena mzanu wina aliyense anakuperekezani pa ulendo wa
lero?
Did any family member or friend accompany you on
today's visit?
1. Yes
2. No
Ngati ndi choncho, kodi iwowo anapempha masiku/maola kapena masiku opuma
kuntchito angati kuti akuperekezeni inuyu?
If yes, how many days/hours did they take off work to
accompany you?
Write '0' if did not take time of work
Write '88' if not working
Write '99' if question not applicable
FAM1R46
Hours
Days
MK
Kodi iwowo anagwiritsa ntchito ndalama zingati pamayendedwe kuti
akuperekezeni inuyo?
How much money did they spend on transportation to
accompany you? (One-way travel)
Write '0' if did not spend any money
Write '99999' if question not applicable
FAM3R48
R50 FAM5 Kodi iwowo anagwiritsa ntchito ndalama ina iriyonse pachinthu chirichonse
china m'mene anakuperekezani?
1. Yes
2. No
MK
How much money did they spend on food/drinks whilst
waiting with you?
Write '0' if did not spend any money
Write '99999' if question not applicable
Kodi iwowo anagwiritsa ntchito ndalama zingati pogula chakudya kapena
zakumwa m'mene ankadikira limodzi ndi inuyo?
R49 FAM4
Did they spend money on anything else whilst
accompanying you?
HTC-105: Follow-up Questionnaire
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Specify what they
spent money on?
Tchulani chinthu chimene
iwowo anagwiritsirapo ntchito
ndalama
FAM6R51
How much money did they spend on this?
Write '0' if did not spend any money
Write '99999' if question not applicable
Kodi anagwiritsa ntchito ndalama zingati pachinthu chimenechi?FAM7R52
MK
R47 FAM2
If they work, how much do they normally earn per day?
Write '88888' if participant does not know
Write '99999' if question not applicable
Ngati amagwira ntchito, kodi amapeza ndalama zochuluka bwanji pa tsiku?
MK
R53 OFFW M'mwezi umodzi wapitawu, kodi munapemphapo kuti musapite kuntchito
kamba kamatenda?
In the last one month, have you taken time off work
because of illness?
1. Yes
2. No
R54 OFFW2 Ngati ndi choncho, kodi ndi masiku/maola angati antchito amene munapempha ?
If yes how many days/hours did you take off work?
Write '0' if did not take time off work
Write '88' if not working
Days
Hours
7963457089
ID
At the clinic today, did the doctor/nurse ask you to
cough up sputum to do some tests?
Lero kuchipatala chaching'ono, kodi dotolo kapena namwino anakupemphani kuti
mukhosomole makhololo kuti awayeze?
TBSP1R61 1. Yes
2. No
R62 TBXR1 Lero kuchipatala chaching'ono, kodi dotolo kapena namwino anakupemphani kuti
mujambulidwe pa chidale panu ndi chipangizo chojambulira mthupi?
At the clinic today, did the doctor/nurse ask you to go
and get an X-Ray of your chest?
1. Yes
2. No
HTC-105: Follow-up Questionnaire
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At the clinic today, did the doctor/nurse take blood from
you to do tests on?
Lero kuchipatala chaching'ono, kodi dotolo kapena namwino anatenga magazi kwa
inuyo kuti awayeze? 1. Yes
2. No
TBBLR63
1. Yes
2. NoAt the clinic today, did the doctor/nurse put a needle
into  you back to take a sample of liquid?
Lero kuchipatala chaching'ono, kodi dotolo kapena namwino anakubayani ndi singano
kumsana kwanu kuti atenge madzi oti awayeze?
TBCSR64
R57 SAWHC Lero kuchipatala chaching'ono, kodi munaonana ndi wopereka uphungu wa  HIV ?
At the clinic today,did you see a HIV counsellor?
1. Yes
2. No
At the clinic today,did you see a Nurse?
Lero kuchipatala chaching'ono, kodi munaonana ndi namwino ? 1. Yes
2. No
SAWNUR58
R59 SAWCO Lero kuchipatala chaching'ono, kodi munaonana ndi Clinical Officer ?
At clinic today,did you see a Clinical Officer?
1. Yes
2. No
At the clinic today,did you see the Doctor?
Lero kuchipatala chaching'ono, kodi munaonana ndi dotolo?SAWDRR60 1. Yes
2. No
R55 OFFW3 Mu mwezi umodzi wapitawu, kodi pali wina aliyense m’banja mwanu kapena mnzanu
amene anakusamalirani chifukwa choti munadwala? 1. Yes
2. No
R56 OFFW4 Ngati zili choncho, mukaphatizika nthawi imene anatero ingakhale yochuluka
bwanji?
If yes how much time did they spend caring for you in
TOTAL
Write '0' if did not spend time caring for participant
Days
Hours
In the last one month, has a family member or friend had
to spend time caring for you because you were ill?
At the clinic today,
did you have any other
tests/investigations
done (Please specify
each one in a separate
box)
Kuchipatala  lero, munayezetsa
matenda ena ali onse (Chonde
fotokozani mwakulemba
mubokosimu)
TBOTSR65
2591457081
ID
Have you been diagnosed with Tuberculosis
in the last 1 month?
Kodi munapezekapo ndi chifuwa cha chikulu cha TB m'mwezi
umodzi wapitawu? 1. Yes
2. No
TBR78
1. Yes
2. NoHave you been admitted to hospital overthe last 1 month?(Excluding for
TB/Malaria/Trauma)
Kodi mwagonekedwapo mchipatala chachikulu m'mwezi
umodzi wapitawu?
HOSR79
Have you been to the Primary Health Clinic
Over the Last Month? (Excluding for
TB/Malaria/Trauma)
Kodi munapitapo kuchipatala chaching'ono miyezi isanu ndi
umodzi yapitayi kamba kachifukwa china chilichonse?
PHCR80
1. Yes
2. No
If YES, COMPLETE
HTC-TB
QUESTIONNAIRE
If YES, COMPLETE
HTC-HOP
QUESTIONNAIRE
If YES, COMPLETE
HTC-PHC
QUESTIONNAIRE
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Name of Drug?ADRUGR66
Tikambiranepo za mankhwala amene anaperekedwa kwa inuyo lero(Kupatula mankhwala ama ARV)?
Can we look at the Medications/Drugs that were given to you today (EXCLUDING ARV DRUGS)?
R67 ADRUGD Dose
R68 ADRUGT Number of tablets given
Name of Drug?ADRUG2R69
R70 ADRUGD2 Dose
R71 ADRUGT2 Number of tablets given
Name of Drug?ADRUG3R72
R73 ADRUGD3 Dose
R74 ADRUGT3 Number of tablets given
Name of Drug?ADRUG4R75
R76 ADRUGD4 Dose
R77 ADRUGT4 Number of tablets given
DDATE
6760457083
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Dzina!la!kafukufuku:!! kusalowa!mthumba!kwa!nchito!yoyeza!ndi!kupereka!uphungu!wa!HIV!!pa!
khomo!ku!Blantyre,!Malawi!–!kuwerengetsera!gwero!la!chisamaliro!cha!
ku!chipatala!
!
Chiyambi(
Mulibwanji,! dzina! langa! ndi! _______________________,! ndikugwira! ntchito! ndi! bungwe! la! Malawi&
Liverpool&Wellcome0Clinical0Research0Programme.!Tikupanga!kafukufuku!wa!HIV,!amene!asali!wa!chilendo!
mu! dziko! muno,! komanso! m’mene! tingaperekere! thandizo! la! kuziyeza! HIV! ! kwa! anthu! amene! angafune!
kudziwa!za!mthupi!mwawo!ngati!ali!ndi!HIV!kapena!ayi.!Ku!mbari! ya!kafukufuku!ameneyu,! tikufuna!kuona!
mtengo!wa!Ndalama!komanso! !zotsatira!zimene!zimabwera!kwa!anthu!amene!alibe!kachirombo!ka!HIV!ndi!
anthu! amene! ali! ndi! kachirombo! ! HIV! ! amene! akufunika! kulandira! thandizo! la! mankhwala! a! chifuwa!
chachikulu!cha!TB!kapena!amene!akufunika!kugonekedwa!ku!chipatala!kuti!athandizidwe!pa!matenda!ena.!!
Pakhoza! kukhala! mawu! ena! amene! simukutha! kumvesetsa.! ! Chonde! ndiuzeni! kuti! ndiime! kaye! pamene!
tikukambirana!za!uthenga!umenewu!ndipo!ndizatenga!nthawi!kuti!ndifotokoze.!Chiganizo!chakuti!mukufuna!
kutenga!nawo!mbari!kapena!ayi,!sichizakupangitsani!kulephera!kupeza!thandizo!limeneli.!
!
Cholinga(cha(kafukufukuyu?(
Kafukufukuyu! ndi! mbari! imodzi! yofufuza! za! Ndalama! zimene! zingagwiritsidwe! ntchito! komanso! phindu!
limene! lingakhalepo! popereka! thandizo! lakuziyeza! HIV! m’makomo! komanso! kudzera! mu! zipata! zing’onoK
zing’ono! ku! Blantyre,!Malawi.! Ku!Malawi,! anthu! ambiri! samadziwa! kuti! ali! ndi! HIV!mwamsanga.! Komabe,!
kupereka! thandizo! la! kuziyeza! HIV! m’makomo! mwa! anthu! ! kwapezeka! kuti! ndi! chinthu! chimene!
chikuvomerezedwa! kwambiri! komanso! kufikira! anthu! amene! ali! ndi! HIV! mwa! m’msanga,! komanso!
asanayambe!kudwala!matenda!ambiri!obwera!chifukwa!cha!ka!chirombo!!ka!HIV.!!Ambiri!mwa!anthu!odwala!
matenda!amenewo!amafunika!kugonekedwa!ku!chipatala,! !zimene!ziri!zinthu!zofuna!Ndalama!zambiri,!kwa!
anthu! opereka! chisamaliro! cha! kuchipatala! komaso!munthu! payekhaKpayekha.! Cholinga! cha! kafukufukuyu!
ndikuwerengetsera!Ndalama! zimene! zimagwiritsidwa!ntchito! komanso!gwero! lake!pakukonza!mwatsopano!
moyo! wa! anthu! amene! akudwala! matenda! obwera! chifukwa! cha! kachirombo! ka! HIV,! amene! akufunika!
kugonekedwa!ku!chipatala.!Uthenga!umenewu!uzatilora!kuti!tiwerengetsere!mongoganizira!Ndalama!zimene!
tingapewe! kuononga,! pamene! tikupereka! thandizo! lakuziyeza! HIV! m’makomo,! komanso! ngati! zimenezi!
zingaonetsere! Ndalama! zoonjezera! pogwira! ntchito! yopereka! thandizo! limeneli.! Tikufuna! kupeza! gwero! la!
kugonekedwa!ku!chipatala!kapena!kupatsidwa!thandizo!la!mankhwala!a!TB,! !pakukhala!ndi!moyo!wathanzi,!
Ndalama! zimene! mumaononga! pofuna! kupeza! chisamaliro! chakuchipatala! ! komanso! Ndalama! zimene!
zimaonongedwa! pamene! mukupatsidwa! thandizo! la! mankhwala.! ! Tikufuna! tipange! kafukufuku! pogwiritsa!
ntchito!tsamba!la!ndondomeko!ya!mafunso!ndi!anthu!amene!amagonekedwa!ku!chipatala!!kapena!ali!ndi!TB.!!!
!
Ndondomeko(!!
Nthawi:!Kafukufukuyu!achitika!nthawi!imene!mwagonekedwa!ku!chipatala.!!!
!
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Kodi(muzafunsidwa(kuti(mutani:!Tidzapempha!kuti!ticheze!ndi!anthu!kuyambira!zaka!18!kupita!m’mwamba,!
amene!agonekedwapo!ku!ma!wodi!akuchipatala!chachikulu!cha!Queen%Elizabeth,!Blantyre!komanso!amene!
angavomereze!kutenga!nawo!mbari!mu!ndondomeko!ya!mafunso!angapo!ndicholinga!chofuna!!kupempha!
uthenga!pa!nkhani!!ya!zotsatirazi:!!za!moyo!wawo,!ngati!ali!ndi!HIV!kapena!ayi,!thandizo!komanso!chisamaliro!
chimene!analandira!kuchokera!ku!chipatala!nthawi!imene!anagonekedwa!kuchipatalako,!!Ndalama!zimene!
anaononga!nthawi!!imene!anagonekedwa!ku!chipatala,!komanso!gwero!lakugonekedwa!mu!chipatala!pofuna!
kutukula!umoyo!wawo.!!Tikufunanso!titakumana!nanu!!nthawi!yomweyo!imenemungagonekedwe!
kuchipatalako,!!ndipo!sabata!linalirilonse!kapena!kuonjezera!apo!kufikira!mpaka!mutatulutsidwa!muchipatala!
.!Nthawi!ina!iriyonse!imene!tingakuoneni,!tidzafuna!kukhala!nanu!kwa!mphindi!zokwana!15.!Tidzaunikanso!
uthenga!wa!ku!chipatala!!okhudzana!ndi!inu!pofuna!kupeza!chifukwa!chimene!munagonekedwa!komanso!
chisamaliro!chakuchipatala!chimene!munalandira!!nthawi!imene!munagonekedwa!kuchipatala.!!
!
Kutenga(nawo(mbari(ndi(ulere:!!mukhoza!kutuluka!mu!kafukufukuyu!nthawi!ina!iriyonse!popanda!kupereka!
chifukwa!komanso!popanda!kuimbidwa!mlandu!wina!uliwonse.!!!
!
Mtengo( wa( ndalama,( mavuto( komanso( ululu:! muzafunsidwa! ngati! muli! ndi! HIV! kapena! ayi.! Mukhoza!
kuhkala! omangika! pokambirana! nkhani! imeneyi.! Simukuyenera! kutidziwitsa! ngati!muli! ndi! HIV! kapena! ayi,!
mukhoza!kukana!kutenga!nawo!mbari,!komanso!mukhoza!kutuluka!mu!ndondomeko!ya!mafunso!nthawi!ina!
iriyonse.! Ngati!mungatuluke!mukafukufukuyu!muzakhalabe! ndi! kuthekera! kopeza! thandizo! kumalo! amene!
amapereka!thandizo!la!HIV.!!Simudzalipira!kena!kalikonse!potenga!nawo!mbari!mukafukufukuyu.!
!
Phindu:! sipadzakhala!phindu! looneka!ndi!maso!kwa! inu!mukatenga!nawo!mbari.! !Komabe,!uthenga!umene!
mungapereke!udzathandiza!kukonza!mwa!tsopano!ntchito!yoyeza!HIV!komanso!thandizo! la!mankhwala!mu!
dela!lanu.!!
!
Kulipiridwa:!mudzapatsidwa!zokumwa!zoziziritsa!kukhosi!nthawi!imene!ndondomeko!ya!mafunso!ikuchitika,!
pofuna!kukulipirani!chifukwa!cha!nthawi!yanu.!!
!
Chinsinsi:! Sitidzapereka! uthenga! okhudzana! ndi! ! anthu! omwe! atatenge! nawo!mbari!mukafukufukuyu! kwa!
wina! aliyense.! Uthenga! umene! titatolere!mukafukufukuyu! ! udzasungidwa!mwa! chinsinsi.! Uthenga! umene!
utazatoleredwe!nthawi! imene!kafukufukuyu!akuchitika!siudzadziwika!ndi!dzina! lanu!koma!ndi!nambala.!Ndi!
opangitsa!kafukufuku!okhawo!amene!atadzadziwe!nambala!yanu,!ndipo!adzatsekera!uthenga!umenewo!ndi!!
loko!komanso!kiyi.!Uthenga!umene!tingatenge!kudzera!mu!kafukufukuyu!uzagawidwa!kwa!inu.!Kudzachitika!
misonkhano!ing’onoKing’ono!mu!dela!ndipo!misonkhano!imeneyi!idzalengezetsedwa.!Ngati!uthenga!ochokera!
mukafukufukuyu! ungalembedwe! mu! mabuku! kapena! kuperekedwa! pa! misonkhano! ya! sayansi! kapena!
misonkhano! yofikira! anthu! am’madela! onse,! ! dzina! lanu! komanso! uthenga! okhudzana! ndi! inu!
sizidzagwiritsidwa!ntchito.!
!
Chilorezo( chakuti( kafukufukuyu( achitike:( komiti! yoyang’anila! za! akafukufuku! ya! College! of! Medicine,!
Blantyre,! Malawi! komanso! ! komiti! ya! ! Univesite! ya! Warwick! Biomedical! Research! Ethics,! Warwick,! UK!
yavomereza!kafukufukuyu.!!
!
Mafunso:!Ngati!mungakhale!ndi!mafunso!enaKaliwonse!okhudzana!ndi!kafukufukuyu,!mukhoza!kumuimbira!
foni!Dr!Hendramoorthy!Maheswaran! (mkulu!wa! kafukufukuyu,! Tel:! 0996151939)! kapena!wapampando!wa!
COMREC!(Tel:!0198!9766). 
!
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Principal Investigator: Dr Hendramoorthy Maheswaran 
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Dzina!la!kafukufuku:!Kusalowa!mthumba!kwa!nchito!yoyeza!ndi!kupereka!uphungu!wa!HIV!pa!!
!!!!!!!!!!!khomo!ku!Blantyre,!Malawi!–!kuchulukitsa!gwero!la!chisamaliro!cha!ku!!
!!!!!!!!!!!chipatala!
!
• Ndapemphedwa!kutenga!nawo!mbari!!mu!kafukufukuyu,!!kusiyanitsa!!mtengo!wa!Ndalama!komanso!gwero!!la!
kugonekedwa!ku!chipatala!!kapena!kufunikira!kwa!kulandira!thandizo!la!mankhwala!a!TB!pofuna!kukhala!ndi!moyo!
wa!thanzi.!!
• Ndalandira,!kuwerenga!komanso!kumvesetsa!uthenga!olembedwa!(tsamba!la!uthenga!wa!otenga!nawo!mbari)!
kukhudzana!ndi!!kafukufukuyu.!
• Ndikumvesetsa!kuti!zimenezi!zizakhala!ndi!kalondoHlondo!wa!ndondomeko!ya!mafunso!!
• Ndadziwitsidwa!kuti!!pali!mavuto!ochepa.!!
• Ndikudziwa!kuti!!pakhoza!kusakhala!phindu!looneka!!kwa!ine!!komanso!sindidzalipilidwa!Ndalama!yoposela!
transipoti!!komanso!zoziziritsira!kukhosi.!
• Nthawi!ina!iriyonse!ndikhoza!kuletsa!kupereka!chilorezo!komanso!kutenga!nawo!mbari!mukafukufukuyu!!popanda!
kuimbidwa!mlandu.!
• Ndapatsidwa!dzina!la!opangitsa!kafukufuku!(Dr!Hendramoorthy!Maheswaran)!!amene!!ndingalumikizane!naye!
mosavuta!pogwiritsa!ntchito!!nambala!komanso!adilesi!!imene!ndinapatsidwa!ya!munthu!ameneyu.!
• Ndakhala!ndi!mwayi!okwanila!ofunsa!mafunso!komanso!(mwakufuna!kwa!ine!ndekha)!kulengezetsa!kuti!ndiri!
okonzeka!kutenga!nawo!mabri!mukafukufukuyu.!!
!!
___________________________!!!!!!!!!!!!!!!!!!!!!_____________________________!!!!!!!!!_____________!
Dzina!la!otenga!nawo!mbari!(sindikizani)!!!!!!!!!Siginichala!ya!otenga!nawo!mbari!! ! !!!!Deti!
!
Ndawerenga!molondola!kapena!kupelekera!umboni!kuwerenga!kolondola!kwa!tsamba!la!chilorezo!kwa!otenga!
nawo!mbari!oyenelera,!ndipo!munthuyo!wakhala!ndi!mwayi!ofunsa!mafunso.!Ndikutsindikiza!kuti!munthuyu!
wapereka!chilorezo!momasuka."
___________________________!!!!!!!!!!!!_______________________________!!!!!!!!!!!!!!!____________!
Dzina!la!membala!ogwira!ntchito!!!!!!!!!!!!!Siginichala!ya!membala!ogwira!ntchito!!!!!!!!!!!!!!!!!!!!!!Deti!
(tsindikizani)!!! !! !!! !!!!!!!!!amene!anatsogolera!ntchito!yopereka!chilorezo!
!
NGATISAKUTHA!KUWERENGA,!Operekera!umboni!amene!amatha!kuwerenga!a!siyinire.(
(
Ndaonelera! kuwerenga! kolondola! kwa! tsamba! la! chilorezoli,! ndipo! munthuyu! anali! ndi! ufulu! ofunsa! mafunso.!
Ndikutsimikiza!kunena!kuti!munthuyo!wapereka!chilorezo!momasuka.!
___________________________!!!!!!!!!!______________________________!!!!!!!!!!!!!!!!!!!_____________!
Dzina!la!mboni!(tsindikizani)! ! !!Siginichala!ya!mboni!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!Deti!
! ! !!!!!!!!!!!!!!!!!!!!!!!!!!!!!! !!!!!!!!!!!!!!!!
Nambala!ya!ID!ya!kafukufuku!
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Appendix XVI: Ward template for 
assessing participant’s eligibility for 
recruitment - Hospital cohort study 
 
 
 
 
 
 
 
 
 
 
!! Date%of%
admission%
Name%of%Patient% Does%patient%have%
provisional%diagnosis%of:%
%
RECRUIT%
Bed%
number%
1%
! ! "Pneumocystis!Carinii!Pneumonia!!!!!!!!!!!!!!!!!!!!!"Candidiasis!
"Cryptococcal!Meningitis!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
"Kaposi’s!Sarcoma!!
Yes!
No!
!
2%
! ! "Pneumocystis!Carinii!Pneumonia!!!!!!!!!!!!!!!!!!!!!"Candidiasis!
"Cryptococcal!Meningitis!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
"Kaposi’s!Sarcoma!!
Yes!
No!
!
3%
! ! "Pneumocystis!Carinii!Pneumonia!!!!!!!!!!!!!!!!!!!!!"Candidiasis!
"Cryptococcal!Meningitis!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
"Kaposi’s!Sarcoma!!
Yes!
No!
!
4%
! ! "Pneumocystis!Carinii!Pneumonia!!!!!!!!!!!!!!!!!!!!!"Candidiasis!
"Cryptococcal!Meningitis!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
"Kaposi’s!Sarcoma!!
Yes!
No!
!
5%
! ! !
RECRUIT%
!
%
6%
! ! "Pneumocystis!Carinii!Pneumonia!!!!!!!!!!!!!!!!!!!!!"Candidiasis!
"Cryptococcal!Meningitis!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
"Kaposi’s!Sarcoma!!
Yes!
No!
!
7%
! ! "Pneumocystis!Carinii!Pneumonia!!!!!!!!!!!!!!!!!!!!!"Candidiasis!
"Cryptococcal!Meningitis!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
"Kaposi’s!Sarcoma!!
Yes!
No!
!
8%
! ! "Pneumocystis!Carinii!Pneumonia!!!!!!!!!!!!!!!!!!!!!"Candidiasis!
"Cryptococcal!Meningitis!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
"Kaposi’s!Sarcoma!!
Yes!
No!
!
9%
! ! "Pneumocystis!Carinii!Pneumonia!!!!!!!!!!!!!!!!!!!!!"Candidiasis!
"Cryptococcal!Meningitis!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
"Kaposi’s!Sarcoma!!
Yes!
No!
!
10%
! ! %
RECRUIT%
%
%
!
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Appendix XVII: HTC-DOC Medical 
data extraction tool - Hospital 
cohort study 
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Appendix XVIII: Adapted ICD 
codebook used to code primary 
medical diagnosis - Hospital cohort 
study 
 
 
 
 
 
 
 
 
 
Queen%Elizabeth%Central%Hospital%Costing%study:%
Classifying%Clinical%Conditions%
!
!
!
Introduction%
A!clinical!classification!software!(CCS)!was!developed!by!the!Agency!for!Healthcare!Research!
and! Quality! (AHRQ).! The! tool! provides! a! method! for! grouping! clinical! diagnosis! into! a!
manageable! number! of! clinically! relevant! categories.! The! classification! system! allows! a!
meaningful!approach!to!group!clinical!diagnosis!to!investigate!health!service!utilisation!and!
costs,! and!health!outcomes.! The! system!collapses! clinical! diagnosis! from! the! International*
Classification* of* Diseases,* 9th* Revision,* Clinical* Modification* (IDCD9DCM),! which! contains!
more! than! 14,000! diagnosis! codes,! into! either! a! singleDlevel! or! multiDlevel! classification!
system.! In! the! singleDlevel! classification! system,! all! codes! in! the! ICDD9DCM! are! aggregated!
into!285!mutually!exclusive!categories,!most!of!which!are!clinically!homogeneous.!The!multiD
level!clinical!classification!system!is!a!hierarchical!system!with!fourDlevels,!with!the!specificity!
of!the!clinical!categories!increasing!with!the!higher!levels.!At!the!first!of!the!four!levels,!the!
clinical! diagnostic! category! is! broad,! whilst! at! the! higher! levels;! the! clinical! diagnosis!
becomes!more!specific.!
!
!!
Methods%
The!CCS!tool!provides!a!simplistic!and!efficient!approach!to!classifying!clinical!diagnosis!by!
the!medical! doctors! reviewing! the! notes! of! patients! recruited! into! the! CostDHTC! Hospital!
costing!study.!The!classification!system!has!been!adapted!into!a!booklet!with!directions!for!
the!medical!doctor! to! follow.!The!booklet!will!be!used! to!classify!both! the!primary!clinical!
condition!necessitating!hospital!admission,!and!all!associated!clinical!diagnosis!made!prior!to!
admission!and!during!the!hospital!admission.!!!!
!
!!!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
! Page%1%%
Figure'1:'Overview'of'how'to'code'clinical'diagnosis'
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
Review!Medical!Notes!
Extract!primary!
clinical!diagnosis!
made!by!doctor!
managing!patient!
that!resulted!in!
hospital!admission!
1) Start!on!Page!2!!
2) Choose!appropriate!clinical!diagnostic!category!–!Level!1!
3) Write!code!number!into!Case!Report!Form!(CRF)!
4) Follow!directions!to!subsequent!pages!to!classify!Level!2!and!Level!
3!and!Level!4!Clinical!Diagnosis.!!
5) Stop!when!directions!state!so!
!
NB:*for*several*clinical*conditions,*classification*system*will*not*be*at*three*levels.**
! Page%2%%
!
WRITE%
CODE%
Medical!Diagnosis!–!LEVEL!1! FollowFup%
coding:%
F>Go%to%page:%%
%
0! No!diagnosis!Made! STOP!
1! Infectious!and!Parasitic!disease!! 3!
2! Neoplasms! 6!
3! Endocrine,!nutritional,!and!metabolic!diseases!and!
immunity!disorders!
7!
4! Diseases!of!blood!and!bloodDforming!organs! 9!
5! Mental!disorders! 12!
6! Diseases!of!the!nervous!system!and!sense!organs! 13!
7! Diseases!of!the!circulatory!system! 15!
8! Diseases!of!the!respiratory!system! 17!
9! Diseases!of!the!digestive!system! 20!
10! Diseases!of!the!genitourinary!system! 23!
11! Complications!of!pregnancy,!childbirth,!and!the!
puerperium!
25!
12! Diseases!of!the!skin!and!subcutaneous!tissue!! 26!
13! Diseases!of!the!musculoskeletal!system! 28!
14! Congenital!anomalies! 30!
15! Certain!conditions!originating!in!the!perinatal!period! 31!
16! Injury!and!poisoning! 32!
17! Symptoms,!signs,!and!illDdefined!conditions!
AND!factors!influencing!health!status!
34!
!
!
!
!
!!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
! Page%3%%
!
!
WRITE%%
CODE%
Level!2:!Infectious!and!Parasitic!disease! FollowFup%
coding:%
F>Go%to%page:%
%
1.1!! Bacterial!infection! 4!
1.2! Mycoses!! 4!
1.3! Viral!infection!! 4!
1.4! Other!infections;!including!parasitic! 4!
1.5!! Immunizations!and!screening!for!infectious!disease!! STOP!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
! Page%4%%
!
!
WRITE%%
CODE%
Level!3:!Infectious!and!Parasitic!disease! FollowFup%
coding:%
F>Go%to%page:%
%
1.1.1!! Tuberculosis!! 5!
1.1.2!! Septicaemia!(except!in!labour)!! 5!
1.1.3!! Sexually!transmitted!infections!(not!HIV!or!hepatitis)! STOP!
1.1.4!! Other!bacterial!infections! STOP!
!
!
1.2.1!! Candidiasis!of!the!mouth!(thrush)!! STOP!
1.2.2!! Other!mycoses!! STOP!
1.2.3! Candidiasis*(excluding*thrush)* STOP!
1.2.4! Cryptococcal*meningitis* STOP!
!
!
1.3.1! HIV!infection! STOP!
1.3.2! Hepatitis! STOP!
1.3.3! Other!viral!infections! ! 5!
!
!
1.4.1! Pneumocystis*Carinii*Pneumonia* STOP!
1.4.2! Malaria* STOP!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
! Page%5%%
!
!
WRITE%
CODE%
Level!4:!Infectious!and!Parasitic!disease! FollowFup%
coding:%
F>Go%to%page:%
%
1.1.1.1! Pulmonary!Tuberculosis! STOP!
1.1.1.2! Tuberculosis!of!meninges!and!central!nervous!system! STOP!
1.1.1.3! Tuberculosis!of!intestines,!peritoneum!and!mesenteric!
glands!
STOP!
1.1.1.4! Tuberculosis!of!bones!and!joint! STOP!
1.1.1.5! Tuberculosis!of!genitourinary!system! STOP!
1.1.1.6! Tuberculosis!of!other!organs! STOP!
1.1.1.7! Miliary!Tuberculosis! STOP!
!
!
1.1.2.1!! Streptococcal!septicaemia!! STOP!
1.1.2.2!! Staphylococcal!septicaemia!! STOP!
1.1.2.3!! E.!Coli!septicaemia!! STOP!
1.1.2.4!! Other!gram!negative!septicaemia!! STOP!
1.1.2.5!! Other!specified!septicaemia!! STOP!
1.1.2.6!! Unspecified!septicaemia! STOP!
!
!
1.3.3.1! Herpes!zoster!infection! STOP!
1.3.3.2! Herpes!simplex!infection! STOP!
1.3.3.3! Other!and!unspecified!viral!infection! STOP!
!
!
1.4.2.1! Uncomplicated!Malaria! STOP!
1.4.2.2! Malaria!Severe!Anaemia! STOP!
1.4.2.3! Malaria,!Cerebral! STOP!
1.4.2.4! Malaria,!Acute!Renal!Failure! STOP!
1.4.2.5! Malaria,!Severe! STOP!
1.4.2.6! Malaria,!Other! STOP!
!
!
!
!
!
!
!
!
!
!
!
!
! Page%6%%
!
!
!
WRITE%
CODE%
Level!2:!Neoplasms!! FollowFup%
coding:%
F>Go%to%page:%
!
2.1! Colorectal!cancer! STOP!
2.2! Other!gastrointestinal!cancer!! STOP!
2.3!! Cancer!of!bronchus;!lung!! STOP!
2.4!! Cancer!of!skin!! STOP!
2.5!! Cancer!of!breast!! STOP!
2.6!! Cancer!of!uterus!and!cervix!! STOP!
2.7!! Cancer!of!ovary!and!other!female!genital!organs!! STOP!
2.8!! Cancer!of!male!genital!organs!! STOP!
2.9!! Cancer!of!urinary!organs!! STOP!
2.10!! Cancer!of!lymphatic!and!hematopoietic!tissue! STOP!
2.11!! Cancer;!other!primary!! STOP!
2.12!! Secondary!malignancies!! STOP!
2.13! Malignant!neoplasm!without!specification!of!site!! STOP!
2.14! Neoplasms!of!unspecified!nature!or!uncertain!behavior!! STOP!
2.15! Maintenance!chemotherapy;!radiotherapy!! STOP!
2.16! Benign!neoplasms! STOP!
2.17* Kaposi’s!Sarcoma! STOP!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
! Page%7%%
!
!
!
WRITE%
CODE%
Level!2:!Endocrine;!nutritional;!and!
metabolic!diseases!and!immunity!disorders!
FollowFup%
coding:%
F>Go%to%page:%
!
3.1! Thyroid!disorders!! 8!
3.2!! Diabetes!mellitus!without!complication!! STOP!
3.3!! Diabetes!mellitus!with!complications!! 8!
3.4!! Other!endocrine!disorders!! STOP!
3.5!! Nutritional!deficiencies!! 8!
3.6!! Disorders!of!lipid!metabolism!! STOP!
3.7!! Gout!and!other!crystal!arthropathies!! STOP!
3.8!! Fluid!and!electrolyte!disorders!! 8!
3.9!! Cystic!fibrosis!! STOP!
3.10!! Immunity!disorders!! STOP!
3.11!! Other!nutritional;!endocrine;!and!metabolic!disorders!! 8!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
! Page%8%%
!
!
!
WRITE%
CODE%
Level!3:!Endocrine;!nutritional;!and!
metabolic!diseases!and!immunity!disorders!
FollowFup%
coding:%
F>Go%to%page:%
!
3.1.1! Thyrotoxicosis!with!or!without!goiter!! STOP!
3.1.2! Other!thyroid!disorders!! STOP!
!
!
3.3.1!! Diabetes!with!ketoacidosis!or!uncontrolled!diabetes!! STOP!
3.3.2!! Diabetes!with!renal!manifestations!! STOP!
3.3.3!! Diabetes!with!ophthalmic!manifestations!! STOP!
3.3.4!! Diabetes!with!neurological!manifestations!! STOP!
3.3.5!! Diabetes!with!circulatory!manifestations!! STOP!
3.3.6!! Diabetes!with!unspecified!complications!! STOP!
3.3.7!! Diabetes!with!other!manifestations!! STOP!
!
!
3.5.1!! Unspecified!proteinDcalorie!malnutrition!! STOP!
3.5.2!! Other!malnutrition!! STOP!
!
!
3.8.1!! Hyposmolality!! STOP!
3.8.2!! Hypovolemia!! STOP!
3.8.3!! Hyperpotassemia!! STOP!
3.8.4!! Hypopotassemia!! STOP!
3.8.5!! Other!fluid!and!electrolyte!disorders!! STOP!
!
!
3.11.1!! Disorders!of!mineral!metabolism! STOP!
3.11.2!! Obesity! STOP!
3.11.3!! Other!and!unspecified!metabolic;!nutritional;!and!endocrine!
disorders!
STOP!
!
!
!
!
!
!
!
!
!
!
!
!
! Page%9%%
!
!
!
WRITE%
CODE%
Level!2:!Diseases!of!the!blood!and!bloodD
forming!organs!
FollowFup%
coding:%
F>Go%to%page:%
!
4.1!! Anemia!! 10!
4.2!! Coagulation!and!hemorrhagic!disorders!! 10!
4.3!! Diseases!of!white!blood!cells!! STOP!
4.4!! Other!hematologic!conditions!! STOP!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
! Page%10%%
!
!
!
!
WRITE%
CODE%
Level!3:!Diseases!of!the!blood!and!bloodD
forming!organs!
FollowFup%
coding:%
F>Go%to%page:%
!
4.1.1!! Acute!posthemorrhagic!anemia! STOP!
4.1.2!! Sickle!cell!anemia!! STOP!
4.1.3!! Deficiency!and!other!anemia!! 11!
!
!
4.2.1!! Coagulation!defects!! STOP!
4.2.2!! Thrombocytopenia!! STOP!
4.2.3!! Other!coagulation!and!hemorrhagic!disorders!! STOP!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
! Page%11%%
!
!
!
WRITE%
CODE%
Level!4:!Diseases!of!the!blood!and!bloodD
forming!organs!
FollowFup%
coding:%
F>Go%to%page:%
!
4.1.3.1!! Iron!deficiency!anemia! STOP!
4.1.3.2!! Other!deficiency!anemia!! STOP!
4.1.3.3!! Aplastic!anemia!! STOP!
4.1.3.4!! Chronic!blood!loss!anemia!! STOP!
4.1.3.5!! Acquired!hemolytic!anemia!! STOP!
4.1.3.6!! Other!specified!anemia!! STOP!
4.1.3.7!! Anemia;!unspecified!! STOP!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
! Page%12%%
!
!
!
WRITE%
CODE%
Level!2:!!Mental!illness! FollowFup%
coding:%
F>Go%to%page:%
!
5.1!! Adjustment!disorders!! STOP!
5.2!! Anxiety!disorders!! STOP!
5.3!! Attention!deficit! STOP!
5.4!! Delirium! STOP!
5.5!! Developmental!disorders!! STOP!
5.6! Disorders!usually!diagnosed!in!infancy! STOP!
5.7!! Impulse!control!disorders!not!elsewhere!classified! STOP!
5.8!! Mood!disorders!! STOP!
5.9!! Personality!disorders! STOP!
5.10!! Schizophrenia!and!other!psychotic!disorders!! STOP!
5.11!! AlcoholDrelated!disorders!! STOP!
5.12!! SubstanceDrelated!disorders! STOP!
5.13!! Suicide!and!intentional!selfDinflicted!injury!! STOP!
5.14!! Screening!and!history!of!mental!health!and!substance!
abuse!codes!!
STOP!
5.15!! Miscellaneous!mental!disorders!! STOP!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
! Page%13%%
!
!
!
WRITE%
CODE%
Level!2:!Diseases!of!the!nervous!system!
and!sense!organs!
FollowFup%
coding:%
F>Go%to%page:%
!
6.1!! Central!nervous!system!infection!! 14!
6.2!! Hereditary!and!degenerative!nervous!system!conditions! 14!
6.3!! Paralysis!! 14!
6.4!! Epilepsy;!convulsions! 14!
6.5!! Headache;!including!migraine!! 14!
6.6!! Coma;!stupor;!and!brain!damage!! STOP!
6.7!! Eye!disorders!! 14!
6.8!! Ear!conditions!! 14!
6.9!! Other!nervous!system!disorders!! 14!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
! Page%14%%
!
WRITE%
CODE%
Level!3:!Diseases!of!the!nervous!system!and!
sense!organs!
FollowFup%
coding:%
F>Go%to%page:%
!
6.1.1!! Meningitis!(except!that!caused!by!TB!or!STD)!! STOP!
6.1.2!! Encephalitis!(except!that!caused!by!TB!or!STD)!! STOP!
6.1.3!! Other!CNS!infection!and!poliomyelitis!! STOP!
!
! ! !!
6.2.1!! Parkinsons!disease!! STOP!
6.2.2!! Multiple!sclerosis!! STOP!
6.2.3!! Other!hereditary!and!degenerative!nervous!system!
conditions!!
STOP!
!
! ! !!
6.3.1!! Hemiplegia!! STOP!
6.3.2!! Other!paralysis!! STOP!
!
! ! !!
6.4.1!! Epilepsy!! STOP!
6.4.2!! Convulsions!! STOP!
!
! ! !!
6.5.1!! Migraine!! STOP!
6.5.2!! Other!headache!! STOP!
!
! ! !!
6.7.1!! Cataract!! STOP!
6.7.2!! Retinal!detachments;!defects;!vascular!occlusion;!and!
retinopathy!!
STOP!
6.7.3!! Glaucoma!! STOP!
6.7.4!! Blindness!and!vision!defects!! STOP!
6.7.5!! Inflammation;!infection!of!eye!(except!that!caused!by!TB!or!
STD)!!
STOP!
6.7.6!! Other!eye!disorders!! STOP!
!
! ! !!
6.8.1!! Otitis!media!and!related!conditions!! STOP!
6.8.2!! Conditions!associated!with!dizziness!or!vertigo!! STOP!
6.8.3!! Other!ear!and!sense!organ!disorders!! STOP!
!
!!
6.9.1!! Disorders!of!the!peripheral!nervous!system!! STOP!
6.9.2!! Other!central!nervous!system!disorders!! STOP!
6.9.3!! Other!nervous!system!symptoms!and!disorders!! STOP!
!
!
!
!
!
! Page%15%%
!
WRITE%
CODE%
Level!2:!Diseases!of!the!circulatory!system! FollowFup%
coding:%
F>Go%to%page:%
!
7.1!! Hypertension!! 16!
7.2!! Diseases!of!the!heart!! 16!
7.3!! Cerebrovascular!disease!! 16!
7.4!! Diseases!of!arteries;!arterioles;!and!capillaries!! 16!
7.5!! Diseases!of!veins!and!lymphatics!! 16!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
! Page%16%%
!
WRITE%
CODE%
Level!3:!Diseases!of!the!circulatory!system! FollowFup%
coding:%
F>Go%to%page:%
!
7.1.1!! Essential!hypertension!! STOP!
7.1.2!! Hypertension!with!complications!and!secondary!
hypertension!!
STOP!
!
!
7.2.1!! Heart!valve!disorders!! STOP!
7.2.2!! PeriD;!endoD;!and!myocarditis;!cardiomyopathy!(except!
that!caused!by!TB!or!STD)!
STOP!
7.2.3!! Acute!myocardial!infarction!! STOP!
7.2.4!! Coronary!atherosclerosis!and!other!heart!disease!! STOP!
7.2.5!! Nonspecific!chest!pain!! STOP!
7.2.6!! Pulmonary!heart!disease!! STOP!
7.2.7!! Other!and!illDdefined!heart!disease!! STOP!
7.2.8!! Conduction!disorders!! STOP!
7.2.9!! Cardiac!dysrhythmias!! STOP!
7.2.10! Cardiac!arrest!and!ventricular!fibrillation!! STOP!
7.2.11! Congestive!heart!failure;!nonhypertensive!! STOP!
!
!
7.3.1!! Acute!cerebrovascular!disease!! STOP!
7.3.2!! Occlusion!or!stenosis!of!precerebral!arteries!! STOP!
7.3.3!! Other!and!illDdefined!cerebrovascular!disease!! STOP!
7.3.4!! Transient!cerebral!ischemia!! STOP!
7.3.5!! Late!effects!of!cerebrovascular!disease!! STOP!
!
!
7.4.1!! Peripheral!and!visceral!atherosclerosis!! STOP!
7.4.2!! Aortic;!peripheral;!and!visceral!artery!aneurysms!! STOP!
7.4.3!! Aortic!and!peripheral!arterial!embolism!or!thrombosis!! STOP!
7.4.4!! Other!circulatory!disease!! STOP!
!
!
7.5.1!! Phlebitis;!thrombophlebitis!and!thromboembolism!! STOP!
7.5.2!! Varicose!veins!of!lower!extremity!! STOP!
7.5.3!! Hemorrhoids!! STOP!
7.5.4!! Other!diseases!of!veins!and!lymphatics!! STOP!
!
!
!
!
!
! Page%17%%
!
!
WRITE%
CODE%
Level!2:!Diseases!of!the!respiratory!system! FollowFup%
coding:%
F>Go%to%page:%
!
8.1!! Respiratory!infections!! 18!
8.2!! Chronic!obstructive!pulmonary!disease!and!bronchiectasis!! 18!
8.3!! Asthma!! 18!
8.4! Aspiration!pneumonitis;!food/vomitus!! STOP!
8.5! Pleurisy;!pneumothorax;!pulmonary!collapse!! 18!
8.6! Respiratory!failure;!insufficiency;!arrest!(adult)! 18!
8.7! Lung!disease!due!to!external!agents!! STOP!
8.8! Other!lower!respiratory!disease!! 18!
8.9!! Other!upper!respiratory!disease! STOP!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
! Page%18%%
!
!
WRITE%
CODE%
Level!3:!Diseases!of!the!respiratory!system! FollowFup%
coding:%
F>Go%to%page:%
!
8.1.1!! Pneumonia!(except!that!caused!by!TB!or!STD)!! 19!
8.1.2!! Influenza!! STOP!
8.1.3!! Acute!and!chronic!tonsillitis!! STOP!
8.1.4!! Acute!bronchitis!! STOP!
8.1.5!! Other!upper!respiratory!infections!! 19!
!
!
8.2.1!! Emphysema!! STOP!
8.2.2!! Chronic!airway!obstruction;!not!otherwise!specified!! STOP!
8.2.3!! Obstructive!chronic!bronchitis!! STOP!
8.2.4!! Other!chronic!pulmonary!disease!! STOP!
!
!
8.3.1!! Chronic!obstructive!asthma!! 19!
8.3.2!! Other!and!unspecified!asthma!! 19!
!
!
8.5.1! Pleurisy;!pleural!effusion!! STOP!
8.5.2! Pulmonary!collapse;!interstitial!and!compensatory!
emphysema!!
STOP!
8.5.3! Empyema!and!pneumothorax!! STOP!
!
!
8.6.1! Respiratory!failure!! STOP!
8.6.2! Other!respiratory!insufficiency!! STOP!
!
!
8.8.1! Postinflammatory!pulmonary!fibrosis! STOP!
8.8.2!! Painful!respiration!! STOP!
8.8.3!! Other!and!unspecified!lower!respiratory!disease!! STOP!
!
!
!
!
!
!
!
!
!
!
!
! Page%19%%
!
!
WRITE%
CODE%
Level!4:!Diseases!of!the!respiratory!system! FollowFup%
coding:%
F>Go%to%page:%
!
8.1.1.1!! Pneumococcal!pneumonia!! STOP!
8.1.1.2!! Other!bacterial!pneumonia!! STOP!
8.1.1.3!! Pneumonia;!organism!unspecified!! STOP!
8.1.1.4!! Other!pneumonia!! STOP!
!
!!
8.1.5.1!! Acute!upper!respiratory!infections!of!multiple!or!
unspecified!sites!!
STOP!
8.1.5.2!! Chronic!sinusitis!! STOP!
8.1.5.3!! Croup!! STOP!
8.1.5.4!! Other!and!unspecified!upper!respiratory!infections!! STOP!
!
!!
8.3.1.1!! Chronic!obstructive!asthma!without!status!asthmaticus!or!
exacerbation!!
STOP!
8.3.1.2!! Chronic!obstructive!asthma!with!status!asthmaticus!! STOP!
8.3.1.3!! Chronic!obstructive!asthma!with!acute!exacerbation!! STOP!
!
!
8.3.2.1!! Other!asthma!without!status!asthmaticus!or!exacerbation!! STOP!
8.3.2.2! Other!asthma!with!status!asthmaticus!! STOP!
8.3.2.3! Other!asthma!with!acute!exacerbation!! STOP!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
! Page%20%%
!
!
WRITE%
CODE%
Level!2:!Diseases!of!the!digestive!system! FollowFup%
coding:%
F>Go%to%page:%
!
9.1!! Intestinal!infection!! STOP!
9.2!! Disorders!of!teeth!and!jaw! STOP!
9.3!! Diseases!of!mouth;!excluding!dental!! STOP!
9.4!! Upper!gastrointestinal!disorders!! 21!
9.5!! Abdominal!hernia!! 21!
9.6!! Lower!gastrointestinal!disorders! 21!
9.7!! Biliary!tract!disease!! 21!
9.8!! Liver!disease!! 21!
9.9! Pancreatic!disorders!(not!diabetes)!! 21!
9.10! Gastrointestinal!hemorrhage! 21!
9.11!! Noninfectious!gastroenteritis!! STOP!
9.12!! Other!gastrointestinal!disorders!! 21!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
! Page%21%%
!
WRITE%%
CODE%
Level!3:!Diseases!of!the!digestive!system! FollowFup%
coding:%
F>Go%to%page:%
!
9.4.1!! Esophageal!disorders!! STOP!
9.4.2!! Gastroduodenal!ulcer!(except!hemorrhage)!! STOP!
9.4.3! Gastritis!and!duodenitis! STOP!
9.4.4!! Other!disorders!of!stomach!and!duodenum!! STOP!
!
! ! !!
9.5.1!! Inguinal!hernia!! STOP!
9.5.2!! Diaphragmatic!hernia!! STOP!
9.5.3!! Other!abdominal!hernia!! STOP!
!
!!
9.6.1!! Appendicitis!and!other!appendiceal!conditions!! STOP!
9.6.2!! Regional!enteritis!and!ulcerative!colitis!! STOP!
9.6.3!! Intestinal!obstruction!without!hernia!! STOP!
9.6.4!! Diverticulosis!and!diverticulitis!! STOP!
9.6.5! Anal!and!rectal!conditions!! STOP!
9.6.6!! Peritonitis!and!intestinal!abscess!! STOP!
!
!!
9.7.1!! Cholelithiasis!with!acute!cholecystitis!! STOP!
9.7.2!! Cholelithiasis!with!other!cholecystitis!! STOP!
9.7.3!! Cholelithiasis!without!mention!of!cholecystitis!! STOP!
9.7.4!! Calculus!of!bile!duct!! STOP!
9.7.5!! Cholecystitis!without!cholelithiasis!! STOP!
9.7.6!! Other!biliary!tract!disease!! STOP!
!
!!
9.8.1!! Liver!disease;!alcoholDrelated!! STOP!
9.8.2!! Other!liver!diseases!! STOP!
!
!!
9.9.1! Acute!pancreatitis! STOP!
9.9.2! Chronic!pancreatitis!! STOP!
9.9.3! Other!pancreatic!disorders!! STOP!
!
!!
9.10.1! Hemorrhage!from!gastrointestinal!ulcer!! STOP!
9.10.2! Melena!! STOP!
9.10.3!! Gastroesophageal!laceration!syndrome!! STOP!
9.10.4!! Other!esophageal!bleeding!! STOP!
9.10.5!! Hemorrhage!of!rectum!and!anus!! STOP!
! Page%22%%
9.10.6!! Hematemesis!! STOP!
9.10.7!! Hemorrhage!of!gastrointestinal!tract!! STOP!
!
!!
9.12.1!! Constipation!! STOP!
9.12.2!! Dysphagia!! STOP!
9.12.3!! Other!and!unspecified!gastrointestinal!disorders! STOP!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
! Page%23%%
!
!
WRITE%
CODE%
Level!2:!Diseases!of!the!genitourinary!
system!
FollowFup%
coding:%
F>Go%to%page:%
!
10.1!! Diseases!of!the!urinary!system!! 24!
10.2!! Diseases!of!male!genital!organs!! 24!
10.3! Diseases!of!female!genital!organs!! 24!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
! Page%24%%
!
!
WRITE%%
CODE%
Level!3:!Diseases!of!the!genitourinary!
system!
FollowFup%
coding:%
F>Go%to%page:%
!
10.1.1!! Nephritis;!nephrosis;!renal!sclerosis!! STOP!
10.1.2!! Acute!and!unspecified!renal!failure!! STOP!
10.1.3!! Chronic!kidney!disease!! STOP!
10.1.4!! Urinary!tract!infections! STOP!
10.1.5!! Calculus!of!urinary!tract!! STOP!
10.1.6!! Other!diseases!of!kidney!and!ureters!! STOP!
10.1.7!! Other!diseases!of!bladder!and!urethra!! STOP!
10.1.8!! Genitourinary!symptoms!and!illDdefined!conditions! STOP!
!
!!
10.2.1!! Hyperplasia!of!prostate!! STOP!
10.2.2!! Inflammatory!conditions!of!male!genital!organs!! STOP!
10.2.3!! Other!male!genital!disorders!! STOP!
!
!!
10.3.1! Nonmalignant!breast!conditions!! STOP!
10.3.2! Inflammatory!diseases!of!female!pelvic!organs!! STOP!
10.3.3!! Endometriosis!! STOP!
10.3.4!! Prolapse!of!female!genital!organs!! STOP!
10.3.5!! Menstrual!disorders!! STOP!
10.3.6!! Ovarian!cyst!! STOP!
10.3.7!! Menopausal!disorders!! STOP!
10.3.8! Female!infertility!! STOP!
10.3.9!! Other!female!genital!disorders!! STOP!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
! Page%25%%
!
!
WRITE%
CODE%
Level!2:!Complications!of!pregnancy;!
childbirth;!and!the!puerperium!
FollowFup%
coding:%
F>Go%to%page:%
!
11.1!! Contraceptive!and!procreative!management! STOP!
11.2!! AbortionDrelated!disorders!! STOP!
11.3!! Complications!mainly!related!to!pregnancy!! STOP!
11.4!! Indications!for!care!in!pregnancy;!labor;!and!delivery!! STOP!
11.5! Complications!during!labor!! STOP!
11.6!! Other!complications!of!birth;!puerperium!affecting!
management!of!mother!!
STOP!
11.7!! Normal!pregnancy!and/or!delivery!! STOP!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
! Page%26%%
!
!
WRITE%
CODE%
Level!2:!Diseases!of!the!skin!and!
subcutaneous!tissue!
FollowFup%
coding:%
F>Go%to%page:%
!
12.1! Skin!and!subcutaneous!tissue!infections!! 27!
12.2!! Other!inflammatory!condition!of!skin!! STOP!
12.3!! Chronic!ulcer!of!skin!! 27!
12.4!! Other!skin!disorders!! STOP!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
! Page%27%%
!
!
WRITE%
CODE%
Level!3:!Diseases!of!the!skin!and!
subcutaneous!tissue!
FollowFup%
coding:%
F>Go%to%page:%
!
12.1.1! Cellulitis!and!abscess!! STOP!
12.1.2!! Other!skin!and!subcutaneous!infections! STOP!
!
!!
12.3.1!! Decubitus!ulcer!! STOP!
12.3.2!! Chronic!ulcer!of!leg!or!foot!! STOP!
12.3.3!! Other!chronic!skin!ulcer!! STOP!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
! Page%28%%
!
!
WRITE%
CODE%
Level!2:!Diseases!of!the!musculoskeletal!
system!and!connective!tissue!
FollowFup%
coding:%
F>Go%to%page:%
!
13.1!! Infective!arthritis!and!osteomyelitis!(except!that!caused!by!
TB!or!STD)!!
STOP!
13.2!! NonDtraumatic!joint!disorders!! 29!
13.3!! Spondylosis;!intervertebral!disc!disorders;!other!back!
problems!!
29!
13.4!! Osteoporosis! STOP!
13.5!! Pathological!fracture!! STOP!
13.6!! Acquired!deformities!! 26!
13.7!! Systemic!lupus!erythematosus!and!connective!tissue!
disorders!!
STOP!
13.8!! Other!connective!tissue!disease!! STOP!
13.9!! Other!bone!disease!and!musculoskeletal!deformities!! STOP!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
! Page%29%%
!
!
WRITE%
CODE%
Level!3:!Diseases!of!the!musculoskeletal!
system!and!connective!tissue!
FollowFup%
coding:%
F>Go%to%page:%
!
13.2.1!! Rheumatoid!arthritis!and!related!disease!! STOP!
13.2.2!! Osteoarthritis!! STOP!
13.2.3!! Other!nonDtraumatic!joint!disorders!! STOP!
!
!!
13.3.1!! Spondylosis!and!allied!disorders!! STOP!
13.3.2!! Intervertebral!disc!disorders!! STOP!
13.3.3!! Other!back!problems!! STOP!
!
!!
13.6.1!! Acquired!foot!deformities!! STOP!
13.6.2!! Other!acquired!deformities!! STOP!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
! Page%30%%
!
!
WRITE%
CODE%
Level!2:!Congenital!anomalies! FollowFup%
coding:%
F>Go%to%page:%
!
14.1!! Cardiac!and!circulatory!congenital!anomalies!! STOP!
14.2! Digestive!congenital!anomalies!! STOP!
14.3! Genitourinary!congenital!anomalies!! STOP!
14.4! Nervous!system!congenital!anomalies!! STOP!
14.5!! Other!congenital!anomalies!! STOP!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
! Page%31%%
!
!
WRITE%
CODE%
Level!2:!Certain!conditions!originating!in!the!
perinatal!period!
FollowFup%
coding:%
F>Go%to%page:%
!
15.1!! Liveborn!! STOP!
15.2!! Short!gestation;!low!birth!weight;!and!fetal!growth!
retardation!!
STOP!
15.3!! Intrauterine!hypoxia!and!birth!asphyxia!! STOP!
15.4!! Respiratory!distress!syndrome!! STOP!
15.5!! Hemolytic!jaundice!and!perinatal!jaundice!! STOP!
15.6!! Birth!trauma!! STOP!
15.7!! Other!perinatal!conditions!! STOP!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
! Page%32%%
!
!
WRITE%
CODE%
Level!2:!Injury!and!poisoning!
! !
FollowFup%
coding:%
F>Go%to%page:%
!
16.1!! Joint!disorders!and!dislocations;!traumaDrelated!! STOP!
16.2!! Fractures! STOP!
16.3!! Spinal!cord!injury!! STOP!
16.4! Intracranial!injury!! STOP!
16.5! Crushing!injury!or!internal!injury!! STOP!
16.6! Open!wounds!! STOP!
16.7! Sprains!and!strains!! STOP!
16.8!! Superficial!injury;!contusion!! STOP!
16.9!! Burns!! STOP!
16.10!! Complications!! STOP!
16.11!! Poisoning! STOP!
16.12!! Other!injuries!and!conditions!due!to!external!causes! STOP!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
! Page%33%%
!
!
!
WRITE%
CODE%
Level!2:!Symptoms;!signs;!and!illDdefined!
conditions!and!factors!influencing!health!
status!
FollowFup%
coding:%
F>Go%to%page:%
%
!
17.1!! Symptoms;!signs;!and!illDdefined!conditions! 34!
17.2!! Factors!influencing!health!care!! 34!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
! Page%34%%
!
!
!
WRITE%
CODE%
Level!3:!Symptoms;!signs;!and!illDdefined!
conditions!and!factors!influencing!health!
status!
FollowFup%
coding:%
F>Go%to%page:%
%
!
17.1.1!! Syncope!! STOP!
17.1.2!! Fever!of!unknown!origin! STOP!
17.1.3!! Lymphadenitis!! STOP!
17.1.4!! Gangrene!! STOP!
17.1.5!! Shock!! STOP!
17.1.6!! Nausea!and!vomiting!! STOP!
17.1.7!! Abdominal!pain!! STOP!
17.1.8!! Malaise!and!fatigue!! STOP!
17.1.9!! Allergic!reactions!! STOP!
!
!!
17.2.1! Rehabilitation!care;!fitting!of!prostheses;!and!adjustment!of!
devices!!
STOP!
17.2.2! Administrative/social!admission!! STOP!
17.2.3! Medical!examination/evaluation! STOP!
17.2.4! Other!aftercare!! STOP!
17.2.5! Other!screening!for!suspected!conditions!(not!mental!
disorders!or!infectious!disease)!!
STOP!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
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Appendix XIX: HTC ward - Hospital 
cohort study    
 
 
 
 
 
 
 
 
 
 
Cost-HTC
HTC-WARD: Daily Ward Admissions
 	 Interviewer ID
	 Date of the monday
of the week for
these records:   d        d          m      o     n             y        y      y       y
&#%!&'#%#%''#' "(!%#$'"'&)#&$"''"'#"'
)%





	


%
Version no: 1.0 Last modified by HM 07/09/2014 Page 1 of 1
DATA OFFICE USE ONLY
Data Officer  ID 2  0  1
  d        d          m      o     n         y        y      y       y
Date form
checked
B06B05 DID DDATE
% %
Week of study

	



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




0753123731
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Appendix XX: HTC 501 Baseline 
socio-demographic questionnaire - 
Hospital Cohort study 
 
 
 
 
 
 
 
 
 
 
  d        d          m      o     n            y        y      y       y
Cost-HTC
HTC-501: Hospital Baseline Questionnare
 " Participant
Barcode
  Interviewer ID 	 #$ Place ofinterview
1. Ward 3A
2. Ward 3B
3. Ward 4A
 
 2  0  1
  $
Telephone number of main contact
person during admission
   (!*"%,
Date of Birth
 Age
 #( Sex 1. Male 2. Female

!" )$$*#!.!%#*"$&!)
If female, are you pregnant? 1. Yes 2. No 99. N/A

!"$ Did the patient consent to
participate?
 "#$ %#*"&$ 
What is your marital status?
(TICK ONE)
1. Married
2. Polygamous marriage
3. Living together as married
4. Never Married
5. Separated
6. Widower/Widow
7. Divorced
Years
PLACE ID
BARCODE HERE
Date of interview
Version no: 1.0 Last modified by HM 06/25/2014 Page 1 of 4
  d        d          m      o     n            y        y      y       y
Write Participants Barcode
  d        d          m      o     n            y        y      y       y
  2  0  1Date of admission

 $ )"# %#,!""#%.$%!%$,$*!,$), --)",$ 
How long have you been together with your
spouse/partner? Months
Years
 # %#&*.'%$*#*$!$,%&)
What is the highest level of formal
schooling you have ever attended?
PRESCHO = 00
STAND 1 = 01
STAND 2 = 02
STAND 3 = 03
STAND 4 = 04
STAND 5 = 05
STAND 6 = 06
STAND 7 = 07
STAND 8 = 08
UNIVE 4 = 18
UNIVE 3 = 17
UNIVE 2 = 16
UNIVE 1 = 15
FORM 6 = 14
FORM 5 = 13
FORM 4 = 12
FORM 3 = 11
FORM 2 = 10
 FORM 1 = 09
ABOVE   = 19
TRAIN COL
TCYR 1 = 20
TCYR 2 = 21
TCYR 3 = 22
TCYR 4 = 23
	 !"$" )(#*"&$ !%#*"$,$.
If NOT MARRIED, do you have a partner
at the moment?
1. Yes
2. No
99. N/A
1. Yes
2. No
3. Absconded
4. Discharged
5. Died
76<26=.2/,76;.6<02>.6
7<1.:?2;.#$ !
4389463265
%&!%#%&$%#*"$.$)*.
7.;@7=:17=;.174-7?6*6@7/<1./7447?26084.*;.<2,3*44<1*<*884@
 " Fridge?
Car?
Bed?
Television?
Motorcycle?
Watch?
Phone?
Koloboyi?
Radio?
 "
 
 $&
 "
1. Yes 2. No
1. Yes 2. No
1. Yes 2. No
1. Yes 2. No
1. Yes 2. No
1. Yes 2. No
1. Yes 2. No
1. Yes 2. No
1. Yes 2. No
 '$
! 
	   
" 

  %"&%##%.,#$ "#$"#$"$#"%%"#
Does any member of your household own any agricultural land?
1. Yes
2. No
 #  
#,.,),*#,!"&%$#+*)%&!&.,!!*-
#%,"!.,$ 
During the past month, how often have you had
problems getting the food you need?
1. Never
2. Sometimes
3. Often
4. Always
 #! ().,'.&)."&%#*$)*,$!*"*&!%#%&$%#$($-!&$!*-
#%&",'$%"$%)$!"$!*-%!,$'
In the past two weeks, has an adult in your house skipped a meal
or ate less in order for there to be enough for the children?
1. Yes
2. No
 "   %#$-*##,$*#*".&$.$)!*&)!.#!)$
How many rooms,including kitchens, are there in your home?
 '$ %#.%,')($))%&!%#%&$%
#*#)*$!*)
At your home, in which way do you
obtain water for domestic use
(TICK ONE)?
1. Piped water inside the dwelling
2. Piped water inside the yard
3. Piped water at kiosk
4. Borehole/well
5. River/Stream
6. Other
'$	 %!%#,#*#!)*$#.#*$)$!%)"!,$ 
At your home,what is the distance to the
closest water access point?
1. Less than 200m
2. Between 200m & 500m
3. Between 500m & 1km
4. More than 1km
#8.,2/@2/7<1.:
Version no: 1.0 Last modified by HM 06/25/2014 Page 2 of 4


	 $  %&!%#%&$%#*#,")($))%#*.
#)*$*,$ 
At your home, what is the MAIN type of
toilet facility available for use by your
household? (TICK ONE)
1. Flush toilet
2. Ventilated pit latrine (VIP)
3. Non-Ventilated pit latrine
4. None
	 $ # %#*#,')($))%#*.#$$#$ $ 1. Yes
2. NoDo you share this toilet facility with other households?
		 $ %&!%#%&$%#*#,')(
$))%-$ &%,*$!'
At your home, what is your
main source of lighting
(TICK ONE)?
1. Collect firewood
2. Buy firewood
3. Batteries
4. Paraffin
5. Animal waste
6. Electricity
7. Candles
8. Charcoal
9. Crop residue/Grass
10. Saw dust
	
 ! #()$-&),!%$$$#$
,!" ,%&.$"#,$,$#$ "
Over the last 4 weeks, who has been the
primary income earner in the household
(TICK ONE)?
1. I  Have
2. Husband/Wife
3. Father
4. Mother
5. Son
6. Daughter
7. Extended Family
8. Other, Specify
Specify,if other
Cost-HTC
HTC-501: Hospital Baseline Questionnare
8932463263
%&#()$-&),#*$"#,&%
$))%-%"&,
1. Yes, Formal Work
2. No, Informal Work
3. On Sick Leave
4. Retired
5. At School, University
6. Housework
7. Other, Specify
Over the last 4 weeks have you been
formally employed(TICK ONE)?
	 !
	 # $))%-$*-$-$!%$$$$#$#*#)!*#"%$*$))%
In your MAIN JOB, what is the main activity at the place of work? (TICK ONE)
99. Not Applicable
1. Agriculture, Forestry, Fishing
2. Mining and Quarrying
3. Manufacturing
4. Electricity, Water, Other Utilities
5. Construction
6. Wholesale and Retail Marketing, Hotel/ Restaurants
7. Transport and Communication
8. Finance and Business
9. Social and Community Services
10. Other, Specify
	  % $))%-$*-$-$!%$#%"$)#$#*#,'&()
In your MAIN JOB, how many hours do you work a week?
Write '999' if not working
Specify,if other
Specify,if other
Version no: 1.0 Last modified by HM 06/25/2014 Page 3 of 4
	 !  %#*#&.$"#.$)!*,'$'.%$(	
&
()($%)(#(%$!%!&$$"%$( MK
What is your TOTAL estimated income per week from
all sources (Before tax/deductions)
Write '999999' if not working
Hours


 
*$(%%()',$%!*.$)*#$#*#!"$,%#$ #,$*	#$,$$)*
#$$),.#'#*#!"$,%$!*-'"#%..!*-#$ #,$*
$1./7447?2609=.;<276;*:.*+7=<5.5+.:;7/@7=:17=;.174-$1.;.*:.26-2>2-=*4;?1767:5*44@
42>.*6-;1*:.5.*4;26@7=:17=;.174-
	  #%.$$*-%!%#$-*##,$*#*#!"$)*!*"*$).!.%,!*#
.($*$.))*!&$!*&%('&#$&
Including yourself, how many adults (aged 18 years and over) live
in the household?

  %#$-*##*#*#!"$$).!.%,.%(&)''.!*,!*#.($*
$.))*
How many children (aged under 18 years of age) live in the household?

 %$*$$*#,$#!*"*,$ "#$"
Are you the head of the household?
1. Yes
2. No

  %#
What is the combined TOTAL household income per week from all sources?
(Ask participant to include the income of all members of the household
including themselves)
Write '888888' if participant does not know
%.%$(&#%.&!%#%&$%#*#&.$"#.$)!*%!
!*"!%$(*$($,%)$$,%#"!*)&)!.$"#.%#,
%$(&!%#%&%#&.!*&)!.&%,%$
MK
Cost-HTC
HTC-501: Hospital Baseline Questionnare
9272463261
DATA OFFICE USE ONLY
Data Officer  IDDIDA50 A51 DDATE Date form
checked 2  0  1
  d        d          m      o     n         y        y      y       y
Version no: 1.0 Last modified by HM 06/25/2014 Page 4 of 4



	  $


  
Where did you have your recent HIV test?

 "# %)()".%-.)(
HIV test result

  % %#*$-.)("#%.$%!%$,$*
Did you test as a Couple? (Couples Testing)
Does not necessarily have to be husband/wife
(!*"#$$-.,"#$)(!*
""'%$)-.,"'%
Date of HIV Test (Write todays
date if tested today)
%!*$"!*)!*#$#*$!-.)(&%(,&
1. At Home: Oral Self-testing in presence of counsellor
2. At Home: Oral Self-testing in Private
3. At Home: Finger Prick VCT (not from Hit-TB Study)
4. HIV Testing Clinic: Refered by Antenatal clinic (ANC)
5. HIV Testing Clinic: Refered by TB clinic
6. HIV Testing Clinic: Refered by health professional(not TB, not ANC)
7. HIV Testing Clinic: Went solely to learn my HIV status
8. Mobile Testing Service
9. Private healthcare provider
10. Hospital: On this admission
11. Hospital: on a previous admission
12. NEVER had an HIV test
13. Other, specify
1. Positive
2. Negative
3. Not disclosed
4. Invalid/indeterminate
5. Not done
  d        d          m      o     n             y        y      y       y
Specify,if other
1. Yes
2. No

 $ #$#*$"&'!*-.)(
!%)('.$*!,$$ 
#*$"&'!*-.)(
For that most recent
failed attempt, why did
you not get the HIV test
done?
1. I changed my mind
2. Clinic/facility closed
3. No HIV counsellor
4. No HIV testing equipment
5. I was told I should wait for the 'Window period"
6. NOT APPLICABLE
9. Other, Specify

  *#-.!*#$,'-&)-$!$)#*$-(!*-.)(!%#(#*$)!*-.)(

Over the last 12 months, how many times have you tried to get a HIV
test, but did not end up having the HIV test? (Failed Attempt)
Specify,if other

 !#$ *#-.!*#$,'-&)-$!$)#,-.)(&%#&!$!*"$'.%)()'.
!*-.)(!%(&)!.&%!*-.)(#,&$)(&%(,&
Over the last 12 months, how many times have you had a HIV test where
you completed the HIV test?(Not including this most recent HIV test)
Cost-HTC
HTC-501: Hospital Baseline Questionnare
7610463265
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direct non-medical and indirect cost 
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cohort study 
 
 
 
 
 
 
 
 
 
Cost-HTC Hospital study
HTC-502: Patient Admission Costs
 # Participant
Barcode
	
 Interviewer ID
 $% Place of
interview
1.Ward 3A
2.Ward 3B
3.Ward 4A
 

PLACE ID
BARCODE HERE
Date of interview
Version no: 1.0 Last modified by HM 06/25/2014 Page 1 of 4
  d        d          m      o     n             y        y      y       y
2  0  1
Write Participant Barcode

+ %)1*4!*!.'1(%,%( ()%*%.%4+*/!)0!*#+3 ()'1$%,0(*0$3%
%)!*!)1*"%'',!*)1*#+*!'! 3
Did you have to pay for any administrative fees/charges to the
hospital when you arrived or when you got admitted?
#
#0%* %$+*$+'+ %)1*(%,%.)0!*#+3$%,0(3* ()5%*#0%
If yes, how much did you pay in hospital charges?
Write '0' if did not pay hospital charges
#
MK
1. Yes
2. No
+ %)1*(%,%( ()%*%.%4+*/!'10%)14!5! 3!*0$%0+4+"1"15%$%0%'!,%*10/%'1
(%)!*!)1*#+*!'! 3
Did you have to pay any money to have any tests/investigations done
on the day you were admitted? (Either at QECH or privately)
(Only include tests/investigations requested by their doctor during admission)
#
#0%%* !)1*(%,%. ()5%*#0%
If yes, how much did you pay?
Write '0' if did not pay any charges
#
MK
1. Yes
2. No
 %# 0/%'1(%)!*!)1*#+*!'! 3(+)1*"%''+3*&%'1$%,0(
$$%'1(1$1!!*(%5!0$
On the day you were admitted, how did you get
to QECH?
1. Ambulance
2. Walked
3. Public transport
4. Own transport
5. Other, SpecifySpecify,if other
 %# + %)1*+*+*# ()5%*#0%,0.*/%,+0%4+'"%'%('1$%,0('+
 ()5+#3%.%0/% 3*0$%0+,+,%0',!*'13!(!.'+'$
How much money did you spend on transportation to
hospital (Cost of one-way travel)?
Write '0' if did not spend money
MK
"1*/++*/!3'1')55%)!*!5%*$%0%'0/%'1(%)!*!)1*0$1*#+*!'! 3
'1$%,0(
%0-:-8<-:;165:)339-.-9;6=0);0)77-5-,65;0-,)>6.),41::165
Write Participants
SPINE ID
$!
%#  TB-ROCC Participant ID
(write 9999999 if not a TB-ROCC participant
!
5104149026
ID
Version no: 1.0 Last modified by HM 06/25/2014 Page 2 of 4
MK1'1('1$%,0(!(0$//,+.0
%  %
On the day you were admitted, did you spend money on anything else?
(write '0' if did not spend any money on item)
              (For each item, write total money spent)
%:12<314-5-4<5)/65-2-,=)4<5)6565/)76,)3)4)7)+015)+0191+065:-


%
#
!
Cost-HTC Hospital study
HTC-502: Patient Admission Costs
MK+ %)1*#3%.%0/*0$%0+* ()5%*#0%,$%*0$1$%)!*!$%How much did you spend on this?
(write '99999' if question not applicable)
 %	

Specify what you
spent money on?
$1(*%$%*0$1$%)!*!
)1*#3%.%0/%.,+*0$%0+
* ()
 %	
On the day you were admitted, did you spend money on anything
else? (Excluding above list)
/%'1(%)!*!)1*#+*!'! 3)1*+*+*#,+ (),$%*$%.%$+*/! % 1. Yes
2. No
	    /%'!(%)!*!)1*#+*!'! 3'+ %)1*#3%.%0/*0$%0+ ()5%*#0%
'1#1(%.5'1 4'+)*/+5+'1)3
On the day you were admitted, how much money did you
spend on food or drinks
Write '0' if did not spend money
MK
MK1*%0%"+*%4)6)*&%.0%)!"+.+%(!
MK+,++/)%.+$,%.',!*/$),10$%*#/$%*#+,+.
$),++

MK+(+#!0%* %)/3$%++0$,/0!* +.++0$.1/$
MK+2(* %*/,0+(+0$!/* +.$+!/
&
&!
 %
MK',1* %)(!1,/* +.(0!/
MK +3',!*!/!*%4+$,%.1'!0+./%*"+.3/$%*#
Did you have to take time of work because of being admitted to
hospital?
+ %)1*&+)'1*0$%0+$%"1'3$+#+*!'! 3'1$%,0(( # 1. Yes
2. No
%  MK%/$1+(%!0,!.
6907149028
ID
Cost-HTC Hospital study
HTC-502: Patient Admission Costs
=)4*)3-=)5<=-51=-514?)5<26,1)5)6565/)5),)3)4)
?15/);1;:12<314-5-4<5)/65-2-,=)4<+017);)3)
+.0$!)%*")%(4)!)!.".%!* $+3)1$ % 0$!4/,!* +*0$!
 44+13!.! )%00! +*
+*+0%*(1 !%0!)/%")!*0%+*! 1* !.,0%!*0+/0/
3.%0!	%" % *+0/,!* *4)+*!4
3.%0!




%"-1!/0%+**+0,,(%(!
MK(++#+*+)+ 0%+*
%  %
	
%
#

MK1*%0%"+*%4)6)*&%.0%)!"+.+%(!	
MK+,++/)%.+$,%.',!*/$),10$%*#/$%*#+,+.
$),++
	
MK+(+#!0%* %)/3$%++0$,/0!* +.++0$.1/$		
MK+2(* %*/,0+(+0$!/* +.$+!/	

&
&!
 %
MK',1* %)(!1,/* +.(0!/	
MK +3',!*!/!*%4+$,%.1'!0+./%*"+.3/$%*#	
MK$'1 4* %',!*5'1)3++ * +..%*'/ 

MK.*/%,+0%.*/,+.00%+*+*!340.2!( 	
					
	
					
Version no: 1.0 Last modified by HM 06/25/2014 Page 3 of 4
 '$%
On the day you were admitted, how many family members or friends
came with you to the hospital?
/%'1(%)!*!)1)#+*!'! 3* %$%(!*#0%',!**5*1*#0%*3!.* %%*1'1
$%,0(
 #
How many of these family members or friends stayed with you in
hospital specifically to look after you during your hospital
admission?
*#0%(!* %**/%)30$1(3)!*!*'1 %'%(%.*%'1$%,0(,*0$3%4+)3!
)1*#+*!'! 3
%  MK%/$1+(%!0,!.	
6049149025
ID
Version no: 1.0 Last modified by HM 06/25/2014 Page 4 of 4
MKHow much money did they spend on this?
Write '0' if did not spend any money
Write '99999' if question not applicable
+ %5%*(%* ()5%*#0%5%)!*!*#3%.%0/*0$%0+,$%*0$1$%)!*!$% %	

Specify what they spent
money on
$1(*%$%*0$1$%)!*!%3+3+
*#3%.%0/%.,+*0$%0+* ()
 %	
	  % 0/%'1(%)!*!)1*#+*!'! 3'+ %%3+3+*#3%.%0/*0$%0+* ()4%*4%.%4+*/!
,$%*0$1$%.%$+*/!$%*$%"1'3$+0%*'1,!.!'!5*%%*14+
1. Yes
2. No
C43 DID Data Officer  ID
DATA OFFICE USE ONLY
C44 Date form
checked 2  0  1
  d        d          m      o     n         y        y      y       y
DDATE
!3-):--5:<9->6<+6473-;-%"6
8<-:;1655)19-=1;07);1-5;
Cost-HTC Hospital study
HTC-502: Patient Admission Costs
On the day you were admitted, did they spend money on anything
else?

 ( #
If they work, how much do they normally earn
per day?
Write '99999' if question not applicable
Write '88888' if participant does not know
#0%)#3%.*0$%0+'+ %),!5* ()5+$1(1'3*&%
,0/%'1
MK
+ %$%(!*1)5*1*&+)'1*0$%0+$%"1'3$+0%)'10!*#!.*%'1$%,0(
Did the family member/friend have to take time off work to come
with you to hospital?

 ( # 1. Yes
2. No
8663149029
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Appendix XXII: HTC 503 Previous 
day direct non-medical and indirect 
cost data collection tool  - Hospital 
cohort study 
 
 
 
 
 
 
 
 
 
Cost-HTC Hospital study
HTC-503: Patient Daily Costs
 " Participant
Barcode
	  Interviewer ID 
 #$ Place ofinterview
1.Ward 3A
2.Ward 3B
3.Ward 4A

PLACE ID
BARCODE HERE
Date of interview
Version no: 1.0 Last modified by HM 06/25/2014 Page 1 of 4
  d        d          m      o     n             y        y      y       y
2  0  1
Write Participant Barcode
,!&!62),*2+)&-&)!)*&+&/&5,+0"*1"+$,4&+2/&4,+0"(2 %&-1)
Yesterday, did you have to pay for any administrative
fees/charges to the hospital?
"
$1&+!& %,+ %,(,!&*2+)&-&/*1"+$,4 %&-1)4+!)*6&+$1&
If yes, how much did you pay in hospital charges?
Write '0' if did not pay hospital charges
"
MK
1. Yes
2. No
,!&*2+)&-&)!)*&+&/&5,+0"(21&*25"6"!4" %&+ %&/& %,+0"+1 %&1,
5,2+&(1%2-&)+2& %&1&("
YESTERDAY, Did you have to pay any money to have any tests/
investigations done? (Either at QECH or privately)
(Only include tests/investigations requested by their doctor)
"
$1&&+!"*2+)&-&/!)*6&+$1&
If yes, how much did you pay?
Write '0' if did not pay any charges
"
MK
1. Yes
2. No
#2+0,,+0"4(2#,1,(,666&*"+"6&+ %&1&(-*"+"*2+)&*2)&*2 %&-1)
$1.;.9=.;<276;*44:./.:<7>1*<1*88.6.-(#$"(>124;<?7=>.:.2617;82<*4
Write Participants
SPINE ID
# 
 $" TB-ROCC Participant ID
(write 9999999 if not a TB-ROCC participant
  ,!&*2+,+,+$!)*6,(4+6&+$1&-6(2!5(-"+6,(2*4
YESTERDAY, how much money did you spend on food or
drinks (IN TOTAL)
Write '0' if did not spend money
MK
1. Routine follow-up
2. Transferred to ward
3. Being discharged
4. Abscounded
5. Transfer to another hospital
6. Died
Reason
for
interview
 '(#
  d        d          m      o     n             y        y      y       y
/*+;,76-.--2;,1*:0.-<:*6;/.::.-
7:-2.->:2<.-*<.*+;76-.-
-2;,1*:0.-<:*6;/.::.-7:-2.-
 
1468436923
ID
Version no: 1.0 Last modified by HM 06/25/2014 Page 2 of 4
Cost-HTC Hospital study
HTC-503: Patient Daily Costs
MK
,!&*2+$4&/&10+1 %&1,+!)*6&+$1&- %&+1%2 %&*"+" %&
How much did you spend on this?
Write '99999' if question not applicable
$
Specify what you
spent money on?
 %2)+& %&+1%2 %&*"+"
*2+$4&/&10&/-,+1 %&1,
+!)*
$
YESTERDAY, did you spend money on anything else?
,!&*2+,+,+$-,!)*- %&+ %&/& %,+0" %,,+'"6"/$ 1. Yes
2. No
MK2(2)(2 %&-1)")1%00-,/1
$$
YESTERDAY, did you spend money on anything else?
(write '0' if did not spend any money on item)
              (For each item, write total money spent)
7-2)%5=6*76760*87-*4*5*8*,126*,12:2,176;.,17763.@.:*

$
"
 
MK2+&1&#,+&5*7*+'&/1&*"#,/,&)"	
MK,-,,0*&/, %-&/(-"+0%*-21%&+$0%&+$,-,/
%*-,,


MK,),$"1&+!&*04 %&,,1%-01"+!,/,,1%/20%
MK,3)+!&+0-1,),1%"0+!,/%,"0
%
% 
$
MK(-2+!&*)"2-0+!,/)1"0
MK!,4(-"+"0"+&5, %-&/2 ("1,/0&+#,/40%&+$
Yesterday, would you have gone to work if you were not in
hospital or ill?
62),*2(+1%(2-&1(2+1 %&1,*2(+-+!(2),4* %&-1)(-"+(2!4)'"	 1. Yes
2. No
$ MK&0%2,)&"1-"/
7196436927
ID
Cost-HTC Hospital study
HTC-503: Patient Daily Costs

 &#$
Yesterday, how family members or friends visited you or stay
with you in hospital?
62),(,!&+!&)"(-"++6+2+$1&*"+"+4"/(2!6(2,++&(-"+
(2(2!&(&/&/+&* %&-1)*2+,
 "
$$
$
" MK2+&1&#,+&5*7*+'&/1&*"#,/,&)"
MK,-,,0*&/, %-&/(-"+0%*-21%&+$0%&+$,-,/
%*-,,

MK,),$"1&+!&*04 %&,,1%-01"+!,/,,1%/20%
MK,3)+!&+0-1,),1%"0+!,/%,"0
%
% 
$
MK(-2+!&*)"2-0+!,/)1"0	
MK!,4(-"+"0"+&5, %-&/2 ("1,/0&+#,/40%&+$

MK%(2!5+!&(-"+6(2*4,,!+!,//&+(0 	
MK/+0&-,1&/+0-,/11&,+,+"451/3") 
>*5A5+*4.>*6=>.62>.625@*6=*6*76760*6-*4*5*@260*<26<1*>2
25.6.*6*426*6=5=,128*<*4*-@=47
,/1%"*&+#*&)5*"*"/#/&"+!%,4*2 %!&!1%"50-"+!5"01"/!5,+
,+,1&+ )2!"&1"*0*"+1&,+"!2+!"/-1&"+1 ,010
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How many of these family members or friends stayed with you in
hospital specifically to look after you during your hospital
admission?
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1&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++0&*41 %2)4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+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1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MKHow much money did they spend on this?
Write '0' if did not spend any money
Write '99999' if question not applicable
,!&6&+)&+!)*6&+$1&6&*"+"+$4&/&10+1 %&1,- %&+1%2 %&*"+" %&$
Specify what they spent
money on?
 %2)+& %&+1%2 %&*"+"&4,4,
+$4&/&10&/-,+1 %&1,+!)*
$
 $ ,!&+,+,+$!)*- %&+1%2 %&+ %,,+'"6"/ 1. Yes
2. No
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DDATE
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Cost-HTC Hospital study
HTC-503: Patient Daily Costs
YESTERDAY, did they spend money on anything else?
	 '"
If they work, how much do they normally earn per
day?
Write '99999' if question not applicable
Write '88888' if participant does not know
$1&*$4&/+1 %&1,(,!&*-"6+!)*6, %2)2(4+'&-10&(2
MK
,!&+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(2+1 %&1,!62),(21&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)"+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1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Did they have to take time off work to spend yesterday with
you in hospital?
	 '" 1. Yes
2. No
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HTC-QOL: Hospital Quality of Life
	 $ Participant
Barcode

  Interviewer
ID
 %& Place of
interview
1. Ward 3A
2. Ward 3B
3. Ward 4A
"
PLACE ID
BARCODE HERE
Date of
interview
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Write Participant Barcode
!52+A+2?7?.A+ "=+=+81+6+6+		 !)
	 #! '6?6?5?:2A+8B+7>2?:35?=9A/>=+7>/8./</
1. Ndilibe ululu kapena sindikumva kuphwanya m'thupi
2. Ndimakhala ndi ululu kapena kumva kuphwanya m'thupi mwapakatikati
3. Ndimakhala ndi ululu kapena kumva kuphwanya m'thupi kwambiri
1. Sindikuda nkhawa kapena kukhumudwa
2. Ndimakhala oda nkhawa kapena okhumudwa mwapakatikati
3. Ndimakhala oda nkhawa kapena okhumudwa kwambiri
1. Ndilibe mavuto ali onse pogwira ntchito zanga za nthawi zonse
2. Ndili ndi mavuto ena pang'ono pogwira ntchito za nthawi wonse
3. Ndimalephera kugwira ntchito zanga za nthawi zonse
*9-23>35+C+>=35?8.3>=35?7981+5?1A3<+8>-23>95?A/</81+8>-23>9C+:+52979C+7,+84+ 5+:/8+5?-23>+
C37/8/C37+8.3=+81+6+>=+
'%'
1. Ndilibe vuto podzisamalira ndekha
2. Ndimakhala ndi mavuto ena posamba kapena podziveka ndekha
3. Ndimalephera kusamba kapena kudziveka ndekha
?.C3=+7+63<+8./52+7A+-23>=+C95?=+7,+8.35?.C3@/5+8./52+%
1. Ndilibe vuto lina lililonse poyenda
2. Ndimakhala ndi mavuto ena poyenda
3. Ndimangobindikira pa kama
 +B/8./.A/ "
2981+837?1?6?6363<98=/:+8=3:+-298./=98B/C+8370?8.9C37/8/
C35?09>959C+,A389C+?79B9A+8?
 ! 		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How would you rate your general
health?
1. Bwino kwambiri
2. Wabwino
3. Bwino pang'ono
4. Si uli bwino
5. Si uli bwino mpang’ono pomwe
 +0?8=9+7/8/A++5?5?52?C+?6/8.9?A?A?3126312>;?/=>398=</0/<>9>9.+B
1. First Interview
2. Follow-up interview
Which Interview?!&
7158562015
Kuti tithandize anthu
kunena za umoyo wawo,
tajambula mlingo woyesela
(chofanana ndi choyesela
kuzizila/kutentha kwa
m'thupi) womwe umoyo
wabwino wayerekezedwa ndi
chizindikiro cha 100
ndipo umoyo woipa
wayelekezedwa ndi
chizindikiro cha 0
Tikufuna mutisonyeze pa
mlingowu mmene umoyo
ulili lero kuti uli
bwino kapena suli bwino
mmene inu mukuganizira.
Lembani mzere kuchokera
pa bokosi pansipa kupita
pa mlingo woyesera umene
ukufotokoza za ubwino
kapena kuipa kwa mmene
umoyo wanu ulili lero.
Mmene
umoyo wanu
ulili lero
	
 (% Write Participants Score Below:
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